Back To Top

You have matched to 387 trials

Guest Profile:  HER2+

Copy link
Sort by zip code: 94107 Hide Map Icon
Why register? Save your profile, save trials, and enter treatment history for more accurate matching.
1

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Purpose: To compare a technology-based supportive cancer care approach with a team-based supportive cancer care approach.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV breast cancer that is newly diagnosed or whose cancer has come back. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials, virtual, weekly for 4 months, then every 2 weeks for 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational materials, in person or by phone, weekly for 4 months, then every 2 weeks for 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The educational materials are designed to assist with advance care planning and symptom management. Topics include surrogate decision-makers, advance directives, and physician orders for life-sustaining treatment. The education is delivered to the participant by an electronic health record message or email, or by a lay health worker. </li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05297734' target='_blank'>ClinicalTrials.gov</a> </li></ul>
1

Supportive Cancer Care Delivered Virtually or by a Health Worker for Stage 0-IV Breast Cancer

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Icon

Nearest Location from 94107:
2 miles
Zuckerberg San Francisco General
San Francisco, CA

Icon

Visits:
Up to 2 to 4 times per month for 1 year

Icon

ClinicalTrials.gov: NCT05297734

Icon

Phase NA

2

Virtual Support and Navigation for People with Stage I-IV Breast Cancer

The Patient Care Outreach, Navigation, Technology and Support 2.0 Study (COUNTS2)

Purpose: To study a virtual patient navigation program to support people with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet started treatment or are currently receiving treatment. You must speak English, Mandarin/Cantonese/Chinese, or Spanish. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Participate in patient navigation program, online or in-person</li> <li class="seamTextUnorderedListItem">Participate in focus groups</li> <li class="seamTextUnorderedListItem">Complete questionnaires, 2 times in 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The focus groups will be used to develop parts of the program specific to culture and language.</li> <li class="seamTextUnorderedListItem">While not able to entirely replace in-person interactions, virtual patient navigation may be used to expand reach and availability of navigation services to a much greater segment of the population.</li> <li class="seamTextUnorderedListItem">Your family member may also be asked to participate in this study.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06648278' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://patientcounts.ucsf.edu/s/About?language=en_CA' target='_blank'>University of California San Francisco: Patient COUNTS</a> </li></ul>
2

Virtual Support and Navigation for People with Stage I-IV Breast Cancer

The Patient Care Outreach, Navigation, Technology and Support 2.0 Study (COUNTS2)
Icon

Nearest Location from 94107:
2 miles
Zuckerberg San Francisco General Hospital
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06648278

Icon

Phase NA

3

DCIS RECAST: Hormone Therapy and Active Surveillance for Women with HR+ DCIS

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Purpose: To study if hormone therapy and active monitoring (MRIs and mammograms) is an effective way to treat and manage DCIS.

Who is this for?: Women with stage 0 (DCIS) hormone receptor positive (ER+ and/or PR+) breast cancer who have not yet received surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1 (if surgery is needed):</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy (standard of care or experimental) for 6 months</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Saliva sample for genetic testing</li> <li class="seamTextUnorderedListItem">Followed by surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2 (if surgery is not needed):</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy (standard of care or experimental) for 6 months</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Saliva sample for genetic testing</li> </ul> <p class="seamTextPara"> Followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy, continue for 2-5 years</li> <li class="seamTextUnorderedListItem">MRI scan or mammogram, alternating every 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">After evaluation at 6 months, participants will either have surgery (if recommended) or continue on the treatment for 2-5 years.</li> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen.</li> <li class="seamTextUnorderedListItem">(Z)-endoxifen is similar to tamoxifen.</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs work by blocking the activity of estrogen in people with mutations in the ESR1 gene.</li> <li class="seamTextUnorderedListItem">Testosterone is a hormone that may reduce the risk of breast cancer.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A mammogram is a breast cancer screening procedure involving taking an x-ray picture of the breast.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06075953' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.quantumleaphealth.org/for-patients/i-spy-recast-dcis-patient/' target='_blank'>Quantum Leap Healthcare Collaborative: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/ductal-carcinoma-in-situ' target='_blank'>Breastcancer.org: DCIS</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>
3

DCIS RECAST: Hormone Therapy and Active Surveillance for Women with HR+ DCIS

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study
Icon

Nearest Location from 94107:
3 miles
UCSF
San Francisco, CA

Icon

Visits:
At least 1 visit every 6 months for 5 years

Icon

ClinicalTrials.gov: NCT06075953

Icon

Phase II

4

MRI Scans to Plan Radiation for Women with Stage 0-III Breast Cancer

Magnetic Resonance Imaging in RadiotheRapy fOr bReast Cancer (MIRROR): A Pilot Study of MRI Simulation

Purpose: To study the use of MRI scans to plan radiation.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who are planning to receive radiation after lumpectomy (adjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A MRI scan may help your doctor plan your radiation treatment.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05902507' target='_blank'>ClinicalTrials.gov</a> </li></ul>
4

MRI Scans to Plan Radiation for Women with Stage 0-III Breast Cancer

Magnetic Resonance Imaging in RadiotheRapy fOr bReast Cancer (MIRROR): A Pilot Study of MRI Simulation
Icon

Nearest Location from 94107:
3 miles
University of California, San Francisco
San Francisco, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT05902507

Icon

Phase NA

5

Body Composition Measurements in Women Undergoing Breast Reconstruction for Breast Cancer or High Risk of Breast Cancer

Investigation Into the Utility of Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction

Purpose: To study how new ways of measuring body composition may be related to outcomes of breast reconstruction surgery.

Who is this for?: Women at high risk for breast cancer or with DCIS (stage 0) or stage I or stage II or stage III breast cancer , and are planning to have a mastectomy with immediate breast reconstruction using implants or tissue expanders, or their own tissue (such as DIEP, msTRAM, or PAP flap reconstruction). You must receive care at University California of San Francisco (UCSF). View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers want to understand whether body composition measurements can help predict surgical complications and recovery outcomes after breast reconstruction.</li> <li class="seamTextUnorderedListItem">This is an observational study, meaning you will receive standard breast reconstruction care, and researchers will collect additional measurements and information.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07546331' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/flap-reconstruction-complications-bmi' target='_blank'>Breastcancer.org:After Flap Reconstruction, Complications More Likely in Women With Higher BMI</a> </li></ul>
5

Body Composition Measurements in Women Undergoing Breast Reconstruction for Breast Cancer or High Risk of Breast Cancer

Investigation Into the Utility of Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction
Icon

Nearest Location from 94107:
3 miles
University of California
San Francisco, CA

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT07546331

Icon

Phase NA

6

Impact of Antibiotics on Infection and the Microbiome in People Receiving a Mastectomy

Microbiome and Association With Implant Infections: Investigating the Impact of Antibiotics on the Gut and Breast Microbiomes Post-mastectomy With Implant-based Breast Reconstruction

Purpose: To study the effects (good and bad) of antibiotics after mastectomy with immediate reconstruction on infection and the microbiome.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer or people at risk of breast cancer who are planning to receive a mastectomy with immediate reconstruction. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cephalexin (Keflex®) antibiotic, before and during surgery</li> <li class="seamTextUnorderedListItem">Cephalexin (Keflex®) antibiotic, daily for at least 7 days after surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cephalexin (Keflex®) antibiotic, before and during surgery</li> <li class="seamTextUnorderedListItem">No antibiotics after surgery (unless infection occurs)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A mastectomy is surgery to remove a breast.</li> <li class="seamTextUnorderedListItem">Women with a strong family history of breast cancer or a BRCA mutation may choose to undergo a mastectomy to reduce their risk of developing breast cancer.</li> <li class="seamTextUnorderedListItem">Cephalexin (Keflex®) is an antibiotic used to prevent infection after surgery.</li> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found on your body.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05020574' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/mastectomy' target='_blank'>Breastcancer.org: Mastectomy</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a682733.html' target='_blank'>MedlinePlus: Cephalexin (Keflex®)</a> </li></ul>
6

Impact of Antibiotics on Infection and the Microbiome in People Receiving a Mastectomy

Microbiome and Association With Implant Infections: Investigating the Impact of Antibiotics on the Gut and Breast Microbiomes Post-mastectomy With Implant-based Breast Reconstruction
Icon

Nearest Location from 94107:
3 miles
University of California, San Francisco
San Francisco, CA

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT05020574

Icon

Phase II

7

Trastuzumab After Surgery for 6 Months or 1 Year for Stage I-III HER2+ Breast Cancer That Responded Completely to Chemotherapy and Trastuzumab Before Surgery

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of receiving HER2 targeted therapy for 6 months vs 1 year.

Who is this for?: People with stage I, stage II, or some stage III HER2 positive (HER2+) breast cancer who had a complete response (no cancer is left) after receiving chemotherapy with trastuzumab (Herceptin®) before surgery (neoadjuvant). You must have received surgery and received or plan to receive radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV or injection, every 3 weeks for 1 year</li> <li class="seamTextUnorderedListItem">Heart tests</li> <li class="seamTextUnorderedListItem">Mammogram, ultrasound scan, or MRI scan</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires, every 6 months for 1.5 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV or injection, every 3 weeks for 6 months</li> <li class="seamTextUnorderedListItem">Heart tests</li> <li class="seamTextUnorderedListItem">Mammogram, ultrasound scan, or MRI scan</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires, every 6 months for 1.5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is a HER2 targeted therapy commonly used to treat HER2+ breast cancer. </li> <li class="seamTextUnorderedListItem">Receiving HER2-targeted therapy for 6 months may work better than receiving this treatment for 1 year in people whose cancer responded completely to chemotherapy with trastuzumab (Herceptin®) before surgery (neoadjuvant).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06876714' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.herceptin.com/' target='_blank'>Genentech: Trastuzumab (Herceptin®)</a> </li></ul>
7

Trastuzumab After Surgery for 6 Months or 1 Year for Stage I-III HER2+ Breast Cancer That Responded Completely to Chemotherapy and Trastuzumab Before Surgery

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
Icon

Nearest Location from 94107:
3 miles
Kaiser Permanente-San Francisco
San Francisco, CA

Icon

Visits:
Every 3 weeks for 6 months or 1 year, then every 6 months for 1.5 years

Icon

ClinicalTrials.gov: NCT06876714

Icon

Phase III

8

GLSI-100 Immunotherapy for HER2 Positive Breast Cancer

A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of GLSI-100, an experimental immunotherapy.

Who is this for?: People with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer who have completed standard treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GLSI-100, by injection, monthly for 6 months, then every 6 months for 2.5 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for GLSI-100, by injection, monthly for 6 months, then every 6 months for 2.5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GLSI-100 is an experimental immunotherapy that targets HER2 positive cells.</li> <li class="seamTextUnorderedListItem">GLSI-100 has two components called GP2 and GM-CSF.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05232916' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://greenwichlifesciences.com/technology/gp2-cancer-immunotherapy/' target='_blank'>Greenwich LifeSciences: GP2 Drug Information Page</a> </li></ul>
8

GLSI-100 Immunotherapy for HER2 Positive Breast Cancer

A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Icon

Nearest Location from 94107:
3 miles
University of California San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
1 visit every month for 6 months, then every 6 months for 2.5 years

Icon

ClinicalTrials.gov: NCT05232916

Icon

Phase III

9

Studying Cannabis to Improve Symptoms for People with Stage I-IV Breast Cancer

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

Purpose: To study the potential benefits and harms of cannabis products for cancer-related symptoms.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive or are receiving (within 2 months) treatment with chemotherapy, targeted therapy, and/or an immune checkpoint inhibitor (pembrolizumab (Keytruda®) or dostarlimab (Jemperli®)). You must be using cannabis products. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys, at home or in person, monthly for 1 year</li> <li class="seamTextUnorderedListItem">Blood sample, 3 times in 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cannabis may help ease symptoms of cancer and side effects of treatment.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06418204' target='_blank'>ClinicalTrials.gov</a> </li></ul>
9

Studying Cannabis to Improve Symptoms for People with Stage I-IV Breast Cancer

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
Icon

Nearest Location from 94107:
3 miles
Kaiser Permanente-San Francisco
San Francisco, CA

Icon

Visits:
3 visits in 1 year

Icon

ClinicalTrials.gov: NCT06418204

Icon

Phase NA

10

Trastuzumab by Injection with Chemotherapy or an Antibody-Drug Conjugate for Stage I HER2 Positive Breast Cancer

A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)

Purpose: To study and compare the safety, side effects, and anti-cancer activity of giving Herceptin Hylecta (trastuzumab by injection) with chemotherapy to giving it with an antibody-drug conjugate.

Who is this for?: People with stage I HER2-positive (HER2+) breast cancer who have already had surgery and completed radiation therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab emtansine/T-DM1 (Kadcyla®), by IV, every 3 weeks, for 4.5 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®)/Herceptin Hylecta, by injection, every 3 weeks, for 7.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every week, for 3 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®)/Herceptin Hylecta, by injection, every 3 weeks, for 11.5 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab emtansine/T-DM1 (Kadcyla®) is an antibody-drug conjugate (ADC). It uses an antibody -— the HER2-targeted therapy trastuzumab (Herceptin®) -— to deliver the chemotherapy DM1 directly to the cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2 positive breast cancer. </li> <li class="seamTextUnorderedListItem">Herceptin Hylecta is a form of trastuzumab that is given by injection instead of by IV. </li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy routinely used to treat breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04893109' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-formulation-herceptin-subcutaneous-use' target='_blank'>FDA Drug Approvals and Database: FDA Approves New Formulation of Herceptin for subcutaneous Use</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/kadcyla' target='_blank'>Breastcancer.org: Trastuzumab Emtansine/T-DM1 (Kadcyla®)</a> </li></ul>
10

Trastuzumab by Injection with Chemotherapy or an Antibody-Drug Conjugate for Stage I HER2 Positive Breast Cancer

A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
Icon

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
1 visit every 3 weeks, for 1 year

Icon

ClinicalTrials.gov: NCT04893109

Icon

Phase II

11

I-SPY 2: Personalized Treatment Before Surgery for Stage II-III Breast Cancer

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of standard of care therapy compared to standard of care therapy with an experimental drug chosen based on your tumor's biomarkers.

Who is this for?: People with stage II or stage III breast cancer who have not yet received treatment and whose cancer is high-risk for recurrence. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and receive the following before surgery: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care therapy</li> <li class="seamTextUnorderedListItem">At least 1 experimental therapy chosen based on your tumor's biomarkers</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">4 MRIs</li> <li class="seamTextUnorderedListItem">2 biopsies</li> <li class="seamTextUnorderedListItem">Blood draws</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy is treatment specific to an individual's tumor type, which are called biomarkers.</li> <li class="seamTextUnorderedListItem">This clinical trial has an adaptive design. This means that experimental drugs will be added during the trial, and experimental drugs that are not more effective than standard of care therapy will be removed.</li> <li class="seamTextUnorderedListItem">At least 80% of people who enroll will receive an experimental drug.</li> <li class="seamTextUnorderedListItem">All drugs will be given before surgery (neoadjuvant therapy). This allows researchers to see how your tumor is responding to the drugs.</li> <li class="seamTextUnorderedListItem">For this trial, cancer is considered high-risk for recurrence if it tests MammaPrint Low (only if your tumor is ER- or ER+, HER2+) or MammaPrint High.</li> <li class="seamTextUnorderedListItem">MammaPrint is a genomic test that identifies genes in your tumor and gives two types of recurrence risk scores: low risk or high risk.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01042379' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ispypatient.org/' target='_blank'>Quantum Leap Healthcare Collaborative: I-SPY Patient Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/mammaprint-test' target='_blank'>Breastcancer.org: MammaPrint</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubmed.ncbi.nlm.nih.gov/32701140/' target='_blank'>Journal Article: Three-Year Follow-Up Analysis for the I-SPY 2 Adaptively Randomized Clinical Trial</a> </li></ul>
11

I-SPY 2: Personalized Treatment Before Surgery for Stage II-III Breast Cancer

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Icon

Nearest Location from 94107:
3 miles
University of California San Francisco (UCSF)
San Francisco, CA

Icon

Visits:
1 visit every week for 3-6 months

Icon

ClinicalTrials.gov: NCT01042379

Icon

Phase II

12

Niraparib Targeted Therapy and Irinotecan Chemotherapy for Advanced Breast Cancer with BRCA1, BRCA2, ATM, and PALB2 Mutations

Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of niraparib PARP inhibitor with irinotecan chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a BRCA1, BRCA2, ATM, and/or PALB2 mutation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®), by mouth, 1 week on, 2 weeks off</li> <li class="seamTextUnorderedListItem">Irinotecan (Camptosar®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®) is a type of targeted therapy called a PARP inhibitor. It works by blocking poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA.</li> <li class="seamTextUnorderedListItem">Irinotecan (Camptosar®) is a type of chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Niraparib (Zejula®) and irinotecan (Camptosar®) are approved to treat certain types of cancer. Their use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, ATM, PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05694715' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a617007.html' target='_blank'>Medline Plus: Niraparib (Zejula®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a608043.html' target='_blank'>Medline Plus: Irinotecan (Camptosar®)</a> </li></ul>
12

Niraparib Targeted Therapy and Irinotecan Chemotherapy for Advanced Breast Cancer with BRCA1, BRCA2, ATM, and PALB2 Mutations

Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes
Icon

Nearest Location from 94107:
3 miles
University of California, San Francisco
San Francisco, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT05694715

Icon

Phase I

13

LOXO-783 Targeted Therapy for Advanced Breast Cancer with a PIK3CA Mutation

A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of LOXO-783, an experimental targeted therapy called a PI3Kα inhibitor, alone or with hormone therapy, targeted therapy, and/or chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) cancer (including breast cancer) with a PIK3CA mutation who have received up to 5 lines of treatment. If your cancer is estrogen receptor positive (ER+), you must be postmenopausal. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 6 groups based on when you enroll: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: LOXO-783 Alone at Different Doses</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: LOXO-783 with Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection or imlunestrant, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: LOXO-783 with Targeted Therapy and Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783, by mouth</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth</li> <li class="seamTextUnorderedListItem">Physician's choice of aromatase inhibitor, by mouth or fulvestrant (Faslodex®), by injection or imlunestrant, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4: LOXO-783 with Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 5: LOXO-783 with Chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783, by mouth</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 6: LOXO-783 Alone</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-783 is an experimental targeted therapy called a PI3Kα inhibitor. If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated which allows cancer cells to grow. LOXO-783 may block the PI3K pathway.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) and imlunestrant are hormone therapies called selective estrogen receptor degraders (SERDs). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is approved, and imlunestrant is experimental.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two enzymes that help cancer grow.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will receive anastrozole (Arimidex®), exemestane (Aromasin®), or letrozole (Femara®).</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are hormone therapies that block some production of estrogen that helps cancer grow.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05307705' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.loxooncology.com/pipeline' target='_blank'>Loxo Oncology/Eli Lilly Drug Information Page: LOXO-783 and Imlunestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://finance.yahoo.com/news/loxo-oncology-lilly-announces-details-130000189.html' target='_blank'>Eli Lilly Press Release: LOXO-783</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.newswire.ca/news-releases/lilly-announces-new-clinical-data-from-verzenio-and-oral-serd-programs-at-the-american-society-of-clinical-oncology-annual-meeting-859069920.html' target='_blank'>Eli Lilly Press Release: Imlunestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/taxol' target='_blank'>Breastcancer.org: Paclitaxel (Taxol®)</a> </li></ul>
13

LOXO-783 Targeted Therapy for Advanced Breast Cancer with a PIK3CA Mutation

A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
Icon

Nearest Location from 94107:
3 miles
UCSF Medical Center at Mission Bay
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05307705

Icon

Phase I

14

BBO-10203 Targeted Therapy with Trastuzumab for Advanced HER2+ or HR+, HER2- Breast Cancer

A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Purpose: To study the safety, best dose, and effects (good and bad) of BBO-10203, an experimental targeted therapy, with trastuzumab (Herceptin®) anti-HER2 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received at least 2 lines of anti-HER2 targeted therapy or hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BBO-10203, by mouth, daily</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, weekly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BBO-10203 is an experimental targeted therapy called a PI3Kα/AKT inhibitor. Blocking PI3Kα and AKT may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06625775' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://bridgebiooncology.com/platform/' target='_blank'>BridgeBio: BBO-10203 Drug Information Page</a> </li></ul>
14

BBO-10203 Targeted Therapy with Trastuzumab for Advanced HER2+ or HR+, HER2- Breast Cancer

A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
Icon

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
At least 1 visit every week

Icon

ClinicalTrials.gov: NCT06625775

Icon

Phase I

15

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of using a tumor's genetic profile to select an FDA-approved targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options. You must have results from a genomic or immunohistochemistry test approved by TAPUR. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive an FDA-approved targeted therapy based on your tumor's genetic profile.</p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted therapy you receive will be selected based on your tumor's genetic profile.</li> <li class="seamTextUnorderedListItem">Your treatment may include one or more of the following: Abemaciclib, Futibatinib, Nivolumab, Ipilimumab, Olaparib, Palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab, Pertuzumab, Vemurafenib, Cobimetinib</li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ALK, ATM, BRAF, BRAF V600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, FGFR1/2/3/4, HER2 (ERBB2), high mutational load and others, KIT, MET, MSI-H, mTOR, NRG1, PALB2, PDGFR, POLD1, POLE, RAF-1, RET, ROS1, TSC, VEGFR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02693535' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.tapur.org/' target='_blank'>ASCO: TAPUR Study Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/clinical-trials/what-tapur-study' target='_blank'>Cancer.Net (Video): What is the TAPUR Study?</a> </li><li class='seamTextUnorderedListItem'><a href='https://old-prod.asco.org/research-data/tapur-study/study-participation' target='_blank'>ASCO: TAPUR Study Participation</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/conference-coverage/asco-2016/dr-edward-kim-on-ascos-tapur-trial' target='_blank'>OncLive (Video): About TAPUR</a> </li></ul>
15

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Icon

Nearest Location from 94107:
3 miles
California Pacific Medical Center Research Institute
San Francisco, CA

Icon

Visits:
Coincides with targeted therapy

Icon

ClinicalTrials.gov: NCT02693535

Icon

Phase II

16

Zanidatamab Targeted Therapy with Chemotherapy for Advanced HER2 Positive Breast Cancer (EmpowHER-303)

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, o...

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of zanidatamab, an experimental anti-HER2 targeted therapy, with chemotherapy compared to trastuzumab (Herceptin®) anti-HER2 targeted therapy with chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received trastuzumab deruxtecan (Enhertu®, T-DXd). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab, by IV</li> <li class="seamTextUnorderedListItem">Chemotherapy, by IV, every 1-2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy, by IV, every 1-2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab is an experimental targeted therapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to 2 distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Zanidatamab is a bispecific antibody that binds to 2 targets on HER2.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2 positive breast cancer.</li> <li class="seamTextUnorderedListItem">In this trial, the chemotherapy drugs are eribulin (Halaven®), gemcitabine (Gemzar®), vinorelbine (Navelbine®), or capecitabine (Xeloda®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06435429' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/zanidatamab-combo-appears-exciting-in-her2-hr-metastatic-breast-cancer' target='_blank'>CancerNetwork: Zanidatamab Combo Appears ‘Exciting’ in HER2+/HR+ Metastatic Breast Cancer</a> </li></ul>
16

Zanidatamab Targeted Therapy with Chemotherapy for Advanced HER2 Positive Breast Cancer (EmpowHER-303)

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, o...
Icon

Nearest Location from 94107:
3 miles
UCSF at Mission Bay MB
San Francisco, CA

Icon

Visits:
Approximately 1 visit every 1-2 weeks

Icon

ClinicalTrials.gov: NCT06435429

Icon

Phase III

17

MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of MEN2312, an experimental KAT6 inhibitor, alone or with elacestrant (Orserdu®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. You must have received no more than 6 lines of therapy for advanced disease, including no more than 2 lines of chemotherapy and/or antibody drug conjugates (ADC). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312, by mouth</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312 is an experimental targeted therapy called a KAT6 inhibitor. Blocking KAT6 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is a hormone therapy called a selective estrogen receptor degrader (SERD). SERDs work by binding to and breaking down estrogen receptors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06638307' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://stemline.com/product-pipeline/' target='_blank'>Stemline Therapeutics: MEN2312 Drug Information Page</a> </li></ul>
17

MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
Icon

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06638307

Icon

Phase I

18

MBRC-201 Antibody-Drug Conjugate for Metastatic Breast Cancer

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of MBRC-201 antibody-drug conjugate.

Who is this for?: People with metastatic (stage IV) breast cancer that is resistant to standard therapies. You must not have received trastuzumab deruxtecan (Enhertu®), datopotamab deruxtecan (Datroway®), or sacituzumab govitecan (Trodelvy®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBRC-201</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07145255' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbracetrx.com/clinical-program-mbrc-201/' target='_blank'>MBrace Therapeutics: MBRC-201</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates (ADC)</a> </li></ul>
18

MBRC-201 Antibody-Drug Conjugate for Metastatic Breast Cancer

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors
Icon

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
Number of visits unavailable, up to 2 years

Icon

ClinicalTrials.gov: NCT07145255

Icon

Phase I-II

19

Targeted Therapy for Advanced Breast Cancer With a BRAF Gene Change

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of plixorafenib (also called FORE8394), a new type of RAF inhibitor pill that specifically targets tumors with certain BRAF gene changes.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. You must have a documented BRAF gene fusion or a rare BRAF V600E mutation confirmed by an approved lab test. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Plixorafenib (FORE8394) by mouth.</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact the research site for the treatment and visit schedule.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Plixorafenib is a pill designed to block a gene change called BRAF, which can cause cancer cells to grow out of control. </li> <li class="seamTextUnorderedListItem">This trial is studying whether blocking BRAF this way can shrink tumors or stop them from growing in people whose cancer has this gene change.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05503797' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/conditions-and-diseases/braf-mutation-and-cancer' target='_blank'>Johns Hopkins Medicine: BRAF Mutation and Cancer</a> </li></ul>
19

Targeted Therapy for Advanced Breast Cancer With a BRAF Gene Change

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
Icon

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05503797

Icon

Phase II

20

CLSP-1025 Immunotherapy for Advanced HLA-A*02:01 Positive Breast Cancer with p53 R175H Mutations

GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Purpose: To study the safety, best dose, and effects (good and bad) of CLSP-1025, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HLA-A*02:01 positive breast cancer with p53 R175H mutations who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CLSP-1025, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CLSP-1025 is an experimental immunotherapy called a T cell engager (TCE).</li> <li class="seamTextUnorderedListItem">A T cell engager (TCE) is a drug that binds to proteins on the surface of T cells (a type of immune cell) and, at the same time, to a different protein on cancer cells.</li> <li class="seamTextUnorderedListItem">This brings the T cells and cancer cells close together so the T cells can more effectively kill the cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06778863' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html' target='_blank'>AstraZeneca: T Cell Engagers</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.clasptx.com/home#science' target='_blank'>Clasp Therapeutics: CLSP-1025 Drug Information Page</a> </li></ul>
20

CLSP-1025 Immunotherapy for Advanced HLA-A*02:01 Positive Breast Cancer with p53 R175H Mutations

GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Icon

Nearest Location from 94107:
3 miles
University of California San Francisco
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06778863

Icon

Phase I

21

XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of XMT-1660, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-1660, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-1660 is an experimental antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XMT-1660's antibody targets B7-H4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called dolasynthen.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05377996' target='_blank'>ClinicalTrials.gov</a> </li></ul>
21

XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Icon

Nearest Location from 94107:
3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05377996

Icon

Phase I-II

22

ORIC-114 Targeted Therapy for Advanced HER2+ Breast Cancer

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ORIC-114, an experimental x, alone or with chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ORIC-114, by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ORIC-114, by mouth, daily</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) and/or pemetrexed (Alimta®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ORIC-114 is an experimental anti-HER2 targeted therapy and blocks EGFR and HER2. Blocking EGFR and HER2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) and pemetrexed (Alimta®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05315700' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://oricpharma.com/pipeline/#oric114' target='_blank'>ORIC Pharmaceuticals: ORIC-114 Drug Information Page</a> </li></ul>
22

ORIC-114 Targeted Therapy for Advanced HER2+ Breast Cancer

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Icon

Nearest Location from 94107:
5 miles
University of California, San Francisco
San Francisco, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05315700

Icon

Phase I-II

23

BMS-986500 CDK4/6 Inhibitor for Advanced HR+ Breast Cancer

A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BMS-986500, a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986500</li> <li class="seamTextUnorderedListItem">Palbociblib (Ibrance®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986500 is a CDK4/6 inhibitor. </li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors block two enzymes, CDK 4 and CDK 6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06997029' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/' target='_blank'>Metastatic Trial Talk: CDK4/6 Inhibitors</a> </li></ul>
23

BMS-986500 CDK4/6 Inhibitor for Advanced HR+ Breast Cancer

A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
Icon

Nearest Location from 94107:
15 miles
Marin Cancer Care
Greenbrae, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06997029

Icon

Phase I

24

Collecting Blood Samples From People With and Without Breast Cancer to Evaluate Tests for Early Cancer Detection

Blinded Reference Set for Multicancer Early Detection Blood Tests

Purpose: To collect blood and tissue samples from people with breast cancer and people without breast cancer to evaluate tests for early cancer detection.

Who is this for?: People 40-75 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet received treatment, or who do not have breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood samples, 2 times</li> <li class="seamTextUnorderedListItem">Provide tissue samples (for people with cancer), 2 times</li> <li class="seamTextUnorderedListItem">Complete questionnaires, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collecting and storing samples of blood and tissue from patients with and without breast cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05334069' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis' target='_blank'>National Cancer Institute: How Cancer Is Diagnosed</a> </li></ul>
24

Collecting Blood Samples From People With and Without Breast Cancer to Evaluate Tests for Early Cancer Detection

Blinded Reference Set for Multicancer Early Detection Blood Tests
Icon

Nearest Location from 94107:
22 miles
Contra Costa Regional Medical Center
Martinez, CA

Icon

Visits:
2 visits in 1 year

Icon

ClinicalTrials.gov: NCT05334069

Icon

Phase NA

25

ctDNA Test to Detect Breast Cancer That Has Come Back or Remains After Treatment

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)

Purpose: To study the ability of Guardant Reveal, a new blood test, to detect residual disease and recurrence after treatment.

Who is this for?: People with stage I, stage II, or stage III breast cancer who have residual disease (leftover cancer cells in your breast or lymph node) after chemotherapy and surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">Guardant Reveal is a new test that detects ctDNA in blood.</li> <li class="seamTextUnorderedListItem">Residual disease refers to cancer cells present after treatment.</li> <li class="seamTextUnorderedListItem">Recurrence refers to cancer that has come back after treatment.</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05059444' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/' target='_blank'>MedLine Plus: What is ctDNA?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.guardanthealthamea.com/guardant-reveal/' target='_blank'>Guardant Health: The Guardant Reveal ctDNA Test</a> </li></ul>
25

ctDNA Test to Detect Breast Cancer That Has Come Back or Remains After Treatment

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
Icon

Nearest Location from 94107:
22 miles
Redwood City
Redwood City, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05059444

Icon

Phase NA

26

Procedure to Prevent Lymphedema After Lymph Node Removal for Women with Stage I-III Breast Cancer

A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Purpose: To determine if immediate lymphatic reconstruction during lymph node removal reduces the risk of developing lymphedema and improves quality of life.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive lymph node removal. You must not have received radiation to the lymph node that will be removed. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Removal of axillary (underarm/armpit) lymph nodes</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Removal of axillary (underarm/armpit) lymph nodes</li> <li class="seamTextUnorderedListItem">Immediate lymphatic reconstruction (LYMPHA) with axillary reverse mapping</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a chronic, progressive, and debilitating condition that occurs with damage to the lymphatic system, which commonly occurs as a result of breast cancer treatment.</li> <li class="seamTextUnorderedListItem">Lymphatic reconstruction (LYMPHA) is when the cut lymphatic vessels are reconnected to your veins.</li> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM) is when a dye is injected into your arm so that your surgeon can see and try to avoid disrupting the lymph nodes and lymphatic channels that drain your arm.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05366699' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/about-your-immediate-lymphatic-reconstruction-ilr-procedure' target='_blank'>Memorial Sloan Kettering Cancer Center: Immediate Lymphatic Reconstruction (ILR)</a> </li><li class='seamTextUnorderedListItem'><a href='https://friedmancenter.org/lymphedema-overview/preventing-lymphedema/' target='_blank'>Friedman Center for Breast and Lymphatic Surgery: LYMPHA Procedure</a> </li><li class='seamTextUnorderedListItem'><a href='https://breast360.org/topic/2017/01/01/axillary-reverse-mapping/' target='_blank'>Breast360.org: Axillary Reverse Mapping</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>
26

Procedure to Prevent Lymphedema After Lymph Node Removal for Women with Stage I-III Breast Cancer

A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
Icon

Nearest Location from 94107:
27 miles
Stanford Cancer Institute
San Francisco, CA

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT05366699

Icon

Phase NA

27

LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4337713 radiopharmaceutical.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that is positive for fibroblast activation protein (FAP) who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4337713, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4337713 targets fibroblast activation protein (FAP) on cells near cancer cells. LY4337713 contains a radioactive molecule that kills the nearby cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07213791' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lillyoncologypipeline.com/molecule/Fibroblast-Activation-Protein-Radioligand/' target='_blank'>Eli Lilly: LY4337713</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>Metastatic Trial Talk: Radiopharmaceuticals</a> </li></ul>
27

LY4337713 Radiopharmaceutical for Fibroblast Activation Protein (FAP)-Positive Advanced Breast Cancer

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
Icon

Nearest Location from 94107:
27 miles
Stanford University Medical Center
Stanford, CA

Icon

Visits:
Number of visits unavailable, 5 years

Icon

ClinicalTrials.gov: NCT07213791

Icon

Phase I

28

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4257496 GRPR radiopharmaceutical with or without standard of care therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer. Your tumor must be positive for gastrin-releasing peptide receptor (GRPR). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496, by IV, up to 9 months</li> <li class="seamTextUnorderedListItem">Standard of care therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496, by IV, up to 9 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4257496 is a radiopharmaceutical that targets GRPR. A radiopharmaceutical is a type of therapy that combines a molecule that targets cancer cells with a radioactive molecule that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Gastrin Releasing Peptide Receptor (GRPR) is a G protein coupled receptor activated by the peptide gastrin-releasing peptide (GRP), which regulates various bodily functions, including gastrointestinal activity and central nervous system processes. GRPR plays a role in normal functions like hormone release and smooth muscle contraction.</li> <li class="seamTextUnorderedListItem">Standard of care options in this trial are fulvestrant (Faslodex®), imlunestrant (Inluriyo®), capecitabine (Xeloda®), abemaciclib (Verzenio®) and aromatase inhibitors- letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07114601' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>Metastatic Trial Talk: Radiopharmaceuticals</a> </li></ul>
28

LY4257496 GRPR Radiopharmaceutical for Advanced ER+ Breast Cancer

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
Icon

Nearest Location from 94107:
27 miles
Stanford University Medical Center
Stanford, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07114601

Icon

Phase I

29

Radiation Therapy Before Surgery For DCIS

A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)

Purpose: To look at the effect radiation therapy has on DCIS cancer cells and surrounding tissue when it is given before surgery.

Who is this for?: Women with ductal carcinoma in situ (DCIS) who has not yet started cancer treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Partial breast irradiation, once a day for 5 days, before surgery</li> <li class="seamTextUnorderedListItem">Lumpectomy or mastectomy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumpectomy or mastectomy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at the effect radiation therapy has on DCIS cancer cells and surrounding tissue when it is given before surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03909282' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/dcis/treatment?gclid=EAIaIQobChMIyOnukvrn5QIVoxx9Ch1_pgdEEAAYAiAAEgIxZvD_BwE' target='_blank'>Breastcancer.org: Treatment for DCIS</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/rads-after-sx-for-dcis-reduces-recurrence-risk' target='_blank'>Breastcancer.org: Radiation Therapy After Surgery for Low-Risk DCIS Reduces Recurrence Risk</a> </li></ul>
29

Radiation Therapy Before Surgery For DCIS

A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)
Icon

Nearest Location from 94107:
28 miles
Stanford University
Stanford, CA

Icon

Visits:
Daily visits for 5 days, followed by surgery

Icon

ClinicalTrials.gov: NCT03909282

Icon

Phase NA

30

Multi-Cancer Detection Blood Test to Screen for Cancer for Healthy People and People with Stage 0 Breast Cancer

The Vanguard Study: Testing a New Way to Screen for Cancer

Purpose: To study how multi-cancer detection (MCD) tests may work as cancer screening tools.

Who is this for?: People, aged 45-75 years, without cancer. People with stage 0 (DCIS) breast cancer may enroll. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MCD blood test</li> <li class="seamTextUnorderedListItem">Review of your medical records</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood test</li> <li class="seamTextUnorderedListItem">Review of your medical records</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A multi-cancer detection (MCD) test measures markers in the blood to screen for multiple cancers at the same time. MCDs may work as cancer screening tools.</li> <li class="seamTextUnorderedListItem">This study will assess how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back normal or abnormal.</li> <li class="seamTextUnorderedListItem">You will be notified of any abnormal test results.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06995898' target='_blank'>ClinicalTrials.gov</a> </li></ul>
30

Multi-Cancer Detection Blood Test to Screen for Cancer for Healthy People and People with Stage 0 Breast Cancer

The Vanguard Study: Testing a New Way to Screen for Cancer
Icon

Nearest Location from 94107:
28 miles
Kaiser Permanente-Division of Research
Pleasanton, CA

Icon

Visits:
2 times within 1 year

Icon

ClinicalTrials.gov: NCT06995898

Icon

Phase NA

31

Comparing Drains During Bilateral Mastectomy with Immediate Breast Reconstruction

A Pilot Study of the Interi Manifold With Traditional Surgical Drains in Implant-Based Breast Reconstruction

Purpose: To compare the safety and effects (good and bad) of Interi Drains to standard of care Jackson-Pratt (JP) Drains during bilateral (both breast) mastectomy.

Who is this for?: Women 18-65 years old with stage I, stage II, or stage III breast cancer who are planning to receive a bilateral (both breasts) mastectomy with immediate reconstruction. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following during surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interi Drain on 1 breast</li> <li class="seamTextUnorderedListItem">Jackson-Pratt (JP) Drain on 1 breast</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Drain log, daily</li> <li class="seamTextUnorderedListItem">Drain removal, 1-3 weeks after surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">During implant-based breast reconstruction, surgical drains are placed to prevent fluid build up.</li> <li class="seamTextUnorderedListItem">The most frequently used drain is a Jackson-Pratt (JP) Drain.</li> <li class="seamTextUnorderedListItem">The Interi Drain system may work better than the JP Drain system.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05975359' target='_blank'>ClinicalTrials.gov</a> </li></ul>
31

Comparing Drains During Bilateral Mastectomy with Immediate Breast Reconstruction

A Pilot Study of the Interi Manifold With Traditional Surgical Drains in Implant-Based Breast Reconstruction
Icon

Nearest Location from 94107:
28 miles
Stanford Hospital and Clinics
Palo Alto, CA

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT05975359

Icon

Phase NA

32

ctDNA Blood Test to Predict Recurrence for Stage I-III Breast Cancer

EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

Purpose: To study the use of a ctDNA blood test to predict recurrence.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">The test being studied in this trial looks for <q>molecular residual disease</q> in the blood, which is when ctDNA is detected.</li> <li class="seamTextUnorderedListItem">Molecular residual disease may indicate that breast cancer is still present after treatment or has come back (recurrence).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06401421' target='_blank'>ClinicalTrials.gov</a> </li></ul>
32

ctDNA Blood Test to Predict Recurrence for Stage I-III Breast Cancer

EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Icon

Nearest Location from 94107:
28 miles
Kaiser Permanente Medical Center
Vallejo, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06401421

Icon

Phase NA

33

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Purpose: To use genetic testing to match people to treatments and help doctors plan better treatments.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received at least 1 line of therapy for advanced disease or who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy based on genetic testing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic tests look at the unique genetic material (genes) of tumor cells.</li> <li class="seamTextUnorderedListItem">People with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: AKT, ERK, MEK, NF1, RAF, RAS</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05564377' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/press-releases/2023/combomatch-precision-medicine-cancer-initiative' target='_blank'>National Cancer Institute: ComboMATCH</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/precision-medicine-breast-cancer/about/pac-20385240' target='_blank'>Mayo Clinic: Precision Medicine for Breast Cancer</a> </li></ul>
33

ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Icon

Nearest Location from 94107:
28 miles
Stanford Cancer Institute Palo Alto
Palo Alto, CA

Icon

Visits:
Please contact research site

Icon

ClinicalTrials.gov: NCT05564377

Icon

Phase II

34

RE104 for People with Stage 0-IV Breast Cancer and Adjustment Disorder With Anxiety and Depression

A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses

Purpose: To study the safety and effects (good and bad) of RE104 for Injection to reduce depression and/or anxiety.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer with adjustment disorder that includes depression and/or anxiety that has lasted for at least 1 month. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: High Dose</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High dose of RE104, by injection</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Low Dose</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low dose of RE104, by injection</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RE104 is a psilocybin-like compound that may help with depression.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer and other serious diseases.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07002034' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://reunionneuro.com/programs/#approach' target='_blank'>Reunion Neuroscience: RE104</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rekindlestudies.com/' target='_blank'>Reunion Neuroscience: REKINDLE Study Information</a> </li></ul>
34

RE104 for People with Stage 0-IV Breast Cancer and Adjustment Disorder With Anxiety and Depression

A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
Icon

Nearest Location from 94107:
53 miles
Providence Medical Foundation
Santa Rosa, CA

Icon

Visits:
9 visits within 2.5 months

Icon

ClinicalTrials.gov: NCT07002034

Icon

Phase II

35

Genomic Test Studying the Tumor Microenvironment for Advanced Breast Cancer

BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting

Purpose: To study the ability of the BostonGene Tumor Portrait test to provide information about tumors and their microenvironment and help make treatment decisions.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy, blood, saliva, and cheek swab samples for the BostonGene Tumor Portrait test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tumor microenvironment describes the cells that surround a tumor and plays a role in both how tumors grow and how they respond to treatment. </li> <li class="seamTextUnorderedListItem">The BostonGene Tumor Portrait test may help make treatment decisions for people with advanced cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06272864' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/breast-cancer-and-tumor-microenvironment/' target='_blank'>Metastatic Trial Talk: The Tumor Microenvironment</a> </li></ul>
35

Genomic Test Studying the Tumor Microenvironment for Advanced Breast Cancer

BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
Icon

Nearest Location from 94107:
61 miles
Stockton Hematology Oncology Medical Group
Stockton, CA

Icon

Visits:
Up to 2 years

Icon

ClinicalTrials.gov: NCT06272864

Icon

Phase NA

36

DB-1310 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of DB-1310, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1310, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1310 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">DB-1310's antibody targets HER3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05785741' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dualitybiologics.com/approach.html?md=1' target='_blank'>DualityBio: ADC Information Page</a> </li></ul>
36

DB-1310 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors
Icon

Nearest Location from 94107:
74 miles
University of California, Davis Comprehensive Cancer Center
Sacramento, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT05785741

Icon

Phase I-II

37

PET/CT Scans with 68Ga-Ga DOTA-5G for Advanced Lobular Breast Cancer

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Purpose: To study if PET/CT scans with 68Ga-Ga DOTA-5G, an experimental radioactive tracer, improve the ability to detect lobular breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) lobular breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 68Ga-Ga DOTA-5G, by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">68Ga-Ga DOTA-5G is an experimental tracer that can look for and attach to cancer cells during PET/CT scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07020806' target='_blank'>ClinicalTrials.gov</a> </li></ul>
37

PET/CT Scans with 68Ga-Ga DOTA-5G for Advanced Lobular Breast Cancer

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Icon

Nearest Location from 94107:
74 miles
University of California Davis
Sacramento, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07020806

Icon

Phase I

38

Tart Cherry Juice to Prevent Nerve Pain During Chemotherapy for People with Stage I-IV Breast Cancer

A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Purpose: To study the ability of tart cherry juice to prevent nerve pain during chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive paclitaxel (Taxol®). You must not have received docetaxel (Taxotere®), nab-paclitaxel (Abraxane®), eribulin (Halaven®), or cisplatin (Platinol®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: High Dose Tart Cherry Juice</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 oz tart cherry juice concentrate mixed with water, by mouth, daily for 2 weeks</li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Low Dose Tart Cherry Juice</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1/4 oz tart cherry juice concentrate mixed with water, by mouth, daily for 2 weeks</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy induced peripheral neuropathy (CIPN), or paclitaxel induced peripheral neuropathy (PIPN), is nerve pain in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06268665' target='_blank'>ClinicalTrials.gov</a> </li></ul>
38

Tart Cherry Juice to Prevent Nerve Pain During Chemotherapy for People with Stage I-IV Breast Cancer

A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Icon

Nearest Location from 94107:
80 miles
University of California Davis Comprehensive Cancer Center
Sacramento, CA

Icon

Visits:
2 visits within 3 months

Icon

ClinicalTrials.gov: NCT06268665

Icon

Phase II

39

BMS-986340 Immunotherapy for Advanced Breast Cancer

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BMS-986340, an experimental CCR8 inhibitor, alone or with nivolumab (Opdivo®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. You must have received at least 1 PD-1 inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986340</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986340</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986340 is an experimental immunotherapy called a CCR8 inhibitor. BMS-986340 blocks the activity of CCR8 on immune cells to activate the immune system to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04895709' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bolderscience.com/trial/NCT04895709/' target='_blank'>Bristol-Myers Squibb: Clinical Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bmsscience.com/?s=BMS-986340+%26plusmn%3B+Nivolumab&search_cat=bms' target='_blank'>Bristol-Myers Squibb: BMS-986340 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bms.com/assets/bms/us/en-us/pdf/CCR8-Immune-Pathway-Fact-Sheet.pdf' target='_blank'>Bristol-Myers Squibb: CCR8 Immune Pathway</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ccr8-monoclonal-antibody-bms-986340?redirect=true' target='_blank'>National Cancer Institute: BMS-986340 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://chemocare.com/chemotherapy/drug-info/opdivo.aspx' target='_blank'>Chemocare: Nivolumab (Opdivo®)</a> </li></ul>
39

BMS-986340 Immunotherapy for Advanced Breast Cancer

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Icon

Nearest Location from 94107:
164 miles
Community Cancer Institute
Clovis, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04895709

Icon

Phase I-II

40

Blood Tests to Monitor for Cancer Coming Back for Stage I-III Triple Negative or Stage II-III HR+ or HER2+ Breast Cancer

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Purpose: To study if detecting minimal residual disease (MRD) can help predict if a patient's cancer will return and if the treatment is working.

Who is this for?: People with stage I, stage II, or some stage III triple negative (ER-, PR-, HER2-) or stage II or some stage III HER2 positive (HER2+) or stage II or some stage III hormone receptor positive (ER+ and/or PR+) breast cancer. People with hormone receptor positive, HER2- cancer must also have 4 or more positive lymph nodes or 1-3 positive lymph nodes and either grade 3 disease or tumor size of 5 cm or larger. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests for MRD monitoring</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tiny bits of cancer DNA that are shed into the blood are called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. The presence of ctDNA in the blood is called minimal residual disease (MRD). MRD can lead to the cancer coming back later.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07211178' target='_blank'>ClinicalTrials.gov</a> </li></ul>
40

Blood Tests to Monitor for Cancer Coming Back for Stage I-III Triple Negative or Stage II-III HR+ or HER2+ Breast Cancer

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Icon

Nearest Location from 94107:
182 miles
Cancer Care Specialist of Reno
Reno, NV

Icon

Visits:
Number of visits unavailable, up to 5 years

Icon

ClinicalTrials.gov: NCT07211178

Icon

Phase NA

41

Bria-IMT Cell Therapy for Advanced Breast Cancer

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of the Bria-IMT regimen, an experimental cell therapy, alone and with retifanlimab (Zynyz®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Bria-IMT Regimen with Immunotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, 1 day every 3 weeks</li> <li class="seamTextUnorderedListItem">SV-BR-1-GM, by injection, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Interferon, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®), by infusion, every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Bria-IMT Regimen Alone</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, 1 day every 3 weeks</li> <li class="seamTextUnorderedListItem">SV-BR-1-GM, by injection, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Interferon, 4 days every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy</li> <li class="seamTextUnorderedListItem">Imaging scans, every 1-2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Bria-IMT regimen is an experimental cell therapy with SV-BR-1-GM cells.</li> <li class="seamTextUnorderedListItem">Before you receive the cell therapy, you will receive cyclophosphamide (Cytoxan®) chemotherapy to prepare your body to receive the cells.</li> <li class="seamTextUnorderedListItem">Interferon is an immunotherapy used to regulate your immune response to the cell therapy.</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also called the BRIA-ABC trial.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06072612' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapy-2-2/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies: A Type of Immunotherapy for MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://briacell.com/briaimt/' target='_blank'>BriaCell Therapeutics: Bria-IMT Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/retifanlimab-dlwr' target='_blank'>National Cancer Institute: Retifanlimab (Zynyz®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>
41

Bria-IMT Cell Therapy for Advanced Breast Cancer

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Icon

Nearest Location from 94107:
250 miles
Comprehensive Blood and Cancer Center
Bakersfield, CA

Icon

Visits:
May require hospitalization

Icon

ClinicalTrials.gov: NCT06072612

Icon

Phase III

42

Fisetin Supplement and Exercise to Improve Health After Treatment for Postmenopausal Women with Stage I-III Breast Cancer

A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors (PROFFi)

Purpose: To study how well fisetin, a nutritional supplement, and exercise prevent frailty (weakness).

Who is this for?: Postmenopausal women with stage I, stage II, or stage III breast cancer who have received chemotherapy within the last year. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Fisetin and Exercise Education Materials</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fisetin, by mouth, 3 days every 2 weeks for 4 months</li> <li class="seamTextUnorderedListItem">Handout on the importance of physical activity</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Physical tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Fisetin and Exercise Program</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fisetin, by mouth, 3 days every 2 weeks for 4 months</li> <li class="seamTextUnorderedListItem">Supervised exercise training, 3 sessions every week for 4 months</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Physical tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Placebo and Exercise Program</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for fisetin, by mouth, 3 days every 2 weeks for 4 months</li> <li class="seamTextUnorderedListItem">Supervised exercise training, 3 sessions every week for 4 months</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Physical tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4: Placebo and Exercise Education Materials</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for fisetin, by mouth, 3 days every 2 weeks for 4 months</li> <li class="seamTextUnorderedListItem">Handout on the importance of physical activity</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Physical tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Frailty is marked by low strength, low energy, slowed walking speed, low physical activity, and/or unintentional weight loss.</li> <li class="seamTextUnorderedListItem">In this study, frailty is measured by walking speed.</li> <li class="seamTextUnorderedListItem">Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement.</li> <li class="seamTextUnorderedListItem">Fisetin may help reduce inflammation and improve outcomes in people with breast cancer who are exercising.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06113016' target='_blank'>ClinicalTrials.gov</a> </li></ul>
42

Fisetin Supplement and Exercise to Improve Health After Treatment for Postmenopausal Women with Stage I-III Breast Cancer

A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors (PROFFi)
Icon

Nearest Location from 94107:
336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06113016

Icon

Phase II

43

Fisetin to Improve Physical Function in Older Women After Chemotherapy

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Frail Older Breast Cancer Survivors

Purpose: To study whether fisetin improves physical function in older women after treatment with chemotherapy.

Who is this for?: Women who were at least 65 years old and postmenopausal when diagnosed with stage I, stage II, or stage III breast cancer. You must have completed chemotherapy within the last year. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fisetin, by mouth, 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for fisetin, by mouth, 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Walking test</li> <li class="seamTextUnorderedListItem">Grip strength test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fisetin is a naturally occurring substance that is found in strawberries and other foods.</li> <li class="seamTextUnorderedListItem">Fisetin eliminates cells that have stopped dividing but have not died.</li> <li class="seamTextUnorderedListItem">Chemotherapy causes a build-up of these cells which may cause inflammation. damage nearby healthy cells, and cause reduced physical function.</li> <li class="seamTextUnorderedListItem">Improving physical function is also called improving frailty.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05595499' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://restorativemedicine.org/digest/fisetin-powerful-polyphenol-supports-healthy-aging/' target='_blank'>Association for the Advancement of Restorative Medicine: Fisetin</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.urmc.rochester.edu/news/story/frailty-in-cancer-patients-young-and-old-is-linked-to-inflammation' target='_blank'>University of Rochester: Frailty and Breast Cancer</a> </li></ul>
43

Fisetin to Improve Physical Function in Older Women After Chemotherapy

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Frail Older Breast Cancer Survivors
Icon

Nearest Location from 94107:
336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05595499

Icon

Phase II

44

Studying the Effects of Anti-Estrogen Therapy on the Brain of Women with Stage I-III Breast Cancer

Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy

Purpose: To see if anti-estrogen therapy affects brain health.

Who is this for?: Women between the ages of 35 and 65 with stage I, stage II, or stage III breast cancer who are taking hormone therapy after surgery. This trial is also enrolling women who have never been diagnosed with breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 Brain fMRI (functional MRI)</li> <li class="seamTextUnorderedListItem">Cognitive testing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use an advanced brain MRI technique called functional MRI (fMRI).</li> <li class="seamTextUnorderedListItem">fMRI measures changes in blood flow that happen during mental activity. </li> <li class="seamTextUnorderedListItem">Research suggests that the cognitive issues experienced by some women who receive treatment for breast cancer--also called <q>chemo brain</q>--may actually be caused by anti-estrogen therapy and not chemotherapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04297020' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medscape.com/viewarticle/932091' target='_blank'>MedScape: In Breast Cancer, Is Chemobrain Really Endocrine Brain?</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Functional_magnetic_resonance_imaging' target='_blank'>Wikipedia: Functional MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=fmribrain' target='_blank'>RadiologyInfo.org: fMRI</a> </li></ul>
44

Studying the Effects of Anti-Estrogen Therapy on the Brain of Women with Stage I-III Breast Cancer

Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy
Icon

Nearest Location from 94107:
336 miles
University of California at Los Angeles
Los Angeles, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT04297020

Icon

Phase NA

45

Zongertinib Targeted Therapy with ADC for Advanced HER2+ Breast Cancer

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cance...

Purpose: To find a dose of zongertinib, an experimental targeted therapy, that people with advanced HER2+ breast cancer can tolerate best when taken with trastuzumab deruxtecan (T-DXd, Enhertu®) or trastuzumab emtansine (T-DM1, Kadcyla®) antibody drug conjugates.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zongertinib (BI 1810631), by mouth</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®), by IV</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zongertinib (BI 1810631), by mouth</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zongertinib is an experimental anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) and trastuzumab emtansine (T-DM1, Kadcyla®) are antibody drug conjugates (ADCs).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s antibody targets HER2 and delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®)'s antibody targets HER2 and delivers an anti-cancer drug called DM1.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06324357' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.boehringer-ingelheim.com/science/human-pharma/clinical-pipeline/oncology/zongertinib-her2-tyrosine-kinase-inhibitor-tki' target='_blank'>Boehringer Ingelheim: Zongertinib (BI 1810631) Drug Information Page</a> </li></ul>
45

Zongertinib Targeted Therapy with ADC for Advanced HER2+ Breast Cancer

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cance...
Icon

Nearest Location from 94107:
336 miles
University of California Los Angeles
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06324357

Icon

Phase I-II

46

IAM1363 Targeted Therapy for Advanced HER2+ or HER2 Mutated Breast Cancer

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of IAM1363, an experimental anti-HER2 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 mutated breast cancer who have received at least 1 line of therapy for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IAM1363, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IAM1363 is an experimental anti-HER2 targeted therapy. Blocking HER2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06253871' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.iambic.ai/pipeline' target='_blank'>Iambic Therapeutics: IAM1363 Drug Information Page</a> </li></ul>
46

IAM1363 Targeted Therapy for Advanced HER2+ or HER2 Mutated Breast Cancer

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations
Icon

Nearest Location from 94107:
336 miles
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
About 1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06253871

Icon

Phase I

47

SGN-B6A in Advanced Breast Cancer

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Purpose: To study the safety, side-effects, anti-cancer activity, and best dose of the antibody-drug conjugate SGN-B6A.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-B6A, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-B6A is an investigational therapy. This means it is only available in a clinical trial.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a cancer therapy that combines an antibody that targets cancer cells with a drug that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">SGN-B6A is an antibody-drug conjugate (ADC) targeting integrin beta-6. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced or metastatic cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04389632' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org' target='_blank'>Metastatic Breast Cancer Network</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biospace.com/article/releases/seattle-genetics-announces-initiation-of-phase-1-clinical-trials-for-two-novel-antibody-based-drug-candidates/' target='_blank'>BioSpace Press Release: Seagen Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates</a> </li></ul>
47

SGN-B6A in Advanced Breast Cancer

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Icon

Nearest Location from 94107:
336 miles
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04389632

Icon

Phase I

48

XB010 ADC for Advanced HR+ or Triple Negative Breast Cancer

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of XB010, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) or triple negative (ER-, PR-, HER2-) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XB010, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XB010 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XB0101's antibody targets 5T4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06545331' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.exelixis.com/clinical-trials-pipeline/' target='_blank'>Exelixis: XB010 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
48

XB010 ADC for Advanced HR+ or Triple Negative Breast Cancer

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
Icon

Nearest Location from 94107:
336 miles
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06545331

Icon

Phase I

49

Inavolisib and Phesgo for Advanced HER2 Positive Breast Cancer with a PIK3CA Mutation

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer...

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of inavolisib, an experimental PI3K inhibitor, with Phesgo anti-HER2 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer with a PIK3CA mutation who have not received treatment for advanced disease (except for hormone therapy if HR+). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Phesgo, by injection, every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inavolisib, by mouth, daily</li> <li class="seamTextUnorderedListItem">Phesgo, by injection, every 3 weeks</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy (optional, if relevant)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Phesgo, by injection, every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for inavolisib, by mouth, daily</li> <li class="seamTextUnorderedListItem">Phesgo, by injection, every 3 weeks</li> <li class="seamTextUnorderedListItem">Standard of care hormone therapy (optional, if relevant)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will first receive induction therapy (initial therapy used when treating a disease) with Phesgo and chemotherapy.</li> <li class="seamTextUnorderedListItem">Inavolisib is an experimental targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Phesgo is a combination of two anti-HER2 targeted therapies: Perjeta® (pertuzumab) and Herceptin® (trastuzumab). It also includes a protein called hyaluronidase which helps your body absorb the targeted therapies.</li> <li class="seamTextUnorderedListItem">Pertuzumab and trastuzumab are typically given by IV. With Phesgo, you can receive these therapies by injection, which shortens the length of time it takes to receive treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05894239' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gene.com/medical-professionals/pipeline/inavolisib-gdc-0077' target='_blank'>Genentech: Inavolisib Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/phesgo' target='_blank'>Breastcancer.org: Phesgo</a> </li></ul>
49

Inavolisib and Phesgo for Advanced HER2 Positive Breast Cancer with a PIK3CA Mutation

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer...
Icon

Nearest Location from 94107:
337 miles
Disney Family Cancer Center
Burbank, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT05894239

Icon

Phase III

50

Antibody-Drug Conjugate KIVU-107 for Advanced Breast Cancer

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of KIVU-107, an antibody-drug conjugate (ADC) that targets a protein called PTK7, which is found on certain cancer cells.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose cancer has progressed on standard treatment or who have no standard treatment options available. Must have not previously been treated with an antibody-drug conjugate (ADC) that contains a topoisomerase 1 inhibitor, or with any PTK7-targeted therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KIVU-107, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">KIVU-107 is a new type of drug called an antibody-drug conjugate (ADC). It is designed to find and attach to cancer cells that have a protein called PTK7 on their surface, and then deliver a cancer-killing substance directly into those cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07229313' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
50

Antibody-Drug Conjugate KIVU-107 for Advanced Breast Cancer

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Icon

Nearest Location from 94107:
338 miles
Kivu Trial Site
Santa Monica, CA

Icon

Visits:
1 visit, every 3 weeks

Icon

ClinicalTrials.gov: NCT07229313

Icon

Phase I

51

A Registry and IORT Radiation Therapy During Lumpectomy for DCIS and Stage I-III Breast Cancer

Research Registry for Intra-Operative Radiotherapy (IORT) During Breast Conserving Surgery in Patients With in Situ and Early Stage Breast Cancer

Purpose: To develop a registry that will allow researchers to study and compare the long-term safety and anti-cancer activity of giving one dose of radiation therapy (IORT) during a lumpectomy to standard of care radiation therapy.

Who is this for?: People with DCIS, stage I, stage II, or stage III breast cancer who are planning to have a lumpectomy (breast conserving surgery). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IORT (Intraoperative radiation therapy), one time during lumpectomy (breast conserving surgery)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy. </li> <li class="seamTextUnorderedListItem">Typically, a lumpectomy (breast conserving surgery) is followed by 4 to 6 weeks of daily radiation therapy.</li> <li class="seamTextUnorderedListItem">In this trial, you will receive intraoperative radiation therapy (IORT) one time during your lumpectomy. </li> <li class="seamTextUnorderedListItem">IORT delivers a high dose of radiation during surgery to the area in the breast where the tumor was removed. This means you only receive one dose, and it may cause less damage to the healthy tissue around the tumor. </li> <li class="seamTextUnorderedListItem">This trial will also create a data registry of people receiving IORT so that researchers can study the long-term safety and anti-cancer activity of this type of radiation therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04603209' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20131203' target='_blank'>Breastcancer.org: Studies Show Risks and Benefits of Intraoperative Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/npcr/value/registries.htm' target='_blank'>CDC: How Cancer Registries Work</a> </li></ul>
51

A Registry and IORT Radiation Therapy During Lumpectomy for DCIS and Stage I-III Breast Cancer

Research Registry for Intra-Operative Radiotherapy (IORT) During Breast Conserving Surgery in Patients With in Situ and Early Stage Breast Cancer
Icon

Nearest Location from 94107:
339 miles
John Wayne Cancer Institute, Providence Saint John's Health Center
Santa Monica, CA

Icon

Visits:
1 visit that coincides with surgery

Icon

ClinicalTrials.gov: NCT04603209

Icon

Phase NA

52

MGC026 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of MGC026, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have not received trastuzumab deruxtecan (Enhertu®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGC026, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGC026 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">MGC026's antibody targets B7-H3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06242470' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://macrogenics.com/pipeline/mgc026/' target='_blank'>MacroGenics: MGC026 Drug Information Page</a> </li></ul>
52

MGC026 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Icon

Nearest Location from 94107:
339 miles
The Angeles Clinic and Research Institute
Los Angeles, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06242470

Icon

Phase I

53

Targeted Therapy for Advanced Breast Cancer With a TP53 Y220C Mutation

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of PC14586, an experimental p53 reactivator, alone or with pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a TP53 Y220C mutation who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PC14586, by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PC14586, by mouth, daily</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PC14586 is an experimental targeted therapy called a p53 reactivator which may stop the mutated p53 protein from working and cause cancer cell death.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: TP53 Y220C</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04585750' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pmvpharma.com/pipeline/' target='_blank'>PMV Pharmaceuticals: PC14586 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>
53

Targeted Therapy for Advanced Breast Cancer With a TP53 Y220C Mutation

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
Icon

Nearest Location from 94107:
339 miles
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04585750

Icon

Phase I-II

54

BL-M07D1 ADC for Advanced HER2 Positive, HER2 Low, and HER2 Expressing Breast Cancer

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of BL-M07D1, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+), HER2 low, or HER2 amplified breast cancer who have received at least 2 lines of therapy. You are also eligible if circulating tumor cells (CTCs) are HER2 amplified. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-M07D1, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-M07D1 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">BL-M07D1's antibody targets HER2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called trastuzumab.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06293898' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://systimmune.com/bl-m07d1' target='_blank'>SystImmune: BL-M07D1 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
54

BL-M07D1 ADC for Advanced HER2 Positive, HER2 Low, and HER2 Expressing Breast Cancer

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Icon

Nearest Location from 94107:
339 miles
START - Los Angeles
Los Angeles, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06293898

Icon

Phase I

55

Dual PARP and Microtubule Polymerization Inhibitor AMXI-5001 for Advanced Breast Cancer.

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

Purpose: To study the best dose, safety, and anti-cancer activity of AMXI-5001--an experimental PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMXI-5001, by mouth, twice daily (4 days on, 3 days off), ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMX-5001 is an experimental PARP inhibitor.</li> <li class="seamTextUnorderedListItem">PARP inhibitors block poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04503265' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://atlasmedx.com/product-pipeline/' target='_blank'>AtlasMedx Drug Information Page: AMXI-5001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor' target='_blank'>NCI Drug Dictionary: PARP Inhibitor</a> </li></ul>
55

Dual PARP and Microtubule Polymerization Inhibitor AMXI-5001 for Advanced Breast Cancer.

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies
Icon

Nearest Location from 94107:
339 miles
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04503265

Icon

Phase I-II

56

NT-175 TCR Immunotherapy for Advanced HLA Positive Breast Cancer with the TP53 R175H Mutation

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of NT-175, an experimental T cell receptor (TCR) immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HLA positive breast cancer with the TP53 R175H mutation who have received at least 1 line of therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis procedure</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fludarabine (Fludara®)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®)</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NT-175 T cell receptor (TCR) immunotherapy, by IV</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interleukin-2 (IL-2)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NT-175 T cell receptor (TCR) immunotherapy is an experimental immunotherapy that trains the immune system to attack cancer cells with the TP53 R175H mutation.</li> <li class="seamTextUnorderedListItem">Leukapheresis is the removal of blood by a machine to collect specific immune cells called T cells that will be modified to target cancer cells.</li> <li class="seamTextUnorderedListItem">The T cells will be grown in a lab, modified, and given back to you through an infusion.</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and fludarabine (Fludara®) are chemotherapy drugs. The main purpose of chemotherapy drugs in this trial is to make the T cells more effective in fighting cancer cells.</li> <li class="seamTextUnorderedListItem">Interleukin-2 (IL-2) may help the T cells live longer in your body.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05877599' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapy-2-2/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies: A Type of Immunotherapy for MBC</a> </li></ul>
56

NT-175 TCR Immunotherapy for Advanced HLA Positive Breast Cancer with the TP53 R175H Mutation

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Icon

Nearest Location from 94107:
339 miles
Research Site
Santa Monica, CA

Icon

Visits:
May require hospitalization

Icon

ClinicalTrials.gov: NCT05877599

Icon

Phase I

57

CX-5461 for Advanced Breast Cancer with a BRCA2 or PALB2 Mutation

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

Purpose: To determine the safety and best dose of CX-5461, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have a BRCA2 or PALB2 germline (genetic) mutation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-5461, by IV, 2 times per month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-5461 is an experimental targeted therapy. </li> <li class="seamTextUnorderedListItem">It targets cells with a Homologous Recombination Deficiency (HRD) mutation. </li> <li class="seamTextUnorderedListItem">It works by slowing down the growth of cancer cells or causing cancer cells to die.</li> <li class="seamTextUnorderedListItem">This trial also is enrolling patients with other types of advanced cancers.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA2, PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04890613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/senhwa-biosciences-receives-us-fda-study-may-proceed-letter-to-treat-brca2-or-palb2-solid-tumors-with-cx-5461-301198347.html' target='_blank'>Senhwa Biosciences Press Release: CX-5461</a> </li></ul>
57

CX-5461 for Advanced Breast Cancer with a BRCA2 or PALB2 Mutation

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation
Icon

Nearest Location from 94107:
339 miles
University of California, Los Angeles
Santa Monica, CA

Icon

Visits:
2 visits per month

Icon

ClinicalTrials.gov: NCT04890613

Icon

Phase I

58

VNX-202 for Stage I-III HER+ Breast Cancer

A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of VNX-202 gene therapy.

Who is this for?: People with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer at high risk for recurrence following standard of care treatment or progressed after neoadjuvant (before surgery) treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">VNX-202, by IV, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">VNX-202 is an experimental gene therapy drug. After IV injection, the liver continuously makes a drug that both targets HER2 and activates immune cells, causing the immune system to kill HER2-positive cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07192432' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://vironexis.com/' target='_blank'>Vironexis: Gene Therapy for Cancer</a> </li></ul>
58

VNX-202 for Stage I-III HER+ Breast Cancer

A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer
Icon

Nearest Location from 94107:
340 miles
Valkyrie Clinical Trials
Los Angeles, CA

Icon

Visits:
Number of visits unavailable, up to 5 years

Icon

ClinicalTrials.gov: NCT07192432

Icon

Phase I-II

59

MBQ-167 Targeted Therapy for Advanced Breast Cancer

A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of MBQ-167, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBQ-167, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBQ-167 is an experimental targeted therapy called a Rac and Cdc42 inhibitor. Blocking Rac and Cdc42 may slow or stop cancer cells from growing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06075810' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbqpharma.com/science/' target='_blank'>MBQ Pharma: MBQ-167 Drug Information Page</a> </li></ul>
59

MBQ-167 Targeted Therapy for Advanced Breast Cancer

A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer
Icon

Nearest Location from 94107:
340 miles
Precision Next Gen Oncology & Research Center
Beverly Hills, CA

Icon

Visits:
About 1 visit every week

Icon

ClinicalTrials.gov: NCT06075810

Icon

Phase I

60

Tart Cherry Concentrate and Fish Oil for Joint Pain Due to Aromatase Inhibitors for Women With Stage I-III Breast Cancer

An Open Label, Randomized, Waitlist Controlled Trial of Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Purpose: To study whether Tart Cherry concentrate and fish oil received together have beneficial effects on joint pain and function.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are receiving an aromatase inhibitor, have a BMI >27, and joint pain. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tart Cherry Concentrate, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Omega 3 Fish Oil, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No supplements</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Tart Cherry concentrate and fish oil after the study is complete (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Joint pain is one side effect of aromatase inhibitors. Aromatase inhibitors are letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Tart Cherry concentrate and fish oil can help with joint stiffness in general.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06123286' target='_blank'>ClinicalTrials.gov</a> </li></ul>
60

Tart Cherry Concentrate and Fish Oil for Joint Pain Due to Aromatase Inhibitors for Women With Stage I-III Breast Cancer

An Open Label, Randomized, Waitlist Controlled Trial of Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Icon

Nearest Location from 94107:
341 miles
Cedars-Sinai Medical Center
Los Angeles, CA

Icon

Visits:
2 visits within 6 months

Icon

ClinicalTrials.gov: NCT06123286

Icon

Phase I

61

Time-Restricted Eating to Reduce Treatment Side Effects for People with Stage II-III Breast Cancer

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

Purpose: To study the effects (good and bad) and anti-cancer activity of time-restricted eating (TRE) during treatment before surgery.

Who is this for?: People with stage II or stage III breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Time-restricted eating (TRE) schedule, 8 hour daily eating period, 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Regular eating schedule, 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fasting may protect healthy cells from chemotherapy and radiation side effects.</li> <li class="seamTextUnorderedListItem">Time-restricted eating (TRE) involves eating within a period of 10 hours or less, followed by fasting for at least 14 hours daily.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04722341' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/can-fasting-reduce-recurrence-risk' target='_blank'>Breastcancer.org: Can Fasting 13 Hours or More at Night Reduce Recurrence Risk?</a> </li></ul>
61

Time-Restricted Eating to Reduce Treatment Side Effects for People with Stage II-III Breast Cancer

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Icon

Nearest Location from 94107:
341 miles
Cedars-Sinai Medical Center
West Hollywood, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04722341

Icon

Phase NA

62

LCB84 Antibody Drug Conjugate With and Without Immunotherapy for Advanced Breast Cancer

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of LCB84, an experimental antibody drug conjugate (ADC), with or without a PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">PD-1 inhibitor, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84 is an experimental targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">LCB84's antibody targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called MMAE.</li> <li class="seamTextUnorderedListItem">PD-1 inhibitors are a type of immunotherapy called immune checkpoint inhibitors. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05941507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/?utm_medium=email&utm_source=subscribers&utm_campaign=Oct2023&utm_content=Email102023' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors' target='_blank'>National Cancer Institute: Immune Checkpoint Inhibitors</a> </li></ul>
62

LCB84 Antibody Drug Conjugate With and Without Immunotherapy for Advanced Breast Cancer

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors
Icon

Nearest Location from 94107:
341 miles
Cedars Sinai Medical Center
Los Angeles, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT05941507

Icon

Phase I-II

63

QXL138AM Immunotherapy for Advanced Breast Cancer

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Purpose: To study the safety, best dose, and effects (good and bad) of QXL138AM, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">QXL138AM, by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">QXL138AM is an experimental immunotherapy called an immunocytokine (MIC).</li> <li class="seamTextUnorderedListItem">Immunocytokines such as QXL138AM may support the immune system's ability to target and kill cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06582017' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-qxl138am-for-pancreatic-cancers' target='_blank'>Targeted Oncology: QXL138AM for Pancreatic Cancer</a> </li></ul>
63

QXL138AM Immunotherapy for Advanced Breast Cancer

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Icon

Nearest Location from 94107:
341 miles
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer
Los Angeles, CA

Icon

Visits:
1 visit every 2 weeks

Icon

ClinicalTrials.gov: NCT06582017

Icon

Phase I

64

Cryoablation Minimally Invasive Alternative to Surgery for Women with DCIS

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Purpose: To study the effects (good and bad) and anti-cancer activity of cryoablation, an experimental alternative to surgery.

Who is this for?: Women with ductal carcinoma in situ (DCIS) who have not received surgery or radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation, 1 time</li> </ul> <p class="seamTextPara"> followed 6 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation is an experimental minimally invasive, cost effective alternative to surgery that is currently being evaluated for early stage breast cancer.</li> <li class="seamTextUnorderedListItem">Cryoablation involves insertion of a probe into the breast that freezes and destroys the abnormal tissue.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05218044' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://helenreybreastcancerfoundation.com/dcis-cryoablation-study' target='_blank'>Helen Rey Breast Cancer Foundation: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cryoablation' target='_blank'>National Cancer Institute: Cryoablation</a> </li></ul>
64

Cryoablation Minimally Invasive Alternative to Surgery for Women with DCIS

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
Icon

Nearest Location from 94107:
342 miles
Office of Dennis R. Holmes, M.D., F.A.C.S.
Glendale, CA

Icon

Visits:
2 visits

Icon

ClinicalTrials.gov: NCT05218044

Icon

Phase NA

65

Comparing Liquid Biopsy Results to Mammogram and Biopsy Results

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

Purpose: To compare liquid biopsy results to mammogram and biopsy results.

Who is this for?: Women who have not been diagnosed with breast cancer and women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not started treatment or have completed treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Liquid biopsy blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A liquid biopsy is a blood test that can detect cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06336928' target='_blank'>ClinicalTrials.gov</a> </li></ul>
65

Comparing Liquid Biopsy Results to Mammogram and Biopsy Results

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
Icon

Nearest Location from 94107:
343 miles
Keck Medicine of USC Koreatown
Los Angeles, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT06336928

Icon

Phase NA

66

ZEN003694 and Abemaciclib Targeted Therapies for Advanced Breast Cancer

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ZEN003694, an experimental BET bromodomain Inhibitor, with abemaciclib (Verzenio®) CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZEN003694, by mouth, daily, 5 days on, 2 days off</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZEN003694 is an experimental targeted therapy called a BET bromodomain inhibitor. It may prevent the growth of tumor cells that overproduce BET protein.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05372640' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zenithepigenetics.com/programs/pipeline' target='_blank'>Zenith Epigenetics Drug Information Page: ZEN-3694</a> </li></ul>
66

ZEN003694 and Abemaciclib Targeted Therapies for Advanced Breast Cancer

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors
Icon

Nearest Location from 94107:
343 miles
Keck Medicine of USC Koreatown
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05372640

Icon

Phase I

67

A Patient Navigation Program for Young Adult Breast Cancer Survivors

Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors

Purpose: To adapt and test a patient navigation program designed to help young adult cancer survivors get the primary care and cancer follow up (surveillance) care that is recommended for them.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are between the ages of 21 and 45. You must have been diagnosed and treated for your cancer at Kaiser Permanente Southern California and have current Kaiser Permanente insurance coverage. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patient navigator who will stay in touch with you over 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A patient navigator is a trained person who helps guide you through the healthcare system so you don't miss important checkups and follow up care. </li> <li class="seamTextUnorderedListItem">Your navigator may reach out by email, text message, phone call, or letter to help you schedule and keep up with recommended primary care visits and cancer follow up care, talk through any care you may be overdue for, and support you in reaching your care goals.</li> <li class="seamTextUnorderedListItem">Researchers are taking an existing navigation program and adapting it to fit the specific needs of young adults who have finished cancer treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07406087' target='_blank'>ClinicalTrials.gov</a> </li></ul>
67

A Patient Navigation Program for Young Adult Breast Cancer Survivors

Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Icon

Nearest Location from 94107:
346 miles
KP Southern California - Department of Research & Evaluation
Pasadena, CA

Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07406087

Icon

Phase NA

68

Manual Breast Massage to Reduce Treatment Side Effects for Women with Stage 0-III Breast Cancer

Feasibility and Effects of Manual Lymphatic Drainage (MLD) Breast Massage in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy

Purpose: To study the ability of manual lymphatic drainage breast massage to reduce treatment related side effects.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have received a lumpectomy and are planning to receive radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Manual lymphatic drainage breast massage, 2 times every week for 2-3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumpectomy and radiation can lead to side effects including swelling called lymphedema, pain, reduced quality of life, and poor body image. </li> <li class="seamTextUnorderedListItem">Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment related side effects after lumpectomy and radiation.</li> <li class="seamTextUnorderedListItem">Manual means you will be giving yourself the massage.</li> <li class="seamTextUnorderedListItem">Each massage is 30-60 minutes.</li> <li class="seamTextUnorderedListItem">You will be asked to complete the massage during radiation and for 1 month after radiation.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06297265' target='_blank'>ClinicalTrials.gov</a> </li></ul>
68

Manual Breast Massage to Reduce Treatment Side Effects for Women with Stage 0-III Breast Cancer

Feasibility and Effects of Manual Lymphatic Drainage (MLD) Breast Massage in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
Icon

Nearest Location from 94107:
348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06297265

Icon

Phase NA

69

Genetic Testing Education for People with Stage 0-IV Breast Cancer

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

Purpose: To gather feedback about genetic testing education with a computer-generated character as an alternative to standard of care genetic testing education with a human genetic counselor.

Who is this for?: People diagnosed with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer before age 50, people with breast cancer in both breasts, people with triple negative (ER-, PR-, HER2-) breast cancer, or men with breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing education with PERLA, computer-generated character, 1 time before testing</li> <li class="seamTextUnorderedListItem">Genetic counseling with genetic counselor, 1 time after testing</li> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Survey</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing education with genetic counselor, 1 time before testing</li> <li class="seamTextUnorderedListItem">Genetic counseling with genetic counselor, 1 time after testing</li> <li class="seamTextUnorderedListItem">Survey</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The computer-generated character in Group 1 is called a patient-facing relational agent (PERLA).</li> <li class="seamTextUnorderedListItem">Many people with cancer are recommended to receive genetic testing as standard of care.</li> <li class="seamTextUnorderedListItem">Lack of access to genetic counseling and testing is one reason people may not receive genetic testing.</li> <li class="seamTextUnorderedListItem">Education about genetic testing before recieving testing in both English and Spanish may lead to better access to genetic testing.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06422455' target='_blank'>ClinicalTrials.gov</a> </li></ul>
69

Genetic Testing Education for People with Stage 0-IV Breast Cancer

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent
Icon

Nearest Location from 94107:
348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06422455

Icon

Phase NA

70

Registry to Study Breast Cancer and Treatment Outcomes for Women with Stage I-III Breast Cancer

A Comprehensive Breast Cancer Survivorship Biorepository

Purpose: To create a registry of biological samples to study breast cancer and treatment outcomes.

Who is this for?: Women with stage I, stage II, or stage III breast cancer that was diagnosed within the last 7 years and who have completed treatment. Your cancer must not have come back (recurrence). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Creation of this collection of biological samples (registry) will allow research into the links between biological features of these samples and cancer outcomes.</li> <li class="seamTextUnorderedListItem">The study will also study the relationship between social determinants of health, environmental exposure, and lifestyle.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish, Chinese, and Korean.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05786664' target='_blank'>ClinicalTrials.gov</a> </li></ul>
70

Registry to Study Breast Cancer and Treatment Outcomes for Women with Stage I-III Breast Cancer

A Comprehensive Breast Cancer Survivorship Biorepository
Icon

Nearest Location from 94107:
348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05786664

Icon

Phase NA

71

MT-4561 Targeted Therapy for Advanced Breast Cancer

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of MT-4561, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MT-4561, by IV, weekly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MT-4561 is an experimental targeted therapy called a BRD4 inhibitor. Blocking BRD4 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06943521' target='_blank'>ClinicalTrials.gov</a> </li></ul>
71

MT-4561 Targeted Therapy for Advanced Breast Cancer

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam
Icon

Nearest Location from 94107:
348 miles
University of Southern California
Los Angeles, CA

Icon

Visits:
1 visit every week

Icon

ClinicalTrials.gov: NCT06943521

Icon

Phase I-II

72

Blood Test to Detect Cancer for Stage 0-III Breast Cancer

EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol

Purpose: To evaluate a test that detects breast cancer in the blood.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not yet received treatment for their cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood sample, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This test looks for cancer in the blood by looking at extracellular vesicles, which are small pieces of cells that break off and enter the bloodstream. They may be involved in cancer progression and communication between cells. Researchers are studying their usefulness as biomarkers, for cancer detection, and for diagnosis.</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer and healthy people.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07186296' target='_blank'>ClinicalTrials.gov</a> </li></ul>
72

Blood Test to Detect Cancer for Stage 0-III Breast Cancer

EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol
Icon

Nearest Location from 94107:
353 miles
City of Hope Duarte Cancer Center
Los Angeles, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07186296

Icon

Phase NA

73

Acolbifene or Low Dose Tamoxifen to Prevent Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast Cancer

Purpose: To compare acolbifene and low dose tamoxifen (Nolvadex®) hormone therapies to prevent breast cancer for postmenopausal women at high risk for breast cancer.

Who is this for?: Premenopausal women at least 35 years old who have a high risk for developing breast cancer. High risk is defined below. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acolbifene, by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Breast biopsy, 2 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low-dose tamoxifen (Nolvadex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Breast biopsy, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High risk is defined as at least 1 of the following: abnormal biopsy; history of DCIS or LCIS (stage 0 breast cancer); high breast density; family history; and/or an ATM, BARD1, BRIP1, CDH1, CHEK2, MSH6, NBN, NF1, PTEN, PMS2, RAD51C, RAD51D, or TP53 gene mutation. You must not have a BRCA1/2 or PALB2 gene mutation.</li> <li class="seamTextUnorderedListItem">People at high risk for breast cancer may receive breast MRI, ultrasound, mammograms, mastectomy, and/or tamoxifen (Nolvadex®).</li> <li class="seamTextUnorderedListItem">Estrogen can cause the development and growth of breast cancer cells. Acolbifene and tamoxifen (Nolvadex®) hormone therapies block the use of estrogen by breast cells.</li> <li class="seamTextUnorderedListItem">The dose of tamoxifen (Nolvadex®) used in this study is four times lower than the standard dose.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05941520' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/tamoxifen-and-raloxifene-for-breast-cancer-prevention.html' target='_blank'>American Cancer Society: Tamoxifen and Raloxifene for Lowering Breast Cancer Risk</a> </li></ul>
73

Acolbifene or Low Dose Tamoxifen to Prevent Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast Cancer
Icon

Nearest Location from 94107:
353 miles
City of Hope Comprehensive Cancer Center
Duarte, CA

Icon

Visits:
2-3 visits within 6 months

Icon

ClinicalTrials.gov: NCT05941520

Icon

Phase II

74

Blood Test to Detect Cancer After Treatment for Stage I-III Breast Cancer

cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR)

Purpose: To evaluate the ability of a blood test to detect whether someone's cancer is gone after completing treatment or if it has returned before it can be detected with standard methods.

Who is this for?: People at least 40 years old with stage I, stage II, or stage III breast cancer who were diagnosed within the last 3 months or whose cancer came back within the last 5 years, and people who do not have breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 10 times within 3 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">When cancer cells die, they release DNA into the bloodstream. This DNA can be detected following a blood test. This is sometimes called a liquid biopsy.</li> <li class="seamTextUnorderedListItem">This trial is testing what detection or no detection of cancer cell DNA (cfDNA) means for the patient.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling healthy people and people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05366881' target='_blank'>ClinicalTrials.gov</a> </li></ul>
74

Blood Test to Detect Cancer After Treatment for Stage I-III Breast Cancer

cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR)
Icon

Nearest Location from 94107:
353 miles
City of Hope
Duarte, CA

Icon

Visits:
10 visits within 3 years

Icon

ClinicalTrials.gov: NCT05366881

Icon

Phase NA

75

Metformin for Insulin Resistance After Chemotherapy for Women with Stage I-III Breast Cancer

Metformin (Dimethylbiguanide) and Insulin Resistance in Women Completing Neoadjuvant and/or Adjuvant Cytotoxic Treatment of Stage I-III Breast Cancer

Purpose: To study the ability of metformin to help treat insulin resistance after completing chemotherapy.

Who is this for?: Women with stage I, stage II, or stage III estrogen receptor negative (ER-) breast cancer who completed chemotherapy between 1 month and 3 years ago. You must not have diabetes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Metformin with Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Metformin, by mouth, daily for 1 year</li> <li class="seamTextUnorderedListItem">Healthy diet and exercise handouts</li> <li class="seamTextUnorderedListItem">Blood samples, 5 times in 2 years </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Healthy diet and exercise handouts</li> <li class="seamTextUnorderedListItem">Blood samples, 5 times in 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Insulin resistance occurs when cells stop responding to insulin and is a risk factor for developing diabetes and heart disease. </li> <li class="seamTextUnorderedListItem">Higher levels of insulin are related to aggressive breast cancer. </li> <li class="seamTextUnorderedListItem">Metformin decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. </li> <li class="seamTextUnorderedListItem">Giving metformin with usual care may be more effective than usual care alone in preventing or reversing insulin resistance in women with stage I-III breast cancer after chemotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06763328' target='_blank'>ClinicalTrials.gov</a> </li></ul>
75

Metformin for Insulin Resistance After Chemotherapy for Women with Stage I-III Breast Cancer

Metformin (Dimethylbiguanide) and Insulin Resistance in Women Completing Neoadjuvant and/or Adjuvant Cytotoxic Treatment of Stage I-III Breast Cancer
Icon

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Icon

Visits:
5 visits in 2 years

Icon

ClinicalTrials.gov: NCT06763328

Icon

Phase III

76

Couples Coping Together Against Cancer: A Supportive Care Program for People With Breast Cancer and Their Partners

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

Purpose: To find out whether a supportive care program called "Couples Coping Together Against Cancer" is helpful and acceptable to people living with cancer and their partners. The program brings together a mobile app, screening for emotional and social needs, education sessions, and counseling to help couples face cancer together.

Who is this for?: People with breast cancer who are in a committed relationship or partnership, where the partner is also willing to take part. This trial is also enrolling people with other types of cancer. You must be receiving care at City of Hope Medical Center in Duarte, California. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You and your partner will: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Get access to the Connecting Care App</li> <li class="seamTextUnorderedListItem">Complete a screening about your emotional, social, and physical wellbeing</li> <li class="seamTextUnorderedListItem">Take part in education sessions, about 30 to 45 minutes each</li> <li class="seamTextUnorderedListItem">Fill out surveys during the study</li> <li class="seamTextUnorderedListItem">You and your partner may also take part in up to 4 counseling sessions, about 30 to 45 minutes each</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study looks at whether the Couples Coping Together Against Cancer program is practical to use and acceptable to patients and their partners. </li> <li class="seamTextUnorderedListItem">Researchers also want to learn how the program affects the emotional, social, and physical wellbeing of both patients and their partners over time. The program combines a mobile app, screening, education sessions, and counseling to help couples cope with cancer together.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07664579' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cityofhope.org/locations/los-angeles/departments-and-services/supportive-care-medicine/couples-program' target='_blank'>City of Hope: Couples Coping Together Against Cancer</a> </li></ul>
76

Couples Coping Together Against Cancer: A Supportive Care Program for People With Breast Cancer and Their Partners

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
Icon

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07664579

Icon

Phase NA

77

Immunotherapy and Radiation for Advanced CEA Positive Breast Cancer

A Phase I Study of M5A-IL2 Immunocytokine Combined With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer or CEA-Positive Metastatic Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of M5A-IL2, an experimental immunotherapy, with standard of care stereotactic body radiation therapy (SBRT).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) CEA+ breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT), 3 sessions within 1 week</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M5A-IL2 (M5A-ICK), by injection, 3 times within 3 days</li> <li class="seamTextUnorderedListItem">PET/CT scans</li> <li class="seamTextUnorderedListItem">MRI scans and/or bone scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carcinoembryonic Antigen (CEA) is a protein that is present in some cancers, including breast cancer.</li> <li class="seamTextUnorderedListItem">M5A-IL2 (M5A-ICK) is an experimental immunotherapy called an immunocytokine.</li> <li class="seamTextUnorderedListItem">Immunocytokines are small proteins that regulate the activity of immune cells that are important for anti-cancer activity.</li> <li class="seamTextUnorderedListItem">The M5A-IL2 immunocytokine (M5A-ICK) combines the cancer targeting features of the M5A antibody with the immune system regulation properties of the cytokine IL-2.</li> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT) uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06130826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/cytokines.html' target='_blank'>American Cancer Society: Cytokines</a> </li></ul>
77

Immunotherapy and Radiation for Advanced CEA Positive Breast Cancer

A Phase I Study of M5A-IL2 Immunocytokine Combined With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer or CEA-Positive Metastatic Breast Cancer
Icon

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Icon

Visits:
At least 6 visits within 2 weeks

Icon

ClinicalTrials.gov: NCT06130826

Icon

Phase I

78

BAY2927088 Targeted Therapy for Advanced Breast Cancer with HER2 Mutations

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BAY2927088, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a HER2 mutation who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BAY2927088, by mouth, daily</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Heart tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancers have changes or mutations to a gene called human epidermal growth receptor 2 (HER2). These mutations can help the cancer grow.</li> <li class="seamTextUnorderedListItem">BAY2927088 is an experimental anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It may block abnormal HER2 which may slow or stop the growth of cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06760819' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/treatments/24984-tyrosine-kinase-inhibitors' target='_blank'>Cleveland Clinic: Tyrosine Kinase Inhibitors</a> </li></ul>
78

BAY2927088 Targeted Therapy for Advanced Breast Cancer with HER2 Mutations

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)
Icon

Nearest Location from 94107:
353 miles
City of Hope - Duarte Cancer Center
Duarte, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06760819

Icon

Phase II

79

Evorpacept Targeted Therapy with Standard of Care Treatment for Advanced HER2+ Breast Cancer

ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of evorpacept, an experimental targeted therapy, with standard of care treatment compared to standard of care treatment alone.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received trastuzumab deruxtecan (Enhertu®, T-DXd). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive all three of the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evorpacept, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evorpacept is an experimental targeted therapy called a CD47 inhibitor that allows immune cells to attack and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Your study doctor will choose one of the following chemotherapy options based on your medical history. Standard of care options in this trial are Capecitabine (Xeloda®), Eribulin (Halaven®), Gemcitabine (Gemzar®), Paclitaxel (Taxol®), or Vinorelbine (Navelbine®).</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07007559' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://alxoncology.com/our-approach/evorpacept/' target='_blank'>ALX Oncology: Evorpacept Drug Information Page</a> </li></ul>
79

Evorpacept Targeted Therapy with Standard of Care Treatment for Advanced HER2+ Breast Cancer

ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Icon

Nearest Location from 94107:
353 miles
City of Hope
Duarte, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT07007559

Icon

Phase II

80

Biomarker Testing to Select an Antibody-Drug Conjugate for Advanced Breast Cancer

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of using biomarkers to select an antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have had a type of blood test called an RNA test. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups depending on your RNA blood test and biopsy results: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, weekly, 2 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enfortumab vedotin (Padcev®), by IV, weekly, 3 weeks on 1 week off</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Echocardiography or multigated acquisition scan (heart scans), 2 times</li> <li class="seamTextUnorderedListItem">Biopsy, two times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing the person's blood and tumor for the presence of the biomarkers, TROP-2, nectin 4, or HER2 to match them to one of three ADCs.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a TROP-2-targeted ADC approved for triple-negative or HR+, HER2- MBC.</li> <li class="seamTextUnorderedListItem">Enfortumab vedotin (Padcev®) is a nectin4-targeted ADC approved for use in other cancers. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a HER2-targeted ADC approved for HER2+ or HER2-low MBC.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06311214' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.trodelvy.com/?utm_source=google&utm_medium=cpc&utm_campaign=us_sem_trmd_onc_dtp_ex_mtnbc_go_na_na_b_standard_branded_1432nn&utm_content=17054576844%3B136230621779%3Bkwd-946345024054&utm_term=trodelvy&gclsrc=aw.ds&gad_source=1&gad_campaignid=17' target='_blank'>Gilead: Sacituzumab Govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.padcev.com/' target='_blank'>Astellas Pharma: Enfortumab Vedotin (Padcev®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://enhertu.com/en/mbc?utm_source=google&utm_medium=cpc&utm_term=trastuzumab%20deruxtecan&utm_campaign=|CN|DTCB|BR|mBC|ENH|AZ|Core|Alone&utm_source=google&utm_medium=cpc&utm_campaign=%7CCN%7CDTCB%7CBR%7CmBC%7CENH%7CAZ%7CCore%7CAlone&utm_content=Alone%' target='_blank'>Daiichi Sankyo: Trastuzumab Deruxtecan (Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates (ADCs)</a> </li></ul>
80

Biomarker Testing to Select an Antibody-Drug Conjugate for Advanced Breast Cancer

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)
Icon

Nearest Location from 94107:
353 miles
City of Hope Comprehensive Cancer Center
Duarte, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06311214

Icon

Phase II

81

PF-08032562 for Advanced Breast Cancer

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of PF-08032562 and fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose cancer has progressed after receiving prior treatment or for whom no standard treatment options are available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-08032562, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">CDK4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07318805' target='_blank'>ClinicalTrials.gov</a> </li></ul>
81

PF-08032562 for Advanced Breast Cancer

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Icon

Nearest Location from 94107:
353 miles
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, CA

Icon

Visits:
Number of visits unavailable, up to 2 years

Icon

ClinicalTrials.gov: NCT07318805

Icon

Phase I

82

NKT5097 Targeted Therapy for Advanced Breast Cancer

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of NKT5097, an experimental CDK2/4 degrader.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKT5097, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKT5097 is an experimental targeted therapy called a CDK2/4 degrader. It breaks down two enzymes, CDK2 and CDK4, that help cancer grow.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07029399' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2023/12/what-is-protein-degradation/' target='_blank'>Dana-Farber Cancer Institute: Protein Degraders for Cancer</a> </li></ul>
82

NKT5097 Targeted Therapy for Advanced Breast Cancer

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors
Icon

Nearest Location from 94107:
353 miles
City of Hope
Duarte, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07029399

Icon

Phase I

83

Zanidatamab Plus Chemotherapy for Stage II-III HER2+ Breast Cancer

A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of zanidatamab (Ziihera®) anti-HER2 bispecific antibody plus chemotherapy.

Who is this for?: People with stage II or stage III HER2 positive (HER2+) breast cancer who are planning to receive therapy before surgery (neoadjuvant) followed by a mastectomy or lumpectomy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab (Ziihera®), by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab (Ziihera®), by IV</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab (Ziihera®) is a bispecific antibody that binds to two places on HER2. It is approved for use in other cancers. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Bispecific antibodies bind to two distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), docetaxel (Taxotere®), and carboplatin (Paraplatin®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are anti-HER2 targeted therapies commonly used to treat HER2+ breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07102381' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ziihera.com/#:~:text=shortness%20of%20breath%20or%20trouble,chest%20discomfort' target='_blank'>Jazz Pharmaceuticals: Zanidatamab (Ziihera®)</a> </li></ul>
83

Zanidatamab Plus Chemotherapy for Stage II-III HER2+ Breast Cancer

A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Icon

Nearest Location from 94107:
359 miles
Oncology Institute
Long Beach, CA

Icon

Visits:
Number of visits unavailable, up to 4 years

Icon

ClinicalTrials.gov: NCT07102381

Icon

Phase II

84

Riluzole to Prevent Memory and Thinking Problems in People who Receiving Chemotherapy

RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)

Purpose: To study if riluzole (Rilutek®) can help prevent problems with memory, thinking, and concentration (often called “chemo brain”).

Who is this for?: People with stage I, stage II, stage III, or stage IV breast cancer who are receiving or planning to receive anthracycline or platinum chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Riluzole (Rilutek®), by mouth, 2 times a day, up to 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Blood tests</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for riluzole, by mouth, 2 times a day, up to 6 months </li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some people who receive treatments for breast cancer experience cognitive problems.</li> <li class="seamTextUnorderedListItem">Problems with thinking, called cognitive impairment, can happen during and after breast cancer treatment.</li> <li class="seamTextUnorderedListItem">These problems can last for years and can affect a person's ability to work or participate in social activities.</li> <li class="seamTextUnorderedListItem">Riluzole (Rilutek®) is a drug used to treat ALS (Lou Gehrig's disease), but it may also be helpful to improve cognition. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Researchers want to learn if this drug can protect brain function during cancer treatment.</li> <li class="seamTextUnorderedListItem">Anthracycline chemotherapy drugs are doxorubicin (Doxil®), epirubicin (Ellence®), mitoxantrone (Novantrone®), and idarubicin (Idamycin®).</li> <li class="seamTextUnorderedListItem">Platinum chemotherapy drugs are cisplatin, oxaliplatin (Eloxatin®), and carboplatin (Paraplatin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07447050' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/managing-cancer/side-effects/changes-in-mood-or-thinking/chemo-brain.html' target='_blank'>American Cancer Society: Changes in Memory, Thinking, and Focus (Chemo Brain)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/chemo-brain' target='_blank'>BreastCancer.org: Chemo Brain: Understanding Brain Fog and How to Treat It</a> </li></ul>
84

Riluzole to Prevent Memory and Thinking Problems in People who Receiving Chemotherapy

RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)
Icon

Nearest Location from 94107:
374 miles
Chao Family Comprehensive Cancer Center, University of California Irvine
Orange, CA

Icon

Visits:
Coincides with usual care, up to 6 months

Icon

ClinicalTrials.gov: NCT07447050

Icon

Phase II

85

Riluzole to Improve Cognition After Treatment for People with Stage I-III Breast Cancer

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: an Interventional Pilot Clinical Trial

Purpose: To study if riluzole (Rilutek®) changes the amount of brain derived neurotrophic factor (BDNF) in your body, which is related to changes in cognition (ability to think).

Who is this for?: People with stage I, stage II, or stage III breast cancer who have cognitive (thinking) issues. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Riluzole (Rilutek®), by mouth, daily for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for riluzole, by mouth, daily for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognition is your ability to think.</li> <li class="seamTextUnorderedListItem">Brain derived neurotrophic factor (BDNF) is a protein that is involved with thinking (cognition) and learning.</li> <li class="seamTextUnorderedListItem">Changing the amount of brain derived neurotrophic factor (BDNF) in your body may improve your cognition.</li> <li class="seamTextUnorderedListItem">Riluzole (Rilutek®) is a drug used to treat ALS (Lou Gehrig's disease), but it may also be helpful to improve cognition. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also available in Chinese, Korean, Vietnamese, and Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06580002' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/riluzole-oral-route/description/drg-20065853' target='_blank'>Mayo Clinic: Riluzole (Rilutek®)</a> </li></ul>
85

Riluzole to Improve Cognition After Treatment for People with Stage I-III Breast Cancer

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: an Interventional Pilot Clinical Trial
Icon

Nearest Location from 94107:
374 miles
Chao Family Comprehensive Cancer Center, University of California Irvine
Orange, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06580002

Icon

Phase II

86

LNCB74 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors (LNCB74-01)

Purpose: To study the safety, best dose, and effects (good and bad) of LNCB74, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LNCB74, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LNCB74 is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in LNCB74 targets B7-H4 proteins. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06774963' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nextcure.com/pipeline/' target='_blank'>NextCure: LNCB74 Drug Information Page</a> </li></ul>
86

LNCB74 Antibody Drug Conjugate for Advanced Breast Cancer

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors (LNCB74-01)
Icon

Nearest Location from 94107:
381 miles
Hoag Family Cancer Institute
Newport Beach, CA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06774963

Icon

Phase I

87

IKS014 for Advanced HER2+ or HER2 Low Breast Cancer

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of IKS014 antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 low breast cancer. You must have received at least 2 lines of HER2-targeting therapy (if HER2+) or at least 1 line of therapy (if HER2 low). If your cancer is hormone receptor positive (ER+ and/or PR+), you must have received palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IKS014, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IKS014 is a HER2-targeting antibody-drug conjugate (ADC). An ADC is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05872295' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.iksuda.com/adc-programs/iks014/' target='_blank'>Iksuda: IKS014</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates (ADCs)</a> </li></ul>
87

IKS014 for Advanced HER2+ or HER2 Low Breast Cancer

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors
Icon

Nearest Location from 94107:
381 miles
Hoag Memorial Hospital Presbyterian
Newport Beach, CA

Icon

Visits:
Every 3 weeks, up to 4 years

Icon

ClinicalTrials.gov: NCT05872295

Icon

Phase I

88

Novilase® Laser Ablation Before Surgery for Women with Stage I-II BRCA Negative Breast Cancer

Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm (BR-003)

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of Novilase® laser ablation to standard of care lumpectomy for small tumors.

Who is this for?: Women with some stage I or stage II breast cancer who have not yet received surgery. You must not have BRCA positive, lobular, or triple negative breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Novilase® laser ablation</li> </ul> <p class="seamTextPara"> followed 1-1.5 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove tumor</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Novilase® laser ablation system kills tumor cells by heating the tissue with a laser.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03463954' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://novilase.com/' target='_blank'>Novian Health: Novilase®</a> </li></ul>
88

Novilase® Laser Ablation Before Surgery for Women with Stage I-II BRCA Negative Breast Cancer

Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm (BR-003)
Icon

Nearest Location from 94107:
435 miles
Eisenhower Health
Rancho Mirage, CA

Icon

Visits:
2 visits within 1.5 months

Icon

ClinicalTrials.gov: NCT03463954

Icon

Phase NA

89

Strong Survivor Virtual Exercise Program for Older Women with Stage 0-III Breast Cancer

Strong Survivors: A Prospective Study of Video-assisted Exercise Program for the Geriatric Breast Cancer Patient

Purpose: To study the effects of the Strong Survivor exercise program on quality of life, fitness, and other physical measurements.

Who is this for?: Women, age 65 and older, with stage 0, stage I, stage II, or stage III breast cancer who received a mastectomy in the last month. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Strong Survivor exercise program, virtual, twice a week for 4 months</li> <li class="seamTextUnorderedListItem">Fitness measurements, 2 times within 4 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times within 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Strong Survivor is a 16-week, virtual program with three core components: aerobic fitness, balance and mobility, and muscle strength and power.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07071896' target='_blank'>ClinicalTrials.gov</a> </li></ul>
89

Strong Survivor Virtual Exercise Program for Older Women with Stage 0-III Breast Cancer

Strong Survivors: A Prospective Study of Video-assisted Exercise Program for the Geriatric Breast Cancer Patient
Icon

Nearest Location from 94107:
441 miles
UCSD
San Diego, CA

Icon

Visits:
2 visits within 4 months

Icon

ClinicalTrials.gov: NCT07071896

Icon

Phase NA

90

Testing a Localization Device, OneMark, for Breast Cancer Surgery and Surveillance

Pilot Post-Marketing Study on the Efficacy of OneMark in Identifying Breast Cancer For Surgery and Over Time in High and Low Density Breast Tissue

Purpose: To study how well the OneMark breast localization device can be seen during breast cancer surgery and over time during breast cancer surveillance compared with standard visualization methods.

Who is this for?: People with stage I or stage II breast cancer who are planning to have surgery or people who are at high risk for breast cancer and are taking part in a surveillance (monitoring) program. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OneMark device</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">There are no extra procedures beyond the surgery, biopsy, or imaging you would already be receiving as part of your usual care.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive the OneMark device either at the time of breast cancer surgery or at the time of a breast biopsy if you are in a breast cancer surveillance program, depending on your situation.</li> <li class="seamTextUnorderedListItem">This study will help researchers compare the visibility of OneMark to a standard breast localization device during surgery.</li> <li class="seamTextUnorderedListItem">Patients may experience benefits if the OneMark device performs as hoped.</li> <li class="seamTextUnorderedListItem">Device placement occurs during procedures patients already need (biopsy or surgery) and will not have any extra procedures beyond standard care.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07087691' target='_blank'>ClinicalTrials.gov</a> </li></ul>
90

Testing a Localization Device, OneMark, for Breast Cancer Surgery and Surveillance

Pilot Post-Marketing Study on the Efficacy of OneMark in Identifying Breast Cancer For Surgery and Over Time in High and Low Density Breast Tissue
Icon

Nearest Location from 94107:
441 miles
University of California, San Diego
La Jolla, CA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07087691

Icon

Phase NA

91

MOMA-313 Targeted Therapy Alone or with PARP Inhibitor for Advanced Breast Cancer with HRD Mutations

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of MOMA-313, an experimental DNA polymerase theta inhibitor, alone or with olaparib (Lynparza®) PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a BRCA1, BRCA2, PALB2, ATM, or CHEK2 mutation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MOMA-313, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MOMA-313, by mouth</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MOMA-313 is an experimental targeted therapy called a DNA polymerase theta inhibitor.</li> <li class="seamTextUnorderedListItem">MOMA-313 was designed to target homologous recombination (HR)-deficient cancers by inhibiting DNA polymerase theta.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">BRCA1, BRCA2, PALB2, ATM, and CHEK2 gene mutations are homologous recombination repair (HRR) or homologous recombination deficient (HRD) mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06545942' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.urologytimes.com/view/study-launches-of-moma-313-in-solid-tumors-including-prostate-cancer' target='_blank'>Urology Times: Study of MOMA-313 in Solid Tumors</a> </li></ul>
91

MOMA-313 Targeted Therapy Alone or with PARP Inhibitor for Advanced Breast Cancer with HRD Mutations

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
Icon

Nearest Location from 94107:
441 miles
Investigative Site #101
La Jolla, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06545942

Icon

Phase I

92

Proton Radiation Therapy After Surgery for Stage I-III Breast Cancer

Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks).

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive radiation after surgery. You must not have a BRCA1/2 mutation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton radiation therapy, daily for 5-6 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton radiation therapy, daily for 3-4 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation is used after surgery to kill any cancer cells that may have been left in the breast.</li> <li class="seamTextUnorderedListItem">Proton therapy is a form of external beam radiation that uses protons (instead of x-rays) to treat the tumor.</li> <li class="seamTextUnorderedListItem">Because the proton beam can be more directly targeted to the tumor, proton therapy may result in fewer side effects than x-ray radiation.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with lobular breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05856773' target='_blank'>ClinicalTrials.gov</a> </li></ul>
92

Proton Radiation Therapy After Surgery for Stage I-III Breast Cancer

Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO)
Icon

Nearest Location from 94107:
446 miles
California Protons Cancer Therapy Center
San Diego, CA

Icon

Visits:
5 visits every week for 1-2 months

Icon

ClinicalTrials.gov: NCT05856773

Icon

Phase III

93

CGT4255 for Advanced HER2+ Breast Cancer with or without ERBB2 Mutations

A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of CGT4255, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive breast cancer or tests positive for a mutation in HER2 (ERRB2). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CGT4255, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing a new targeted drug called CGT4255, which is designed to block ERBB2 (HER2) driven cancer growth.</li> <li class="seamTextUnorderedListItem">In HER2 positive breast cancer, the ERBB2 gene is overactive, which causes the cancer cells to produce too much HER2 protein on their surface.</li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of tumors that have these mutations.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07361562' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/about-breast-cancer/her2-positive-breast-cancer-treatment-research/' target='_blank'>Breast Cancer Research Foundation: HER2-Positive Breast Cancer: Testing, Treatment, Research</a> </li></ul>
93

CGT4255 for Advanced HER2+ Breast Cancer with or without ERBB2 Mutations

A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression
Icon

Nearest Location from 94107:
595 miles
START Mountain Region
West Valley City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07361562

Icon

Phase I

94

PLN-101095 Immunotherapy with Pembrolizumab for Advanced Breast Cancer

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembro...

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of PLN-101095, an experimental immunotherapy, with pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. You must have received pembrolizumab (Keytruda®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PLN-101095</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PLN-101095 is an experimental immunotherapy. PLN-101095 may help pembrolizumab (Keytruda®) work better.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06270706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://pliantrx.com/oncology/' target='_blank'>Pliant Therapeutics: PLN-101095 Drug Information Page</a> </li></ul>
94

PLN-101095 Immunotherapy with Pembrolizumab for Advanced Breast Cancer

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembro...
Icon

Nearest Location from 94107:
595 miles
START Mountain Region
West Valley City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06270706

Icon

Phase I

95

Guided Meditation to Reduce Anxiety During Radiation for Stage 0-III Breast Cancer

Med-RT BG: An Interventional Trial Using Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

Purpose: To study the effect of brief mindfulness-guided meditations during radiation on feelings of anxiety.

Who is this for?: People with stage 0 (DCIS), I, stage II, or stage III breast cancer who are planning to receive 15-25 daily breast radiation treatments. You must not be planning to receive deep inspiration breath hold treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guided meditation, by audio, 10 to 15 minutes</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The mindfulness-guided meditation recordings teach you several practices aimed at reducing anxiety, including directing non-judgmental attention to different parts of the body, focusing on breathing, accepting negative thoughts, and shifting attention to pleasant thoughts.</li> <li class="seamTextUnorderedListItem">Deep inspiration breath hold treatment is when you hold your breath briefly while the radiation is delivered. Holding your breath protects your heart by moving it out of the way of the radiation.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07166042' target='_blank'>ClinicalTrials.gov</a> </li></ul>
95

Guided Meditation to Reduce Anxiety During Radiation for Stage 0-III Breast Cancer

Med-RT BG: An Interventional Trial Using Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
Icon

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07166042

Icon

Phase III

96

Whole Breast Radiation in 5 Days or 9 Days for Women with Stage 0-III Breast Cancer

FAST NOVEMBER: A Phase II Randomized Trial of a 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of radiation delivered to the whole breast in 5 days or 9 days.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have received a lumpectomy and are planning to receive radiation to the whole breast. You must have negative lymph nodes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, daily for 5 days</li> <li class="seamTextUnorderedListItem">Questionnaire</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, daily for 9 days</li> <li class="seamTextUnorderedListItem">Questionnaire</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">You must be receiving your radiation treatments at the University of Utah in Salt Lake City.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06961955' target='_blank'>ClinicalTrials.gov</a> </li></ul>
96

Whole Breast Radiation in 5 Days or 9 Days for Women with Stage 0-III Breast Cancer

FAST NOVEMBER: A Phase II Randomized Trial of a 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Icon

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute/University of Utah
Salt Lake City, UT

Icon

Visits:
5 or 9 visits within 2 weeks

Icon

ClinicalTrials.gov: NCT06961955

Icon

Phase II

97

Non-Invasive Brain Stimulation for Nerve Pain Due to Chemotherapy for Women with Stage I-III Breast Cancer

Repetitive Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Breast and Gynecologic Cancer Survivors: A Pilot Study

Purpose: To study if repetitive transcranial magnetic stimulation (rTMS) can reduce nerve pain due to chemotherapy.

Who is this for?: Women with stage I, stage II, or stage III breast cancer with nerve pain that started within 1 month of receiving certain chemotherapy drugs and has not gotten better with pain medication. You must have completed active treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Repetitive Transcranial Magnetic Stimulation (rTMS), 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some types of chemotherapy can cause nerve pain due to nerve damage. This is called peripheral neuropathy.</li> <li class="seamTextUnorderedListItem">Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive way to stimulate nerve cells in the brain.</li> <li class="seamTextUnorderedListItem">You must have received at least one of the following chemotherapy drugs: paclitaxel (Taxol®), docetaxel (Taxotere®), cisplatin, oxaliplatin (Eloxatin®), carboplatin (Paraplatin®), vinblastine (Velban®), vincristine (Oncovin®), vinorelbine (Navelbine®), vinflunine (Javlor®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07120100' target='_blank'>ClinicalTrials.gov</a> </li></ul>
97

Non-Invasive Brain Stimulation for Nerve Pain Due to Chemotherapy for Women with Stage I-III Breast Cancer

Repetitive Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Breast and Gynecologic Cancer Survivors: A Pilot Study
Icon

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable, up to 2 years

Icon

ClinicalTrials.gov: NCT07120100

Icon

Phase NA

98

Video About Opioid Use for Women With Stage I-III Breast Cancer or Healthy Women Planning to Receive a Mastectomy and Reconstruction

SAVE Trial: SAfe Opioid Use Video Education

Purpose: To study a video about the opioid epidemic and opioid use and disposal.

Who is this for?: Women with stage I, stage II, or stage III breast cancer, or women at high risk for breast cancer, who are planning to receive breast reconstruction with an abdominal flap after mastectomy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual surgical care and inpatient pain management</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual surgical care and inpatient pain management</li> <li class="seamTextUnorderedListItem">Video, 3 minutes, before surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Opioids are overprescribed and overused after surgery, contributing to the current opioid misuse crisis. Nearly half of people who received a mastectomy and reconstruction receive opioids for a long time.</li> <li class="seamTextUnorderedListItem">The video in this trial describes how to receive over-the-counter pain medication alongside opioids to best control pain, how opioids should be used only to treat pain related to the surgery, and the proper disposal of unused opioids.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07044583' target='_blank'>ClinicalTrials.gov</a> </li></ul>
98

Video About Opioid Use for Women With Stage I-III Breast Cancer or Healthy Women Planning to Receive a Mastectomy and Reconstruction

SAVE Trial: SAfe Opioid Use Video Education
Icon

Nearest Location from 94107:
602 miles
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07044583

Icon

Phase NA

99

Heat Treatment Before Surgery for Women with Stage I-III Breast Cancer

A Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of heat treatment with the Muse MRgFUS before surgery (neoadjuvant).

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive a lumpectomy. You must not have received radiation, hormone therapy, or chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Heat treatment of half of tumor with Muse MRgFUS system</li> </ul> <p class="seamTextPara"> followed 2-3 weeks later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove tumor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Muse MRgFUS System applies focused ultrasound (FUS) waves to a tumor, which ablates (heats) the tumor tissue to kill cancer cells.</li> <li class="seamTextUnorderedListItem">Only half of your tumor will be ablated before surgery to ensure that no information about you tumor is lost that would impact your care. Because current care often includes testing the tumor, retaining a portion of viable tumor before surgery is advised by the clinical team.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05291507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-04667&loc=0&ni=10&pn=357&rl=1' target='_blank'>National Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/interventional-radiology/procedures/tumor/' target='_blank'>Johns Hopkins: Tumor Ablation (Heat Treatment)</a> </li></ul>
99

Heat Treatment Before Surgery for Women with Stage I-III Breast Cancer

A Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
Icon

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Icon

Visits:
4 visits

Icon

ClinicalTrials.gov: NCT05291507

Icon

Phase I

100

ETX-19477 PARG Inhibitor for Advanced Breast Cancer

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ETX-19477, an experimental PARG inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ETX-19477, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ETX-19477 is experimental targeted therapy called a PARG (poly ADP ribose glycohydrolase) inhibitor.</li> <li class="seamTextUnorderedListItem">Blocking PARG may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06395519' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://8five8tx.com/pipeline' target='_blank'>858 Therapeutics: ETX-19477 Drug Information Page</a> </li></ul>
100

ETX-19477 PARG Inhibitor for Advanced Breast Cancer

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)
Icon

Nearest Location from 94107:
602 miles
START Center for Cancer Care - Mountain Region
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06395519

Icon

Phase I-II

101

Exercise for Fatigue for People with Advanced Breast Cancer Receiving Trastuzumab Deruxtecan

ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study

Purpose: To study the safety and effects (good and bad) of a home-based, unsupervised exercise program for cancer-related fatigue.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+), HER2-low, or hormone receptor-positive (HR+), HER2-low or HER2-ultralow breast cancer who are receiving trastuzumab deruxtecan (Enhertu®) and experiencing fatigue. You must not be participating in an exercise program as defined by the study investigators. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, at home, for 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Physical function tests</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No exercise</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Physical function tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The exercise program is an individualized, home-based, unsupervised, whole-body resistance training and aerobic exercise program.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07203378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/special-topics/enhertu-hrpos-her2low/' target='_blank'>Metastatic Trial Talk: Trastuzumab Deruxtecan (Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/fatigue-2/' target='_blank'>Metastatic Trial Talk: Fatigue</a> </li></ul>
101

Exercise for Fatigue for People with Advanced Breast Cancer Receiving Trastuzumab Deruxtecan

ENERGIZE: Engagement With a Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu: A Single-Center Pilot Study
Icon

Nearest Location from 94107:
602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable, 3 months

Icon

ClinicalTrials.gov: NCT07203378

Icon

Phase II

102

JAB-2485 Targeted Therapy for Advanced ER+, Triple Negative, or ARID1A Mutated Breast Cancer

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of JAB-2485, an experimental Aurora A inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) ER positive (ER+), triple negative (ER-, PR-, HER2-), or ARID1A mutated breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">JAB-2485, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">JAB-2485 is an experimental targeted therapy called an Aurora A inhibitor. Aurora A inhibitors may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ARID1A</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05490472' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aurora-a-kinase-inhibitor-jab-2485' target='_blank'>National Cancer Institute: JAB-2485</a> </li></ul>
102

JAB-2485 Targeted Therapy for Advanced ER+, Triple Negative, or ARID1A Mutated Breast Cancer

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors
Icon

Nearest Location from 94107:
602 miles
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05490472

Icon

Phase I-II

103

Exercise to Improve Thinking Ability After Treatment for Women with Stage I-III Breast Cancer

Enhancing Cognitive Function in Breast Cancer Survivors Through Community-based Exercise Training (BRAIN)

Purpose: To study whether an exercise program improves cognitive function (the ability to think).

Who is this for?: Postmenopausal women with stage I, stage II, or some stage III breast cancer who have completed treatment between 3 months ago and 2 years ago. You must regularly perform at least 20 minutes of exercise up to 2 days every week. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised exercise sessions, 20 sessions within 6 months</li> <li class="seamTextUnorderedListItem">MRI scan, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Walking test</li> <li class="seamTextUnorderedListItem">Wear an accelerometer</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education sessions, in-person or virtual, monthly for 9 months</li> <li class="seamTextUnorderedListItem">Education resources and 1 year subscription to Mayo Clinic Health Letter</li> <li class="seamTextUnorderedListItem">MRI scan, 2 times within 6 months</li> <li class="seamTextUnorderedListItem">Walking test</li> <li class="seamTextUnorderedListItem">Wear an accelerometer</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Free fitness center membership, 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Problems with thinking (cognition) affect daily functioning, quality of life, and long-term health. </li> <li class="seamTextUnorderedListItem">Aerobic exercise may help improve these problems and is generally considered safe, tolerable, and accessible.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, treadmill walking is the primary mode of exercise. However, you will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by your exercise trainer.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, the sessions will cover cancer support and discussion of cancer-related wellness topics such as stress management and coping.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will receive a free 6 month fitness membership after the study.</li> <li class="seamTextUnorderedListItem">An accelerometer is a device that measures how fast you walk.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04816006' target='_blank'>ClinicalTrials.gov</a> </li></ul>
103

Exercise to Improve Thinking Ability After Treatment for Women with Stage I-III Breast Cancer

Enhancing Cognitive Function in Breast Cancer Survivors Through Community-based Exercise Training (BRAIN)
Icon

Nearest Location from 94107:
650 miles
Mayo Clinic in Arizona
Phoenix, AZ

Icon

Visits:
At least 2 visits within 6 months

Icon

ClinicalTrials.gov: NCT04816006

Icon

Phase NA

104

SHY-ONC6, Targeted Therapy, for Advanced Triple Negative (TNBC) or Hormone Receptor Positive (HR+) Breast Cancer

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of SHY-ONC6, a new medicine called a proteasome inhibitor. SHY-ONC6 works by blocking the proteasome, the part of a cell that clears out old and damaged proteins. When this recycling system is blocked, damaged proteins build up inside cancer cells, which can cause the cancer cells to die. This is the first study testing SHY-ONC6 in people.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that is either triple negative (ER-, PR-, HER2-) or hormone receptor positive (ER+ and/or PR+) whose cancer has progressed or who have no standard treatment options available. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SHY-ONC6, by mouth, once daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SHY-ONC6 is a proteasome inhibitor. The proteasome is like a cell's recycling center. It breaks down proteins the cell no longer needs. Cancer cells depend on this process to stay healthy and keep growing. </li> <li class="seamTextUnorderedListItem">SHY-ONC6 is designed to block the proteasome so that unwanted proteins pile up inside the cancer cells, which can stop them from growing or cause them to die.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07705334' target='_blank'>ClinicalTrials.gov</a> </li></ul>
104

SHY-ONC6, Targeted Therapy, for Advanced Triple Negative (TNBC) or Hormone Receptor Positive (HR+) Breast Cancer

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors
Icon

Nearest Location from 94107:
657 miles
HonorHealth Research Institute
Scottsdale, AZ

Icon

Visits:
About 1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT07705334

Icon

Phase I

105

Genetic Testing for Diverse Groups of People with Breast Cancer

Gemini - Cancer Genetic Testing in Ethnic Populations

Purpose: To use genetic testing to identify genetic mutations and make treatment decisions.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing looks for changes, sometimes called mutations or variants, in your DNA.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04475640' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease and Control: Genetic Testing</a> </li></ul>
105

Genetic Testing for Diverse Groups of People with Breast Cancer

Gemini - Cancer Genetic Testing in Ethnic Populations
Icon

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04475640

Icon

Phase NA

106

Hypofractionated Radiation Before or After Breast Surgery for Women With Stage I-III Breast Cancer

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Non-Metastatic Breast Cancer Before or After Breast Surgery for Different Breast Cancer Risk Groups

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of hypofractionated radiotherapy given before or after breast surgery.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Radiation Before Surgery</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy</li> <li class="seamTextUnorderedListItem">Radiation, daily for 5 days</li> <li class="seamTextUnorderedListItem">Breast surgery</li> <li class="seamTextUnorderedListItem">Scans</li> <li class="seamTextUnorderedListItem">Biopsy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Radiation After Surgery</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy</li> <li class="seamTextUnorderedListItem">Breast surgery</li> <li class="seamTextUnorderedListItem">Radiation, daily for 5 days</li> <li class="seamTextUnorderedListItem">Scans</li> <li class="seamTextUnorderedListItem">Biopsy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth. </li> <li class="seamTextUnorderedListItem">Hypofractionated radiation is a type of radiation therapy in which larger doses (fractions) of radiation are given to you in fewer sessions over a shorter period than conventional radiation therapy. This schedule reduces treatment time.</li> <li class="seamTextUnorderedListItem">Radiation given before surgery with a hypofractionated schedule may have fewer side effects, be more effective, and lead to a better appearance of the breast than if given after surgery.</li> <li class="seamTextUnorderedListItem">Scans may include CT, MRI, PET, mammogram, and/or ultrasound.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06635980' target='_blank'>ClinicalTrials.gov</a> </li></ul>
106

Hypofractionated Radiation Before or After Breast Surgery for Women With Stage I-III Breast Cancer

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Non-Metastatic Breast Cancer Before or After Breast Surgery for Different Breast Cancer Risk Groups
Icon

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Icon

Visits:
13 visits within 5 years

Icon

ClinicalTrials.gov: NCT06635980

Icon

Phase II

107

GI-102 Bispecific Antibody Alone or With Immunotherapy for Advanced Breast Cancer

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patient...(KEYNOTE-G08)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of GI-102, an experimental bispecific antibody, alone or with other anti-cancer drugs.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 5 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV or injection, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy, by IV, every 1-3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 5</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102 is an experimental immunotherapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two different targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd) is an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s antibody targets HER2 and delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">The chemotherapies being used in this study are doxorubicin (Doxil®), paclitaxel (Taxol®), and eribulin (Halaven®).</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®) is a targeted therapy called a VEGF inhibitor. Blocking VEGF may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05824975' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li></ul>
107

GI-102 Bispecific Antibody Alone or With Immunotherapy for Advanced Breast Cancer

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patient...(KEYNOTE-G08)
Icon

Nearest Location from 94107:
660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

Icon

Visits:
At least 1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT05824975

Icon

Phase I-II

108

Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer

Inflammatory Breast Cancer (IBC) Registry

Purpose: To collect and study blood and tissue samples and clinical data from people with newly diagnosed and untreated breast cancer, including inflammatory breast cancer.

Who is this for?: People with newly diagnosed and untreated stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Additional blood drawn during a routine blood draw</li> <li class="seamTextUnorderedListItem">Core, breast tissue, and skin biopsy (performed for diagnosis)</li> <li class="seamTextUnorderedListItem">Medical history interview</li> <li class="seamTextUnorderedListItem">Clinical data collected from your medical records</li> <li class="seamTextUnorderedListItem">Photographs of both breasts</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inflammatory breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen.</li> <li class="seamTextUnorderedListItem">Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for inflammatory breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00477100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2006-1072.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/sites-types/ibc' target='_blank'>NCI: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li></ul>
108

Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer

Inflammatory Breast Cancer (IBC) Registry
Icon

Nearest Location from 94107:
671 miles
Banner - MD Anderson Cancer Center
Gilbert, AZ

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT00477100

Icon

Phase NA

109

WOKVAC Vaccine with Chemotherapy and Two Anti-HER2 Targeted Therapies Before Surgery for Stage I-III, HER2 Positive, HR Negative Breast Cancer

A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy

Purpose: To study the anti-cancer activity, safety and side effects of giving the WOKVAC vaccine in combination with the chemotherapy paclitaxel (Taxol®) and the anti-HER2 targeted therapies trastuzumab (Herceptin®) and pertuzumab (Perjeta®) before surgery.

Who is this for?: People with stage I, stage II or stage III, HER2 positive (HER2+), hormone negative (ER- and PR-) breast cancer who have not yet had surgery. If you have already started chemotherapy before surgery, you will be allowed to enroll but will not receive the vaccine. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following for three months before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">WOKVAC vaccine, by injection, 3 times</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every week (2 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pertuzumab, (Perjeta®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">WOKVAC is an experimental vaccine designed to stimulate your immune system to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy routinely used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®) and trastuzumab (Herceptin®) are HER2-targeted therapies used to treat HER2 positive (HER2+) breast cancer.</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®) is approved to treat early-stage HER2 positive breast cancer with tumors 2 cm or larger or with positive lymph nodes. It's use in this trial may be considered experimental depending upon the size of your tumors and if your lymph nodes are positive for cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04329065' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.wingsofkaren.org/dr-king---dr-disis' target='_blank'>Wings of Karen: WOKVAC Vaccine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/neoadjuvant-therapy/' target='_blank'>Susan G. Komen: Neoadjuvant Therapies for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/perjeta-plus-herceptin-and-chemo-shows-benefits' target='_blank'>Breastcancer.org: Adding Perjeta to Herceptin and Chemotherapy After Surgery Shows Benefits in Early-Stage HER2-Positive Breast Cancer</a> </li></ul>
109

WOKVAC Vaccine with Chemotherapy and Two Anti-HER2 Targeted Therapies Before Surgery for Stage I-III, HER2 Positive, HR Negative Breast Cancer

A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy
Icon

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Icon

Visits:
1 or 2 visits a week, for 3 months before surgery

Icon

ClinicalTrials.gov: NCT04329065

Icon

Phase II

110

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Multi-Functional Magnetic Resonance Imaging Modalities for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy

Purpose: To study if MRI scans can earlier and more accurately predict and evaluate response to neoadjuvant (before surgery) chemotherapy.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans, 4 times over the course of chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment, like chemotherapy, before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies. </li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan is a type of scan that uses a very strong magnet and no radiation or x-ray energy to take very detailed pictures of parts of the body.</li> <li class="seamTextUnorderedListItem">MRI scans are often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment to measure the tumor size changes in response to treatment and plan for surgery.</li> <li class="seamTextUnorderedListItem">MRI scans are used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment.</li> <li class="seamTextUnorderedListItem">You will receive 4 MRI scans: before treatment, after the first treatment cycle, midway through treatment, and at the end of treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05704062' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>
110

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Multi-Functional Magnetic Resonance Imaging Modalities for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy
Icon

Nearest Location from 94107:
682 miles
University of Washington
Seattle, WA

Icon

Visits:
4 visits

Icon

ClinicalTrials.gov: NCT05704062

Icon

Phase NA

111

Virtual Weight Loss Program for Latina Women After Treatment

Using a SMART Design to Evaluate Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors

Purpose: To study if a culturally appropriate weight loss program helps Latina breast cancer survivors lose weight.

Who is this for?: Hispanic/Latina women with stage I, stage II, or stage III breast cancer who were diagnosed within the last 5 years and have completed treatment (except hormone therapy). You must have a BMI >30. You must not smoke or have diabetes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Weight loss and exercise program, virtual</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Cook for Your Life website</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Weight loss, exercise, and health education program, virtual</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Cook for Your Life website</li> </ul> <p class="seamTextPara"> After 1 month, participants who do not achieve weight loss will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Weight loss, exercise, and health education program, virtual</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Cook for Your Life website</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Weight loss, exercise, and health education program, virtual</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Cook for Your Life website</li> <li class="seamTextUnorderedListItem">Personalized health coaching sessions, by phone, 14 sessions</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Weight loss, exercise, and health education program, virtual</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Cook for Your Life website</li> <li class="seamTextUnorderedListItem">Personalized health coaching sessions, by phone, 14 sessions</li> <li class="seamTextUnorderedListItem">Receive a bag of groceries, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Approximately 80% of Latinas in the United States are overweight, which can lead to poor breast cancer outcomes.</li> <li class="seamTextUnorderedListItem">A culturally appropriate program to promote and maintain weight loss in Latina breast cancer survivors is needed.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05930483' target='_blank'>ClinicalTrials.gov</a> </li></ul>
111

Virtual Weight Loss Program for Latina Women After Treatment

Using a SMART Design to Evaluate Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors
Icon

Nearest Location from 94107:
682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

Icon

Visits:
At least 2 visits in 1 year

Icon

ClinicalTrials.gov: NCT05930483

Icon

Phase NA

112

AVA6000 Chemotherapy for Advanced Breast Cancer

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AVA6000, an experimental chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received standard treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVA6000, by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVA6000 is an experimental form of doxorubicin chemotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04969835' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://avacta.com/therapeutics/precision/' target='_blank'>Avacta Life Sciences: AVA6000 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>
112

AVA6000 Chemotherapy for Advanced Breast Cancer

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours
Icon

Nearest Location from 94107:
682 miles
Fred Hutchinson Cancer Center
Seattle, WA

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT04969835

Icon

Phase I

113

Tamoxifen Hormone Therapy to Reduce Breast Density and Breast Cancer Risk for Premenopausal Women

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

Purpose: To study the ability of low dose tamoxifen (Nolvadex®) to decrease breast density and breast cancer risk.

Who is this for?: Premenopausal women 18-55 years old who have a history of estrogen receptor positive (ER+) DCIS and have completed treatment at least 3 months ago, who have a history of LCIS, who have received abnormal biopsy results, or who have a high risk for breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily for 6 months to 2 years</li> <li class="seamTextUnorderedListItem">Mammograms, 4 times within 1.5 years</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 1.5 years</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dense breasts are a risk factor for breast cancer.</li> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). It works by blocking the effects of the hormone estrogen in the breast.</li> <li class="seamTextUnorderedListItem">Tamoxifen reduces breast density, even at low doses, and is approved for the prevention of breast cancer.</li> <li class="seamTextUnorderedListItem">The researchers may change your tamoxifen dose according to changes in your breast density as seen on a mammogram.</li> <li class="seamTextUnorderedListItem">DCIS or LCIS are also known as stage 0 breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06184750' target='_blank'>ClinicalTrials.gov</a> </li></ul>
113

Tamoxifen Hormone Therapy to Reduce Breast Density and Breast Cancer Risk for Premenopausal Women

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial
Icon

Nearest Location from 94107:
752 miles
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, AZ

Icon

Visits:
4 visits within 1.5 years

Icon

ClinicalTrials.gov: NCT06184750

Icon

Phase II

114

Registry to Study Cancer Prevention, Detection, and Treatment

Integrated Cancer Repository for Cancer Research

Purpose: To create a registry to study strategies for prevention, screening, early detection, and personalized treatment of cancer.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer, people at high risk for breast cancer, or people who have not been diagnosed with breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood and urine samples during routine visits</li> <li class="seamTextUnorderedListItem">Provide tissue samples from surgery or biopsy</li> <li class="seamTextUnorderedListItem">Questionnaires, 1 time every year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This registry will compare samples between people with breast cancer, people at high risk for breast cancer, and people who do not have breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02012699' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://icare2project.org' target='_blank'>iCaRe2 Project</a> </li></ul>
114

Registry to Study Cancer Prevention, Detection, and Treatment

Integrated Cancer Repository for Cancer Research
Icon

Nearest Location from 94107:
804 miles
Bozeman Health Deaconess Hospital
Bozeman, MT

Icon

Visits:
Coincides with routine care, at least 1 visit every year

Icon

ClinicalTrials.gov: NCT02012699

Icon

Phase NA

115

Psilocybin and Psychotherapy to Support Fear of Recurrence for Women with Stage I-II Breast Cancer

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission

Purpose: To study whether psilocybin and psychotherapy can reduce the fear of recurrence (cancer coming back).

Who is this for?: Women with stage I or stage II breast cancer who completed treatment at least 6 months ago. You must have a support person who agrees to take you home after receiving psilocybin. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Psilocybin, 1 time</li> <li class="seamTextUnorderedListItem">Psychotherapy, 4 times</li> <li class="seamTextUnorderedListItem">Surveys, 5 times within 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Psilocybin is a molecule found in psychedelic (magic) mushrooms.</li> <li class="seamTextUnorderedListItem">Psilocybin plus psychotherapy may reduce distress in people with cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling other people with breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06430541' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://nyulangone.org/news/mental-health-benefits-one-dose-psychedelic-drug-last-years-people-cancer' target='_blank'>New York University Langone Health: Psilocybin and Mental Health in People with Cancer</a> </li></ul>
115

Psilocybin and Psychotherapy to Support Fear of Recurrence for Women with Stage I-II Breast Cancer

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission
Icon

Nearest Location from 94107:
941 miles
University of Colorado Cancer Center
Aurora, CO

Icon

Visits:
5 visits within 6 months

Icon

ClinicalTrials.gov: NCT06430541

Icon

Phase I

116

Registry to Study Immune System Response to Breast Cancer in Women Under Age 50

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction

Purpose: To determine how the immune system responds to different types of tumors or to tumors that develop during or after a pregnancy. Some of the breast cancer tissue collected in this study will be used to create models that develop and test new drug treatments.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are 50 years or younger. View full eligibility criteria

What's involved?

<p class="seamTextPara"> All participants will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue, blood, and urine samples, if recently diagnosed</li> <li class="seamTextUnorderedListItem">Tissue donation only, if enrolled after treatment has begun or has ended</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are interested in learning more about the role the immune system plays in cancer. </li> <li class="seamTextUnorderedListItem">This study is looking specifically at the level of immune suppression seen in breast cancer that occurs in women under age 50.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01503190' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/tips/immune/' target='_blank'>Breastcancer.org: Understanding Your Immune System</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.youngsurvival.org/' target='_blank'>Young Survival Coalition</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/faculty/Pages/VirginiaFBorges,MD.aspx' target='_blank'>Lead Researcher: Virginia F. Borges, MD</a> </li></ul>
116

Registry to Study Immune System Response to Breast Cancer in Women Under Age 50

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction
Icon

Nearest Location from 94107:
941 miles
University of Colorado Denver
Aurora, CO

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT01503190

Icon

Phase NA

117

ATX-295 Targeted Therapy for Advanced Breast Cancer

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

Purpose: To study the safety, best dose, and effects (good and bad) of ATX-295, an experimental KIF18A inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATX-295, by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATX-295 is an experimental type of targeted therapy called a KIF18A inhibitor.</li> <li class="seamTextUnorderedListItem">Blocking KIF18A may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">KIF18A is a protein important for cell division, especially in tumors with high chromosomal instability (CIN) and TP53 mutations.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06799065' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://accenttx.com/approach-pipeline/' target='_blank'>Accent Therapeutics: ATX-295 (KIF18A Inhibitor) Drug Information Page</a> </li></ul>
117

ATX-295 Targeted Therapy for Advanced Breast Cancer

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer
Icon

Nearest Location from 94107:
941 miles
University of Colorado Denver
Aurora, CO

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06799065

Icon

Phase I

118

Patritumab Deruxtecan Antibody Drug Conjugate with Anti-HER2 Targeted Therapy for Advanced HER2+ Breast Cancer

HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of patritumab deruxtecan (MK-1022), an experimental antibody drug conjugate (ADC), with other anti-HER2 targeted therapies.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer. You must not have received more than 5 previous lines of anti-HER2 targeted therapy. You must not have leptomeningeal metastases (leptomeningeal disease). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups based on your treatment history: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Recieved T-DXd and 2-5 Lines of Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Received up to 5 Lines of Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Received T-DXd and up to 3 Lines of Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan is an experimental HER3-targeted antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells. </li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Patritumab deruxtecan's antibody targets HER3 and delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are anti-HER2 targeted therapies commonly used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps HER2+ cancer cells grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06686394' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update on Antibody-Drug Conjugates (ADCs) for MBC</a> </li></ul>
118

Patritumab Deruxtecan Antibody Drug Conjugate with Anti-HER2 Targeted Therapy for Advanced HER2+ Breast Cancer

HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer
Icon

Nearest Location from 94107:
941 miles
University of Colorado Anschutz Medical Campus ( Site 0057)
Aurora, CO

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06686394

Icon

Phase I-II

119

Shorter Versus Longer Lymph Node Radiation for Stage I-III Node-Positive Breast Cancer

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of shorter lymph node radiation.

Who is this for?: People with some stage I, stage II, or stage III breast cancer with positive lymph nodes and negative margins after surgery who are planning to receive lymph node radiation. Surgery and chemotherapy (if recommended) must have been completed in the last 3 months. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, delivered in many fractions</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, delivered in fewer fractions</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07076485' target='_blank'>ClinicalTrials.gov</a> </li></ul>
119

Shorter Versus Longer Lymph Node Radiation for Stage I-III Node-Positive Breast Cancer

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Icon

Nearest Location from 94107:
946 miles
Banner MD Anderson Northern Colorado
Loveland, CO

Icon

Visits:
Number of visits not specified

Icon

ClinicalTrials.gov: NCT07076485

Icon

Phase II

120

Zanidatamab Targeted Therapy for Advanced HER2 Positive Breast Cancer

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of zanidatamab, an experimental targeted therapy.

Who is this for?: People with advanced HER2 positive (HER2+ (IHC3+)) breast cancer who have received trastuzumab deruxtecan (T-DXd, Enhertu®) and have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab (ZW25) is an experimental anti-HER2 targeted therapy and bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 positive is IHC 3+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06695845' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zymeworks.com/pipeline#zanidatamab' target='_blank'>Zymeworks Drug Information Page: Zanidatamab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/dr-montero-on-zanidatamab-and-evorpacept-in-her2-expressing-metastatic-breast-cancer' target='_blank'>OncLive: Zanidatamab for Metastatic HER2+ Breast Cancer</a> </li></ul>
120

Zanidatamab Targeted Therapy for Advanced HER2 Positive Breast Cancer

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Icon

Nearest Location from 94107:
946 miles
Rocky Mountain Cancer Center
Littleton, CO

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06695845

Icon

Phase II

121

EIK1004 Targeted Therapy for Advanced Breast Cancer with HRR Mutations

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors (EIK1004-001)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of EIK1004 (IMP1707), an experimental PARP1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have not ever received chemotherapy and hormone therapy (if hormone receptor positive). You must have a BRCA1, BRCA2, PALB2, ATM, or CHEK2 gene mutation. You must not have received more than 1 PARP inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EIK1004 (IMP1707), by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EIK1004 is an experimental targeted therapy called a PARP1 inhibitor.</li> <li class="seamTextUnorderedListItem">PARP inhibitors stop the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP).</li> <li class="seamTextUnorderedListItem">BRCA1, BRCA2, PALB2, ATM, and CHEK2 gene mutations are homologous recombination repair (HRR) or homologous recombination deficient (HRD) mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06907043' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
121

EIK1004 Targeted Therapy for Advanced Breast Cancer with HRR Mutations

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors (EIK1004-001)
Icon

Nearest Location from 94107:
948 miles
Sarah Cannon Research Institute at HealthOne
Denver, CO

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06907043

Icon

Phase I-II

122

MDX2001 Immunotherapy for Advanced Breast Cancer

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of MDX2001, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MDX2001, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MDX2001 is an experimental immunotherapy called a tetraspecific antibody. MDX2001 may help target the immune system to help identify and kill tumor cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06239194' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.modextherapeutics.com/pipeline/' target='_blank'>ModeX Therapeutics: MDX2001 Drug Information Page</a> </li></ul>
122

MDX2001 Immunotherapy for Advanced Breast Cancer

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Icon

Nearest Location from 94107:
948 miles
Sarah Cannon Research Institute
Denver, CO

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06239194

Icon

Phase I-II

123

Live, Virtual Exercise Training to Increase Physical Activity and Quality of Life for Stage 0-III Breast Cancer

Efficacy of a Group-based Videoconference Intervention to Increase Physical Activity in Cancer Survivors

Purpose: To study how live, virtual group exercise compares to recorded videos for increasing physical activity, improving physical fitness and quality of life, and reducing loneliness.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who were diagnosed within the last 5 years, have completed their cancer treatment, and are not planning additional treatment in the next 9 months. Current hormone therapy and immunotherapy are allowed. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Live, group-based exercise, virtual, 1-hour sessions twice a week for 3 months</li> <li class="seamTextUnorderedListItem">Behavior change discussion sessions, 5 times within 3 months</li> <li class="seamTextUnorderedListItem">Wear a fitbit</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times within 6 months</li> <li class="seamTextUnorderedListItem">Physical fitness tests, 3 times within 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Recorded exercise sessions, virtual, 1-hour sessions twice a week for 3 months</li> <li class="seamTextUnorderedListItem">Wear a fitbit</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times within 6 months</li> <li class="seamTextUnorderedListItem">Physical fitness tests, 3 times within 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Moderate to vigorous exercise improves physical fitness and overall health, but only about 14% of cancer survivors get the recommended amount of exercise.</li> <li class="seamTextUnorderedListItem">Strategies to increase exercise can include support and instruction. Delivering support and instruction with live, virtual programming may be effective for increasing exercise.</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07290309' target='_blank'>ClinicalTrials.gov</a> </li></ul>
123

Live, Virtual Exercise Training to Increase Physical Activity and Quality of Life for Stage 0-III Breast Cancer

Efficacy of a Group-based Videoconference Intervention to Increase Physical Activity in Cancer Survivors
Icon

Nearest Location from 94107:
949 miles
Human Performance Clinical Research Lab
Fort Collins, CO

Icon

Visits:
Number of visits unavailable, 9 months

Icon

ClinicalTrials.gov: NCT07290309

Icon

Phase NA

124

Sulforaphane Nutritional Supplement to Reduce Heart Problems from Doxorubicin Chemotherapy

Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)

Purpose: To study if sulforaphane (Avmacol®) reduces heart problems caused by doxorubicin (Adriamycin®) chemotherapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive doxorubicin (Adriamycin®) chemotherapy. You must not have received radiation to your chest, and if your tumor is HER2-positive, you must not be receiving trastuzumab (Herceptin®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sulforaphane (Avmacol®), by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood tests, 7 times in 1 year</li> <li class="seamTextUnorderedListItem">Heart function tests, 2 times in 1 year</li> <li class="seamTextUnorderedListItem">PET scan, 3 times in 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for sulforaphane (Avmacol®), by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Blood tests, 7 times in 1 year</li> <li class="seamTextUnorderedListItem">Heart function tests, 2 times in 1 year</li> <li class="seamTextUnorderedListItem">PET scan, 3 times in 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®) is a chemotherapy commonly used to treat breast cancer. It can cause injury to the heart in about 10-20% of patients.</li> <li class="seamTextUnorderedListItem">There is a need to develop new strategies that prevent the harmful effects of doxorubicin (Adriamycin®) but maintain its effectiveness as a cancer therapy.</li> <li class="seamTextUnorderedListItem">Sulforaphane (Avmacol®) is an experimental dietary supplement derived from broccoli and other cruciferous vegetables. It may keep normal cells healthy and enhance cancer cell sensitivity to doxorubicin (Adriamycin®).</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03934905' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/adriamycin' target='_blank'>Breastcancer.org: Doxorubicin (Adriamycin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.avmacol.com/' target='_blank'>Nutramax Laboratories: Sulforaphane (Avmacol®)</a> </li></ul>
124

Sulforaphane Nutritional Supplement to Reduce Heart Problems from Doxorubicin Chemotherapy

Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)
Icon

Nearest Location from 94107:
1185 miles
Texas Tech University Health Sciences Center
Lubbock, TX

Icon

Visits:
At least 7 visits within 1 year

Icon

ClinicalTrials.gov: NCT03934905

Icon

Phase I-II

125

A Registry for People with Triple Negative or ER Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT)

Purpose: To learn more about the relationship between genetic mutations and cancer outcomes.

Who is this for?: People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER Low (1%-10% ER) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> This is a data collection (registry) study. You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER Low breast cancer.</li> <li class="seamTextUnorderedListItem">Studies have found a relationship between triple negative breast cancer and inherited BRCA1 and BRCA2 mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PTEN, P53, and PALB2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>ASCO: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Expressions</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ghr.nlm.nih.gov/condition/breast-cancer' target='_blank'>NIH Genetics Home Reference: Breast Cancer</a> </li></ul>
125

A Registry for People with Triple Negative or ER Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT)
Icon

Nearest Location from 94107:
1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays, KS

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT02302742

Icon

Phase NA

126

Vagus Nerve Stimulation for Heart Problems in People with Stage I-IV Breast Cancer

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

Purpose: To study if low level vagus nerve stimulation will improve heart function.

Who is this for?: People at least 50 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received doxorubicin (Adriamycin®) and/or anti-HER2 targeted therapy within the last 3 months. You must also meet at least 1 of the following criteria: previous chest radiation, type 2 diabetes, high blood pressure, current smoker, obesity, and/or certain heart conditions. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Heart function tests, 2 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Low level stimulation to one ear with handheld device, 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Heart function tests, 2 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Low level stimulation to one ear (at a different location than group 1) with handheld device, 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">These medications include some chemotherapy and anti-HER2 targeted therapy drugs.</li> <li class="seamTextUnorderedListItem">Stimulation of a nerve called the vagus nerve can have beneficial effects on the heart. Part of the vagus nerve is in the ear.</li> <li class="seamTextUnorderedListItem">The vagus nerve stimulation sessions are 1 hour.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05921253' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/some-meds-up-heart-risk-in-overweight-women' target='_blank'>Breastcancer.org: Anthracyclines, Anti-HER2 Medications, and Heart Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.parasym.co/about-parasym.html' target='_blank'>Parasym: Vagus Nerve Stimulation</a> </li></ul>
126

Vagus Nerve Stimulation for Heart Problems in People with Stage I-IV Breast Cancer

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)
Icon

Nearest Location from 94107:
1387 miles
Stephenson Cancer Center
Oklahoma City, OK

Icon

Visits:
2 visits within 2 weeks

Icon

ClinicalTrials.gov: NCT05921253

Icon

Phase I

127

ISM3091 Targeted Therapy for Advanced Breast Cancer

A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ISM3091 in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of ISM3091, an experimental USP1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ISM3091, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ISM3091 is an experimental targeted therapy called a USP1 inhibitor. Inhibiting USP1 may stop cancer cells from repairing DNA and growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05932862' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://insilico.com/pipeline_target_usp1' target='_blank'>InSilico Medicine: ISM3091 Drug Information Page</a> </li></ul>
127

ISM3091 Targeted Therapy for Advanced Breast Cancer

A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ISM3091 in Patients With Advanced Solid Tumors
Icon

Nearest Location from 94107:
1387 miles
Exelixis Clinical Site #13
Oklahoma City, OK

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05932862

Icon

Phase I

128

Surveys and Patient Navigation to Improve Completion of Radiation Therapy for African American, Native American, or Hispanic People With Stage 0-III Breast Cancer

Impact of Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Purpose: To learn about completion of radiation therapy by underrepresented people with cancer and if patient navigators can help patients complete their recommended radiation.

Who is this for?: African American, Native American, or Hispanic people with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive radiation therapy as treatment for their cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys, 3 times within 6 months</li> <li class="seamTextUnorderedListItem">Navigation services</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The surveys are culturally appropriate and adapted from <q>Walking Forward,</q> a patient navigator program that provides culturally appropriate community education on cancer, screening, and treatment, including barriers to radiation therapy and concerns about transportation.</li> <li class="seamTextUnorderedListItem">Patient navigation is when trained people help patients receive the care they need. Patient navigation may improve patient access to radiation.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with prostate cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07014618' target='_blank'>ClinicalTrials.gov</a> </li></ul>
128

Surveys and Patient Navigation to Improve Completion of Radiation Therapy for African American, Native American, or Hispanic People With Stage 0-III Breast Cancer

Impact of Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Icon

Nearest Location from 94107:
1388 miles
OU Health Stephenson Cancer Center
Oklahoma City, OK

Icon

Visits:
Number of visits unavailable, 6 months.

Icon

ClinicalTrials.gov: NCT07014618

Icon

Phase NA

129

Radioligand Therapy for Advanced Breast Cancer

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DWJ155 and Safety and Imaging Properties of [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of [177Lu]Lu-DWJ155, an investigational radioligand therapy, in people with certain advanced cancers.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that has progressed despite treatment and who have no other standard treatment options available. If you have HER2+ breast cancer, you must have progressed after at least 2 prior lines of therapy for advanced disease. This trial is also enrolling people with other advanced cancers. View full eligibility criteria

What's involved?


What's being studied?


How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07660055' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2025/09/5-things-to-know-about-radioligand-therapy/' target='_blank'>Dana Farber: 5 Things to Know About Radioligand Therapy</a> </li></ul>
129

Radioligand Therapy for Advanced Breast Cancer

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DWJ155 and Safety and Imaging Properties of [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Icon

Nearest Location from 94107:
1414 miles
Nebraska Cancer Specialists
Omaha, NE

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07660055

Icon

Phase I

130

Plan to Control Pain Due to Lumpectomy Without Opioids for Stage I-III Breast Cancer

The Utility of Enhanced Recovery After Surgery (ERAS) Protocols in Breast Conserving Surgery: A Randomized Control Trial (ERAS)

Purpose: To study whether the ERAS plan reduces the use of opioids after lumpectomy.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive a lumpectomy and sentinel lymph node biopsy. You must not have cancer in your lymph nodes as determined with imaging or physical exam. You must not have yet received treatment for your breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental (ERAS Plan)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carbohydrate drink, by mouth, twice before surgery</li> <li class="seamTextUnorderedListItem">Acetaminophen (Tylenol®), by mouth, before surgery</li> <li class="seamTextUnorderedListItem">Celecoxib (Celebrex®), by mouth, before surgery</li> <li class="seamTextUnorderedListItem">Acetaminophen (Tylenol®), Scopolamine, Dexamethasone, and/or Ondansetron (optional), after surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acetaminophen (Tylenol®), Scopolamine, Dexamethasone, and/or Ondansetron (optional), after surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enhanced Recovery After Surgery (ERAS) is a plan that aims to maximize pain control after surgery without the use of opioids.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06938581' target='_blank'>ClinicalTrials.gov</a> </li></ul>
130

Plan to Control Pain Due to Lumpectomy Without Opioids for Stage I-III Breast Cancer

The Utility of Enhanced Recovery After Surgery (ERAS) Protocols in Breast Conserving Surgery: A Randomized Control Trial (ERAS)
Icon

Nearest Location from 94107:
1418 miles
University of Nebraska Medical Center
Omaha, NE

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06938581

Icon

Phase NA

131

Chemotherapy Treatment At Home for People with Advanced Breast Cancer

Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic

Purpose: To compare the safety and effects (good and bad) of receiving paclitaxel (Taxol®) chemotherapy at home and at a clinic.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who are receiving chemotherapy, trastuzumab (Herceptin®), leuprolide (Lupron®), or goserelin (Zoladex®). You must live within 35 miles from Mayo Clinic in Jacksonville, FL. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Treatment At Home</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive paclitaxel (Taxol®) chemotherapy at home, 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Treatment At Clinic and Home</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive paclitaxel (Taxol®) chemotherapy at clinic, 2 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive paclitaxel (Taxol®) chemotherapy at home, 4 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Providing cancer treatment at home, versus in the clinic, may help reduce mental and financial distress and increase treatment compliance, especially for marginalized patients and communities.</li> <li class="seamTextUnorderedListItem">Home health appointments include chemotherapy administration, routine vital sign monitoring, and routine lab tests.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05969860' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/medical-professionals/cancer/news/high-quality-advanced-cancer-care-conducted-at-home/mac-20538184' target='_blank'>Mayo Clinic: Cancer CARE Beyond Walls</a> </li></ul>
131

Chemotherapy Treatment At Home for People with Advanced Breast Cancer

Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic
Icon

Nearest Location from 94107:
1454 miles
Altru Cancer Center
Grand Forks, ND

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05969860

Icon

Phase II

132

Reishi Mushroom Extract for Fatigue and Pain for People with Stage 0-III Breast Cancer

Reishi Mushroom Extract for Fatigue and/or Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial

Purpose: To study the ability of Reishi mushroom extract to reduce fatigue, joint pain, and/or muscle pain.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III estrogen receptor positive (ER+) breast cancer who are receiving an aromatase inhibitor and experiencing fatigue. You must not be receiving a CDK4/6 inhibitor or olaparib (Lynparza®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Reishi mushroom extract, by mouth, daily for the first month</li> <li class="seamTextUnorderedListItem">Placebo for Reishi mushroom extract, by mouth, daily for the second month</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for Reishi mushroom extract, by mouth, daily for the first month</li> <li class="seamTextUnorderedListItem">Reishi mushroom extract, by mouth, daily for the second month</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor-positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Side effects of aromatase inhibitors may include fatigue, joint pain, and/or muscle pain.</li> <li class="seamTextUnorderedListItem">Studies suggest that Reishi mushroom extract has beneficial effects including reducing fatigue.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06028022' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors and Pain</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancercare.org/questions/11' target='_blank'>Cancer Care: Aromatase Inhibitors and Fatigue</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/nutrition/reishi-mushroom-benefits#TOC_TITLE_HDR_8' target='_blank'>Healthline: Reishi Mushroom Extract</a> </li></ul>
132

Reishi Mushroom Extract for Fatigue and Pain for People with Stage 0-III Breast Cancer

Reishi Mushroom Extract for Fatigue and/or Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial
Icon

Nearest Location from 94107:
1455 miles
Sanford Worthington Medical Center
Worthington, MN

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06028022

Icon

Phase II

133

AVA6103 Targeted Therapy for Advanced Hormone Receptor Positive Breast Cancer

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of AVA6103, a targeted therapy. AVA6103 is designed to release a cancer fighting drug at the tumor itself, using a protein called FAP that is found around many tumors, in an effort to fight the cancer while limiting damage to healthy tissue.

Who is this for?: People with advanced (stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer who have received all standard treatments that are approved for their cancer, or who are not able to receive those treatments, or who have chosen not to receive them. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVA6103, by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying AVA6103, a drug that is activated by a protein called FAP, which is commonly found around tumors. </li> <li class="seamTextUnorderedListItem">Once activated, AVA6103 releases a cancer fighting compound directly at the tumor site. The goal is to attack the cancer while sparing more of the healthy tissue around it.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07454642' target='_blank'>ClinicalTrials.gov</a> </li></ul>
133

AVA6103 Targeted Therapy for Advanced Hormone Receptor Positive Breast Cancer

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Icon

Nearest Location from 94107:
1471 miles
NEXT Oncology
Irving, TX

Icon

Visits:
About 1 visit every 2 to 3 weeks

Icon

ClinicalTrials.gov: NCT07454642

Icon

Phase I

134

Tucatinib Targeted Therapy and Doxil Chemotherapy for Advanced HER2+ Breast Cancer

Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of tucatinib (Tukysa®) tyrosine kinase inhibitor with doxorubicin (Doxil®) chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received anti-HER2 targeted therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Doxorubicin (Doxil®), by IV, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps HER2+ cancer cells grow.</li> <li class="seamTextUnorderedListItem">Doxorubicin (Doxil®) is a chemotherapy drug commonly used to treat breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05748834' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/tukysa' target='_blank'>Breastcancer.org: Tucatinib (Tukysa®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/doxil' target='_blank'>Breastcancer.org: Doxorubicin (Doxil®)</a> </li></ul>
134

Tucatinib Targeted Therapy and Doxil Chemotherapy for Advanced HER2+ Breast Cancer

Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer
Icon

Nearest Location from 94107:
1478 miles
Texas Oncology- San Antonio
San Antonio, TX

Icon

Visits:
1 visit every month

Icon

ClinicalTrials.gov: NCT05748834

Icon

Phase II

135

Phone App and Patient Navigator to Help Latina Women with Hormone Receptor Positive (ER+ and/or PR+) Breast Cancer Take Their Hormone Therapy

mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health

Purpose: To find out whether a bilingual (English and Spanish) phone app called the HT Helper App, used together with support from a patient navigator, can help people take their hormone therapy the way it was prescribed.

Who is this for?: Hispanic/Latina women with stage I or stage II or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have been prescribed hormone therapy and started it within the past 1 to 24 months. You must be facing one or more everyday (non-medical) barriers that make it harder to take your medication, such as income, health insurance, education, health literacy, or language. You can take part in the study in English or Spanish. You must be receiving care at the Mays Cancer Center at UT Health San Antonio. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HT Helper App plus support from a patient navigator</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Support from a patient navigator alone</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Everyone will complete checkups and questionnaires about medication use, side effects, confidence, social support, quality of life, and mood.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy lowers the chance of breast cancer coming back and reduces the risk of dying from it, but many people find it hard to keep taking it every day. </li> <li class="seamTextUnorderedListItem">The app is designed to increase education, build confidence, make it easier to talk with the care team, and connect people with resources that address everyday barriers such as cost, insurance, education, health literacy, and language.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07706127' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/side-effects' target='_blank'>BreastCancerTrials.org: Side Effects of Hormonal Therapy for Breast Cancer</a> </li></ul>
135

Phone App and Patient Navigator to Help Latina Women with Hormone Receptor Positive (ER+ and/or PR+) Breast Cancer Take Their Hormone Therapy

mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health
Icon

Nearest Location from 94107:
1481 miles
The University of Texas Health Science Center at San Antonio
San Antonio, TX

Icon

Visits:
5 visits over 18 months

Icon

ClinicalTrials.gov: NCT07706127

Icon

Phase NA

136

Ketogenic Diet Before Surgery for Stage I or II Breast Cancer

Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer

Purpose: To study how following a ketogenic diet for 3 weeks before breast cancer surgery affects the immune environment inside the tumor. Researchers want to learn whether a low-carbohydrate, high-fat diet changes the balance of certain immune cells (called macrophages) in the tumor, and how it affects ketone levels, blood sugar, and quality of life.

Who is this for?: Women who are postmenopausal, with stage I or stage II breast cancer, who are planning to have breast surgery (mastectomy or partial mastectomy) and who do not need treatment before surgery. You must be receiving care at Mays Cancer Center, UT Health San Antonio. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ketogenic diet (low-carbohydrate, high-fat) for 3 weeks before your scheduled breast surgery</li> <li class="seamTextUnorderedListItem">Meet with a dietitian </li> <li class="seamTextUnorderedListItem">Check your blood sugar and ketone levels daily at home</li> <li class="seamTextUnorderedListItem">Keep a daily diary of your food intake and physical activity</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is looking at whether eating a ketogenic diet for the three weeks before breast cancer surgery changes the immune cells inside the tumor. </li> <li class="seamTextUnorderedListItem">Doctors will compare tissue from the original biopsy to tissue removed during surgery, looking at the balance between two types of immune cells called macrophages.</li> <li class="seamTextUnorderedListItem">Researchers are looking to find out how eating a high-fat, low-carbohydrate ketogenic, or keto diet alters the immune system.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07574671' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.moffitt.org/endeavor/archive/can-the-keto-diet-improve-cancer-treatment/' target='_blank'>Moffitt Cancer Center: Can the Keto Diet Improve Cancer Treatment?</a> </li></ul>
136

Ketogenic Diet Before Surgery for Stage I or II Breast Cancer

Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer
Icon

Nearest Location from 94107:
1481 miles
Mays Cancer Center, UT Health San Antonio
San Antonio, TX

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT07574671

Icon

Phase NA

137

SYS6043 Antibody Drug Conjugate for Advanced Breast Cancer

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of SYS6043, an experimental B7-H3 targeted antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that have progressed after standard treatments or who have no standard treatment options available. You must not have received an antibody drug conjugate (ADC). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SYS6043 by IV, once every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SYS6043 is an experimental antibody drug conjugate (ADC) that uses an antibody to deliver chemotherapy directly to cancer cells with the B7-H3 protein.</li> <li class="seamTextUnorderedListItem">B7-H3 is a protein found on some cancer cells that helps them hide from the immune system.</li> <li class="seamTextUnorderedListItem">By blocking or targeting B7-H3, treatments like SYS6043 may make it easier for the immune system to recognize and attack the cancer.</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07424547' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
137

SYS6043 Antibody Drug Conjugate for Advanced Breast Cancer

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Icon

Nearest Location from 94107:
1481 miles
NEXT Oncology San Antonio
San Antonio, TX

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT07424547

Icon

Phase I

138

IDOV-Immune for Advanced Breast Cancer

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of IDOV-Immune, a specially designed virus that targets and destroys cancer cells while helping the immune system recognize and fight the cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose cancer has progressed or who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IDOV-Immune, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Close monitoring for 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IDOV-Immune is a type of oncolytic virus therapy, which means it uses a modified virus designed to enter and destroy cancer cells. </li> <li class="seamTextUnorderedListItem">It may also help the immune system recognize and attack the tumor.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06910657' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oncolytic-viruses/' target='_blank'>Oncolytic Viruses: Using Viruses to Kill Cancer Cells</a> </li></ul>
138

IDOV-Immune for Advanced Breast Cancer

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors
Icon

Nearest Location from 94107:
1481 miles
South Texas Accelerated Research Therapeutics
San Antonio, TX

Icon

Visits:
At least 1 visit

Icon

ClinicalTrials.gov: NCT06910657

Icon

Phase I

139

Chemotherapy and Targeted Therapy Before Surgery for HER2 Positive Breast Cancer

A Randomized Trial of Neoadjuvant THP vs TCHP for HER2-amplified/Positive Breast Cancer (NeoTHERa)

Purpose: To compare two chemotherapy combinations, one with carboplatin and one without, both given alongside HER2 targeted therapy (trastuzumab and pertuzumab), to see which is more effective at eliminating cancer in the breast and lymph nodes before surgery. The trial also uses a genomic test called HER2DX to see if it can predict which patients are more likely to respond.

Who is this for?: People with stage II or stage III HER2 positive (HER2+) breast cancer who have not had surgery, chemotherapy, anti-HER2 therapy, immunotherapy, hormonal therapy, or radiation for their current breast cancer and are planning to have breast surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Treatment is followed by breast surgery</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is looking at whether leaving out carboplatin from a standard HER2 positive breast cancer treatment regimen before surgery still leads to the cancer being completely eliminated by the time of surgery (called a <q>pathologic complete response</q> or pCR). </li> <li class="seamTextUnorderedListItem">Researchers want to know if the carboplatin adds benefit , or if the same result can be achieved without it, potentially reducing side effects. </li> <li class="seamTextUnorderedListItem">The trial also uses a genomic (gene-based) test called HER2DX, done on a tumor tissue sample taken before treatment, to see if it can predict which patients will respond well.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07220135' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/about-breast-cancer/her2-positive-breast-cancer-treatment-research/' target='_blank'>Breast Cancer Research Foundation: HER2-Positive Breast Cancer: Testing, Treatment, Research</a> </li></ul>
139

Chemotherapy and Targeted Therapy Before Surgery for HER2 Positive Breast Cancer

A Randomized Trial of Neoadjuvant THP vs TCHP for HER2-amplified/Positive Breast Cancer (NeoTHERa)
Icon

Nearest Location from 94107:
1496 miles
KUCC - Overland Park
Overland Park, KS

Icon

Visits:
At least 1 visit every 3 weeks for about 4-5 months and then surgery

Icon

ClinicalTrials.gov: NCT07220135

Icon

Phase II

140

Tamoxifen With or Without Omega-3 Fatty Acids to Reduce the Risk of Breast Cancer for Overweight Postmenopausal Women

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

Purpose: To study if tamoxifen (Nolvadex®) hormone therapy with or without omega-3 fatty acids decreases breast cancer risk in postmenopausal women who are overweight or obese.

Who is this for?: Postmenopausal women 45-65 years old who are overweight or obese and have at least 1 of the following breast cancer risk factors: abnormal biopsy results; history of DCIS (stage 0) or LCIS (stage 0); dense breasts; family history of breast cancer; or a mutation in ATM, BARD1, CDH1, CHEK2, NF1, PTEN, RAD51C, RAD51D, or STK11. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Tamoxifen Alone</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 1 time</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Tamoxifen with Omega-3 Fatty Acids</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Omega-3 fatty acids (Lovaza®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Mammogram, 1 time</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen.</li> <li class="seamTextUnorderedListItem">Tamoxifen is approved by the FDA for preventing breast cancer in women at increased risk. </li> <li class="seamTextUnorderedListItem">Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver and may help prevent cancer in overweight or obese individuals.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06195306' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/treatments/9785-tamoxifen' target='_blank'>Cleveland Clinic: Tamoxifen (Nolvadex®)</a> </li></ul>
140

Tamoxifen With or Without Omega-3 Fatty Acids to Reduce the Risk of Breast Cancer for Overweight Postmenopausal Women

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer
Icon

Nearest Location from 94107:
1500 miles
University of Kansas Cancer Center
Kansas City, KS

Icon

Visits:
At least 2 visits in 6 months

Icon

ClinicalTrials.gov: NCT06195306

Icon

Phase II

141

Comparing 2 Ways to Control Pain During Breast Reconstruction Surgery

ESPBs Vs TAPs for Satisfactory Analgesia Following DIEP Surgery

Purpose: To compare 2 ways to give anesthesia/pain medication to control pain for breast reconstruction surgery.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive breast reconstruction surgery with a deep inferior epigastric perforator (DIEP) flap. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine and dexamethasone, by injection into back, before reconstruction surgery</li> <li class="seamTextUnorderedListItem">Questionnaire about pain, 4 times in 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine and dexamethasone, by injection into abdomen, by injection, before reconstruction surgery</li> <li class="seamTextUnorderedListItem">Questionnaire about pain, 4 times in 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast reconstruction with a deep inferior epigastric perforator (DIEP) flap involves using skin and fat from your abdomen to rebuild the breast.</li> <li class="seamTextUnorderedListItem">Bupivacaine and dexamethasone are common anesthesia/pain medications for breast cancer surgery.</li> <li class="seamTextUnorderedListItem">Giving bupivacaine and dexamethasone by injection into nerves in your back instead of abdomen may work better to control pain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06091241' target='_blank'>ClinicalTrials.gov</a> </li></ul>
141

Comparing 2 Ways to Control Pain During Breast Reconstruction Surgery

ESPBs Vs TAPs for Satisfactory Analgesia Following DIEP Surgery
Icon

Nearest Location from 94107:
1500 miles
University of Kansas Medical Center
Kansas City, KS

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT06091241

Icon

Phase NA

142

Collecting Blood and Tissue Samples From People with Newly Diagnosed Breast Cancer

Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study

Purpose: To study how well a blood test can find tiny amounts of cancer DNA (called circulating tumor DNA, or ctDNA) left behind after treatment.

Who is this for?: People with with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet received treatment. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">The goal is to improve future blood‑based tests that may help doctors monitor cancer more closely.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07318051' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/?utm_campaign=2026_ONC_Clinician_Signatera_Genome&utm_source=google&utm_medium=cpc&utm_term=clinical%20performance%20of%20signatera%20genome&matchtype=b&device=c&utm_' target='_blank'>Natera: Signatera™ Genome Ultrasensitive ctDNA detection</a> </li></ul>
142

Collecting Blood and Tissue Samples From People with Newly Diagnosed Breast Cancer

Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
Icon

Nearest Location from 94107:
1500 miles
Natera, Inc.
Austin, TX

Icon

Visits:
Every six weeks, for up to two years.

Icon

ClinicalTrials.gov: NCT07318051

Icon

Phase NA

143

Registry to Study Stage I-IV HER2 Positive Breast Cancer

Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)

Purpose: To study HER2 positive breast cancer tumors and outcomes.

Who is this for?: People with stage I, stage II, stage II, or stage IV (metastatic) HER2 positive (HER2+) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples</li> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use tumor and blood samples to understand how differences in HER2+ tumors cause differences in treatment response and outcomes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06603597' target='_blank'>ClinicalTrials.gov</a> </li></ul>
143

Registry to Study Stage I-IV HER2 Positive Breast Cancer

Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)
Icon

Nearest Location from 94107:
1502 miles
The University of Kansas Cancer Center
Westwood, KS

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06603597

Icon

Phase NA

144

Robotic Nipple Sparing Mastectomy for Women with DCIS, Stage I-III Breast Cancer, or at High Risk for Breast Cancer

Safety and Feasibility of Robotic Single-port (SP) Nipple Sparing Mastectomy: A Single Institution, Single Arm Pilot Trial

Purpose: To study the safety and effects (good and bad) of nipple sparing mastectomy with da Vinci single port (SP) Surgical System.

Who is this for?: Women with DCIS, stage I, stage II, or some stage III breast cancer, or at high risk for breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nipple sparing mastectomy with da Vinci single port (SP) Surgical System</li> <li class="seamTextUnorderedListItem">Immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm®)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A mastectomy is surgery to remove a breast.</li> <li class="seamTextUnorderedListItem">A nipple sparing mastectomy (NSM) leaves most of the healthy breast skin, including the nipple.</li> <li class="seamTextUnorderedListItem">The da Vinci single port (SP) Surgical System is an experimental surgery system designed for surgeons to perform minimally invasive surgery, such as nipple sparing mastectomy.</li> <li class="seamTextUnorderedListItem">The da Vinci SP Surgical System is approved for use during other surgeries.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05245812' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.intuitive.com/en-us/patients/procedures/general-surgery##' target='_blank'>Intuitive Surgical Device Information Page: Da Vinci Surgical System</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cedars-sinai.org/health-library/diseases-and-conditions/n/nipple-sparing-mastectomy.html' target='_blank'>Cedars-Sinai: Nipple Sparing Mastectomy</a> </li></ul>
144

Robotic Nipple Sparing Mastectomy for Women with DCIS, Stage I-III Breast Cancer, or at High Risk for Breast Cancer

Safety and Feasibility of Robotic Single-port (SP) Nipple Sparing Mastectomy: A Single Institution, Single Arm Pilot Trial
Icon

Nearest Location from 94107:
1509 miles
UT Southwestern
Dallas, TX

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT05245812

Icon

Phase NA

145

Gut Microbiome and Chemotherapy-Induced Nausea in Women with Stage I-III Breast Cancer

A Pilot Study of the Associations Between Chemotherapy-Induced Nausea in Breast Cancer Patients and Gut Microbiome Composition Profiles

Purpose: To study how changes in bacteria in the gut (microbiome) may be associated with chemotherapy-induced nausea.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. You must be receiving care at Mayo Clinic Arizona or Mayo Clinic Florida. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide stool samples, 2 times</li> <li class="seamTextUnorderedListItem">Complete questionnaires, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found in the digestive tract. Most of the microbiome consists of bacteria in your digestive system. These bacteria can be beneficial or harmful. The harmful bacteria cause disease, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">Nausea is a common side effect of many types of chemotherapy.</li> <li class="seamTextUnorderedListItem">You will provide stool samples 2 times: 1) When you begin the trial, and 2) 3-5 days after starting chemotherapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05417867' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hsph.harvard.edu/nutritionsource/microbiome/' target='_blank'>Harvard University: What is the Microbiome?</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/about-us/news-personal-stories/can-gut-bacteria-help-treat-breast-cancer' target='_blank'>Breast Cancer Now: Gut Bacteria and Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/nausea' target='_blank'>Breastcancer.org: Nausea</a> </li></ul>
145

Gut Microbiome and Chemotherapy-Induced Nausea in Women with Stage I-III Breast Cancer

A Pilot Study of the Associations Between Chemotherapy-Induced Nausea in Breast Cancer Patients and Gut Microbiome Composition Profiles
Icon

Nearest Location from 94107:
1539 miles
Mayo Clinic Health System in Mankato
Mankato, MN

Icon

Visits:
2 visits

Icon

ClinicalTrials.gov: NCT05417867

Icon

Phase NA

146

Axelopran for Advanced Breast Cancer in People Using Opioid Pain Medicine

A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of axelopran to see if it can help control cancer growth while also improving symptoms like constipation and overall quality of life.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. If your cancer is hormone receptor positive (ER+ and/or PR+), it must have returned or worsened after treatment with hormone therapy. You must have received at least one line of chemotherapy for advanced breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axelopran alone, by mouth, daily, for 6 weeks</li> <li class="seamTextUnorderedListItem">10 study visits and assessments, 1-2 hours each, over 6 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axelopran is a study medicine that is designed to ease opioid‑related bowel problems while also being studied for its potential to help slow or stabilize cancer growth.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07354919' target='_blank'>ClinicalTrials.gov</a> </li></ul>
146

Axelopran for Advanced Breast Cancer in People Using Opioid Pain Medicine

A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)
Icon

Nearest Location from 94107:
1576 miles
HealthPartners Frauenshuh Cancer Research Center
Saint Louis Park, MN

Icon

Visits:
10 visits over 6 weeks

Icon

ClinicalTrials.gov: NCT07354919

Icon

Phase II

147

PRE-I-SPY: Targeted Therapy and Immunotherapy for Advanced HER2+ or HER2 Low Breast Cancer

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial (PRE-I-SPY-PI)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of various combinations of targeted therapy and immunotherapy drugs for people with advanced breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 low breast cancer who have received no more than 1 line of therapy for advanced disease. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evorpacept (ALX148) is an experimental immunotherapy called a CD47 inhibitor. Blocking CD47 may help stimulate the immune system to attack and cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a type of immunotherapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) uses the HER2-targeted antibody trastuzumab to deliver the chemotherapy DM1 directly to the cancer cells.</li> <li class="seamTextUnorderedListItem">Zanidatamab is an experimental targeted therapy called a bispecific antibody that binds to 2 targets on HER2.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to 2 distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/FISH -.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05868226' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.quantumleaphealth.org/for-patients/i-spy-trials/' target='_blank'>Quantum Leap Healthcare Collaborative: Trial Information Page</a> </li></ul>
147

PRE-I-SPY: Targeted Therapy and Immunotherapy for Advanced HER2+ or HER2 Low Breast Cancer

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial (PRE-I-SPY-PI)
Icon

Nearest Location from 94107:
1584 miles
University of Minnesota Masonic Cancer Center
Minneapolis, MN

Icon

Visits:
1 visit every 2-3 weeks

Icon

ClinicalTrials.gov: NCT05868226

Icon

Phase I-II

148

Blood Sample Collection to Better Predict Breast Cancer Risk for Healthy Women

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

Purpose: To study genetic and other factors to learn how non-cancerous breast diseases might lead to breast cancer.

Who is this for?: Women who had a breast biopsy at Mayo Clinic between 2002-2022 that was not cancer. You must not have been diagnosed with breast cancer within 6 months of this biopsy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood or saliva (spit) sample</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Features in the blood and breast tissue from people with non-cancerous breast disease may help predict breast cancer risk.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07207564' target='_blank'>ClinicalTrials.gov</a> </li></ul>
148

Blood Sample Collection to Better Predict Breast Cancer Risk for Healthy Women

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07207564

Icon

Phase NA

149

Breathing and Walking for Brain and Mental Health for People with Stage 0-IV Breast Cancer and Caregivers

Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)

Purpose: To study the ability of breathing training and walking to improve brain and mental health.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or metastatic (stage IV) breast cancer. Caregivers may also participate. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breathing exercises, with mobile app, daily for 4-6 months</li> <li class="seamTextUnorderedListItem">Breathing exercises, virtual weekly or in-person monthly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking exercises, with mobile app, daily for 6 months</li> <li class="seamTextUnorderedListItem">Walking exercises, in person, weekly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking exercises, with mobile app, daily for 6 months</li> <li class="seamTextUnorderedListItem">Walking exercises, in person, weekly (optional)</li> <li class="seamTextUnorderedListItem">Breathing exercises, by mobile app, daily for 2 months</li> <li class="seamTextUnorderedListItem">Breathing exercises, virtual weekly or in-person monthly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The relationship among breathing, cardiovascular (heart and blood flow) effects in the brain, and mental health is important for people with cancer and their caregivers.</li> <li class="seamTextUnorderedListItem">Breathing training is also called respiratory training and may increase the amount of oxygen that the brain receives.</li> <li class="seamTextUnorderedListItem">Breathing and walking exercises are 30 minutes.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer and multiple sclerosis.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06788886' target='_blank'>ClinicalTrials.gov</a> </li></ul>
149

Breathing and Walking for Brain and Mental Health for People with Stage 0-IV Breast Cancer and Caregivers

Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
At least 2 visits in 6 months

Icon

ClinicalTrials.gov: NCT06788886

Icon

Phase NA

150

Interview About Radiation Dermatitis for People with Stage 0-IV Breast Cancer

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

Purpose: To use interviews to study the experiences of people with radiation dermatitis (burn).

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving or recently completed radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation dermatitis (burn) is a common side effect of radiation.</li> <li class="seamTextUnorderedListItem">It involves itchy skin, skin changing color, and swelling.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06953245' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21995-radiation-burns' target='_blank'>Cleveland Clinic: Radiation Dermatitis</a> </li></ul>
150

Interview About Radiation Dermatitis for People with Stage 0-IV Breast Cancer

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT06953245

Icon

Phase NA

151

Vaccine Before Surgery for HER2-Expressing DCIS

A Phase IB Trial of Neoadjvuant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS

Purpose: To study the best dose, safety, and effects (good and bad) of a HER2 vaccine called H2NVAC.

Who is this for?: Women with DCIS that is HER2-expressing and who have not have had any other treatments for this DCIS. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 vaccine H2NVAC, by injection, once every 2 weeks, for 2 months</li> <li class="seamTextUnorderedListItem">GM-CSF, by injection, once every 2 weeks for 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedure</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Giving the H2NVAC vaccine before surgery allows researchers to study the effect that it has on cancer cells. </li> <li class="seamTextUnorderedListItem">Cancer vaccines are a type of immunotherapy. They are designed to teach the immune system to see and kill cancer cells.</li> <li class="seamTextUnorderedListItem">HER2-expressing DCIS will have an immunohistochemistry of +1, +2, or +3.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04144023' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/what-are-cancer-vaccines' target='_blank'>ASCO Cancer.net: What are Cancer Vaccines?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/forefront/researchers-testing-vaccine-against-dcis' target='_blank'>Mayo Clinic: Vaccine for DCIS</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youtube.com/watch?v=-gJfkmv5ZIs' target='_blank'>Dr. Susan Love Research Foundation: Breast Cancer Vaccines (Video)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearch.org/immunotherapy/treatment-types/cancer-vaccines' target='_blank'>Cancer Research Institute: Cancer Vaccines, Preventive, Therapeutic, Personalized</a> </li></ul>
151

Vaccine Before Surgery for HER2-Expressing DCIS

A Phase IB Trial of Neoadjvuant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
Every 2 weeks, for 2 months

Icon

ClinicalTrials.gov: NCT04144023

Icon

Phase I

152

Studying Blood Sugar During Hormone Therapy for Postmenopausal Women with Stage 0-IV HR+ Breast Cancer

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Purpose: To study the effect of hormone therapy on blood sugar.

Who is this for?: Postmenopausal women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving (within 6 months of starting) or planning to receive an aromatase inhibitor or tamoxifen (Nolvadex®), as well as postmenopausal women without breast cancer. You must not have diabetes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sugar tests, 2 times within 1 year</li> <li class="seamTextUnorderedListItem">Body composition scan</li> <li class="seamTextUnorderedListItem">Phone calls, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Results from people with breast cancer will be compared to people without breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06557057' target='_blank'>ClinicalTrials.gov</a> </li></ul>
152

Studying Blood Sugar During Hormone Therapy for Postmenopausal Women with Stage 0-IV HR+ Breast Cancer

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
At least 2 times within 1 year

Icon

ClinicalTrials.gov: NCT06557057

Icon

Phase NA

153

Neoadjuvant Chemo & Radiation But No Surgery for Stage I-II Triple Negative or ER Low, HER2- or HER2 Positive Breast Cancer

Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy

Purpose: To study the effects (good and bad) of avoiding surgery but still using radiation therapy in women whose biopsy shows their tumor disappeared after they received neoadjuvant chemotherapy.

Who is this for?: Women 40 or older with stage I or stage II triple negative (ER-, PR-, HER2-) or ER Low (1%-10% ER) or HER2 positive (HER2+) breast cancer. You must have already had chemotherapy to shrink your tumor, but no other treatments View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An image-guided biopsy (a biopsy that uses imaging such as CT, ultrasound, MRI or mammography)</li> <li class="seamTextUnorderedListItem">If the biopsy does not show any evidence of disease, you will then have radiation therapy</li> <li class="seamTextUnorderedListItem">If the biopsy show evidence of disease, you will have surgery then radiation therapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neoadjuvant chemotherapy (treatment given before surgery) is used to shrink tumors before surgery. The tumor may even disappear. When this occurs, researchers think it may be possible for patients to avoid surgery.</li> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling women with triple negative as well as ER Low breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02945579' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation' target='_blank'>Breastcancer.org: Radiation Therapy</a> </li></ul>
153

Neoadjuvant Chemo & Radiation But No Surgery for Stage I-II Triple Negative or ER Low, HER2- or HER2 Positive Breast Cancer

Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic
Rochester, MN

Icon

Visits:
Weekly study visits during radiation treatment

Icon

ClinicalTrials.gov: NCT02945579

Icon

Phase NA

154

3D Ultrasound Scan to Study Lymph Nodes for Women with Stage I-III Breast Cancer

3D Ultrasound Imaging of the Axillary Lymph Nodes

Purpose: To compare the ability of 2D and 3D ultrasound scans to tell the difference between lymph nodes with and without cancer.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive a lymph node biopsy or lymph node clip placement. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2D ultrasound scan (standard of care)</li> <li class="seamTextUnorderedListItem">3D ultrasound scan (experimental)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05704283' target='_blank'>ClinicalTrials.gov</a> </li></ul>
154

3D Ultrasound Scan to Study Lymph Nodes for Women with Stage I-III Breast Cancer

3D Ultrasound Imaging of the Axillary Lymph Nodes
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT05704283

Icon

Phase I

155

Registry of Samples with Residual Disease After Neoadjuvant Treatment for Stage I-III Breast Cancer

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

Purpose: To use blood and tissue samples to find ways to treat people with breast cancer in the future.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are receiving chemotherapy or hormone therapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Tissue samples during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People with breast cancer who receive treatment before surgery (neoadjuvant) and still have breast cancer at the time of surgery have a high (greater than 50%) risk of cancer coming back. Cancers like this may be different than ones in which there is no cancer remaining after neoadjuvant treatment.</li> <li class="seamTextUnorderedListItem">Cancer tissue from surgery will be used to grow the cancer in a lab to study why it is different and how to treat it.</li> <li class="seamTextUnorderedListItem">Blood samples will be used to look at biomarkers to study how the cancer is different and find new ways to identify and treat it.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04703244' target='_blank'>ClinicalTrials.gov</a> </li></ul>
155

Registry of Samples with Residual Disease After Neoadjuvant Treatment for Stage I-III Breast Cancer

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic
Rochester, MN

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT04703244

Icon

Phase NA

156

Ultrasound Scans to Diagnose Breast Cancer and Monitor Response to Treatment for Stage I-III Breast Cancer

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

Purpose: To study how well breast ultrasound scans can diagnose breast cancer and measure response to treatment.

Who is this for?: People who are planning to receive or have received a breast biopsy, and people with stage I, stage II, or some stage III breast cancer who are planning to receive chemotherapy and/or hormone therapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast ultrasound scan, up to 5 times in 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body.</li> <li class="seamTextUnorderedListItem">Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer and may help measure response to earlier treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04799535' target='_blank'>ClinicalTrials.gov</a> </li></ul>
156

Ultrasound Scans to Diagnose Breast Cancer and Monitor Response to Treatment for Stage I-III Breast Cancer

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
Up to 5 visits in 1 year

Icon

ClinicalTrials.gov: NCT04799535

Icon

Phase NA

157

Novel Marker to See Lymph Nodes with Cancer on an Ultrasound Scan for Women with Stage I-III Breast Cancer

A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Optimized Ultrasound Twinkling Marker Observed for Sonographic Targeting (UTMOST2 Trial)

Purpose: To study the ability of a novel marker to show lymph nodes with cancer on an ultrasound scan.

Who is this for?: Women with some stage I, stage II, or stage III breast cancer with at least one positive lymph node. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasound-guided placement of the experimental marker</li> <li class="seamTextUnorderedListItem">Ultrasound scan</li> <li class="seamTextUnorderedListItem">Mammogram</li> <li class="seamTextUnorderedListItem">Surgery to remove the marker and cancer</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy markers are used to identify the sites of cancer in breasts and lymph nodes. These markers help guide surgeons. Standard clip markers can be hard to see on an ultrasound scan.</li> <li class="seamTextUnorderedListItem">This trial is testing a different kind of marker called an ultrasound twinkling marker that may be more visible on an ultrasound scan.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06999798' target='_blank'>ClinicalTrials.gov</a> </li></ul>
157

Novel Marker to See Lymph Nodes with Cancer on an Ultrasound Scan for Women with Stage I-III Breast Cancer

A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Optimized Ultrasound Twinkling Marker Observed for Sonographic Targeting (UTMOST2 Trial)
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
4 visits within 9 months

Icon

ClinicalTrials.gov: NCT06999798

Icon

Phase I

158

Surveys and 3D-Printed Breast Prosthesis for Stage I-III Breast Cancer After Mastectomy Without Breast Reconstruction

Patient Reported Outcomes Post-Mastectomy and In-house 3D-printed Individualized External Breast Prostheses

Purpose: To study whether a 3D-printed breast prosthesis fits well, is comfortable, and improves quality of life.

Who is this for?: People with stage I, stage II, or stage III breast cancer who have received a mastectomy but not breast reconstruction. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">Body measurements for prosthesis planning</li> <li class="seamTextUnorderedListItem">Prosthesis fitting</li> <li class="seamTextUnorderedListItem">Prosthesis</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Not all people who receive a mastectomy want to or are able to receive breast reconstruction. Another option is an external breast prosthesis that is worn on the outside of the body to replace the breast that was removed during the mastectomy.</li> <li class="seamTextUnorderedListItem">Traditional breast prostheses may be uncomfortable and not fit right. A 3D-printed breast prosthesis may fit better and increase quality of life.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07047872' target='_blank'>ClinicalTrials.gov</a> </li></ul>
158

Surveys and 3D-Printed Breast Prosthesis for Stage I-III Breast Cancer After Mastectomy Without Breast Reconstruction

Patient Reported Outcomes Post-Mastectomy and In-house 3D-printed Individualized External Breast Prostheses
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
6 visits within 1 year

Icon

ClinicalTrials.gov: NCT07047872

Icon

Phase NA

159

Registry for People with Metastatic Breast Cancer, Breast Cancer That Has Come Back, or Male Breast Cancer

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Purpose: To create a collection of tissue samples and patient information.

Who is this for?: Women with stage I, stage II, or stage III breast cancer that has come back (recurred) or stage IV (metastatic) breast cancer, and men with breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor biopsy sample</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue and blood samples and patient information can be used to improve researchers' understanding of the development, progression, and treatment of breast cancer.</li> <li class="seamTextUnorderedListItem">In this study, information is being collected about metastatic breast cancer, recurrent breast cancer (breast cancer that has come back), and Male Breast Cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06217874' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20309083' target='_blank'>Mayo Clinic: Trial page</a> </li></ul>
159

Registry for People with Metastatic Breast Cancer, Breast Cancer That Has Come Back, or Male Breast Cancer

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06217874

Icon

Phase NA

160

Goserelin (Zoladex®) for Ovarian Function Suppression in Women who have completed treatment with Stage I-III Hormone Receptor Positive (ER+) Breast Cancer

MC250301, OptiOFS: A Randomized Phase II Trial of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Breast Cancer

Purpose: To study the effects (good and bad), and anti-cancer activity of giving goserelin (Zoladex®) as an injection to lower estrogen through ovarian function suppression. The trial is also looking at whether a longer acting version given every 3 months works as well as the standard monthly injection.

Who is this for?: Premenopausal women who have completed treatment for stage I, stage II, or stage III hormone receptor positive (ER+) breast cancer and have no signs of cancer now. You must already be receiving ovarian function suppression with monthly goserelin (Zoladex®) injections in the abdomen, along with an aromatase inhibitor or tamoxifen, for at least 6 months, and you must plan to continue ovarian function suppression for at least the next 12 months. You must be receiving care at Mayo Clinic in Rochester, Minnesota. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, about every 4 weeks</li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, about every 3 months</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In premenopausal women, the ovaries are the main source of estrogen, and some breast cancers grow in response to estrogen. </li> <li class="seamTextUnorderedListItem">Goserelin lowers the amount of estrogen the ovaries make, which is called ovarian function suppression. </li> <li class="seamTextUnorderedListItem">Goserelin is usually given as an injection in the abdomen once a month. This trial is studying whether giving the injection in the upper buttock area, and whether giving a longer acting version every 3 months, keeps estrogen just as low as the standard monthly abdominal injection.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07460752' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/hormone-therapy/ovarian-suppression/' target='_blank'>Susan G. Komen: Ovarian Suppression</a> </li></ul>
160

Goserelin (Zoladex®) for Ovarian Function Suppression in Women who have completed treatment with Stage I-III Hormone Receptor Positive (ER+) Breast Cancer

MC250301, OptiOFS: A Randomized Phase II Trial of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Breast Cancer
Icon

Nearest Location from 94107:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
At least 1 visit every 1 to 3 months, up to 9 months

Icon

ClinicalTrials.gov: NCT07460752

Icon

Phase II

161

Training to Improve Thinking Ability After Treatment for Women with Stage I-III Breast Cancer

Pilot Testing of Metacognitive Strategy Training to Address Cancer-related Cognitive Impairment in Breast Cancer

Purpose: To study if training can improve cognition (ability to think) and quality of life.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who completed treatment between 6 months and 3 years ago and are having cognitive (thinking) problems. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Training to improve cognition, in person, weekly for 2.5 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times in 3 months</li> <li class="seamTextUnorderedListItem">Cognitive tests, 2 times in 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Phone call, weekly for 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times in 3 months</li> <li class="seamTextUnorderedListItem">Cognitive tests, 2 times in 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most breast cancer survivors have problems with cognition (thinking), which includes planning, problem-solving, multitasking, memory, and processing speed after cancer treatment.</li> <li class="seamTextUnorderedListItem">In this trial, the training includes identifying 5 goals, creating a plan to achieve each goal, carrying out the plan, and checking to see if the plan worked.</li> <li class="seamTextUnorderedListItem">Training sessions are 45 minutes each and are led by a trained occupational therapist.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06545045' target='_blank'>ClinicalTrials.gov</a> </li></ul>
161

Training to Improve Thinking Ability After Treatment for Women with Stage I-III Breast Cancer

Pilot Testing of Metacognitive Strategy Training to Address Cancer-related Cognitive Impairment in Breast Cancer
Icon

Nearest Location from 94107:
1623 miles
University of Missouri
Columbia, MO

Icon

Visits:
Up to 1 visit every week for 3 months

Icon

ClinicalTrials.gov: NCT06545045

Icon

Phase NA

162

Non-Radioactive Tracer During Surgery for Women with Stage 0 (DCIS or LCIS) Breast Cancer or Women at High Risk for Breast Cancer

Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0).

Purpose: To study how well a non-radioactive tracer helps surgeons see sentinel lymph nodes during surgery.

Who is this for?: Women with stage 0 (DCIS or LCIS) breast cancer or women who are at high risk for breast cancer who are planning to receive surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery with non-radioactive tracer, by injection</li> </ul> <p class="seamTextPara"> If cancer is found in the samples removed during surgery, then you will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove sentinel lymph nodes with non-radioactive main tracer</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove sentinel lymph nodes with radioactive main tracer</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial also helps people avoid an unnecessary (not needed) second surgery if no cancer is found in the tissue removed during their first surgery.</li> <li class="seamTextUnorderedListItem">A sentinel lymph node biopsy is used to see if breast cancer cells are found in the sentinel node, the first lymph node under the arm to which the cancer cells are most likely to have spread.</li> <li class="seamTextUnorderedListItem">Tracers are dyes or substances used during surgery or scans to help doctors see inside your body.</li> <li class="seamTextUnorderedListItem">The standard of care tracer is radioactive.</li> <li class="seamTextUnorderedListItem">In this study, the experimental tracer is called superparamagnetic iron oxide (SPIO). It is magnetic instead of radioactive.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04722692' target='_blank'>ClinicalTrials.gov</a> </li></ul>
162

Non-Radioactive Tracer During Surgery for Women with Stage 0 (DCIS or LCIS) Breast Cancer or Women at High Risk for Breast Cancer

Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0).
Icon

Nearest Location from 94107:
1643 miles
Baylor College Of Medicine
Houston, TX

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT04722692

Icon

Phase III

163

A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy

Decision Making Tool for Contralateral Prophylactic Mastectomy

Purpose: To learn more about an online decision support tool that helps you and your doctor discuss whether or not you should have a contralateral prophylactic mastectomy (removal of breast that does not have cancer).

Who is this for?: Women recently diagnosed with DCIS or stage I, stage II, or stage III breast cancer and are seeing a surgeon at MD Anderson Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will complete a questionnaire before and after using the decision support tool.</p>

What's being studied?

<p class="seamTextPara"> If you take part in this study, you will complete a questionnaire about the decision support tool.</p>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02918474' target='_blank'>ClinicalTrials.gov</a> </li></ul>
163

A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy

Decision Making Tool for Contralateral Prophylactic Mastectomy
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT02918474

Icon

Phase NA

164

Hypnosis During Lumpectomy to Reduce Pain and Pain Medication for Stage 0-I Breast Cancer

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

Purpose: To study whether hypnosedation before and during breast cancer surgery reduces the use of pain medication, reduces pain and stress, and leads to faster recovery.

Who is this for?: People newly diagnosed with stage 0 (DCIS) or stage I breast cancer who are planning to receive a lumpectomy and have not yet received any treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypnosedation before and during surgery</li> <li class="seamTextUnorderedListItem">General anesthesia during surgery (if needed)</li> <li class="seamTextUnorderedListItem">Local anesthesia</li> <li class="seamTextUnorderedListItem">Medication for pain and nausea</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypnosedation before surgery</li> <li class="seamTextUnorderedListItem">General anesthesia during surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General anesthesia during surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li> <li class="seamTextUnorderedListItem">For local anesthesia, you are awake but receive medicine to numb the breast during surgery.</li> <li class="seamTextUnorderedListItem">For general anesthesia, you are asleep during surgery.</li> <li class="seamTextUnorderedListItem">Hypnosedation allows the patient to dissociate from the place they're in and become deeply relaxed. This may allow the use of local rather than general anesthesia.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05766891' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/cancer-frontline/breast-cancer-surgery-without-anesthesia.h00-159225723.html' target='_blank'>MD Anderson Cancer Center: Hypnosedation for Some Breast Cancer Surgeries</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tmc.edu/news/2018/03/hypnosis-operating-room/' target='_blank'>Texas Medical Center: Hypnosis in the Operating Room</a> </li></ul>
164

Hypnosis During Lumpectomy to Reduce Pain and Pain Medication for Stage 0-I Breast Cancer

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT05766891

Icon

Phase II-III

165

Radiation Therapy Using MRI Imaging for People with Stage 0-III Breast Cancer

The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (MOMENTUM)

Purpose: To study if radiation with the MR-Linac machine is more effective with fewer side effects than traditional radiation.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive, are receiving, or have received radiation with the MR-Linac machine. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation with MR-Linac machine</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.</li> <li class="seamTextUnorderedListItem">Radiation therapy for cancer has strong side effects.</li> <li class="seamTextUnorderedListItem">The MR-Linac machine uses MRI imaging to deliver radiation.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">The MR-Linac machine may allow more precise delivery of radiation. Radiation delivered this way may be more effective with fewer side effects.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04075305' target='_blank'>ClinicalTrials.gov</a> </li></ul>
165

Radiation Therapy Using MRI Imaging for People with Stage 0-III Breast Cancer

The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (MOMENTUM)
Icon

Nearest Location from 94107:
1643 miles
Md Anderson Cancer Center
Houston, TX

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT04075305

Icon

Phase NA

166

Virtual Health Coaching for People with Stage 0-IV Breast Cancer

Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors

Purpose: To study the use of virtual health coaching to improve well-being, including management of other health conditions, mental and social wellness, and healthy lifestyle behaviors.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer, and people without a history of breast cancer. If you have stage 0-III breast cancer, you must have completed treatment within the last year. If you have metastatic (stage IV) breast cancer, you must have been diagnosed with metastatic disease within the past year. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Immediately Start Coaching</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual health coaching, up to 4 times weekly, during first 6 months</li> <li class="seamTextUnorderedListItem">Provide stool samples, 2 times within 6 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires during second 6 months</li> <li class="seamTextUnorderedListItem">Wear a FitBit, 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Delayed Start Coaching</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires during first 6 months</li> <li class="seamTextUnorderedListItem">Provide stool samples, 2 times within 6 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual health coaching, up to 4 times weekly, during second 6 months</li> <li class="seamTextUnorderedListItem">Wear a FitBit, 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This program aims to support people's ability to manage their symptoms and their general wellness (including physical, mental, and social well-being, as well as following healthcare recommendations).</li> <li class="seamTextUnorderedListItem">Coaching consists of weekly calls and information about exercise, physical health, emotional health, and financial health.</li> <li class="seamTextUnorderedListItem">This study is also studying the relationship between symptoms and gut health and if coaching improves gut health.</li> <li class="seamTextUnorderedListItem">People that live in your household who do not have cancer will also be eligible to participate in this study.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05349227' target='_blank'>ClinicalTrials.gov</a> </li></ul>
166

Virtual Health Coaching for People with Stage 0-IV Breast Cancer

Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors
Icon

Nearest Location from 94107:
1643 miles
UT Health Houston
Houston, TX

Icon

Visits:
At least 2 visits within 1 year

Icon

ClinicalTrials.gov: NCT05349227

Icon

Phase NA

167

Virtual Program to Improve the Quality of Life of Black Women with Stage 0-III Breast Cancer

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

Purpose: To study whether the BBCSI course improves the quality of life of Black breast cancer survivors.

Who is this for?: Black women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer that was diagnosed within the last 4 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete the BBCSI course, virtual, 1 hour per week for 6 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times</li> <li class="seamTextUnorderedListItem">Provide urine sample</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Black Breast Cancer Survivors Intervention (BBCSI) is a community-based and peer-led course developed to help improve the quality of life of Black breast cancer survivors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06885203' target='_blank'>ClinicalTrials.gov</a> </li></ul>
167

Virtual Program to Improve the Quality of Life of Black Women with Stage 0-III Breast Cancer

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
Icon

Nearest Location from 94107:
1643 miles
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable, 1 year

Icon

ClinicalTrials.gov: NCT06885203

Icon

Phase NA

168

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT

Purpose: To study the safety and effectiveness of using a PET/CT scan with the experimental tracer F-18.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or DCIS. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">F-18 tracer, by IV, then a PET/CT scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this imaging trial is called fluorine F 18 fluorthanatrace (F-18)--it binds to PARP expressing tumor cells (PARP is a protein over expressed in certain cancers). </li> <li class="seamTextUnorderedListItem">You do not need to have an inherited BRCA1/2 mutation to enroll in this trial but researchers are studying whether F-18 works better in inherited BRCA1/2+ cancers. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of solid tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03604315' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/10123-pet-scan' target='_blank'>Cleveland Clinic: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluorthanatrace' target='_blank'>NCI Drug Dictionary: Fluorine F 18 Fluorthanatrace</a> </li></ul>
168

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
1 to 2 visits

Icon

ClinicalTrials.gov: NCT03604315

Icon

Phase I

169

Data Collection to Study Proton Therapy Side Effects

Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults

Purpose: To help researchers predict the risk of side effects of proton therapy and understand the long-term benefit of proton therapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive proton therapy at University of Texas M. D. Anderson Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Review of side effects, weekly during proton therapy, then 1-4 visits every year</li> <li class="seamTextUnorderedListItem">Questionnaires, weekly during proton therapy, then every 2 weeks for 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will be monitored for safety and side effects during the visits.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00991094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/radiation-therapy/proton-therapy' target='_blank'>American Society for Clinical Oncology: Proton Therapy</a> </li></ul>
169

Data Collection to Study Proton Therapy Side Effects

Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
1 visit every week until end of proton therapy, then 1-4 visits every year

Icon

ClinicalTrials.gov: NCT00991094

Icon

Phase NA

170

Using a Biobridge Scaffold During Lymphedema Surgery

LymphBridge: Prospective Evaluation of the BioBridge Scaffold as an Adjunct to Lymph Node Transplant for Upper Extremity Lymphedema

Purpose: To investigate the safety and effects (good and bad) of using an experimental device called a Biobridge scaffold during surgery to treat lymphedema.

Who is this for?: People who have completed breast cancer treatment at least three years ago, have no evidence of disease, and have been diagnosed with lymphedema. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vascularized Lymph Node Transplant surgery (VLNT) </li> <li class="seamTextUnorderedListItem">BioBridge Collagen Matrix inserted into your body during surgery </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vascularized Lymph Node Transplant surgery (VLNT)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that may develop as a side effect of some breast cancer therapies. </li> <li class="seamTextUnorderedListItem">Lymphedema happens when there is a blockage in your lymphatic system (a part of your immune system) that stops the lymph fluid from draining well. The fluid buildup causes the abnormal swelling. </li> <li class="seamTextUnorderedListItem">The surgery used in this trial to help with your lymphedema is called a vascularized lymph node transfer.</li> <li class="seamTextUnorderedListItem">Your doctor will insert a Biobridge scaffold during your vascularized lymph node transfer. </li> <li class="seamTextUnorderedListItem">The Biobridge scaffold is made of collagen and may help lymph vessels grow around lymph blockages.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04606030' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/breast-cancer-lymphedema-after-treatment' target='_blank'>Johns Hopkins Medicine: Breast Cancer, Lymphedema After Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://intermountainhealthcare.org/services/cancer-care/treatments-and-procedures/lymphedema-treatment/our-services/vascularized-lymph-node-transfer/' target='_blank'>Intermountain Healthcare: Vascularized Lymph Node Transfer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fibralignbio.com/biobridge-2/' target='_blank'>Fibralign Corporation Medical Device Information Page: Biobridge</a> </li></ul>
170

Using a Biobridge Scaffold During Lymphedema Surgery

LymphBridge: Prospective Evaluation of the BioBridge Scaffold as an Adjunct to Lymph Node Transplant for Upper Extremity Lymphedema
Icon

Nearest Location from 94107:
1643 miles
MD Anderson
Houston, TX

Icon

Visits:
1 visit that coincides with surgery

Icon

ClinicalTrials.gov: NCT04606030

Icon

Phase NA

171

Immune System Changes Before and After Radiation for People with Breast Cancer

Quantifying Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Purpose: To measure the change in the level of immune cells in tumors before and after radiation.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation</li> <li class="seamTextUnorderedListItem">Biopsies</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05406232' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation-therapy' target='_blank'>Breastcancer.org: Radiation</a> </li></ul>
171

Immune System Changes Before and After Radiation for People with Breast Cancer

Quantifying Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT05406232

Icon

Phase NA

172

Magseed Marker to Identify Axillary Lymph Nodes Before Surgery for Stage I-III Breast Cancer

A Prospective Open Label Study of the Use of Magseed® Markers and Sentimag® to Localize Axillary Lymph Nodes With Biopsy-proven Metastases in Breast Cancer Patients (MAGELLAN)

Purpose: To study the accuracy and safety of using Magseed markers to help doctors identify axillary lymph nodes and plan surgery.

Who is this for?: People with stage I, stage II, or some stage III node positive breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placement of Magseed marker with ultrasound, before chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magseed is a small device inserted near the lymph nodes that is used to identify axillary (armpit or underarm) lymph nodes with cancer cells.</li> <li class="seamTextUnorderedListItem">The Magseed can be seen by doctors with a handheld device during surgery.</li> <li class="seamTextUnorderedListItem">The Magseed is removed during surgery along with the positive lymph nodes.</li> <li class="seamTextUnorderedListItem">Node positive means that cancer has spread to the lymph nodes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03796559' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.endomag.com/patients/magseed-marker-patient-guide/' target='_blank'>Hologic: Magseed® Marker</a> </li></ul>
172

Magseed Marker to Identify Axillary Lymph Nodes Before Surgery for Stage I-III Breast Cancer

A Prospective Open Label Study of the Use of Magseed® Markers and Sentimag® to Localize Axillary Lymph Nodes With Biopsy-proven Metastases in Breast Cancer Patients (MAGELLAN)
Icon

Nearest Location from 94107:
1643 miles
Baylor Medicine
Houston, TX

Icon

Visits:
1 visit, then coincides with surgery

Icon

ClinicalTrials.gov: NCT03796559

Icon

Phase NA

173

Oncology Nurse Navigator to Help Manage Other Health Conditions for People with Stage I-III Breast Cancer

Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities

Purpose: To study if the OPTIMISE program improves care, health outcomes, and quality of life for people with other health conditions transitioning from receiving care from an oncologist to a primary care physician (PCP).

Who is this for?: People with stage I, stage II, or some stage III breast cancer who have not started treatment or started treatment less than 3 months ago. You must have other health conditions and receive care at Harris Health in Houston, Texas. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: OPTIMISE Program</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Work with oncology nurse navigator, 3 times in 4 months</li> <li class="seamTextUnorderedListItem">Create survivorship care plan</li> <li class="seamTextUnorderedListItem">Reminders to follow up with primary care physician</li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Create survivorship care plan</li> <li class="seamTextUnorderedListItem">Meet with nurse about survivorship care plan</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many people with cancer have other health conditions that also have to be managed after cancer treatment ends.</li> <li class="seamTextUnorderedListItem">Primary care physicians (PCPs) typically manage other non-cancer health conditions.</li> <li class="seamTextUnorderedListItem">The OPTIMISE program is designed to improve your ability to manage other health conditions and coordinate the transition of care from oncologists to PCPs from diagnosis through the first year after cancer treatment.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other kinds of cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05323409' target='_blank'>ClinicalTrials.gov</a> </li></ul>
173

Oncology Nurse Navigator to Help Manage Other Health Conditions for People with Stage I-III Breast Cancer

Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities
Icon

Nearest Location from 94107:
1643 miles
Baylor College of Medicine
Houston, TX

Icon

Visits:
At least 3 visits in 4 months

Icon

ClinicalTrials.gov: NCT05323409

Icon

Phase NA

174

Registry of Breast MRI After Treatment for Women with Dense Breasts

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue

Purpose: To study people with dense breast tissue (tissue that is more difficult to see on mammogram) who received a breast MRI scan.

Who is this for?: Women 18-50 years old with stage I, stage II, or stage III breast cancer and dense breast tissue who have completed treatment and are planning to receive a breast MRI scan. You must be receiving care at MD Anderson Cancer Center in Houston, Texas. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, in-person or by phone/email, 2 times before and after breast MRI scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In people with dense breast tissue, breast cancer is difficult to see on a mammogram.</li> <li class="seamTextUnorderedListItem">Breast MRI may improve detection of breast cancer in people with dense breast tissue.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06127797' target='_blank'>ClinicalTrials.gov</a> </li></ul>
174

Registry of Breast MRI After Treatment for Women with Dense Breasts

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
Icon

Nearest Location from 94107:
1643 miles
MD Anderson Cancer Center
Houston, TX

Icon

Visits:
Up to 2 visits

Icon

ClinicalTrials.gov: NCT06127797

Icon

Phase NA

175

2 Radiation Schedules Before Mastectomy with Reconstruction for People with Stage I-III Breast Cancer

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation

Purpose: To compare the safety and anti-cancer activity of 2 different radiation therapy schedules before surgery (neoadjuvant).

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive a mastectomy with immediate reconstruction. You must not have received radiation to the affected breast or be undergoing a mastectomy for a breast cancer recurrence. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypofractionated radiation</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conventionally fractionated radiation</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conventionally fractionated radiation is the standard radiation amount and number of doses.</li> <li class="seamTextUnorderedListItem">Hypofractionated radiation uses fewer doses than conventionally fractionated radiation.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to kill tumor cells.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05774678' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation-therapy' target='_blank'>Breastcancer.org: Radiation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.foxchase.org/clinical-care/departments-programs/clinical-departments/radiation-oncology/techniques/hypofractionation' target='_blank'>Fox Chase Cancer Center: Hypofractionated Radiation Therapy</a> </li></ul>
175

2 Radiation Schedules Before Mastectomy with Reconstruction for People with Stage I-III Breast Cancer

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05774678

Icon

Phase III

176

Studying the Effects of Tamoxifen in People with ER+ Breast Cancer

Neutrophil Functions in Breast Cancer

Purpose: To study the long-term effects of tamoxifen (Nolvadex®) on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects.

Who is this for?: Pre-menopausal and post-menopausal women with stage I, stage II, stage III, or stage IV (metastatic) estrogen receptor positive (ER+) breast cancer receiving treatment with tamoxifen for at least 6 months. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neutrophil extracellular traps (NET) are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system.</li> <li class="seamTextUnorderedListItem">Treatment with tamoxifen (Nolvadex®) increases the production of NETs.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05056857' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/drugs/9785-tamoxifen' target='_blank'>Cleveland Clinic: Tamoxifen (Nolvadex®)</a> </li></ul>
176

Studying the Effects of Tamoxifen in People with ER+ Breast Cancer

Neutrophil Functions in Breast Cancer
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05056857

Icon

Phase NA

177

ctDNA Blood Test to Decide who Can Stop Treatment Early for HER2 Positive or Triple Negative Breast Cancer

Optimization of Adjuvant Systemic Therapy in Patients With Early HER2-Positive (HER2+) Breast Cancer or Triple Negative Breast Cancer (TNBC) That Achieved a Pathological Complete Response (pCR) After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease (MRD-Negative): A Phase II Clinical Trial (The MolecularPCR Trial)

Purpose: To study the effects (good and bad) of a blood test that finds tiny amounts of leftover cancer DNA (called ctDNA). Researchers want to know if it can help identify people who may be able to safely shorten their standard treatment after breast cancer surgery.

Who is this for?: People with stage I, stage II, or some stage III, HER2 positive, or triple negative breast cancer (ER negative or ER low, PR negative or PR low, HER2 negative) breast cancer. You must have already completed chemotherapy plus targeted therapy or immunotherapy before surgery, and your surgery must have shown no remaining cancer in the breast or lymph nodes (a complete response). You must be willing to stop your standard treatment early if a blood test shows no leftover cancer DNA in your blood 4 to 6 weeks after surgery. You must be receiving care at M D Anderson Cancer Center in Houston, Texas. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following depending on your type of breast cancer: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1 (Triple Negative Breast Cancer)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda), by IV, up to 3 more cycles, only if your blood test still shows leftover cancer DNA</li> <li class="seamTextUnorderedListItem">Blood draws </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2 (HER2 Positive Breast Cancer)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin), with or without pertuzumab (Perjeta), by IV, up to 3 more cycles, only if your blood test still shows leftover cancer DNA</li> <li class="seamTextUnorderedListItem">You may also receive hormone therapy chosen by your doctor if needed</li> <li class="seamTextUnorderedListItem">Blood draws</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying whether a blood test that detects tiny amounts of leftover cancer DNA circulating in the blood (ctDNA) can guide doctors in safely shortening standard treatment after breast cancer surgery.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda) is a type of immunotherapy. It is an antibody that helps the immune system recognize and attack cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin) and pertuzumab (Perjeta) are targeted therapies. They are antibodies that attach to a protein called HER2 found on some cancer cells. This blocks the signals that tell the cells to grow and helps the immune system destroy them.</li> <li class="seamTextUnorderedListItem">Researchers want to learn how many people stay cancer free for 3 years after stopping treatment early based on their ctDNA blood test results.</li> <li class="seamTextUnorderedListItem">The goal is to see whether this approach keeps working as well at preventing the cancer from coming back, while lowering the amount of treatment and side effects.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07407920' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/testing/biomarker/ctdna' target='_blank'>Living Beyond Breast Cancer: Circulating tumor DNA (ctDNA) tests</a> </li></ul>
177

ctDNA Blood Test to Decide who Can Stop Treatment Early for HER2 Positive or Triple Negative Breast Cancer

Optimization of Adjuvant Systemic Therapy in Patients With Early HER2-Positive (HER2+) Breast Cancer or Triple Negative Breast Cancer (TNBC) That Achieved a Pathological Complete Response (pCR) After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease (MRD-Negative): A Phase II Clinical Trial (The MolecularPCR Trial)
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Every 3 months, for 3 years

Icon

ClinicalTrials.gov: NCT07407920

Icon

Phase II

178

Neoadjuvant Zanidatamab Targeted Therapy with Hormone Therapy for Stage I-III HER2+ Breast Cancer

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of zanidatamab, an experimental anti-HER2 targeted therapy, with letrozole (Femara®) and tamoxifen (Nolvadex®) hormone therapies before surgery (neoadjuvant).

Who is this for?: Women with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer who have not yet received treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab (ZW25), by IV, every 2 weeks for 3 months</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth</li> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zanidatamab (ZW25) is an experimental anti-HER2 targeted therapy and bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific antibody binds to two distinct targets and may work better than traditional antibody drugs.</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. It is commonly used to treat hormone receptor positive breast cancer.</li> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is a type of hormone therapy called a selective estrogen receptor modulator (SERM). SERMs work by blocking the activity of estrogen.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05035836' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zymeworks.com/pipeline#zanidatamab' target='_blank'>Zymeworks Drug Information Page: Zanidatamab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/femara' target='_blank'>Breastcancer.org: Letrozole (Femara®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen (Nolvadex®)</a> </li></ul>
178

Neoadjuvant Zanidatamab Targeted Therapy with Hormone Therapy for Stage I-III HER2+ Breast Cancer

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Every 2 weeks for 3 months

Icon

ClinicalTrials.gov: NCT05035836

Icon

Phase II

179

Fecal Microbiota Transplantation for Immunotherapy-Related Diarrhea or Colitis in People with Stage I-IV Breast Cancer

Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients

Purpose: To study the ability of a fecal microbiota transplantation to improve immune checkpoint inhibitor-related diarrhea and colitis.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who developed diarrhea and/or colitis after receiving treatment with dostarlimab (Jemperli®) or pembrolizumab (Keytruda®) immune checkpoint inhibitors. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Loperamide, by mouth, 1 time</li> </ul> <p class="seamTextPara"> followed 4 hours later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fecal microbiota transplantation during colonoscopy, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A fecal microbiota transplantation consists of taking healthy bacteria (microbiota or microbiome) from the feces or stool of a healthy donor and transferring them to the colon of the recipient during a colonoscopy.</li> <li class="seamTextUnorderedListItem">A colonoscopy is a procedure in which a flexible camera is inserted through the anus to examine the colon/intestines.</li> <li class="seamTextUnorderedListItem">Loperamide is a drug used to treat diarrhea.</li> <li class="seamTextUnorderedListItem">Colitis is inflammation of the colon/intestines.</li> <li class="seamTextUnorderedListItem">Your body is home to many bacteria, viruses, and fungi, which are collectively called the microbiome.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04038619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0663.html' target='_blank'>MD Anderson Cancer Center: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/fecal-transplant' target='_blank'>Johns Hopkins Medicine: Fecal Microbiota Transplantation</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a682280.html' target='_blank'>MedlinePlus: Loperamide</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy' target='_blank'>Breastcancer.org: Immune Checkpoint Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li></ul>
179

Fecal Microbiota Transplantation for Immunotherapy-Related Diarrhea or Colitis in People with Stage I-IV Breast Cancer

Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
5 visits within 3 months

Icon

ClinicalTrials.gov: NCT04038619

Icon

Phase I

180

Tumor Treating Fields Device for Advanced Breast Cancer

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of Tumor Treating Fields (TTF), an experimental wearable device, with targeted therapy or chemotherapy and immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups based on your type of cancer: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: TTF with Targeted Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Treating Fields (TTF), daily</li> <li class="seamTextUnorderedListItem">Cabozantinib (Cabometyx® or Cometriq®), by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: TTF with Chemotherapy and Immunotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Treating Fields (TTF), daily</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Treating Fields (TTF) consists of experimental wearable devices that use electrical fields at different frequencies to stop the growth of tumor cells by interrupting cancer cells' ability to divide.</li> <li class="seamTextUnorderedListItem">Cabozantinib (Cabometyx® or Cometriq®) is a type of targeted therapy called a tyrosine kinase inhibitor. Tyrosine kinase inhibitors work by blocking proteins that signal cancer cells to multiply, which may help keep cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-L1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®) is a type of chemotherapy drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05092373' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verywellhealth.com/tumor-treating-fields-ttf-4584149' target='_blank'>Verywell Health: Tumor Treating Fields (TTF)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a616037.html' target='_blank'>MedlinePlus: Cabozantinib (Cabometyx® or Cometriq®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/abraxane' target='_blank'>Breastcancer.org: Nab-paclitaxel (Abraxane®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/tecentriq' target='_blank'>Breastcancer.org: Atezolizumab (Tecentriq®)</a> </li></ul>
180

Tumor Treating Fields Device for Advanced Breast Cancer

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05092373

Icon

Phase I

181

Procedure During Lymph Node Surgery to Prevent Lymphedema for Stage III Breast Cancer

Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy in Patients With Inflammatory Breast Cancer: A Prospective, Randomized Study

Purpose: To study if a procedure called lymphovenous bypass completed during lymph node surgery can prevent lymphedema (arm swelling).

Who is this for?: People with advanced or inflammatory (some stage III) breast cancer who are planning to receive lymph node surgery (axillary lymph node dissection) and radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Indocyanine green, by IV</li> <li class="seamTextUnorderedListItem">Imaging to see lymph nodes</li> <li class="seamTextUnorderedListItem">Lymphovenous bypass during lymph node surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care during lymph node surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that develops as a side effect of breast cancer treatments like surgery and radiation therapy.</li> <li class="seamTextUnorderedListItem">Lymphedema can affect arm function and quality of life.</li> <li class="seamTextUnorderedListItem">The surgery that removes lymph nodes from your underarm area is called an axillary lymph node dissection (ALND).</li> <li class="seamTextUnorderedListItem">The lymphovenous bypass procedure creates a path for lymph fluid to flow away from the arms. It is usually done after a diagnosis of lymphedema.</li> <li class="seamTextUnorderedListItem">Performing lymphovenous bypass before underarm lymph node surgery may help prevent lymphedema from forming.</li> <li class="seamTextUnorderedListItem">Indocyanine green (ICG) is a tracer routinely used for lymph node surgery that helps locate cancer in the body.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03941756' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/about-your-lymphovenous-bypass-lvb-surgery-lymphedema' target='_blank'>Memorial Sloan Kettering Cancer Center: About Your Lymphovenous Bypass (LVB) Surgery for Lymphedema</a> </li></ul>
181

Procedure During Lymph Node Surgery to Prevent Lymphedema for Stage III Breast Cancer

Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy in Patients With Inflammatory Breast Cancer: A Prospective, Randomized Study
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT03941756

Icon

Phase NA

182

Cyclophosphamide, Axatilimab, and Retifanlimab for Advanced Triple Negative or Inflammatory Breast Cancer

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cyclophosphamide (Cytoxan®) chemotherapy, axatilimab (Niktimvo®) targeted therapy, and retifanlimab (Zynyz®) immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or hormone receptor positive (ER+ and PR+) inflammatory breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by mouth</li> <li class="seamTextUnorderedListItem">Axatilimab (Niktimvo®), by IV</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Axatilimab (Niktimvo®) is used to treat rejection of transplanted cells and may have anti-cancer activity.</li> <li class="seamTextUnorderedListItem">Retifanlimab (Zynyz®) is a PD-1 inhibitor. PD-1 inhibitors are a type of immunotherapy also called a checkpoint inhibitor. They work by getting the immune system to go after cancer cells by blocking the PD-1 protein.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06959537' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.niktimvo.com/niktimvo-patient-information' target='_blank'>Incyte: Axatilimab (Niktimvo®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zynyz.com/scac/?utm_source=google&utm_medium=psearch&utm_campaign=zyn-dtc-br-zynyz-phrase&utm_id=psearchrt9e&gad_source=1&gad_campaignid=22526170965&gbraid=0AAAAABZyZLqUc0VaUPDduSUyY43CjUMIU&gclid=Cj0KCQiAxJXJBhD_ARIsAH_JGjjIq6PGMymOkH7Wnw_GnH' target='_blank'>Incyte: Retifanlimab (Zynyz®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immunotherapy/' target='_blank'>Metastatic Trial Talk: Immunotherapy</a> </li></ul>
182

Cyclophosphamide, Axatilimab, and Retifanlimab for Advanced Triple Negative or Inflammatory Breast Cancer

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Icon

Nearest Location from 94107:
1643 miles
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable, 1 year

Icon

ClinicalTrials.gov: NCT06959537

Icon

Phase I

183

Targeted Therapy Avapritinib for Advanced Breast Cancer with a CKIT or PDGFRA Mutation

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

Purpose: To study the safety, side effects and anti-cancer activity of the targeted therapy avapritinib (Ayvakit).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumor tests positive for a CKIT or a PDGFRA mutation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Avapritinib (Ayvakit), by mouth, daily, ongoing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Avapritinib (Ayvakit) is an experimental type of targeted therapy called a tyrosine kinase inhibitor. It works by targeting certain CKIT and PDGFRA kinases.</li> <li class="seamTextUnorderedListItem">Avapritinib (Ayvakit) is approved for use in some people with advanced GIST cancer, but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancers that test positive for CKIT or PDGFRA.</li> <li class="seamTextUnorderedListItem">Targets or mutations: CKIT, PDGFRA</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04771520' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/avapritinib' target='_blank'>NCI A to Z List of Cancer Drugs: Avapritinib (Ayvakit)</a> </li><li class='seamTextUnorderedListItem'><a href='https://ayvakit.com' target='_blank'>Blueprint Medicines Drug Information Page: Ayvakit (Avapritinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/january-25-2020/fda-approves-avapritinib-for-pdgfra-mutated-gastrointestinal-stromal-tumor/' target='_blank'>The ASCO Post: FDA Approves Avapritinib for the Treatment of PDGFRA-Mutated Gastrointestinal Stromal Tumor</a> </li></ul>
183

Targeted Therapy Avapritinib for Advanced Breast Cancer with a CKIT or PDGFRA Mutation

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
Icon

Nearest Location from 94107:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04771520

Icon

Phase II

184

Taxol Before Surgery for Stage I-III Breast Cancer

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Purpose: To study the effects (good and bad) that the chemotherapy paclitaxel (Taxol®) has on the tumor.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who have not yet had breast surgery or any other treatment for their cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, for up to 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A chemotherapy will be given before surgery (neoadjuvant treatment).</li> <li class="seamTextUnorderedListItem">Giving chemotherapy before surgery can shrink the tumor.</li> <li class="seamTextUnorderedListItem">It also lets researchers study whether the drug works better for certain types of tumors.</li> <li class="seamTextUnorderedListItem">The chemotherapy being used in this study is paclitaxel (Taxol®). It is commonly used to treat breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03096418' target='_blank'>ClinicalTrials.gov</a> </li></ul>
184

Taxol Before Surgery for Stage I-III Breast Cancer

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Icon

Nearest Location from 94107:
1655 miles
University of Iowa Health Care/Holden Comprehensive Cancer Center
Iowa City, IA

Icon

Visits:
Weekly visits for 3 months

Icon

ClinicalTrials.gov: NCT03096418

Icon

Phase IV

185

Exercise and Creatine Supplement to Increase Strength of Women After Chemotherapy

An Open-label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors (THRIVE)

Purpose: To study if creatine supplements can help people with breast cancer respond more quickly to exercise and improve strength.

Who is this for?: Women with stage I, stage II, and stage III breast cancer who have completed chemotherapy in the last 6 months, and women who have not been diagnosed with breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Creatine and Exercise</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Creatine, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Exercise sessions, virtual, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Wear a Fitbit</li> <li class="seamTextUnorderedListItem">Strength and walking tests, 2 times in 3 months</li> <li class="seamTextUnorderedListItem">DEXA scan, 2 times in 3 months</li> <li class="seamTextUnorderedListItem">MRI scan, 2 times in 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Exercise Only</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise sessions, virtual, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Wear a Fitbit</li> <li class="seamTextUnorderedListItem">Strength and walking tests, 2 times in 3 months</li> <li class="seamTextUnorderedListItem">DEXA scan, 2 times in 3 months</li> <li class="seamTextUnorderedListItem">MRI scan, 2 times in 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is comparing information from women who have never had breast cancer to women who have completed chemotherapy for breast cancer.</li> <li class="seamTextUnorderedListItem">Creatine is a supplement that may help you improve strength and physical function.</li> <li class="seamTextUnorderedListItem">A Fitbit is device you wear on your wrist that tracks your physical activity.</li> <li class="seamTextUnorderedListItem">DEXA scans use x-ray energy to measure bone density (thickness and strength of bones).</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06395506' target='_blank'>ClinicalTrials.gov</a> </li></ul>
185

Exercise and Creatine Supplement to Increase Strength of Women After Chemotherapy

An Open-label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors (THRIVE)
Icon

Nearest Location from 94107:
1683 miles
The University of Texas Medical Branch, Galveston
Galveston, TX

Icon

Visits:
2 visits in 3 months

Icon

ClinicalTrials.gov: NCT06395506

Icon

Phase NA

186

Artificial Intelligence-Generated Education About Breast Reconstruction for Stage 0-III Breast Cancer or People at High Risk for Breast Cancer

ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction

Purpose: To study the usefulness of artificial intelligence-generated patient education about breast reconstruction options.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, or people at high risk for breast cancer, who are planning to receive a mastectomy and a consultation about breast reconstruction surgery options. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education generated by ChatGPT about breast reconstruction </li> <li class="seamTextUnorderedListItem">Survey</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard education about breast reconstruction</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">For the experimental group, participants will receive ChatGPT-generated patient-tailored education about breast reconstruction options.</li> <li class="seamTextUnorderedListItem">For the control group, participants will receive standard patient education that includes a description of breast reconstruction options, including which option is most suitable, as well as a description of the risk of complications and expected recovery after surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06981208' target='_blank'>ClinicalTrials.gov</a> </li></ul>
186

Artificial Intelligence-Generated Education About Breast Reconstruction for Stage 0-III Breast Cancer or People at High Risk for Breast Cancer

ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
Icon

Nearest Location from 94107:
1739 miles
Washington University School of Medicine
St Louis, MO

Icon

Visits:
1 or 2 visits

Icon

ClinicalTrials.gov: NCT06981208

Icon

Phase NA

187

Surgery to Improve Lymphedema for People with Stage I-IV Breast Cancer

The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial

Purpose: To study the ability of lymphatic surgery to improve quality of life compared to standard of care treatment.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are experiencing lymphedema for at least 3 months. You must have received lymphedema treatment for at least 3 months. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphatic surgery, 1-2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conservative complex physical decongestion therapy</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that develops as a side effect of breast cancer treatments like surgery and radiation therapy.</li> <li class="seamTextUnorderedListItem">Standard of care treatment for lymphedema is called conservative complex physical decongestion therapy.</li> <li class="seamTextUnorderedListItem">This includes manual massage to increase lymph drainage, local compression with bandages and garments, physical exercise, and careful skin care. However, these treatments are not always successful and only address symptoms.</li> <li class="seamTextUnorderedListItem">Lymphatic surgery may be able to address the cause of lymphedema to drain and restore the flow of lymph fluid.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05890677' target='_blank'>ClinicalTrials.gov</a> </li></ul>
187

Surgery to Improve Lymphedema for People with Stage I-IV Breast Cancer

The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial
Icon

Nearest Location from 94107:
1739 miles
Washington University School of Medicine in St. Louis
St Louis, MO

Icon

Visits:
Coincides with surgery or routine care

Icon

ClinicalTrials.gov: NCT05890677

Icon

Phase NA

188

Cryoablation for Breast Cancer

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cryoablation.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer, or people with stage I, stage II, or stage III breast cancer who refuse or are unable to receive surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation, 1 time</li> <li class="seamTextUnorderedListItem">Imaging scans, 4 times in 3 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation is a procedure in which an extremely cold liquid or device is used to freeze and destroy cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05972343' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cryoablation' target='_blank'>National Cancer Institute: Cryoablation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/cryotherapy' target='_blank'>Breastcancer.org: Cryotherapy</a> </li></ul>
188

Cryoablation for Breast Cancer

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry
Icon

Nearest Location from 94107:
1739 miles
Washington University School of Medicine
St Louis, MO

Icon

Visits:
At least 5 visits within 3 years

Icon

ClinicalTrials.gov: NCT05972343

Icon

Phase NA

189

Ultra-Hypofractionated Compared to Hypofractionated Radiation for Stage I-III Node Positive Breast Cancer

SWIFT RT: Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of standard of care hypofractionated radiation with experimental ultra-hypofractionated radiation.

Who is this for?: People with stage I, stage II, or some stage III node positive breast cancer who have received surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypofractionated radiation, 16 sessions within 3-4 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultra-hypofractionated radiation, 5 sessions within 1-2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.</li> <li class="seamTextUnorderedListItem">Hypofractionated radiation consists of 16 sessions within 3-4 weeks.</li> <li class="seamTextUnorderedListItem">Ultra-hypofractionated radiation consists of 5 sessions within 1-2 weeks.</li> <li class="seamTextUnorderedListItem">Both types of radiation provide radiation to the breast, chest wall, and lymph nodes.</li> <li class="seamTextUnorderedListItem">Node positive means cancer has spread to your lymph nodes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06559540' target='_blank'>ClinicalTrials.gov</a> </li></ul>
189

Ultra-Hypofractionated Compared to Hypofractionated Radiation for Stage I-III Node Positive Breast Cancer

SWIFT RT: Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
Icon

Nearest Location from 94107:
1739 miles
Washington University School of Medicine
St Louis, MO

Icon

Visits:
5-16 visits within 1 month

Icon

ClinicalTrials.gov: NCT06559540

Icon

Phase II

190

Targeted Therapy and Hormone Therapy Before Surgery for Stage I-III Triple Positive Breast Cancer

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers Hoosier Cancer Research Network BRE17-141

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of neratinib (Nerlynx®) and trastuzumab (Herceptin®) anti-HER2 targeted therapies with letrozole (Femara®) or anastrozole (Arimidex®) hormone therapies before surgery (neoadjuvant).

Who is this for?: Postmenopausal women and men with stage I, stage II, or some stage III triple positive (ER+, PR+, HER2+) breast cancer who have not yet received surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily for 3 weeks</li> </ul> <p class="seamTextPara"> followed 3 weeks later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks for 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily for 3 weeks</li> </ul> <p class="seamTextPara"> followed 3 weeks later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks for 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily for 3 weeks</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily for 3 weeks</li> </ul> <p class="seamTextPara"> followed 3 weeks later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) or anastrozole (Arimidex®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks for 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) and trastuzumab (Herceptin®) are anti-HER2 targeted therapies used to treat HER2 positive breast cancer.</li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) and anastrozole (Arimidex®) are a type of hormone therapy called aromatase inhibitors. They are commonly used to treat hormone receptor positive breast cancer.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04886531' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/nerlynx' target='_blank'>Breastcancer.org: Neratinib (Nerlynx®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/femara' target='_blank'>Breastcancer.org: Letrozole (Femara®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/arimidex' target='_blank'>Breastcancer.org: Anastrozole (Arimidex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li></ul>
190

Targeted Therapy and Hormone Therapy Before Surgery for Stage I-III Triple Positive Breast Cancer

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers Hoosier Cancer Research Network BRE17-141
Icon

Nearest Location from 94107:
1761 miles
University of Wisconsin
Madison, WI

Icon

Visits:
Every 3 weeks for 6 months

Icon

ClinicalTrials.gov: NCT04886531

Icon

Phase II

191

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Purpose: To collect information to develop a Guardant360 blood test that can measure treatment response.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) who have received 0-1 lines of therapy for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 is a blood test that identifies genomic biomarkers and mutations to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">This trial is collecting information to develop a future version of Guardant360 that can measure treatment response.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05935384' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/tumor-marker-tests' target='_blank'>Breastcancer.org: Breast Cancer Biomarkers and Biomarker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://guardanthealth.com/products/tests-for-patients-with-advanced-cancer/' target='_blank'>Guardant Health: Guardant360 Test Information Page</a> </li></ul>
191

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Icon

Nearest Location from 94107:
1849 miles
Orchard Healthcare Research Inc.
Skokie, IL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05935384

Icon

Phase NA

192

Time-Restricted Eating During Chemotherapy for Women with Breast Cancer

Time Restricted Eating During Chemotherapy for Breast Cancer

Purpose: To study whether time-restricted eating (limiting food intake to an 8-hour window each day) is a practical and acceptable approach for women with breast cancer who are starting chemotherapy.

Who is this for?: Women with stage I, stage II, stage III, or stage IV breast cancer who are starting chemotherapy. You must not have type 1 or insulin-dependent type 2 diabetes, or be currently enrolled in a weight loss program. You must be receiving care at the University of Illinois Chicago and Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1 </i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will eat all your food within a self-selected 8-hour window each day (starting at 10:00 am, 11:00 am, or 12:00 pm), then fast for the remaining 16 hours</li> <li class="seamTextUnorderedListItem">You will follow this plan daily for 6 months (24 weeks).</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will follow standard nutrition recommendations for people receiving chemotherapy.</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Early research suggests that fasting around the time of chemotherapy may help improve how well treatment works and reduce side effects. </li> <li class="seamTextUnorderedListItem">This study will look at whether time-restricted eating affects treatment side effects, fatigue, quality of life, body weight and composition, and blood sugar and hormone levels during the 6-month study period.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07387445' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/fasting-improves-quality-of-life-during-chemo' target='_blank'>Breastcancer.org: Short-Term Fasting Improves Quality of Life During Chemotherapy</a> </li></ul>
192

Time-Restricted Eating During Chemotherapy for Women with Breast Cancer

Time Restricted Eating During Chemotherapy for Breast Cancer
Icon

Nearest Location from 94107:
1853 miles
University of Illinois Chicago
Chicago, IL

Icon

Visits:
Number of visits unavailable, up to 6 months.

Icon

ClinicalTrials.gov: NCT07387445

Icon

Phase NA

193

Biomarker Tests to Plan Treatment Before Surgery for Stage I-III HER2+ Breast Cancer

BRE-10: BIomarker OptimizatioN of NeOadjuVAnt Therapy in BrEast Cancer: The INNOVATE Trial

Purpose: To use the MammaPrint® and/or BluePrint® tests to determine who should receive neoadjuvant (before surgery) chemotherapy.

Who is this for?: People with newly diagnosed stage I, stage II, or stage III HER2 positive (HER2+) breast cancer who have not yet received treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MammaPrint® and/or BluePrint® tests</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy, by IV, every 3 weeks (if needed based on test results)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MammaPrint® and BluePrint® are genetic tests that use tumor samples to help guide treatment decisions and determine risk of recurrence (cancer coming back).</li> <li class="seamTextUnorderedListItem">In this trial, you may receive at least 1 of the following chemotherapy drugs: nab-paclitaxel (Abraxane®), paclitaxel (Taxol®), docetaxel (Taxotere®), pertuzumab (Perjeta®), trastuzumab (Herceptin®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06441890' target='_blank'>ClinicalTrials.gov</a> </li></ul>
193

Biomarker Tests to Plan Treatment Before Surgery for Stage I-III HER2+ Breast Cancer

BRE-10: BIomarker OptimizatioN of NeOadjuVAnt Therapy in BrEast Cancer: The INNOVATE Trial
Icon

Nearest Location from 94107:
1853 miles
University of Illinois
Chicago, IL

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT06441890

Icon

Phase II

194

Experimental Chemotherapy Before Surgery Plus Standard of Care for Women with High-Risk Stage I-II Breast Cancer

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

Purpose: To study the safety, dose, anti-cancer activity, and the effects on the immune system of giving a low dose of an experimental chemotherapy before surgery.

Who is this for?: Women with stage I or stage II breast cancer that is considered high-risk for recurrence. See below for this trial's definition of high-risk. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azacitidine, by injection, daily, for 5 days in a row</li> <li class="seamTextUnorderedListItem">followed by the standard of care for your stage and subtype of breast cancer</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial defines high-risk breast cancer as having a primary tumor greater than 1 cm, and the cancer is:</li> <li class="seamTextUnorderedListItem">Triple-negative (ER-, PR-, HER2-), or</li> <li class="seamTextUnorderedListItem">Estrogen-receptor positive and either HER2-positive, node-positive, progesterone-receptor negative, or has a clinical high expression on the MammaPrint, Oncotype, or Endopredict test. </li> <li class="seamTextUnorderedListItem">Azacitidine is a chemotherapy approved for use in other diseases, but its use in breast cancer is considered experimental.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04891068' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a607068.html' target='_blank'>MedLinePlus: Azacitidine</a> </li></ul>
194

Experimental Chemotherapy Before Surgery Plus Standard of Care for Women with High-Risk Stage I-II Breast Cancer

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Icon

Nearest Location from 94107:
1853 miles
University of Illinois Cancer Center
Chicago, IL

Icon

Visits:
At least 5 visits over 1 month

Icon

ClinicalTrials.gov: NCT04891068

Icon

Phase II

195

HER2 Vaccine for High-Risk Stage I-III HER2+ Breast Cancer

Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a HER2 vaccine to activate the immune system to kill breast cancer cells.

Who is this for?: People with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer that is high risk. You must have received HER2 targeted therapy for at least 6 months. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 vaccine, by injection, 4 times within 6 months</li></ul>

What's being studied?


How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06949410' target='_blank'>ClinicalTrials.gov</a> </li></ul>
195

HER2 Vaccine for High-Risk Stage I-III HER2+ Breast Cancer

Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer
Icon

Nearest Location from 94107:
1946 miles
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Indianapolis, IN

Icon

Visits:
4 visits within 6 months

Icon

ClinicalTrials.gov: NCT06949410

Icon

Phase I

196

NearWave Imaging Device to Measure Treatment Response for Women with Stage II-III HER2+ or Triple Negative Breast Cancer

NearWave Optical Molecular Monitoring for Predicting Complete Pathological Response (pCR) to Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients

Purpose: To study the use of the NearWave imaging device to monitor tumors during treatment and predict treatment response.

Who is this for?: Women with newly diagnosed stage II or some stage III HER2 positive (HER2+) or triple negative (ER-, PR-, HER2-) breast cancer who are planning to receive treatment before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NearWave optical molecular monitoring before, during, and after chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The NearWave system uses a non-invasive handheld imaging device.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06744465' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://nearwave.co/' target='_blank'>NearWave: Information Page</a> </li></ul>
196

NearWave Imaging Device to Measure Treatment Response for Women with Stage II-III HER2+ or Triple Negative Breast Cancer

NearWave Optical Molecular Monitoring for Predicting Complete Pathological Response (pCR) to Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients
Icon

Nearest Location from 94107:
1946 miles
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN

Icon

Visits:
At least 3 visits within 5 months

Icon

ClinicalTrials.gov: NCT06744465

Icon

Phase NA

197

Vaccine for Metastatic HER2+, HER2 Low, or EGFR+ Breast Cancer

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of an experimental HER2 B cell peptide vaccine.

Who is this for?: People with advanced HER2 positive (HER2+), HER2 low, and/or EGFR positive (EGFR+) breast cancer who have received at least 1 line of therapy for advanced disease. You must not have received more than 3 lines of chemotherapy in the last 2 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 B cell peptide vaccine, by injection, 3 visits within 3 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 B cell peptide vaccine booster, by injection, every 6 months (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The HER2 B cell peptide vaccine is an experimental vaccine designed to stimulate your immune system to go after and kill HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06414733' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancer.iu.edu/patients/clinical-trials/61428' target='_blank'>Indiana University: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/immune-system/vaccines' target='_blank'>Breastcancer.org: Breast Cancer and Vaccines</a> </li></ul>
197

Vaccine for Metastatic HER2+, HER2 Low, or EGFR+ Breast Cancer

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors
Icon

Nearest Location from 94107:
1946 miles
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Indianpolis, IN

Icon

Visits:
At least 3 visits within 3 months

Icon

ClinicalTrials.gov: NCT06414733

Icon

Phase I

198

Bone Health in People Receiving Immunotherapy for Breast Cancer

Pilot Study Assessment of Bone Mineral Density Changes During Treatment With Anti-PD-1 Immunotherapy Agents

Purpose: To study the safety, effects (good and bad), and anti‑cancer treatment related impact on bone health in people receiving anti‑PD‑1 immunotherapy.

Who is this for?: People with stage I or stage II or stage III breast cancer who are about to start, or have recently started (within the last 4 weeks), anti‑PD‑1 immunotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DXA scan</li> <li class="seamTextUnorderedListItem">HR‑pQCT scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DXA scan is a low‑dose X‑ray commonly used to check bone strength.</li> <li class="seamTextUnorderedListItem">HR‑pQCT scan is a high‑resolution 3‑D scan of bone structure.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07555210' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/5-questions-about-bone-health-and-cancer.h00-159379578.html' target='_blank'>MD Anderson: 5 questions about bone health and cancer</a> </li></ul>
198

Bone Health in People Receiving Immunotherapy for Breast Cancer

Pilot Study Assessment of Bone Mineral Density Changes During Treatment With Anti-PD-1 Immunotherapy Agents
Icon

Nearest Location from 94107:
1958 miles
Vanderbilt-Ingram Cancer Center
Nashville, TN

Icon

Visits:
3 visits in 3 months

Icon

ClinicalTrials.gov: NCT07555210

Icon

Phase NA

199

Time‑Restricted Eating During Treatment for HER2‑Positive or Triple‑Negative Breast Cancer

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of time‑restricted eating during treatment.

Who is this for?: People with Stage I or Stage II or Stage III HER2 positive or triple‑negative breast cancer who are planning to receive neoadjuvant treatment before surgery. You must identify as Alaska Native or American Indian and receive care at the Alaska Native Medical Center. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are studying whether time‑restricted eating during cancer treatment can improve how well tumors respond before surgery and help people complete treatment with fewer delays or dose reductions. </li> <li class="seamTextUnorderedListItem">Time-restricted eating (TRE) involves eating within a period of 10 hours or less, followed by fasting for at least 14 hours daily.</li> <li class="seamTextUnorderedListItem">Fasting may protect healthy cells from chemotherapy and radiation side effects.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06802172' target='_blank'>ClinicalTrials.gov</a> </li></ul>
199

Time‑Restricted Eating During Treatment for HER2‑Positive or Triple‑Negative Breast Cancer

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
Icon

Nearest Location from 94107:
2005 miles
Alaska Native Medical Center (ANMC)
Anchorage, AK

Icon

Visits:
At least 5 visits in 6 months

Icon

ClinicalTrials.gov: NCT06802172

Icon

Phase NA

200

PET/MRI Scans to Monitor Response to Trastuzumab (Herceptin®) for Women with Stage II-III HER2+ Breast Cancer

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

Purpose: To determine if PET/MRI scans with 18F-FMISO can help monitor and predict the effect of trastuzumab (Herceptin®).

Who is this for?: Women with newly diagnosed stage II or stage III HER2 positive (HER2+) breast cancer who have not yet received treatment and are planning to receive trastuzumab (Herceptin®) before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/MRI scan with 18F-FMISO and gadoteridol (Prohance®), by IV, 2-3 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">18F-FMISO is an experimental imaging tracer for use in PET/MRI scans.</li> <li class="seamTextUnorderedListItem">Gadoteridol (Prohance®) is a standard of care imaging contrast agent for use in PET/MRI scans.</li> <li class="seamTextUnorderedListItem">The results of this study will not change your treatment plan, but it may help doctors and researchers better understand how best to treat people with breast cancer in the future.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04332588' target='_blank'>ClinicalTrials.gov</a> </li></ul>
200

PET/MRI Scans to Monitor Response to Trastuzumab (Herceptin®) for Women with Stage II-III HER2+ Breast Cancer

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
Icon

Nearest Location from 94107:
2013 miles
The University of Alabama at Birmingham
Birmingham, AL

Icon

Visits:
3-4 visits

Icon

ClinicalTrials.gov: NCT04332588

Icon

Phase I

201

Nerve Monitoring During Underarm Lymph Node Removal Surgery to Protect Nerves and Reduce Pain in People With Breast Cancer

Feasibility of Using Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) to Provide Early Identification and Protection of the Intercostalbrachial Nerve (ICBN), Medial Branch Cutaneous Nerve (MBCN), and Their Branches

Purpose: This study is testing whether two techniques used during surgery can help find and protect the small nerves that run through the underarm area. The study uses nerve monitoring, which sends gentle electrical signals to locate nerves, along with bipolar electrocautery, a surgical tool that creates less heat spread than the standard tool. Researchers want to learn whether these methods can reliably locate and shield these nerves during surgery.

Who is this for?: People with stage I, stage II, or stage III breast cancer, who are planning to have surgery to remove the lymph nodes under the arm (axillary lymph node dissection). You must be receiving care at the University of Cincinnati. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following during your surgery to remove the underarm lymph nodes: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nerve monitoring and bipolar electrocautery to help locate and protect the nerves</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are studying whether nerve monitoring and bipolar electrocautery can be used together during underarm lymph node surgery to identify certain nerves and their branches that are often hard to see. </li> <li class="seamTextUnorderedListItem">Nerve monitoring works by sending a small electrical signal that helps the surgeon pinpoint where a nerve is, even when it cannot be seen. </li> <li class="seamTextUnorderedListItem">Bipolar electrocautery is a tool that produces less current and heat than the standard tool, which may help avoid injuring nearby nerves. Because injury to these nerves is a known cause of ongoing pain after this surgery, the study is looking at whether protecting them is possible using these techniques.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07528638' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/armpit-discomfort' target='_blank'>Breastcancer.org: Armpit Discomfort</a> </li></ul>
201

Nerve Monitoring During Underarm Lymph Node Removal Surgery to Protect Nerves and Reduce Pain in People With Breast Cancer

Feasibility of Using Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) to Provide Early Identification and Protection of the Intercostalbrachial Nerve (ICBN), Medial Branch Cutaneous Nerve (MBCN), and Their Branches
Icon

Nearest Location from 94107:
2040 miles
University of Cincinnati
Cincinnati, OH

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT07528638

Icon

Phase NA

202

Pain Blocking Drugs Given During Mastectomy for Stage I-III Breast Cancer or People at High Risk for Breast Cancer

Post-mastectomy Recovery: A Randomized Clinical Trial Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks

Purpose: To compare pain-blocking drugs given during surgery for pain blocking and pain management after a mastectomy.

Who is this for?: People with stage I, stage II, or stage III breast cancer, or people at high risk for breast cancer, who are planning to receive a mastectomy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine, by injection during surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine (Marcaine®), by injection during surgery</li> <li class="seamTextUnorderedListItem">Liposomal bupivacaine (Exparel®), by injection during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine (Marcaine®) and liposomal bupivacaine (Exparel®) are FDA-approved drugs for blocking pain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06574022' target='_blank'>ClinicalTrials.gov</a> </li></ul>
202

Pain Blocking Drugs Given During Mastectomy for Stage I-III Breast Cancer or People at High Risk for Breast Cancer

Post-mastectomy Recovery: A Randomized Clinical Trial Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
Icon

Nearest Location from 94107:
2040 miles
University of Cincinnati Medical Center
Cincinnati, OH

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT06574022

Icon

Phase IV

203

Laser Therapy for Treatment of Vaginal Dryness in Breast Cancer Survivors

The Revitalize Trial: Reducing Vaginal Atrophy With Fractional CO2 Laser for Breast Cancer Survivors

Purpose: To study whether vaginal fractional CO2 laser therapy can reduce vaginal dryness, a side effect of breast cancer treatment. This trial will also look at whether the laser therapy can improve comfort during sexual activity and overall quality of life.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, who completed primary treatment at least 12 months ago, have vaginal dryness (rated 4 or higher on a 0–10 scale) that has been present for at least 3 months, and are postmenopausal (naturally or due to cancer treatment, including ovarian suppression). May be receiving ongoing adjuvant endocrine therapy (such as an aromatase inhibitor or tamoxifen, with or without ovarian suppression). View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vaginal dryness is a common side effect of breast cancer treatments such as chemotherapy and endocrine therapies (like tamoxifen or aromatase inhibitors), which lower estrogen levels. </li> <li class="seamTextUnorderedListItem">Researchers will measure how much the laser therapy reduces vaginal dryness, improves comfort during sexual activity, and improves quality of life.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05379153' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/vaginal-dryness' target='_blank'>Breastcancer.org: Vaginal Dryness</a> </li></ul>
203

Laser Therapy for Treatment of Vaginal Dryness in Breast Cancer Survivors

The Revitalize Trial: Reducing Vaginal Atrophy With Fractional CO2 Laser for Breast Cancer Survivors
Icon

Nearest Location from 94107:
2051 miles
Trinity Health IHA - Obstetrics and Gynecology West Arbor
Ann Arbor, MI

Icon

Visits:
Approximately 3 visits over 3 months, plus follow-up visits over 2 years.

Icon

ClinicalTrials.gov: NCT05379153

Icon

Phase III

204

Supervised Exercise Program After Treatment for Black Women with Stage 0-III Breast Cancer

Breast Cancer Resiliency Through Exercise Program (B-REP): Pilot Study

Purpose: To study how a supervised resistance exercise program affects the physical and social health of Black women after breast cancer treatment.

Who is this for?: Black, African American, and/or Afro-Latina women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who have completed treatment within the last 5 years. You must exercise less than 2 times every week. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised resistance exercise program, 4 months</li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Information about physical activity for people with cancer</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised exercise may improve a person's ability to exercise correctly, attitude about exercise, and physical and social health.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, each exercise session will be 35-45 minutes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06100263' target='_blank'>ClinicalTrials.gov</a> </li></ul>
204

Supervised Exercise Program After Treatment for Black Women with Stage 0-III Breast Cancer

Breast Cancer Resiliency Through Exercise Program (B-REP): Pilot Study
Icon

Nearest Location from 94107:
2054 miles
University of Michigan
Ann Arbor, MI

Icon

Visits:
At least 3 visits within 6 months

Icon

ClinicalTrials.gov: NCT06100263

Icon

Phase NA

205

Virtual Platform to Track Medication Safety and Concerns for Stage 0-IV Breast Cancer

Patient Engagement in Using the Technology for Self-Tracking Medication Safety Events

Purpose: To study the usefulness of a self-monitoring platform for tracking medication safety events and concerns.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving treatment for their cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use of the online platform to track your experiences or concerns about taking your medications, including symptoms, for 6 months</li> <li class="seamTextUnorderedListItem">Educational materials and resources, virtual, for 6 months</li> <li class="seamTextUnorderedListItem">Follow-up from a nurse practitioner, virtual, as needed over the 6 months</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patients receiving cancer treatment by mouth often have challenges with managing complex treatments, side effects, and interactions with food or other drugs at home.</li> <li class="seamTextUnorderedListItem">In this study, patients go online to track their experiences or concerns about taking their medications, including symptoms. This online platform may help people take better care of their health.</li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07291414' target='_blank'>ClinicalTrials.gov</a> </li></ul>
205

Virtual Platform to Track Medication Safety and Concerns for Stage 0-IV Breast Cancer

Patient Engagement in Using the Technology for Self-Tracking Medication Safety Events
Icon

Nearest Location from 94107:
2054 miles
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Icon

Visits:
Number of visits unavailable, up to 1 year

Icon

ClinicalTrials.gov: NCT07291414

Icon

Phase NA

206

Temporary Tattoo Ink to Mark the Area for Radiation for Women with Stage 0-III Breast Cancer

A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery

Purpose: To study the safety and effects (good and bad) of Magic Ink for marking the site for radiation.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive radiation after surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magic Ink, by injection</li> <li class="seamTextUnorderedListItem">Skin assessment, 2 times</li> <li class="seamTextUnorderedListItem">Survey</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typically, tattoos are placed on the breast to mark the area for radiation. These tattoos are permanent.</li> <li class="seamTextUnorderedListItem">Magic Ink is a temporary skin marker that can only be seen with ultraviolet light.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07095114' target='_blank'>ClinicalTrials.gov</a> </li></ul>
206

Temporary Tattoo Ink to Mark the Area for Radiation for Women with Stage 0-III Breast Cancer

A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery
Icon

Nearest Location from 94107:
2088 miles
Karmanos Cancer Institute
Detroit, MI

Icon

Visits:
3 visits within 3 months

Icon

ClinicalTrials.gov: NCT07095114

Icon

Phase NA

207

PET/CT Scan with 18F-FETrp Tracer for Stage I-IV Breast Cancer

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

Purpose: To study whether an experimental tracer called 18F-FETrp can distinguish between tumor and non-tumor tissue on a PET/CT scan.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FETrp, by injection, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FETrp (1-(2-(18F)fluoroethyl)-L-tryptophan) is an experimental tracer for PET imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic (body processes) information obtained from the PET scan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05556473' target='_blank'>ClinicalTrials.gov</a> </li></ul>
207

PET/CT Scan with 18F-FETrp Tracer for Stage I-IV Breast Cancer

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers
Icon

Nearest Location from 94107:
2088 miles
Karmanos Cancer Institute
Detroit, MI

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT05556473

Icon

Phase I

208

Genetic Counseling Education for African American Cancer Survivors

A Community-Engaged Approach to Culturally Adapting an Intervention to Increase Uptake of Genetic Testing Among African American Cancer Survivors

Purpose: To develop and test an online educational program about genetic counseling and testing that is culturally tailored for African American cancer survivors.

Who is this for?: African American people who completed active treatment for stage I or stage II or stage III breast cancer enrolled in the Detroit Research on Cancer Survivors (Detroit ROCS) group, receive or have received care at Karmanos Cancer Institute, and have not previously had genetic counseling or genetic testing. You must have been diagnosed with breast cancer on or after January 1, 2013, and meet at least one of the following criteria for breast cancer: you were diagnosed with breast cancer at age 50 or younger OR have a personal history of triple-negative breast cancer (ER-, PR-, HER2-) or have at least one close relative (parent, sibling, child, grandparent, aunt, or uncle) diagnosed with breast cancer before age 50. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers want to know whether a culturally adapted online genetic counseling education program can increase the number of African American cancer survivors who choose to pursue genetic counseling and testing. </li> <li class="seamTextUnorderedListItem">The study also looks at how beliefs, attitudes, knowledge, perceived risk, family communication about cancer, and experiences of discrimination affect a person's decision to get genetic testing.</li> <li class="seamTextUnorderedListItem">The goal is to increase the number of people who follow through with genetic counseling and testing, which can help identify inherited cancer risks that may affect them and their families.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07436078' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/risk-factor/gene-mutations-genetic-testing/' target='_blank'>Susan G. Komen: Genetic Testing</a> </li></ul>
208

Genetic Counseling Education for African American Cancer Survivors

A Community-Engaged Approach to Culturally Adapting an Intervention to Increase Uptake of Genetic Testing Among African American Cancer Survivors
Icon

Nearest Location from 94107:
2088 miles
Karmanos Cancer Institute
Detroit, MI

Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07436078

Icon

Phase NA

209

Tango Dance Lessons to Reduce Nerve Pain for People with Stage I-IV Breast Cancer

DANCE-BASED AVENUES to ADVANCE NONPHARMACOLOGIC TREATMENT of CHEMOTHERAPY EFFECTS (DAANCE): a MULTICENTER TRIAL

Purpose: To study if tango dance lessons can reduce nerve pain caused by chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who completed treatment with paclitaxel (Taxol®) or docetaxel (Taxotere®) chemotherapy at least 3 months ago. You must have nerve pain (neuropathy). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tango dance lessons, 2 times every week for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 3 months</li> <li class="seamTextUnorderedListItem">Body function tests, 3 times in 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care, 1 month</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 3 months</li> <li class="seamTextUnorderedListItem">Body function tests, 3 times in 3 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tango dance lessons, 2 times every week for 2 months (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 80% of people with cancer who receive some chemotherapy drugs called taxanes experience neuropathy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain in your hands and feet from nerve damage as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy decreases quality of life and increases the risk of falling. Treatment options are limited.</li> <li class="seamTextUnorderedListItem">Taxanes are paclitaxel (Taxol®) and docetaxel (Taxotere®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06749210' target='_blank'>ClinicalTrials.gov</a> </li></ul>
209

Tango Dance Lessons to Reduce Nerve Pain for People with Stage I-IV Breast Cancer

DANCE-BASED AVENUES to ADVANCE NONPHARMACOLOGIC TREATMENT of CHEMOTHERAPY EFFECTS (DAANCE): a MULTICENTER TRIAL
Icon

Nearest Location from 94107:
2105 miles
The Ohio State University
Columbus, OH

Icon

Visits:
2 visits every week for 2 months

Icon

ClinicalTrials.gov: NCT06749210

Icon

Phase II

210

HyperSight CT Imaging Scans to Improve Radiation for People with Stage I-IV Breast Cancer

A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients

Purpose: To study if HyperSight CBCT imaging scans can improve the speed and accuracy of radiation.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who planning to receive or are receiving radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following during radiation sessions: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HyperSight cone beam CT (CBCT) imaging scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">CT scans can be used to help plan radiation.</li> <li class="seamTextUnorderedListItem">HyperSight cone beam CT (CBCT) imaging scans may be faster and more accurate than standard of care CT scans.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06681233' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tanner.org/cancer-care/what-we-offer/diagnosis-and-treatment/radiation-therapy/hypersight-radiation-therapy-clearly-an-advantage-in-cancer-care' target='_blank'>Tanner Health: HyperSight Imaging</a> </li></ul>
210

HyperSight CT Imaging Scans to Improve Radiation for People with Stage I-IV Breast Cancer

A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients
Icon

Nearest Location from 94107:
2107 miles
Stefanie Spielman Comprehensive Breast Center
Columbus, OH

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT06681233

Icon

Phase NA

211

Studying How Food Affects Breast Cancer Risk

Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute

Purpose: To study the relationship between the food people eat and breast cancer risk.

Who is this for?: People with stage 0 (LCIS) breast cancer or people at high risk for breast cancer who receive care at Ohio State University Comprehensive Cancer Center. You must not have been diagnosed with ductal carcinoma in situ (DCIS). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical exam, 2 times every year for 5 years</li> <li class="seamTextUnorderedListItem">Questionnaires, yearly for 5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Information collected in this study may help doctors identify risk factors that can be changed, screen high risk patients early, improve prevention, and provide the best treatments early.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05178498' target='_blank'>ClinicalTrials.gov</a> </li></ul>
211

Studying How Food Affects Breast Cancer Risk

Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
2 visits every year for 5 years

Icon

ClinicalTrials.gov: NCT05178498

Icon

Phase NA

212

Radiation During Breast Cancer Surgery in Women Age 65 and Older

Intraoperative Radiation Therapy (IORT) Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

Purpose: To develop a registry that will allow researchers to study the 5-year risk of a local breast cancer recurrence after intraoperative radiation therapy (IORT).

Who is this for?: Women age 65 or older with stage II or stage III low- risk breast cancer who will be treated with partial mastectomy (lumpectomy) and radiation during surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IORT (Intraoperative radiation), during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intraoperative radiation therapy (IORT) is given right after the tumor has been removed while you are still in the operating room.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03536897' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/intraoperative-radiation-therapy/about/pac-20385150' target='_blank'>Mayo Clinic: Intraoperative radiation therapy (IORT)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tricitymed.org/2016/10/iort-breast-cancer-treatment-primer/' target='_blank'>Tricity Medicine: IORT as Breast Cancer Treatment: A Primer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uptodate.com/contents/overview-of-the-approach-to-early-breast-cancer-in-older-women' target='_blank'>UpToDate: Overview of the approach to early breast cancer in older women</a> </li></ul>
212

Radiation During Breast Cancer Surgery in Women Age 65 and Older

Intraoperative Radiation Therapy (IORT) Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
Icon

Nearest Location from 94107:
2108 miles
Mount Carmel West Hospital
Columbus, OH

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT03536897

Icon

Phase NA

213

Focused Massage During Radiation Treatment for Breast Cancer

A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer

Purpose: To study the effects of a focused upper body chair massage on pain, arm and shoulder mobility, and quality of life in people with breast cancer who are receiving radiation treatment.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive radiation treatment. You must be receiving care at The Ohio State University Comprehensive Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Focused upper body massage (upper back, neck, shoulders, arms, and hands) after each radiation treatment session.</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many people with breast cancer experience muscle and joint pain, stiffness, and discomfort in the upper body during radiation treatment. This study is looking at whether a short, focused chair massage offered right after each radiation session can help ease that pain and discomfort, improve how well the arms and shoulders move and function, and support overall quality of life.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07447700' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/complementary-therapy/types/massage' target='_blank'>Breastcancer.org: Massage Therapy for Breast Cancer</a> </li></ul>
213

Focused Massage During Radiation Treatment for Breast Cancer

A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer
Icon

Nearest Location from 94107:
2108 miles
The Ohio State University
Columbus, OH

Icon

Visits:
Coincides with your radiation treatment visits, up to 10 weeks.

Icon

ClinicalTrials.gov: NCT07447700

Icon

Phase NA

214

Minoxidil for Hormone Therapy-Induced Hair Loss in People with Stage I-IV Breast Cancer

A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients

Purpose: To study the safety and ability of 2 methods of administering minoxidil to treat hair loss (alopecia) caused by hormone therapy.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving treatment with tamoxifen (Nolvadex®) or an aromatase inhibitor and are experiencing hair loss. You must not have received chemotherapy within the last 2 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Topical Administration</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minoxidil, by foam to scalp, daily for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Oral Administration</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minoxidil, by mouth, daily for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People receiving endocrine therapy, also called hormone therapy, commonly report hair loss or thinning. This side effect is called endocrine therapy-induced alopecia (EIA).</li> <li class="seamTextUnorderedListItem">Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early termination of hormone therapy in women with breast cancer.</li> <li class="seamTextUnorderedListItem">Minoxidil, sometimes called Rogaine®, is a drug that may promote hair growth and reduce hair loss.</li> <li class="seamTextUnorderedListItem">Oral minoxidil may work the same as topical minoxidil in treating EIA in people with breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05417308' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss' target='_blank'>Breastcancer.org: Hair Loss (Alopecia)</a> </li></ul>
214

Minoxidil for Hormone Therapy-Induced Hair Loss in People with Stage I-IV Breast Cancer

A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05417308

Icon

Phase I

215

Breathing Exercise Training for Women with Breast Cancer Receiving Chemotherapy

Effects of Inspiratory Muscle Training Among Breast Cancer Patients Undergoing Active Treatment (IMACT)

Purpose: To study the activity of inspiratory muscle training (breathing exercises) in women receiving chemotherapy for breast cancer.

Who is this for?: People with stage I or stage II or stage III breast cancer, who have recently started chemotherapy (within 3 weeks). View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing whether breathing exercises using a handheld device can help improve the strength of the muscles used for breathing. </li> <li class="seamTextUnorderedListItem">Breast cancer and chemotherapy can weaken muscles, including those used for breathing, and may cause fatigue and reduced activity levels. </li> <li class="seamTextUnorderedListItem">The study is comparing low-intensity vs. high-intensity breathing training to see which approach works better.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07386444' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/shortness-breath-dyspnea' target='_blank'>MSK: Shortness of Breath (Dyspnea)</a> </li></ul>
215

Breathing Exercise Training for Women with Breast Cancer Receiving Chemotherapy

Effects of Inspiratory Muscle Training Among Breast Cancer Patients Undergoing Active Treatment (IMACT)
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07386444

Icon

Phase NA

216

Studying Immune Cells in Women with Stage I-IV Breast Cancer

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Purpose: To study immune cells involved in breast cancer.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who have not yet received surgery, or women with stage IV (metastatic) breast cancer. You must be receiving care at the Ohio State Comprehensive Cancer Center or Stefanie Spielman Comprehensive Breast Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample</li> <li class="seamTextUnorderedListItem">Tumor and/or lymph node samples (if removed during surgery)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Natural killer (NK) cells are immune cells that identify and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Myeloid derived suppressor cells (MDSC) are immune cells that kill NK cells, which helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this study, researchers will look for and study these types of immune cells in the blood, tumor, and/or lymph node samples.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04022616' target='_blank'>ClinicalTrials.gov</a> </li></ul>
216

Studying Immune Cells in Women with Stage I-IV Breast Cancer

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
At least 1 visit

Icon

ClinicalTrials.gov: NCT04022616

Icon

Phase NA

217

The Sleep After Breast Cancer (ABC) Study for Stage I-III HR+ Breast Cancer

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

Purpose: To see how sleep quality changes during and after breast cancer treatment, and how sleep affects stress, inflammation, and signs of faster aging, in diverse populations.

Who is this for?: People with stage I or stage II or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have had surgery but have not yet received other treatment. You must be receiving care at The Ohio State University Comprehensive Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear a wrist-based sleep tracking device (similar to a fitness tracker)</li> <li class="seamTextUnorderedListItem">Complete surveys</li> <li class="seamTextUnorderedListItem">Provide cheek swab, saliva and hair samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Anxiety and insomnia (sleep problems) are among the most common side effects of breast cancer.</li> <li class="seamTextUnorderedListItem">Researchers want to learn why some patients experience poor sleep and how factors such as stress, social support, and the places people live may affect sleep quality. </li> <li class="seamTextUnorderedListItem">The study also looks at how sleep may be linked to stress, inflammation, and signs of faster biological aging.</li> <li class="seamTextUnorderedListItem">The study includes participants from different racial and ethnic backgrounds and from a variety of communities, including rural, urban, and Appalachian areas.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07341503' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancerworld.net/sleep-cancer-why-rest-matters-more-than-you-think/#:~:text=The%20immune%20system%2C%20crucial%20for,with%20sleep%20patterns%20than%20others.' target='_blank'>Cancer World: Sleep & Cancer: Why Rest Matters More Than You Think?</a> </li></ul>
217

The Sleep After Breast Cancer (ABC) Study for Stage I-III HR+ Breast Cancer

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
Number of visits unavailable, over 9 months

Icon

ClinicalTrials.gov: NCT07341503

Icon

Phase NA

218

MIND Diet and Nutrition Counseling to Improve Brain Function for People with Stage II-IV HR+ Breast Cancer

Protecting the Brain From Toxic Side Effects of Chemotherapy: a Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

Purpose: To study the impact of the Neurodegenerative Delay (MIND) diet on your cognition (ability to think).

Who is this for?: Postmenopausal women 45 to 75 years old with stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+) breast cancer who are planning to begin treatment within 1 month. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nutrition counseling about the MIND diet, 8 in-person sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General health (non-diet) counseling, 8 in-person sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer treatment can lead to cognition (ability to think) problems and low quality of life.</li> <li class="seamTextUnorderedListItem">The Neurodegenerative Delay (MIND) diet is high in anti-inflammatory nutrients (omega-3, carotenoids, B vitamins, etc.) and limits foods that are not healthy for the brain (butter, cheese, red meat, fried foods, sugar, etc.).</li> <li class="seamTextUnorderedListItem">The MIND diet may help improve brain function during cancer treatment.</li> <li class="seamTextUnorderedListItem">Cognition is your ability to think.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05984888' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.osu.edu/wellness/exercise-and-nutrition/the-mind-diet' target='_blank'>Ohio State University: The MIND Diet and Brain Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21032-chemo-brain' target='_blank'>Cleveland Clinic: Chemotherapy and Brain Function Problems</a> </li></ul>
218

MIND Diet and Nutrition Counseling to Improve Brain Function for People with Stage II-IV HR+ Breast Cancer

Protecting the Brain From Toxic Side Effects of Chemotherapy: a Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
8 visits within 9 months

Icon

ClinicalTrials.gov: NCT05984888

Icon

Phase NA

219

Interview and Survey About a Support Program for People With Advanced Breast Cancer

Living Well With Advanced Breast Cancer

Purpose: To study the use of supportive care to better understand what has helped people, what has been hard, and what kind of help they still need.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer and their caregivers. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Survey</li> <li class="seamTextUnorderedListItem">Interview</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Living Well with Advanced Breast Cancer is a program at Ohio State that aims to address the physical, social, emotional and spiritual concerns of people living with advanced breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07227038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/cancers-conditions-and-treatment/cancer-types/breast-cancer/specialty-clinics-and-programs/living-well-with-advanced-breast-cancer' target='_blank'>Ohio State University: Living Well with Advanced Breast Cancer</a> </li></ul>
219

Interview and Survey About a Support Program for People With Advanced Breast Cancer

Living Well With Advanced Breast Cancer
Icon

Nearest Location from 94107:
2108 miles
Ohio State University Comprehensive Cancer Center
Columbus, OH

Icon

Visits:
1 day

Icon

ClinicalTrials.gov: NCT07227038

Icon

Phase NA

220

Reducing Skin Reactions From Proton Radiation Therapy for People with Stage 0-III Breast Cancer

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

Purpose: To study the ability of the "Spot Delete" method to reduce skin reactions during pencil beam scanning (PBS) proton radiation therapy.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have received surgery. You must not have received radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CT scan, 1 time</li> <li class="seamTextUnorderedListItem">Pencil beam scanning (PBC) proton radiation therapy with <q>Spot Delete</q> method</li> <li class="seamTextUnorderedListItem">Digital photographs, weekly for 2.5 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Pencil beam scanning (PBS) proton therapy may safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor.</li> <li class="seamTextUnorderedListItem">Radiation therapy, including pencil beam scanning proton therapy, can cause skin reactions.</li> <li class="seamTextUnorderedListItem">The <q>Spot Delete</q> method may prevent protons from stopping in the skin, which is thought to cause skin redness.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06006806' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21995-radiation-burns' target='_blank'>Cleveland Clinic: Skin Reactions from Radiation Therapy</a> </li></ul>
220

Reducing Skin Reactions From Proton Radiation Therapy for People with Stage 0-III Breast Cancer

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
Icon

Nearest Location from 94107:
2113 miles
Thompson Proton Center
Knoxville, TN

Icon

Visits:
1 visit every week for 2.5 months

Icon

ClinicalTrials.gov: NCT06006806

Icon

Phase NA

221

Exercise and Nutrition Support During Chemotherapy for Older Women with Stage I-III Breast Cancer

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)

Purpose: To study if exercise plus support to increase protein intake will make it easier for older women to receive chemotherapy as prescribed.

Who is this for?: Women at least 65 years old with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Exercise and Nutrition Support</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, 1 session in person, then 2 sessions at home every week during chemotherapy</li> <li class="seamTextUnorderedListItem">Meeting with dietician, virtual</li> <li class="seamTextUnorderedListItem">Diet journal</li> <li class="seamTextUnorderedListItem">Body and memory tests, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Health Education</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health educational materials on tablet during chemotherapy appointments</li> <li class="seamTextUnorderedListItem">Body and memory tests, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">If you are in Group 1, you will work with an exercise coach to perform muscle strengthening exercises and aerobic exercises. </li> <li class="seamTextUnorderedListItem">If you are in Group 1, you will also meet with a dietitian to make sure you are eating enough protein during chemotherapy. You will keep a daily protein checklist and share this with the exercise coach each week.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will receive a tablet with information about meditation, stretching and gentle movement, relaxation, and creative arts during chemotherapy appointments.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05535192' target='_blank'>ClinicalTrials.gov</a> </li></ul>
221

Exercise and Nutrition Support During Chemotherapy for Older Women with Stage I-III Breast Cancer

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)
Icon

Nearest Location from 94107:
2168 miles
Case Western Reserve University/University Hospitals Cleveland
Cleveland, OH

Icon

Visits:
At least 2 visits within 2-7 months

Icon

ClinicalTrials.gov: NCT05535192

Icon

Phase NA

222

Probiotic Supplement for Women With Breast Cancer

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients

Purpose: To study how well a probiotic can change the mix of microorganisms (like bacteria and fungi) in the gut microbiome and breast tissue in people with breast cancer.

Who is this for?: Women with stage I or stage II or stage III or stage IV (invasive ductal carcinoma [IDC] or invasive lobular carcinoma [ILC]) breast cancer. You must agree to avoid unpasteurized fermented foods and probiotics and to keep your usual diet and activity level before the study starts and while you are in the study. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The gut microbiome is made up of bacteria, viruses, and other organisms that live in the digestive tract and help keep us healthy.</li> <li class="seamTextUnorderedListItem">A probiotic, called BIOHM, is a food supplement that is believed to balance bacteria and fungi in the body.</li> <li class="seamTextUnorderedListItem">This study is looking at whether taking BIOHM may help change the body’s microbiome in people with breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04362826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/diet-nutrition/dietary-supplements/known/probiotics' target='_blank'>Breastcancer.org: Probiotics and Breast Cancer</a> </li></ul>
222

Probiotic Supplement for Women With Breast Cancer

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients
Icon

Nearest Location from 94107:
2172 miles
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, OH

Icon

Visits:
At least 2 visits in 6 weeks

Icon

ClinicalTrials.gov: NCT04362826

Icon

Phase NA

223

Scalp Cooling to Reduce Hair Loss During Chemotherapy for Breast Cancer

Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region

Purpose: To study whether the Paxman Scalp Cooling System (a cap-like device that cools the scalp during chemotherapy) can help prevent or reduce hair loss and improve quality of life for people with breast cancer receiving chemotherapy. This trial will also look at whether certain genetic variations (differences in specific genes) affect a person's likelihood of experiencing hair loss during chemotherapy and how well hair grows back afterward.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive a type of chemotherapy known to cause hair loss (such as anthracycline or taxane). You must be receiving care at Ballad Health Cancer Care, Kingsport, Tennessee. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Scalp Cooling</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paxman Scalp Cooling System, worn before, during, and after each chemotherapy infusion</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Blood or tissue sample for genetic testing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: No scalp cooling treatment</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Blood or tissue sample for genetic testing</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying whether using a scalp cooling device during chemotherapy can reduce hair loss (called chemotherapy-induced alopecia) and improve quality of life for people with breast cancer in the Appalachian Highlands region. </li> <li class="seamTextUnorderedListItem">This trial is also looking at two specific genetic variations (one in the CACNB4 gene and one in the ABCB1 gene) that have been linked to hair loss from chemotherapy in other populations, to see if they are relevant in this region's population.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07422376' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss/cold-caps-scalp-cooling' target='_blank'>Breastcancer.org: Cold Caps and Scalp Cooling Systems</a> </li></ul>
223

Scalp Cooling to Reduce Hair Loss During Chemotherapy for Breast Cancer

Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
Icon

Nearest Location from 94107:
2181 miles
Ballad Health Cancer Care
Kingsport, TN

Icon

Visits:
Coincides with your chemotherapy schedule

Icon

ClinicalTrials.gov: NCT07422376

Icon

Phase NA

224

Studying the Impact of Chemotherapy on Muscle Health for Women with Stage I-III Breast Cancer

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients

Purpose: To study how chemotherapy affects muscle health.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are receiving chemotherapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Muscle measurement while exercising on a stationary bike, up to 6 times</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Muscle measurement is done while you wear a mask and non-invasive device on your leg to measure oxygen levels.</li> <li class="seamTextUnorderedListItem">These sessions will take about 30 minutes.</li> <li class="seamTextUnorderedListItem">This study is also enrolling women with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06672497' target='_blank'>ClinicalTrials.gov</a> </li></ul>
224

Studying the Impact of Chemotherapy on Muscle Health for Women with Stage I-III Breast Cancer

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
Icon

Nearest Location from 94107:
2223 miles
Prisma Health Cancer Institute
Greenville, SC

Icon

Visits:
Up to 6 visits

Icon

ClinicalTrials.gov: NCT06672497

Icon

Phase NA

225

X-PACT Radiation For Advanced Breast Cancer

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

Purpose: To study the safety and effects (good and bad) of X-ray Psoralen Activated Cancer Therapy (X-PACT), an experimental type of radiation therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have progressed following standard therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">X-PACT radiation with injection, 5-7 sessions over 1.5-4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">X-PACT stands for X-ray Psoralen Activated Cancer Therapy.</li> <li class="seamTextUnorderedListItem">X-PACT consists of injections inside tumors.</li> <li class="seamTextUnorderedListItem">Injections contain drugs that have anti-cancer properties when activated with x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04389281' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.immunolight.com/cancer' target='_blank'>Immunolight Drug Information Page: X-PACT</a> </li><li class='seamTextUnorderedListItem'><a href='https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162078' target='_blank'>Journal Article: X-PACT</a> </li></ul>
225

X-PACT Radiation For Advanced Breast Cancer

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma
Icon

Nearest Location from 94107:
2223 miles
Prisma Health
Greenville, SC

Icon

Visits:
At least 5 visits over the first 1.5 months, then 2 visits over the next 2-3 months

Icon

ClinicalTrials.gov: NCT04389281

Icon

Phase I

226

Nerve Stimulation (taVNS) Device for Pain and Symptom Management in Women with Breast Cancer

Home-based Pain and Symptom Management for Breast Cancer Survivors: a Triple- Blinded RCT Pilot Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Purpose: To study whether a small, wearable device that gently stimulates a nerve in the ear, called transcutaneous auricular vagus nerve stimulation (taVNS), can help manage pain and other symptoms such as anxiety, depression, fatigue, and sleep problems in breast cancer survivors. This study will also explore how taVNS may affect the gut microbiome and brain activity related to pain.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer ,who have completed their primary treatment (surgery, radiation, and/or chemotherapy) and are now on a stable survivorship care plan (such as hormone therapy or supportive care) and have been experiencing pain rated 4 or higher (out of 10) for at least 10 days in the past month. You must be receiving care at Florida State University (Tallahassee, Florida) to participate in this study. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Active taVNS device, worn on the ear, 2 times per day, 30 minutes each session</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sham (inactive) taVNS device, worn on the ear, 2 times per day, 30 minutes each session</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">You will also be asked to:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Keep an online daily diary of your device use and any side effects</li> <li class="seamTextUnorderedListItem">Complete surveys and questionnaires at the start of the study, at 4 weeks, and at 8 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive technique that stimulates the vagus nerve through the ear. The device clips onto the outer ear (the auricular branch of the vagus nerve runs close to the skin there), delivering mild electrical pulses without any needles or surgery.</li> <li class="seamTextUnorderedListItem">The gentle electrical stimulation travels along the vagus nerve to the brain, which may help regulate pain signals, mood, and the body's stress response.</li> <li class="seamTextUnorderedListItem">Studies are exploring its potential to reduce pain, anxiety, depression, fatigue, and sleep problems, particularly in people managing chronic conditions or cancer-related side effects.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07500012' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uab.edu/uabmagazine/spring-summer-2026/why-tavns-is-transforming-vagus-nerve-stimulation' target='_blank'>University of Alabama: Why taVNS is Transforming Vagus Nerve Stimulation</a> </li></ul>
226

Nerve Stimulation (taVNS) Device for Pain and Symptom Management in Women with Breast Cancer

Home-based Pain and Symptom Management for Breast Cancer Survivors: a Triple- Blinded RCT Pilot Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Icon

Nearest Location from 94107:
2229 miles
Florida State University
Tallahassee, FL

Icon

Visits:
3 in-person visits over 8 weeks

Icon

ClinicalTrials.gov: NCT07500012

Icon

Phase NA

227

Contrast-Enhanced Mammograms After Treatment for Women with Stage 0-III Breast Cancer

Outcome of Biennial Screening Contrast-Enhanced Mammography (CEM) in Women With a Personal History of Breast Cancer (PHBC)

Purpose: To study if contrast-enhanced mammograms every other year in addition to standard of care mammograms every year improve breast cancer detection.

Who is this for?: Women 30-79 years old with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who completed treatment at least 1 year ago. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced mammograms, 3 times in 4 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will also receive your regularly scheduled yearly mammograms while in this study.</li> <li class="seamTextUnorderedListItem">Contrast-enhanced mammograms are FDA-approved scans that are used in addition to regular mammograms and ultrasound scans.</li> <li class="seamTextUnorderedListItem">Contrast-enhanced mammograms are similar to standard mammograms but include an IV injection of contrast, which makes tissue and blood vessels more visible in scans.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06105749' target='_blank'>ClinicalTrials.gov</a> </li></ul>
227

Contrast-Enhanced Mammograms After Treatment for Women with Stage 0-III Breast Cancer

Outcome of Biennial Screening Contrast-Enhanced Mammography (CEM) in Women With a Personal History of Breast Cancer (PHBC)
Icon

Nearest Location from 94107:
2252 miles
UPMC Magee at the Lemieux Sports Complex
Cranberry Township, PA

Icon

Visits:
3 visits in 4 years

Icon

ClinicalTrials.gov: NCT06105749

Icon

Phase NA

228

Exercise to Improve Muscle Mass After Treatment for Stage 0-III Breast Cancer

EXERT-BCH: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer to Improve Hypertrophy

Purpose: To compare the ability of 2 group exercise programs to increase muscle mass for women after breast cancer treatment.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have completed treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistance training in a small group, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Strength measurements</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Strength and conditioning training in a small group, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Strength measurements</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise to build muscle mass in people who have been treated for breast cancer may reduce toxicity from treatment, increase time to tumor progression, and prolong survival.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06115486' target='_blank'>ClinicalTrials.gov</a> </li></ul>
228

Exercise to Improve Muscle Mass After Treatment for Stage 0-III Breast Cancer

EXERT-BCH: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer to Improve Hypertrophy
Icon

Nearest Location from 94107:
2260 miles
Allegheny General Hospital
Pittsburgh, PA

Icon

Visits:
3 times per week for 3 months

Icon

ClinicalTrials.gov: NCT06115486

Icon

Phase NA

229

Exercise After Treatment for Women with Stage 0-III Breast Cancer

EXERT-BCHC: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

Purpose: To study the effect of four exercise programs on body measurements.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have received treatment for their breast cancer and have been prescribed exercise. You must not currently be receiving chemotherapy or radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program in which 3 exercises are performed consecutively with minimal rest</li> <li class="seamTextUnorderedListItem">Body measurements, monthly for 5 months</li> <li class="seamTextUnorderedListItem">Questionnaires, monthly for 5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program in which 6 exercises are performed consecutively with no rest between sets</li> <li class="seamTextUnorderedListItem">Body measurements, monthly for 5 months</li> <li class="seamTextUnorderedListItem">Questionnaires, monthly for 5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program in which 5 repetitions are performed, followed by resting for 20 seconds</li> <li class="seamTextUnorderedListItem">Body measurements, monthly for 5 months</li> <li class="seamTextUnorderedListItem">Questionnaires, monthly for 5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program in which 5 repetitions are performed, followed by resting for 20 seconds, plus additional repetitions</li> <li class="seamTextUnorderedListItem">Body measurements, monthly for 5 months</li> <li class="seamTextUnorderedListItem">Questionnaires, monthly for 5 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise is often recommended for people who have completed treatment for breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07023887' target='_blank'>ClinicalTrials.gov</a> </li></ul>
229

Exercise After Treatment for Women with Stage 0-III Breast Cancer

EXERT-BCHC: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
Icon

Nearest Location from 94107:
2260 miles
Allegheny General Hospital
Pittsburgh, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07023887

Icon

Phase NA

230

Exercise Program and Protein Supplement to Improve Strength During Chemotherapy for Women with Stage I-III Breast Cancer

NeoChemoPRT: a Randomized Study of Resistance Training and Post-Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer

Purpose: To study if an exercise program and high dose of protein supplement will improve body composition and strength for people receiving chemotherapy before surgery (neoadjuvant).

Who is this for?: Women with stage I, stage II, or some stage III breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Exercise with Low Dose of Protein</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistance (strength) exercise program, 6 months</li> <li class="seamTextUnorderedListItem">20 grams of protein supplement, after each exercise session</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Exercise with High Dose of Protein</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistance (strength) exercise program, 6 months</li> <li class="seamTextUnorderedListItem">60 grams of protein supplement, after each exercise session</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistence training is a type of exercise aimed at improving muscular strength and endurance.</li> <li class="seamTextUnorderedListItem">Protein supplements can help your body build muscle.</li> <li class="seamTextUnorderedListItem">In this study, the protein is made of whey, which is a dairy product.</li> <li class="seamTextUnorderedListItem">The whey is non-GMO, grass-fed, soy and gluten free, unflavored, and unsweetened.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06858449' target='_blank'>ClinicalTrials.gov</a> </li></ul>
230

Exercise Program and Protein Supplement to Improve Strength During Chemotherapy for Women with Stage I-III Breast Cancer

NeoChemoPRT: a Randomized Study of Resistance Training and Post-Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer
Icon

Nearest Location from 94107:
2260 miles
Allegheny General Hospital
Pittsburgh, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06858449

Icon

Phase NA

231

Vaccine to Prevent Breast Cancer for Women with ER+ DCIS

A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Purpose: To study the safety and ability of an experimental MUC1 peptide vaccine to prevent breast cancer in people with DCIS.

Who is this for?: Postmenopausal women with stage 0 (DCIS) estrogen receptor positive (ER+) breast cancer who are planning to receive surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MUC1 peptide vaccine with Poly ICLC (Hiltonol®), by injection, 3-4 times within 3-9 months</li> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitor, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Not all DCIS will progress to invasive breast cancer.</li> <li class="seamTextUnorderedListItem">Vaccines for DCIS may allow for less treatment. </li> <li class="seamTextUnorderedListItem">The MUC1 peptide vaccine is an experimental immunotherapy. The vaccine targets MUC1, which is a protein expressed by DCIS.</li> <li class="seamTextUnorderedListItem">Poly ICLC (Hiltonol®) is an immunotherapy that stimulates immune cells to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06218303' target='_blank'>ClinicalTrials.gov</a> </li></ul>
231

Vaccine to Prevent Breast Cancer for Women with ER+ DCIS

A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Icon

Nearest Location from 94107:
2264 miles
UPMC Magee Womens Hospital
Pittsburgh, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06218303

Icon

Phase I

232

CTC‑EXPRESS: Using Blood Tests to Help Guide Treatment and Monitoring in Advanced Breast Cancer

CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer

Purpose: To find out whether special blood tests, that look for cancer cells and cancer‑related genetic material circulating in the blood, can help doctors make better decisions about breast cancer treatment and monitoring.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HR+/HER2- breast cancer before starting first line of treatment or triple negative breast cancer who are starting any line of treatment, or HER2+ breast cancer after receiving first line of treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, taken during routine appointments</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are studying special blood tests that look for cancer cells and cancer‑related genetic material circulating in the blood. These test results help doctors choose treatments, understand how well treatment is working, and track whether the cancer is changing or progressing.</li> <li class="seamTextUnorderedListItem">Advanced blood tests can count cancer cells (CTC enumeration), check cancer markers on those cells (CTC expression), and look for cancer‑related DNA and RNA floating in the blood (cfDNA/RNA).</li> <li class="seamTextUnorderedListItem">When you can join depends on the type of breast cancer you have: HR+/HER2‑ breast cancer before starting first‑line treatment; Triple negative breast cancer starting any line of treatment, and HER2‑positive breast cancer starting second‑line treatment or later</li> <li class="seamTextUnorderedListItem">This is an observational study, and no experimental drugs are given as part of the study.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06833853' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/liquid-biopsy/' target='_blank'>Metastatic Trial Talk: Understanding Liquid Biopsies for MBC</a> </li></ul>
232

CTC‑EXPRESS: Using Blood Tests to Help Guide Treatment and Monitoring in Advanced Breast Cancer

CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer
Icon

Nearest Location from 94107:
2264 miles
UPMC Magee Womens Hospital
Pittsburgh, PA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT06833853

Icon

Phase NA

233

Resistance Exercise Program for Women With Stage 0-III Breast Cancer

Lifting More Than Weights: Feasibility of Implementing a Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management

Purpose: To study how biological, psychological, and social factors affect a person's willingness to do personalized resistance exercise.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer whose diagnosis was within the last 1 to 3 years and who receive treatment at West Virginia University (WVU) Cancer Institute. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Strength after Breast Cancer (SABC) exercise program, 45-minute sessions twice a week for 3 months</li> <li class="seamTextUnorderedListItem">Keep an exercise log</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Strength measurements</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear and tear on the body due to stress and a person's education, income, and type of job may affect their ability and willingness to start and continue exercise to improve their health after breast cancer. A person's confidence in their abilities, expectations, and social support may also influence willingness to exercise.</li> <li class="seamTextUnorderedListItem">The Strength after Breast Cancer (SABC) is an exercise program that improves body composition, body image, strength, and upper body using supervised sessions followed by unsupervised sessions with follow-up. The program includes resistance bands and a physical therapy workout plan.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06960720' target='_blank'>ClinicalTrials.gov</a> </li></ul>
233

Resistance Exercise Program for Women With Stage 0-III Breast Cancer

Lifting More Than Weights: Feasibility of Implementing a Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
Icon

Nearest Location from 94107:
2273 miles
West Virginia University
Morgantown, WV

Icon

Visits:
Number of visits unavailable, 3 months

Icon

ClinicalTrials.gov: NCT06960720

Icon

Phase NA

234

Support Services for Black Survivors of Stage 0-III Breast Cancer in Western New York

Thriving Beyond Breast Cancer: Post-Treatment Supportive Services Programming for Black Women to Alleviate Disparities During Survivorship

Purpose: To study whether a post-treatment supportive service program helps Black women transition into survivorship.

Who is this for?: Black or African American people with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who live in western New York and have completed breast cancer treatment (except hormone therapy if recommended) within the last year. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Group support and peer mentoring sessions, in person, 2-hour sessions, weekly for up to 1 year</li> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The post-treatment supportive service program combines group support sessions and one-on-one peer mentoring sessions. The group support sessions include traditional support groups, education, activities, such as cooking lessons, celebrations, or facility tours, and guest speakers. The peer mentoring sessions are held with a long-term breast cancer survivor mentor who helps the mentee perform monthly self-assessments, create plans to help improve modifiable risk factors, and connect the mentee to providers or resources as needed.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06833255' target='_blank'>ClinicalTrials.gov</a> </li></ul>
234

Support Services for Black Survivors of Stage 0-III Breast Cancer in Western New York

Thriving Beyond Breast Cancer: Post-Treatment Supportive Services Programming for Black Women to Alleviate Disparities During Survivorship
Icon

Nearest Location from 94107:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Icon

Visits:
Weekly for up to 1 year

Icon

ClinicalTrials.gov: NCT06833255

Icon

Phase NA

235

Navigation to Provide Access to Support Services for Women with Stage 0-4 Breast Cancer

Addressing Disparities in Breast Cancer Care: An Approach to Health Equity

Purpose: To study a program that helps women with breast cancer receive and manage breast cancer care.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Support from patient navigator</li> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The patient navigator will help connect you with support services, manage obstacles to care, and support your ability to manage cancer treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06350500' target='_blank'>ClinicalTrials.gov</a> </li></ul>
235

Navigation to Provide Access to Support Services for Women with Stage 0-4 Breast Cancer

Addressing Disparities in Breast Cancer Care: An Approach to Health Equity
Icon

Nearest Location from 94107:
2299 miles
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06350500

Icon

Phase NA

236

Home-Based Respiratory Muscle Training to Reduce Chemotherapy Side Effects for People with Stage I-IV Breast Cancer

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Purpose: To study how home-based respiratory muscle training is useful for minimizing side effects during chemotherapy treatment.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive chemotherapy. You must not have received radiation to the left chest wall. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care, 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Respiratory muscle training using a respiratory muscle training device, 1.5 months (optional)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Respiratory muscle training using a respiratory muscle training device, 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Respiratory muscle training is a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training.</li> <li class="seamTextUnorderedListItem">Respiratory muscle training may decrease heart and lung side effects of chemotherapy and improve your quality of life.</li> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05787834' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://umiamihealth.org/en/treatments-and-services/ear,-nose,-and-throat-(ent)/speech-therapy/respiratory-muscle-training#:~:text=Respiratory%20muscle%20training%20(RMT)%20is,%2C%20improve%20respiration%20(breathing).' target='_blank'>University of Miami: Respiratory Muscle Training</a> </li></ul>
236

Home-Based Respiratory Muscle Training to Reduce Chemotherapy Side Effects for People with Stage I-IV Breast Cancer

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity
Icon

Nearest Location from 94107:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05787834

Icon

Phase NA

237

Photoacoustic Imaging (A Scan That Uses Waves and Light) to Study Breast Tissue and Tumors in Women

Photoacoustic Imaging of Human Breast

Purpose: To study breast tissue and tumors by using photoaccoustic imaging (a type of scan that uses sound and light to study tissue).

Who is this for?: Women diagnosed with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received or are planning to receive a breast MRI. You may also enroll if you have not been diagnosed with breast cancer but are scheduled to receive an MRI to look at a suspicious mass (lump) in your breast. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Photoacoustic imaging of the breast, for about 30 minutes, once</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">You may choose to repeat this process up to 10 times (on separate days)</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Research shows that mammograms are more difficult to read in women with dense breasts.</li> <li class="seamTextUnorderedListItem">Photoacoustic imaging is a type of scan that uses sound and light to study breast tissue.</li> <li class="seamTextUnorderedListItem">Researchers are studying whether photoacoustic imaging makes it easier to see tumors in women with dense breasts.</li> <li class="seamTextUnorderedListItem">They are also studying if they can learn anything new about breast tissue and tumors with this experimental imaging technique.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03897270' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Photoacoustic_imaging' target='_blank'>Wikipedia: Photoacoustic Imaging</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/types/breast/breast-changes/dense-breasts' target='_blank'>NCI Breast Cancer: Dense Breasts</a> </li><li class='seamTextUnorderedListItem'><a href='https://dmm.biologists.org/content/12/7/dmm039636' target='_blank'>Journal Article: Photoacoustic Imaging as a Tool to Probe the Tumour Microenvironment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005545/' target='_blank'>Journal Article: Photoacoustic Imaging of Breast Cancer</a> </li></ul>
237

Photoacoustic Imaging (A Scan That Uses Waves and Light) to Study Breast Tissue and Tumors in Women

Photoacoustic Imaging of Human Breast
Icon

Nearest Location from 94107:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT03897270

Icon

Phase NA

238

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors

Purpose: To study how breast cancer develops resistance to treatment with CDK 4/6 inhibitors and how to predict response to treatment with CDK 4/6 inhibitors.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or people with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) node positive breast cancer. You must have completed treatment with or currently be receiving treatment with a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, fluid, and biopsy samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your samples may be used to help your doctor make treatment decisions.</li> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>
238

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
Icon

Nearest Location from 94107:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04526587

Icon

Phase NA

239

Personalized Exercise and Healthy Living Program During Chemotherapy for Breast Cancer (STEPS BC)

Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC)

Purpose: To find out whether a virtual healthy living program, with or without a personalized virtual exercise program, helps people keep up their ability to exercise, protect their heart health, and maintain their quality of life during chemotherapy for breast cancer.

Who is this for?: People with stage I, stage II, or stage III breast cancer. All types are welcome (any ER, PR, or HER2 status). You should be scheduled to receive chemotherapy (before or after surgery) and able to join within 3 weeks of starting chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized virtual exercise sessions plus virtual health education workshops </li> <li class="seamTextUnorderedListItem">You will also receive a Fitbit and resistance bands </li> <li class="seamTextUnorderedListItem">Heart MRI</li> <li class="seamTextUnorderedListItem">Stationary bike test</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual health education workshops only, on the same schedule. </li> <li class="seamTextUnorderedListItem">Heart MRI</li> <li class="seamTextUnorderedListItem">Stationary bike test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is testing a healthy living program made up of virtual classes on topics like nutrition, managing stress, and sleep, offered with or without personalized virtual exercise sessions built around each person's needs. </li> <li class="seamTextUnorderedListItem">The goal is to learn whether adding the exercise sessions helps people stay more active and better protect their heart health and quality of life while going through chemotherapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07474090' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/exercise' target='_blank'>BreastCancer.org: Exercise and Breast Cancer</a> </li></ul>
239

Personalized Exercise and Healthy Living Program During Chemotherapy for Breast Cancer (STEPS BC)

Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC)
Icon

Nearest Location from 94107:
2314 miles
Wake Forest NCORP RB
Winston-Salem, NC

Icon

Visits:
Number of visits unavailable, up to 6 months

Icon

ClinicalTrials.gov: NCT07474090

Icon

Phase NA

240

Program to Stop Nicotine Use Before Surgery for Women with Stage 0-III Breast Cancer

Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction

Purpose: To study the effect of an education program designed to help women stop using nicotine products.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive reconstruction during surgery and who currently use nicotine products. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education program designed to help people stop using nicotine, up to 4 sessions in 2-6 months</li> <li class="seamTextUnorderedListItem">Surveys, 3 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nicotine use in people with breast cancer is associated with worse survival and more surgery problems compared to people who do not use nicotine.</li> <li class="seamTextUnorderedListItem">People who use nicotine are not usually able to receive reconstruction during surgery, which can be emotionally challenging.</li> <li class="seamTextUnorderedListItem">Being able to receive reconstruction during surgery may motivate people to quit nicotine.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06461650' target='_blank'>ClinicalTrials.gov</a> </li></ul>
240

Program to Stop Nicotine Use Before Surgery for Women with Stage 0-III Breast Cancer

Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
Icon

Nearest Location from 94107:
2351 miles
University of Florida
Gainesville, FL

Icon

Visits:
Up to 4 visits in 6 months

Icon

ClinicalTrials.gov: NCT06461650

Icon

Phase NA

241

Cavity Marking for Stage 0-III Breast Cancer During Lumpectomy

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

Purpose: To study a new way to mark the surgical margins following tumor removal to allow more accurate radiotherapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive a lumpectomy, reconstruction, and radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placement of clips for marking surgical margins during surgery</li> <li class="seamTextUnorderedListItem">CT scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying a way to mark the cavity after surgery so that the margins of the cavity can be seen better on a CT scan, which is used to plan radiation. This cavity marking may also allow more accurate identification of the surgical margins in patients who need additional surgery.</li> <li class="seamTextUnorderedListItem">Margins are the area around where the tumor was removed. A negative margin means cancer was not found in the margin, and a positive margin means cancer was found in the margin.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06903468' target='_blank'>ClinicalTrials.gov</a> </li></ul>
241

Cavity Marking for Stage 0-III Breast Cancer During Lumpectomy

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
Icon

Nearest Location from 94107:
2351 miles
University of Florida
Gainesville, FL

Icon

Visits:
2 visits within 2 months

Icon

ClinicalTrials.gov: NCT06903468

Icon

Phase NA

242

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of epidiferphane, an experimental nutritional supplement, with chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning on receiving treatment with chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Docetaxel (Taxotere®), every 3 weeks; paclitaxel (Taxol®), weekly; or nab-paclitaxel (Abraxane®), weekly; 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane is an experimental nutritional supplement that may reduce chemotherapy symptoms.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), paclitaxel (Taxol®), and nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with lobular breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05074290' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epidiferphane' target='_blank'>National Cancer Institute: Epidiferphane</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>
242

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
Icon

Nearest Location from 94107:
2351 miles
University of Florida
Gainesville, FL

Icon

Visits:
1 visit every 1-3 weeks for 3 months

Icon

ClinicalTrials.gov: NCT05074290

Icon

Phase I-II

243

Memory Problems During Chemotherapy in People with Stage I-III Breast Cancer

Longitudinal Pilot Mechanistic Study of the Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants

Purpose: To study if and how your cognitive functioning skills, like memory and concentration, change as you receive chemotherapy.

Who is this for?: Women with newly diagnosed stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy, and women who do not have breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will undergo the following over 3-5 months: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">6 cognitive tests, during chemotherapy and 1 month after chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive tests study your cognition, which is your ability to think.</li> <li class="seamTextUnorderedListItem">Women without breast cancer will also be enrolled for comparison.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03137095' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/managing-cancer/side-effects/changes-in-mood-or-thinking/chemo-brain.html' target='_blank'>American Cancer Society: What is Chemo Brain?</a> </li></ul>
243

Memory Problems During Chemotherapy in People with Stage I-III Breast Cancer

Longitudinal Pilot Mechanistic Study of the Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants
Icon

Nearest Location from 94107:
2352 miles
University of Rochester
Rochester, NY

Icon

Visits:
6 visits over 3-5 months

Icon

ClinicalTrials.gov: NCT03137095

Icon

Phase NA

244

Imaging to Improve Manual Lymphatic Drainage for Lymphedema for People with Stage 0-III Breast Cancer

A Pilot Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer

Purpose: To study the use of lymphatic mapping with ICG to improve manual lymphatic drainage for people with lymphedema.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive axillary lymph node dissection and lymphatic system mapping with indocyanine green (ICG). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Manual lymphatic drainage, using images from lymphatic mapping with ICG, at home, daily for 2 years</li> <li class="seamTextUnorderedListItem">Arm measurements</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Manual lymphatic drainage, using standard methods, at home, daily for 2 years</li> <li class="seamTextUnorderedListItem">Arm measurements</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that develops as a side effect of breast cancer treatments like surgery and radiation therapy.</li> <li class="seamTextUnorderedListItem">1 in 5 people treated for breast cancer will develop lymphedema after treatment.</li> <li class="seamTextUnorderedListItem">Arm massage and manual lymphatic drainage are currently used to treat lymphedema.</li> <li class="seamTextUnorderedListItem">This trial is studying manual lymphatic drainage guided by the individual patient's anatomy as seen with ICG, a tracer used for imaging scans.</li> <li class="seamTextUnorderedListItem">A tracer, like ICG, helps doctors see and follow where something goes, like the flow of lymph fluid, during tests or surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06327490' target='_blank'>ClinicalTrials.gov</a> </li></ul>
244

Imaging to Improve Manual Lymphatic Drainage for Lymphedema for People with Stage 0-III Breast Cancer

A Pilot Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
Icon

Nearest Location from 94107:
2354 miles
University of Florida
Gainesville, FL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06327490

Icon

Phase II

245

Digital Tool and Patient Navigators to Improve Access to Healthy Food for Stage 0-IV Breast Cancer

The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)

Purpose: To study whether the MyCarePulse digital tool and ASCENT patient navigator program can help people get access to healthy food.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer whose diagnosis was within the last year, speak English or Spanish, and live in Florida. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Standard of care</li> <li class="seamTextUnorderedListItem">MyCarePulse</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">MyCarePulse</li> <li class="seamTextUnorderedListItem">ASCENT patient navigator</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MyCarePulse is a digital tool that assesses the need for food assistance. </li> <li class="seamTextUnorderedListItem">The ASCENT patient navigator program is designed to improve access to nutritious food, improve one's confidence in eating a healthy diet, and improve diet quality compared to standard of care.</li> <li class="seamTextUnorderedListItem">Patient navigators can provide individualized support and connect people with community resources to promote healthy eating.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07042243' target='_blank'>ClinicalTrials.gov</a> </li></ul>
245

Digital Tool and Patient Navigators to Improve Access to Healthy Food for Stage 0-IV Breast Cancer

The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)
Icon

Nearest Location from 94107:
2354 miles
University of Florida
Gainesville, FL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07042243

Icon

Phase NA

246

Rowing for Heart Health After Treatment for Women with Stage I-III Breast Cancer

Indoor Rowing as a Novel Exercise Therapy for Cardiovascular Rehabilitation in Middle-Aged and Older Breast Cancer Survivors Following Chemotherapy

Purpose: To study how rowing exercise affects heart health for breast cancer survivors.

Who is this for?: Women 40 to 80 years old with stage I, stage II, or stage III breast cancer who completed primary treatment between 6 months and 2 years ago. You must not have heart disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Heart tests</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise with indoor rowing machine after study completion (optional)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise with indoor rowing machine, 3 days every week for 3 months</li> <li class="seamTextUnorderedListItem">Heart tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">People who have received chemotherapy and some other types of breast cancer treatment have a higher risk for heart disease that people who have not.</li> <li class="seamTextUnorderedListItem">Exercise may decrease the risk of heart disease.</li> <li class="seamTextUnorderedListItem">Each rowing exercise is about 50 minutes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05848141' target='_blank'>ClinicalTrials.gov</a> </li></ul>
246

Rowing for Heart Health After Treatment for Women with Stage I-III Breast Cancer

Indoor Rowing as a Novel Exercise Therapy for Cardiovascular Rehabilitation in Middle-Aged and Older Breast Cancer Survivors Following Chemotherapy
Icon

Nearest Location from 94107:
2354 miles
Integrative Cardiovasculal Physiology Laboratory, University of Florida
Gainesville, FL

Icon

Visits:
3 visits every week for 3 months

Icon

ClinicalTrials.gov: NCT05848141

Icon

Phase NA

247

Walking to Reduce Fatigue for Older Women After Treatment

Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors (EXERGISE)

Purpose: To study if walking can reduce fatigue.

Who is this for?: Women at least 60 years old with stage I, stage II, or stage III breast cancer who completed treatment between 3 months and 1 year ago. You must be experiencing fatigue (feeling tired). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking at research center, 30 minutes per session, 3 days every week for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking at home, 30 minutes per session, 5 days every week for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many people experience fatigue (feeling tired) after cancer treatment.</li> <li class="seamTextUnorderedListItem">Older breast cancer survivors experience more fatigue than younger survivors.</li> <li class="seamTextUnorderedListItem">Aerobic exercise (such as walking) can improve fatigue in younger breast cancer survivors, but these effects are not as strong in older people. New methods are needed to reduce fatigue in older breast cancer survivors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05684367' target='_blank'>ClinicalTrials.gov</a> </li></ul>
247

Walking to Reduce Fatigue for Older Women After Treatment

Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors (EXERGISE)
Icon

Nearest Location from 94107:
2354 miles
Institute on Aging; University of Florida
Gainesville, FL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05684367

Icon

Phase NA

248

Registry to Study Heart Problems from Chemotherapy in People with Stage I-III Breast Cancer

Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)

Purpose: To study the TRPC6 biomarker to predict and prevent chemotherapy-related cardiac toxicity.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are receiving or are planning to receive chemotherapy or trastuzumab (Herceptin®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">Understanding how the TRPC6 biomarker is involved in these changes may allow early intervention against cardiac toxicity and also identify new biomarkers to protect long-term cardiac health.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05507879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/16858-chemotherapy--the-heart-cardiotoxicity#:~:text=Cardiotoxicity%20is%20a%20term%20for,radiation%20therapy%20to%20the%20chest.' target='_blank'>Cleveland Clinic: Cardiotoxicity and Cancer Treatment</a> </li></ul>
248

Registry to Study Heart Problems from Chemotherapy in People with Stage I-III Breast Cancer

Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)
Icon

Nearest Location from 94107:
2354 miles
University of Florida
Gainesville, FL

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT05507879

Icon

Phase NA

249

CBD Before Surgery for People with Breast Cancer

A Phase 1a "Window Trial" of Cannabidiol (CBD) For Breast Cancer Primary Tumors

Purpose: To study whether taking cannabidiol (CBD) before surgery can cause changes in breast cancer tumor cells, specifically affecting how quickly cells are growing and whether cells are dying. This trial also aims to learn whether CBD may help reduce anxiety during the waiting period before surgery.

Who is this for?: People with stage I, stage II, or stage III breast cancer, who are scheduled for surgery (lumpectomy or mastectomy) between 5 days and 2 months from starting the study. Must not have started neoadjuvant (before surgery) chemotherapy or hormone therapy. Must not regularly use marijuana, cannabis, or CBD products (more than 4 times in the past 30 days) and are not taking certain medications that interact with CBD (such as blood thinners, seizure medications, or certain antibiotics). You must be receiving care at the Medical University of South Carolina. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CBD (cannabidiol), by mouth, twice daily, for 5 days to 2 months (until your surgery date)</li> <li class="seamTextUnorderedListItem">Questionnaires </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, twice daily, for 5 days to 2 months (until your surgery date)</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers want to know whether taking CBD by mouth before breast surgery causes biological changes in the tumor, specifically, whether it slows how fast cancer cells are dividing (measured by a marker called Ki67) and whether it causes cancer cells to die. </li> <li class="seamTextUnorderedListItem">Researchers also want to understand whether CBD is safe for breast cancer patients and whether it reduces anxiety in the time between diagnosis and surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06148038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/complementary-therapy/types/medical-cannabis' target='_blank'>BreastCancerTrials.org: Medical Cannabis: Marijuana, CBD, and Breast Cancer</a> </li></ul>
249

CBD Before Surgery for People with Breast Cancer

A Phase 1a "Window Trial" of Cannabidiol (CBD) For Breast Cancer Primary Tumors
Icon

Nearest Location from 94107:
2377 miles
Medical University of South Carolina
Charleston, SC

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT06148038

Icon

Phase I

250

A Healthy Living and Weight Management Program for Women With Stage I-III Breast Cancer Living in Rural Communities

Development and Pilot Testing of a Novel Intervention to Reduce Cardiovascular Disease Risk Among Breast Cancer Survivors Living in Rural, Medically Underserved Communities

Purpose: To test whether a remote healthy living program called WeCan-Rural can help breast cancer survivors build healthy habits around eating, physical activity, and weight, and better manage symptoms like pain, fatigue, and emotional distress. The goal is to lower the risk of heart disease after cancer treatment.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who finished treatment (hormone therapy is allowed) within the last 5 years. You must be living in a rural or medically underserved community, have a body mass index over 30, and be healthy enough to take part in physical activity at home. You should also have at least moderate levels of one or more symptoms in the past month (pain, fatigue, sadness, or distress). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">WeCan-Rural program: 12 weekly sessions, about 1 hour each, held over Zoom with a trained therapist. Sessions cover healthy eating, physical activity, weight management, and ways to cope with symptoms. </li> <li class="seamTextUnorderedListItem">You will also receive tools to track your progress, including an activity tracker, a scale, and a blood pressure monitor.</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard health information: a booklet from the National Cancer Institute about life after cancer treatment.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at a program called WeCan-Rural, which was designed for breast cancer survivors who live in rural areas where healthy food, healthcare, and safe places to be active can be harder to reach. </li> <li class="seamTextUnorderedListItem">Many survivors also live with lasting symptoms like pain, fatigue, and emotional distress that make healthy habits harder to keep. The program teaches skills for healthy eating, exercise, and managing symptoms through approaches like relaxation and pacing, all delivered by video so people can join from home. </li> <li class="seamTextUnorderedListItem">Researchers want to see whether the program helps improve weight, symptoms, diet, physical activity, and confidence in managing one's own health, and whether it improves heart health markers such as blood pressure, cholesterol, and blood sugar, compared with standard health information.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07426952' target='_blank'>ClinicalTrials.gov</a> </li></ul>
250

A Healthy Living and Weight Management Program for Women With Stage I-III Breast Cancer Living in Rural Communities

Development and Pilot Testing of a Novel Intervention to Reduce Cardiovascular Disease Risk Among Breast Cancer Survivors Living in Rural, Medically Underserved Communities
Icon

Nearest Location from 94107:
2382 miles
Scotland Health
Laurinburg, NC

Icon

Visits:
2 clinic visits, about 12 weeks apart

Icon

ClinicalTrials.gov: NCT07426952

Icon

Phase NA

251

Blood Test to Detect Breast Cancer at High Risk of Recurrence for Stage II-III HR+, HER2- Breast Cancer

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Purpose: To study if ctDNA detection can identify people at high risk of recurrence after surgery and guide better treatment decisions.

Who is this for?: People with stage II or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received surgery. You must have cancer in 1 to 3 of your lymph nodes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood test, every 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li> <li class="seamTextUnorderedListItem">ctDNA testing can detect minimal residual disease (MRD) with a blood test. MRD is cancer in the body that is too small to be seen on a scan. The presence of MRD may indicate that cancer is at high risk of coming back.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07025785' target='_blank'>ClinicalTrials.gov</a> </li></ul>
251

Blood Test to Detect Breast Cancer at High Risk of Recurrence for Stage II-III HR+, HER2- Breast Cancer

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
Icon

Nearest Location from 94107:
2382 miles
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Icon

Visits:
Every 3 months

Icon

ClinicalTrials.gov: NCT07025785

Icon

Phase NA

252

Ultrasound for High-Risk Women or Women with Stage II-III Breast Cancer

VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients

Purpose: To study the relationship between tissue characteristics measured with ultrasound and breast tumors and response to chemotherapy.

Who is this for?: Women with a suspicious breast lesion or women with stage II or stage III breast cancer who plan to receive treatment before surgery (neoadjuvant) and who receive care at the University of North Carolina Hospitals. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasound scan, up to 3 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tissue characteristics measured in this study may be biomarkers of cancer and response to treatment before surgery.</li> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06878547' target='_blank'>ClinicalTrials.gov</a> </li></ul>
252

Ultrasound for High-Risk Women or Women with Stage II-III Breast Cancer

VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
Icon

Nearest Location from 94107:
2382 miles
University of North Carolina at Chapel Hill
Chapel Hill, NC

Icon

Visits:
Up to 3 visits

Icon

ClinicalTrials.gov: NCT06878547

Icon

Phase NA

253

Studying Tumor Blood Flow to Make Treatment Decisions for People with Stage 0-IV Breast Cancer

Intravital Microscopy (IVM) in Human Solid Tumors

Purpose: To use Human Intravital Microscopy (HIVM) to study tumor blood flow and gather information to make treatment decisions.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Human Intravital Microscopy (HIVM) with fluorescein, by IV, during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Human Intravital Microscopy (HIVM) is a procedure completed during surgery to study tumor blood vessels and blood flow.</li> <li class="seamTextUnorderedListItem">IVM can determine if your blood vessels work well enough to be able to receive some types of cancer treatment.</li> <li class="seamTextUnorderedListItem">Fluorescein is used during HIVM to see how blood flows.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03823144' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/cancer-the-blood-and-circulation' target='_blank'>Cancer Research UK: Cancer and Blood Circulation</a> </li></ul>
253

Studying Tumor Blood Flow to Make Treatment Decisions for People with Stage 0-IV Breast Cancer

Intravital Microscopy (IVM) in Human Solid Tumors
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic Florida
Jacksonville, FL

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT03823144

Icon

Phase NA

254

Nerve Reconstruction to Maintain Feeling in the Nipple After Mastectomy for Women with Stage 0-II Breast Cancer

Randomized Feasibility Study to Determine the Feasibility of Neurotization of the Nipple Areolar Complex at the Time of Nipple Sparing Mastectomy and Prosthetic Based Reconstruction

Purpose: To study if a surgical technique using a nerve graft, also called nerve reconstruction, will maintain feeling in the nipple after a nipple-sparing mastectomy.

Who is this for?: Women with stage 0 (DCIS), stage I, or stage II node negative breast cancer who are planning to receive a nipple-sparing mastectomy and have not had previous breast radiation, breast reduction, or breast augmentation. You must have a bra cup size of A to C. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care nipple-sparing mastectomy</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care nipple-sparing mastectomy with nerve graft</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A mastectomy is surgery to remove the breast.</li> <li class="seamTextUnorderedListItem">Nerve damage can occur during a mastectomy. When nerves are damaged, you may feel numbness, also known as loss of sensation.</li> <li class="seamTextUnorderedListItem">A nerve graft, also called nerve reconstruction, replaces nerves damaged during the mastectomy.</li> <li class="seamTextUnorderedListItem">This nerve graft surgery can be performed during nipple-sparing mastectomy and reconstruction and may maintain feeling in the nipple and improve quality of life.</li> <li class="seamTextUnorderedListItem">Node negative means cancer has not spread to your lymph nodes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06153836' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nebraskamed.com/cancer/breast-cancer/breast-reconstruction/mastectomies-and-nipples-what-are-the-options-for-breast-reconstruction' target='_blank'>University of Nebraska: Restoring Nipple Sensation After Mastectomy</a> </li></ul>
254

Nerve Reconstruction to Maintain Feeling in the Nipple After Mastectomy for Women with Stage 0-II Breast Cancer

Randomized Feasibility Study to Determine the Feasibility of Neurotization of the Nipple Areolar Complex at the Time of Nipple Sparing Mastectomy and Prosthetic Based Reconstruction
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT06153836

Icon

Phase II

255

Pain Management Program During Hormone Therapy for Stage 0-III Breast Cancer

A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors

Purpose: To study if a pain management program reduces pain from hormone therapy, improves quality of life, and increases the chance that people will receive hormone therapy as recommended.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving letrozole (Femara®), anastrozole (Arimidex®), or exemestane (Aromasin®) aromatase inhibitor and experiencing pain. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Pain management program, 2 days</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times in 6 months</li> </ul> <p class="seamTextPara"> followed 6 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pain management program, 2 days (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The pain management program is a 2 day class that uses cognitive behavioral therapy (CBT) and focuses on skills to improve pain control, fatigue, sleep problems, thinking problems, and stress.</li> <li class="seamTextUnorderedListItem">The program also educates you about the effectiveness of aromatase inhibitors in prolonging survival without cancer coming back.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06831838' target='_blank'>ClinicalTrials.gov</a> </li></ul>
255

Pain Management Program During Hormone Therapy for Stage 0-III Breast Cancer

A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
5 visits in 6 months

Icon

ClinicalTrials.gov: NCT06831838

Icon

Phase NA

256

WBF-038 Prebiotic and Probiotic to Prevent Bone Loss for Women with Stage 0-III HR+ Breast Cancer Who Are Receiving an Aromatase Inhibitor

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Purpose: To study how well WBF-038 probiotic and prebiotic works to prevent bone loss in women who are starting to receive an aromatase inhibitor.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who plan to begin receiving an aromatase inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">WBF-038, by mouth, daily for 1 year</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Bone density tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor-positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors can lead to reduced bone density.</li> <li class="seamTextUnorderedListItem">WBF-038 is a combination of prebiotics (food for healthy bacteria) and probiotics (healthy bacteria).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07044310' target='_blank'>ClinicalTrials.gov</a> </li></ul>
256

WBF-038 Prebiotic and Probiotic to Prevent Bone Loss for Women with Stage 0-III HR+ Breast Cancer Who Are Receiving an Aromatase Inhibitor

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
7 visits within 1 year 3 months

Icon

ClinicalTrials.gov: NCT07044310

Icon

Phase II

257

Improving Skin and Quality of Life During Hormone Therapy for Women with Stage 0-III Breast Cancer

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Purpose: To study changes in skin quality and self-esteem during hormone therapy after meeting with an aesthetician.

Who is this for?: Postmenopausal women with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are planning to receive one of the following aromatase inhibitors: letrozole (Femara®), anastrozole (Arimidex®), or exemestane (Aromasin®). You must not have received chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visits with aesthetician</li> <li class="seamTextUnorderedListItem">Skin photos and measurements</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Skin quality may change after beginning to receive an aromatase inhibitor, such as letrozole (Femara®), anastrozole (Arimidex®), or exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Skin changes may affect a person's self-esteem.</li> <li class="seamTextUnorderedListItem">Aestheticians are skin care professionals. </li> <li class="seamTextUnorderedListItem">Meeting with an aesthetician may improve skin quality and therefore self-esteem.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06401889' target='_blank'>ClinicalTrials.gov</a> </li></ul>
257

Improving Skin and Quality of Life During Hormone Therapy for Women with Stage 0-III Breast Cancer

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
At least 2 visits

Icon

ClinicalTrials.gov: NCT06401889

Icon

Phase NA

258

Studying Complications After Surgery for Women with Stage I-III Breast Cancer

Postoperative Outcomes and Patient Satisfaction for Patients Admitted to the Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement

Purpose: To study differences in complications after surgery based on where people receive care after surgery.

Who is this for?: Women with stage I, stage II, or some stage III breast cancer or women at high risk for breast cancer who received a mastectomy with reconstruction at Mayo Clinic in Jacksonville, FL. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">After surgery at Mayo Clinic, people are admitted to the hospital, discharged (sent home) from the hospital, or stay at the Mayo Clinic Care Hotel.</li> <li class="seamTextUnorderedListItem">The Care Hotel offers people a comfortable environment to receive in-person and virtual nursing care in a hotel setting.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06783179' target='_blank'>ClinicalTrials.gov</a> </li></ul>
258

Studying Complications After Surgery for Women with Stage I-III Breast Cancer

Postoperative Outcomes and Patient Satisfaction for Patients Admitted to the Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT06783179

Icon

Phase NA

259

Receiving Cancer Treatment at Home Instead of in the Clinic for Stage I-IV Breast Cancer

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

Purpose: To study whether providing cancer treatment in the home is preferred over the traditional clinic setting.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who live in the Florida panhandle area, who are receiving and tolerating standard treatment for their cancer, and who plan to continue to receive these medications for the next 3 months or more. You must not be receiving all your medications by mouth. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In-home standard of care cancer treatment through CCBW, up to 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times within 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typically, drug-related cancer treatment is provided at a medical center, which causes patients to have to spend time away from their family and friends. Treatment at a medical center may contribute to the physical, emotional, social, and financial burden of having cancer.</li> <li class="seamTextUnorderedListItem">The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team to provide cancer treatment in the patient's home and may be preferred over the traditional clinic setting.</li> <li class="seamTextUnorderedListItem">At the end of the 3 months of the trial, participants may choose to continue to receive in-home treatment for another 3 months or return to the clinic.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07285044' target='_blank'>ClinicalTrials.gov</a> </li></ul>
259

Receiving Cancer Treatment at Home Instead of in the Clinic for Stage I-IV Breast Cancer

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07285044

Icon

Phase II

260

Registry to Study Immune Response to Anti-HER2 Targeted Therapy for Stage I-IV HER2+ Breast Cancer

Immune Response to Anti-HER2 Therapies

Purpose: To study the relationship between immune cell response and treatment with anti-HER2 targeted therapy.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer who are planning to begin treatment with anti-HER2 targeted therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 3 times within 4 months, 1 time at disease recurrence or progression</li> <li class="seamTextUnorderedListItem">Tumor samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tumor samples will be used for genetic testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04517838' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li></ul>
260

Registry to Study Immune Response to Anti-HER2 Targeted Therapy for Stage I-IV HER2+ Breast Cancer

Immune Response to Anti-HER2 Therapies
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
At least 3 visits

Icon

ClinicalTrials.gov: NCT04517838

Icon

Phase NA

261

Personalized Vaccine with Pembrolizumab for Advanced Breast Cancer

A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a personalized neoantigen peptide vaccine, an experimental type of immunotherapy, with pembrolizumab (Keytruda®), a type of immunotherapy called a PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that have received at least 1 line of standard treatment. If you have triple negative (ER-, PR-, HER2-) breast cancer, you must currently be receiving treatment with pembrolizumab (Keytruda®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), by IV, 1 session</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized neoantigen peptide vaccine, by injection, 4 times in 2 weeks, then every 3 weeks</li> <li class="seamTextUnorderedListItem">Sargramostim, by injection, 4 times in 2 weeks, then every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require at least 1 biopsy</li> <li class="seamTextUnorderedListItem">May require 1 additional vaccine</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The neoantigen peptide vaccine will be personalized to your cancer based on your blood and biopsy results.</li> <li class="seamTextUnorderedListItem">Personalized neoantigen peptide vaccines are an experimental type of immunotherapy.</li> <li class="seamTextUnorderedListItem">The vaccine is designed to target certain proteins (neoantigens) on tumor cells.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Before you receive the vaccine, you will be given the chemotherapy drug cyclophosphamide (Cytoxan®) to prepare your immune system to receive the vaccine.</li> <li class="seamTextUnorderedListItem">Sargramostim is a type of immunotherapy that stimulates your body to produce more immune cells to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05269381' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20529594?_ga=2.9537585.506318734.1653082699-1752475516.1651774270' target='_blank'>Mayo Clinic: Clinical Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/breast-cancer-vaccine-explainer/' target='_blank'>Breast Cancer Research Foundation: Breast Cancer Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/cytoxan' target='_blank'>Breastcancer.org: Cyclophosphamide (Cytoxan®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/drugs/20884-sargramostim-gm-csf-injection' target='_blank'>Cleveland Clinic: Sargramostim</a> </li></ul>
261

Personalized Vaccine with Pembrolizumab for Advanced Breast Cancer

A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Icon

Nearest Location from 94107:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
5 visits in 3 weeks, then 1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT05269381

Icon

Phase I-II

262

Online Tool for Making Surgery Decisions for Young Women With Stage 0-III Breast Cancer

Optimizing Surgical Decisions in Young Adults With Breast Cancer (CONSYDER)

Purpose: To understand and improve the breast surgery decision-making process for young women newly diagnosed with breast cancer.

Who is this for?: Women up to 44 years old with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have not yet received surgery. Your breast cancer must not have recurred (come back). View full eligibility criteria

What's involved?

<p class="seamTextPara"> Based on when you enroll, you will take part in 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Surveys, 2-3 times within 6 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time (optional)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to online CONSYDER decision tool</li> <li class="seamTextUnorderedListItem">Surveys, 2-3 times within 6 months</li> <li class="seamTextUnorderedListItem">Interview, 1 time (optional)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">People in Group 1 will have access to the online CONSYDER decision tool after 6 months.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CONSYDER is an online tool that is designed to provide useful information to young people with breast cancer. </li> <li class="seamTextUnorderedListItem">CONSYDER was also designed to improve communication between young women and their surgeons with the purpose of helping patients make surgical decisions.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06275126' target='_blank'>ClinicalTrials.gov</a> </li></ul>
262

Online Tool for Making Surgery Decisions for Young Women With Stage 0-III Breast Cancer

Optimizing Surgical Decisions in Young Adults With Breast Cancer (CONSYDER)
Icon

Nearest Location from 94107:
2385 miles
Duke Cancer Institute
Durham, NC

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06275126

Icon

Phase NA

263

Decision Tool for Women With Stage 0-III Breast Cancer or Women at High Risk for Breast Cancer Considering Breast Reconstruction Surgery

Breast Reconstruction Decision Aid (RECONJOINT)

Purpose: To study the effectiveness of the Breast Reconstruction Decision Aid Tool called RECONJOINT for breast reconstruction surgery.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, or women at high risk for breast cancer, who are considering receiving a mastectomy followed by breast reconstruction. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Participate in focus group</li> <li class="seamTextUnorderedListItem">Usual care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RECONJOINT</li> <li class="seamTextUnorderedListItem">Enhanced usual care</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RECONJOINT is a breast reconstruction decision aid.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07335354' target='_blank'>ClinicalTrials.gov</a> </li></ul>
263

Decision Tool for Women With Stage 0-III Breast Cancer or Women at High Risk for Breast Cancer Considering Breast Reconstruction Surgery

Breast Reconstruction Decision Aid (RECONJOINT)
Icon

Nearest Location from 94107:
2385 miles
Duke Cancer Institute (Data collection only)
Durham, NC

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07335354

Icon

Phase NA

264

Radar Reflector Device (SAVI Scout MD) to Guide Breast Conserving Surgery (Lumpectomy) in Women With Breast Cancer

Clinical Evaluation and Outcomes of Multi-signal SAVI Scout (Scout MD) Localized Breast Conserving Surgery

Purpose: To find out how accurate and how easy to use the SAVI Scout MD system is for surgeons during breast conserving surgery (lumpectomy). The system uses tiny radar reflectors that are placed in the breast days or weeks before surgery, instead of wires. These reflectors help the surgeon find the tumor more precisely and may lower the chance of needing a second surgery.

Who is this for?: Women with DCIS (Stage 0) or stage I or stage II or stage III breast cancer that can be seen on ultrasound, mammogram, or MRI, and who are planning to have breast conserving surgery (lumpectomy) that needs more than one marker to guide the surgeon to the tumor. This trial is not for women who are having a mastectomy. You must be receiving care at Moffitt Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Before your surgery, several small radar reflectors will be placed in the breast</li> <li class="seamTextUnorderedListItem">Imaging (ultrasound, mammogram, or MRI) </li> <li class="seamTextUnorderedListItem">During your breast conserving surgery (lumpectomy), the surgeon will use the SAVI Scout MD system to locate and remove the tumor.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at how accurate and how easy to use the SAVI Scout MD system is for guiding breast conserving surgery. </li> <li class="seamTextUnorderedListItem">The system uses tiny radar reflectors placed in the breast before surgery instead of wires. Each reflector gives off its own signal, so the surgeon can find more than one spot in the breast. This may help the surgeon remove the cancer more precisely and may lower the chance of needing a second surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07686250' target='_blank'>ClinicalTrials.gov</a> </li></ul>
264

Radar Reflector Device (SAVI Scout MD) to Guide Breast Conserving Surgery (Lumpectomy) in Women With Breast Cancer

Clinical Evaluation and Outcomes of Multi-signal SAVI Scout (Scout MD) Localized Breast Conserving Surgery
Icon

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Icon

Visits:
Coincides with surgery, follow up for 6 weeks

Icon

ClinicalTrials.gov: NCT07686250

Icon

Phase II

265

Dendritic Cell Vaccine With Neoadjuvant Therapy for HER2 Positive Breast Cancer

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of a dendritic cell vaccine, an experimental immunotherapy, with targeted therapy and chemotherapy before surgery (neoadjuvant).

Who is this for?: People with stage I, stage II, or some stage III HER2 positive (HER2+) breast cancer who have not received surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Apheresis procedure to remove white blood cells</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dendritic cell vaccine, weekly for 6 weeks, then 3 times within 6 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks for 5 months</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks for 5 months</li> </ul> <p class="seamTextPara"> followed 2 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Abraxane®), by IV, weekly for 3 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove tumor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The dendritic cell vaccine is an experimental immunotherapy that boosts the immune system to recognize and destroy cancer cells.</li> <li class="seamTextUnorderedListItem">You will receive a dendritic cell vaccine made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The white blood cells, called dendritic cells, are removed from your body during a procedure called apheresis. These cells are processed in a lab so that they will see and go after HER2+ cancer cells, and then they will be injected as a vaccine.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are types of anti-HER2 targeted therapy used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Abraxane®) is a chemotherapy drug commonly used for breast cancer.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment, like hormone therapy or targeted therapy, before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05325632' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/immunotherapy/types/vaccines-to-treat-cancer' target='_blank'>Cancer Research UK: Dendritic Cell Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy#section-cancer-vaccines' target='_blank'>Breastcancerorg: Cancer Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancerorg: Trastuzumab (Herceptin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/perjeta' target='_blank'>Breastcancerorg: Pertuzumab (Perjeta®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/abraxane' target='_blank'>Breastcancerorg: Paclitaxel (Abraxane®)</a> </li></ul>
265

Dendritic Cell Vaccine With Neoadjuvant Therapy for HER2 Positive Breast Cancer

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer
Icon

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Icon

Visits:
1 visit every week

Icon

ClinicalTrials.gov: NCT05325632

Icon

Phase II

266

CT Scan to Detect Metastasis for Stage I-III Node Positive Breast Cancer

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery

Purpose: To use CT scans to determine how often node positve breast cancer spreads outside of the breast (metastasis) after chemotherapy and surgery.

Who is this for?: People with stage I, stage II, or stage III node positive breast cancer. You must have received at least 2 months of doxorubicin (Adriamycin®), paclitaxel (Taxol®), or docetaxel (Taxotere®) before surgery (neoadjuvant) and surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CT scan, 1-2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06833502' target='_blank'>ClinicalTrials.gov</a> </li></ul>
266

CT Scan to Detect Metastasis for Stage I-III Node Positive Breast Cancer

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery
Icon

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Icon

Visits:
1-2 times in 6 months

Icon

ClinicalTrials.gov: NCT06833502

Icon

Phase II

267

The MIND Diet to Improve Thinking Problems for Women with Stage I-III Breast Cancer

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

Purpose: To study the safety and effects (good and bad) of the MIND diet for cognitive problems (thinking problems).

Who is this for?: Women with stage I, stage II, or stage III breast cancer who completed cancer treatment 6 months to 3 years ago and have cancer-related cognitive problems (thinking problems). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Consume the MIND diet, for 3 months</li> <li class="seamTextUnorderedListItem">Check in with a diet coach and dietitian, weekly</li> <li class="seamTextUnorderedListItem">Questionnaires and cognitive tests, 2 times within 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual diet</li> <li class="seamTextUnorderedListItem">Check-in sessions will be about general health (e.g., healthy hair, skin, eyesight), not diet</li> <li class="seamTextUnorderedListItem">Questionnaires and cognitive tests, 2 times within 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The MIND diet is a combination of the Mediterranean and DASH diets and emphasizes eating high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07018986' target='_blank'>ClinicalTrials.gov</a> </li></ul>
267

The MIND Diet to Improve Thinking Problems for Women with Stage I-III Breast Cancer

The MIND-BC Study: MIND Diet for Breast Cancer Cognition
Icon

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Icon

Visits:
2 times within 3 months

Icon

ClinicalTrials.gov: NCT07018986

Icon

Phase NA

268

Surgical Procedure to Prevent Lymphedema in Women with Breast Cancer

Prospective, Randomized Clinical Trial for Immediate Lymphatic Reconstruction to Prevent Breast Cancer Related Lymphedema

Purpose: To study the safety and effects (good and bad) of performing Immediate Lymphatic Reconstruction (ILR), a microsurgical procedure done at the time of axillary lymph node removal, and if it can reduce the risk of developing breast cancer-related lymphedema (arm swelling).

Who is this for?: Women with stage I or stage II or stage III breast cancer, who are scheduled to undergo axillary lymph node dissection (ALND) and are considered at high risk for developing lymphedema. You must not have had a previous ALND, and must not have had prior radiation to the underarm area. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immediate Lymphatic Reconstruction (ILR), performed during your axillary lymph node dissection surgery. </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary lymph node dissection only, without ILR.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer-related lymphedema is swelling of the arm that can develop after lymph nodes are removed from the underarm area.</li> <li class="seamTextUnorderedListItem">This trial is studying whether a microsurgical procedure called Immediate Lymphatic Reconstruction (ILR), performed at the same time as axillary lymph node dissection, can lower the chances of lymphedema developing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07127003' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/about-your-immediate-lymphatic-reconstruction-ilr-procedure' target='_blank'>Memorial Sloan Kettering Cancer Center: Immediate Lymphatic Reconstruction (ILR)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>
268

Surgical Procedure to Prevent Lymphedema in Women with Breast Cancer

Prospective, Randomized Clinical Trial for Immediate Lymphatic Reconstruction to Prevent Breast Cancer Related Lymphedema
Icon

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Icon

Visits:
Up to every 3 months for 2 years

Icon

ClinicalTrials.gov: NCT07127003

Icon

Phase NA

269

Magtrace® Tracer for Sentinel Lymph Node Biopsy for Stage 0-III Breast Cancer

A Prospective Open Label Study of Patient Reported Outcome Measures and Efficacy Following the Use of 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Lumpectomy (MAGProm)

Purpose: To study skin discoloration and sentinel lymph node detection when using Magtrace® non-radioactive tracer during sentinel lymph node biopsy (SLNB). You must not have received radiation to the breast that will receive the lumpectomy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who are planning to receive a lumpectomy and sentinel lymph node biopsy (SLNB) with Magtrace®. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magtrace®, by injection</li> <li class="seamTextUnorderedListItem">Lumpectomy</li> <li class="seamTextUnorderedListItem">Questionnaires, every 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li> <li class="seamTextUnorderedListItem">A sentinel lymph node biopsy is used to see if breast cancer cells are found in the sentinel node--the first lymph node under the arm to which the cancer cells are most likely to have spread.</li> <li class="seamTextUnorderedListItem">Magtrace® is a non-radioactive tracer that can help surgeons find cancer cells in sentinel lymph nodes during lumpectomy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06610539' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.endomag.com/resources/faqs/magtrace/' target='_blank'>Endomagnetics: Magtrace®</a> </li></ul>
269

Magtrace® Tracer for Sentinel Lymph Node Biopsy for Stage 0-III Breast Cancer

A Prospective Open Label Study of Patient Reported Outcome Measures and Efficacy Following the Use of 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Lumpectomy (MAGProm)
Icon

Nearest Location from 94107:
2406 miles
UNC, Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Icon

Visits:
Two times a year for up to 2 years

Icon

ClinicalTrials.gov: NCT06610539

Icon

Phase NA

270

Radiation with a Boost After Lumpectomy for Women with Stage 0-III Breast Cancer

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of 5 radiation sessions with a tumor bed boost every other day.

Who is this for?: Women at least 50 years old with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who have received a lumpectomy and are planning to receive radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation with simultaneous integrated tumor bed boost (SIB), 5 times every other day in 2 weeks (excluding weekends)</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A simultaneous integrated tumor bed boost (SIB) is extra radiation to the area of the breast that is most likely to develop recurrence.</li> <li class="seamTextUnorderedListItem">A previous study showed that 1 week of radiation had similar effects as the traditional 3 weeks of radiation for early stage breast cancer after surgery.</li> <li class="seamTextUnorderedListItem">This allows people to minimize the number of visits while still reducing their risk of recurrence.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06902311' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/radiation-therapy/what-to-expect/' target='_blank'>Susan G Komen: Radiation</a> </li></ul>
270

Radiation with a Boost After Lumpectomy for Women with Stage 0-III Breast Cancer

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
Icon

Nearest Location from 94107:
2406 miles
University of North Carolina
Chapel Hill, NC

Icon

Visits:
5 visits in 2 weeks

Icon

ClinicalTrials.gov: NCT06902311

Icon

Phase II

271

Online Tool to Help Make Decisions about Reconstruction Choices

Dissemination of a Breast Reconstruction Decision Tool Through Social Media and Online Communities- AIM1-B

Purpose: To study the safety, effects (good and bad), and usability of an online decision tool called BREASTChoice, which helps people make informed decisions about breast reconstruction after surgery.

Who is this for?: Women with DCIS (stage 0) or stage I or stage II or stage III or high risk for breast cancer who have had breast surgery (such as a mastectomy or lumpectomy) within the past 8 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys </li> <li class="seamTextUnorderedListItem">Use the BREASTChoice tool on your own mobile device while sharing your thoughts out loud (called a <q>think-aloud</q> method)</li> <li class="seamTextUnorderedListItem">Take part in a semi-structured interview about the tool</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are looking at whether the BREASTChoice decision tool is easy to understand and use on a mobile device. They want to know if people feel the tool helps them learn about breast reconstruction options and supports them in making a decision that matches their personal preferences.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07396766' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/surgery/breast-reconstruction/' target='_blank'>Susan G. Komen: Breast Reconstruction</a> </li></ul>
271

Online Tool to Help Make Decisions about Reconstruction Choices

Dissemination of a Breast Reconstruction Decision Tool Through Social Media and Online Communities- AIM1-B
Icon

Nearest Location from 94107:
2406 miles
The University of North Carolina
Chapel Hill, NC

Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07396766

Icon

Phase NA

272

Studying Brain and Heart Changes During Chemotherapy for Women with Stage I-III Breast Cancer

Investigating Cellular Senescence and Organ Aging in Breast Cancer Patients Undergoing Adjuvant Chemotherapy: A Novel Approach Utilizing Organ Specific Age Proteomics

Purpose: To study brain and heart changes before and after chemotherapy.

Who is this for?: Women 22-65 years old with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. You must be receiving care at UNC Lineberger Comprehensive Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 2 times in 8 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People receiving chemotherapy often have heart and thinking problems (cognition).</li> <li class="seamTextUnorderedListItem">Information from this study may help doctors in the future identify people at the highest risk for these problems and make treatment decisions.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06789653' target='_blank'>ClinicalTrials.gov</a> </li></ul>
272

Studying Brain and Heart Changes During Chemotherapy for Women with Stage I-III Breast Cancer

Investigating Cellular Senescence and Organ Aging in Breast Cancer Patients Undergoing Adjuvant Chemotherapy: A Novel Approach Utilizing Organ Specific Age Proteomics
Icon

Nearest Location from 94107:
2406 miles
University of North Carolina
Chapel Hill, NC

Icon

Visits:
2 visits in 8 months

Icon

ClinicalTrials.gov: NCT06789653

Icon

Phase NA

273

Behavioral Program to Improve Communication With Your Healthcare Team for Women With Stage I-IV Breast Cancer

Carolina Breast Cancer Study: Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes in the Carolina Breast Cancer Study, Phase 4

Purpose: To study whether a behavioral intervention increases confidence in a person's ability to communicate with their healthcare team about health concerns.

Who is this for?: Women with newly diagnosed stage I, stage II, stage III, or stage IV (metastatic) breast cancer who live in North Carolina. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li> <li class="seamTextUnorderedListItem">Provide blood or saliva sample</li> <li class="seamTextUnorderedListItem">Behavioral program, 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The behavioral program includes self-assessments, symptom reporting tools, interactions with nurses and educators, webinars and newsletters, and educational materials. Participants will learn about the study results.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07214610' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/resources-support/prepare-for-visit/' target='_blank'>Metastatic Trial Talk: Communicating With Your Healthcare Team</a> </li></ul>
273

Behavioral Program to Improve Communication With Your Healthcare Team for Women With Stage I-IV Breast Cancer

Carolina Breast Cancer Study: Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes in the Carolina Breast Cancer Study, Phase 4
Icon

Nearest Location from 94107:
2406 miles
University of North Carolina at Chapel Hill
Chapel Hill, NC

Icon

Visits:
Number of visits unavailable, up to 15 years

Icon

ClinicalTrials.gov: NCT07214610

Icon

Phase NA

274

Identifying Tumor Markers That Predict Treatment Response for Advanced Breast Cancer

Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior

Purpose: To collect biological specimens and clinical information to identify tumor markers that predict treatment response.

Who is this for?: People with advanced (stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following at diagnosis, during chemotherapy, and prior to surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Core biopsy</li> <li class="seamTextUnorderedListItem">Blood sampling</li> <li class="seamTextUnorderedListItem">Assessment of tumor markers</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are trying to find ways to determine which tumors will respond to which treatments.</li> <li class="seamTextUnorderedListItem">Studying tumor tissue and blood samples from patients before and after cancer treatments may help researchers identify tumor markers that can guide treatment choices.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01000883' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/mbc-pharmacogenomics/' target='_blank'>Metastatic Trial Talk: Why Does The Same Drug Work Differently In Different People?</a> </li></ul>
274

Identifying Tumor Markers That Predict Treatment Response for Advanced Breast Cancer

Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Icon

Nearest Location from 94107:
2406 miles
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, NC

Icon

Visits:
3 visits

Icon

ClinicalTrials.gov: NCT01000883

Icon

Phase NA

275

Nutrition Education for Women with Non-Metastatic Breast Cancer After Treatment

Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

Purpose: To understand how women with breast cancer feel about making dietary changes and whether education can help support healthier choices.

Who is this for?: Women with stage I or stage II or stage III breast cancer who have completed standard treatment. Participants may still be taking hormone (endocrine) therapy but must not have cancer that has come back or spread. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete 3 questionnaires sent by email</li> <li class="seamTextUnorderedListItem">Review a short 2-page educational brochure about diet, weight, and cancer</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study looks at how women with cancer understand diet and whether they feel willing and able to make healthier food choices after reviewing educational information. It focuses on awareness of processed foods and making changes to improve eating habits.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07389967' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/about-breast-cancer/breast-cancer-diet-nutrition/' target='_blank'>Breast Cancer Research Foundation: How Diet Impacts Breast Cancer Risk and Outcomes</a> </li></ul>
275

Nutrition Education for Women with Non-Metastatic Breast Cancer After Treatment

Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
Icon

Nearest Location from 94107:
2419 miles
UNC Cancer Hospital
Chapel Hill, NC

Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07389967

Icon

Phase NA

276

Video Versus Fact Sheet to Increase Genetic Counseling and Testing for Latina Women With Stage 0-IV Breast Cancer or High-Risk Women

Testing a Narrative Intervention to Enhance Genetic Counseling and Testing (CONTIGO)

Purpose: To compare a culturally targeted video and a Spanish-language fact sheet for enhancing genetic counseling, increasing genetic testing, and improving psychosocial outcomes.

Who is this for?: Latina women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer or healthy women with a family history of cancer that suggests hereditary breast and ovarian cancer who speak Spanish. You must not have received genetic counseling or testing. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch the video: <q>Is My Cancer Hereditary? Rosa Visits a Genetic Counselor,</q> virtual</li> <li class="seamTextUnorderedListItem">Surveys, 3 times within 4 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Read a fact sheet, virtual</li> <li class="seamTextUnorderedListItem">Surveys, 3 times within 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The culturally targeted video is in Spanish with English subtitles. It provides education about genetic counseling and testing and hereditary breast and ovarian cancer to at-risk Latinas.</li> <li class="seamTextUnorderedListItem">The fact sheet includes information about genes, breast cancer, risk factors for hereditary breast and ovarian cancer, genetic counseling and testing, and resources.</li> <li class="seamTextUnorderedListItem">All participants will be offered genetic counseling and testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05130606' target='_blank'>ClinicalTrials.gov</a> </li></ul>
276

Video Versus Fact Sheet to Increase Genetic Counseling and Testing for Latina Women With Stage 0-IV Breast Cancer or High-Risk Women

Testing a Narrative Intervention to Enhance Genetic Counseling and Testing (CONTIGO)
Icon

Nearest Location from 94107:
2430 miles
Virginia Commonwealth University
Richmond, VA

Icon

Visits:
3 visits within 4 months

Icon

ClinicalTrials.gov: NCT05130606

Icon

Phase NA

277

Improving Sleep Problems and Weight Loss for Women After Treatment

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer (COIN)

Purpose: To study the ability of a cognitive behavioral therapy (CBT) program to improve sleep problems before losing weight.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who were diagnosed within the last 10 years and have completed treatment (except hormone therapy). You must also be overweight (BMI > 25), planning to lose weight, and experiencing sleep problems. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive behavioral therapy (CBT) sessions to improve sleep, virtual, 6 times within 2 months</li> <li class="seamTextUnorderedListItem">Videos about weight loss, 19 videos</li> <li class="seamTextUnorderedListItem">Electronic sleep diary, 1 week</li> <li class="seamTextUnorderedListItem">Body measurements, 4 times</li> <li class="seamTextUnorderedListItem">DEXA scans, 2 times</li> <li class="seamTextUnorderedListItem">Smart watch</li> <li class="seamTextUnorderedListItem">Questionnaires, 5 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education sessions about sleep and cancer, virtual, 6 times within 2 months</li> <li class="seamTextUnorderedListItem">Body measurements, 4 times</li> <li class="seamTextUnorderedListItem">DEXA scans, 2 times</li> <li class="seamTextUnorderedListItem">Smart watch</li> <li class="seamTextUnorderedListItem">Questionnaires, 5 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The cognitive behavioral therapy (CBT) program combines education and behavioral techniques to reduce sleep problems (insomnia).</li> <li class="seamTextUnorderedListItem">Cognitive behavioral therapy (CBT) is a type of therapy that focuses on the relationship between thoughts, feelings, and behaviors.</li> <li class="seamTextUnorderedListItem">All participants will follow a program with the goals of increasing physical activity, improving diet, and losing weight.</li> <li class="seamTextUnorderedListItem">Wearable devices such as smart watches and FitBits are used to track your physical activity.</li> <li class="seamTextUnorderedListItem">A DEXA scan measures fat, muscle, and bone density.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05780814' target='_blank'>ClinicalTrials.gov</a> </li></ul>
277

Improving Sleep Problems and Weight Loss for Women After Treatment

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer (COIN)
Icon

Nearest Location from 94107:
2433 miles
Sibley Memorial Hospital
Washington D.C., DC

Icon

Visits:
4 visits within 1 year 2 months

Icon

ClinicalTrials.gov: NCT05780814

Icon

Phase NA

278

Fasting to Improve Adherence to Chemotherapy for Women with Stage I-III Breast Cancer

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming (GAMMER) Study in Early Stage Breast Cancer Receiving Chemotherapy

Purpose: To study if fasting (not eating) for 1-2 days during chemotherapy helps women continue receiving chemotherapy as prescribed.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive one of the following chemotherapy treatments: dose dense doxorubicin (Doxil®) and cyclophosphamide (Cytoxan®) (called ddAC) or docetaxel (Taxotere®) and cyclophosphamide (Cytoxan®) (called TC). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fast (not eat, except for water) for 1-2 days during chemotherapy</li> <li class="seamTextUnorderedListItem">Stool (poop) samples, weekly for 3 weeks</li> <li class="seamTextUnorderedListItem">Blood samples, weekly for 1 month</li> <li class="seamTextUnorderedListItem">Questionnaires, weekly for 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Previous research suggests that fasting during chemotherapy is safe and can prevent some toxic effects of chemotherapy without causing chronic weight loss.</li> <li class="seamTextUnorderedListItem">Fasting may allow people to experience less issues during chemotherapy (tolerance) and receive chemotherapy as prescribed (adherence).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06536881' target='_blank'>ClinicalTrials.gov</a> </li></ul>
278

Fasting to Improve Adherence to Chemotherapy for Women with Stage I-III Breast Cancer

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming (GAMMER) Study in Early Stage Breast Cancer Receiving Chemotherapy
Icon

Nearest Location from 94107:
2433 miles
Sibley Memorial Hospital
Washington D.C., DC

Icon

Visits:
1 visit every week for 1 month

Icon

ClinicalTrials.gov: NCT06536881

Icon

Phase NA

279

Azeliragon to Decrease Cardiotoxicity and Cognitive Decline During Chemotherapy in Women with Stage I-III Breast Cancer

RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer

Purpose: To study the ability of azeliragon to decrease cardiotoxicity (heart damage caused by cancer treatment) and cognitive decline side effects of chemotherapy.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who have not yet received treatment and are planning to receive chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Azeliragon with AC/T Chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®), 5.5 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 5.5 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), 5.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Azeliragon with CT Chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), 3-4 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 3-4 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Azeliragon with TCHP Chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), 4 months</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), 4 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), 4 months</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), 4 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4: Azeliragon with Combination of Chemotherapy and Targeted Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), 4 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 3-4 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), 5.5 months</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), depending on type of cancer</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), 4 months, depending on type of cancer</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon is an experimental drug that may reduce cardiotoxicity and cognitive decline side effects of chemotherapy. It is also being studied for treating Alzheimer's and glioblastoma, a type of brain cancer.</li> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity. </li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®), cyclophosphamide (Cytoxan®), paclitaxel (Taxol®), docetaxel (Taxotere®), and carboplatin (Paraplatin®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and Pertuzumab (Perjeta®) are anti-HER2 targeted therapies routinely used to treat HER2 positive breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05256745' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/16858-chemotherapy--the-heart-cardiotoxicity#:~:text=Cardiotoxicity%20refers%20to%20any%20heart,radiation%20therapy%20to%20the%20chest.' target='_blank'>Cleveland Clinic: Cardiotoxicity Cancer Treatment and the Heart</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-azeliragon-for-gbm' target='_blank'>OncLive: Azeliragon for Brain Cancer and Cancer Treatment-Related Complications</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>
279

Azeliragon to Decrease Cardiotoxicity and Cognitive Decline During Chemotherapy in Women with Stage I-III Breast Cancer

RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer
Icon

Nearest Location from 94107:
2434 miles
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., DC

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05256745

Icon

Phase I-II

280

Virtual Reality Program to Teach Heart Health for Women with Stage 0-III Breast Cancer Receiving Trastuzumab or Anthracycline Chemotherapy

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2

Purpose: This trial is studying whether a virtual reality (VR) program called SurviVRSE can help breast cancer survivors learn about heart-related side effects that can come from certain cancer treatments. The program uses education modules and games to teach patients how to spot signs of treatment-related heart problems and which heart-healthy habits (like physical activity) may help protect their hearts.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, who are currently receiving trastuzumab (Herceptin®) or an anthracycline-based chemotherapy, and also currently receiving immunotherapy (such as pembrolizumab (Keytruda®) or atezolizumab (Tecentriq®)). You must be receiving care at Virginia Commonwealth University (VCU) in Richmond, Virginia. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual reality (VR) program </li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments (like trastuzumab and anthracycline chemo) can affect your heart</li> <li class="seamTextUnorderedListItem">Regular physical activity, good sleep, and not using tobacco are generally linked to better heart function and may help offset some cardiovascular risk from cancer treatment</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07426913' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uclahealth.org/news/release/detecting-heart-issues-breast-cancer-survivors' target='_blank'>UCLA Health: Detecting heart issues in breast cancer survivors</a> </li></ul>
280

Virtual Reality Program to Teach Heart Health for Women with Stage 0-III Breast Cancer Receiving Trastuzumab or Anthracycline Chemotherapy

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2
Icon

Nearest Location from 94107:
2436 miles
Adult Outpatient Pavilion
Richmond, VA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT07426913

Icon

Phase NA

281

Understanding Barriers to Follow-Up After a Positive Breast Cancer Screening Result

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

Purpose: To study a community-based outreach program for screening, diagnosis, and treatment of breast cancer.

Who is this for?: Women, age 40-74 years, who received a result of "positive" for breast cancer following screening. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Referral for follow-up after receiving a <q>positive</q> breast cancer screening result</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at differences between adults who accept or decline follow-up after a <q>positive</q> cancer screening result. The researchers are looking for factors that prevent or make it easier for someone to receive cancer screening, diagnosis, treatment, and clinical trial screening. They are also seeking to understand people's feelings towards navigators who may help people receive these services.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people who were screened for other cancers.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07231159' target='_blank'>ClinicalTrials.gov</a> </li></ul>
281

Understanding Barriers to Follow-Up After a Positive Breast Cancer Screening Result

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
Icon

Nearest Location from 94107:
2437 miles
Adventhealth
Orlando, FL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07231159

Icon

Phase NA

282

Azelaic Acid For People With Stage 0-III Breast Cancer Who Are Receiving Radiation

Pilot Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of azelaic acid.

Who is this for?: People who are Black, Asian, Hispanic/Latin, of Mediterranean rim or Pacific rim origin, or who tan easily in the sun with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have received a lumpectomy or mastectomy and are planning to receive breast radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azelaic acid, on the skin, daily, 1 week before, during, and 3 weeks after radiation</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azelaic acid is a cream approved to treat acne and other skin conditions.</li> <li class="seamTextUnorderedListItem">Its use in this study is considered experimental.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06966388' target='_blank'>ClinicalTrials.gov</a> </li></ul>
282

Azelaic Acid For People With Stage 0-III Breast Cancer Who Are Receiving Radiation

Pilot Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
Icon

Nearest Location from 94107:
2438 miles
Virginia Commonwealth University
Richmond, VA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06966388

Icon

Phase I

283

Radiation After Recurrence for Stage 0-III Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation: Phase 2 Multi-institutional Study (PRESERVE)

Purpose: To study if 5 radiation treatments after a second lumpectomy and previous radiation to the breast is safe for people whose breast cancer has come back (recurrence).

Who is this for?: People with stage 0 (DCIS), stage I, some stage II, or some stage III node negative breast cancer that has come back (recurrence) at least 5 years after completing treatment. You must have recieved a second lumpectomy after the recurrence. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, daily for 5 days</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard treatment for breast cancer often includes lumpectomy (also called partial mastectomy) and radiation to prevent recurrence.</li> <li class="seamTextUnorderedListItem">If recurrence happens, standard treatment is usually a mastectomy or a second lumpectomy followed by additional radiation.</li> <li class="seamTextUnorderedListItem">Node negative means that cancer has not spread to the lymph nodes.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05592938' target='_blank'>ClinicalTrials.gov</a> </li></ul>
283

Radiation After Recurrence for Stage 0-III Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation: Phase 2 Multi-institutional Study (PRESERVE)
Icon

Nearest Location from 94107:
2438 miles
Virgina Community University Massey Comprehensive Cancer Center
Richmond, VA

Icon

Visits:
5 visits in 1 week

Icon

ClinicalTrials.gov: NCT05592938

Icon

Phase NA

284

Registry of Mammograms to Improve Artificial Intelligence Analysis of Scans

UCF MammoChat: An AI-Driven Platform for Personalized Breast Cancer Patient Support -Image Repository

Purpose: To develop artificial intelligence (AI) models to better read diagnostic mammograms.

Who is this for?: People who have received a mammogram. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide consent to donate your mammogram.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Around half of women will receive a false positive mammogram result (a report of cancer when cancer is not actually present). This creates anxiety.</li> <li class="seamTextUnorderedListItem">Artificial intelligence (AI) may be able to better read mammograms to reduce false positive results. AI models need to be improved for different racial groups, age ranges, ethnicities, and different types of breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07214883' target='_blank'>ClinicalTrials.gov</a> </li></ul>
284

Registry of Mammograms to Improve Artificial Intelligence Analysis of Scans

UCF MammoChat: An AI-Driven Platform for Personalized Breast Cancer Patient Support -Image Repository
Icon

Nearest Location from 94107:
2446 miles
University of Central Florida
Orlando, FL

Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07214883

Icon

Phase NA

285

Broccoli Microgreens for Obese Women with Stage I-III Breast Cancer

Metabotyping of a Functional Food, Broccoli Microgreen, in Obese Breast Cancer Survivors

Purpose: To study if people can stick to a diet that includes broccoli microgreens (BMG) every day and how their bodies respond.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who completed cancer treatment at least 2 months and no more than 5 years ago and who are obese (BMI >30 kg/m²). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One cup of broccoli microgreens (BMG), by mouth, daily for 2 weeks</li> <li class="seamTextUnorderedListItem">Blood test</li> <li class="seamTextUnorderedListItem">Provide stool (poop) sample</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Obesity can increase the risk of cancer coming back.</li> <li class="seamTextUnorderedListItem">Broccoli microgreens (BMG) are young broccoli plants that may help prevent cancer and improve health.</li> <li class="seamTextUnorderedListItem">Results from this study may help create new diet strategies to improve health and reduce cancer risk in patients who are overweight or obese.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07032545' target='_blank'>ClinicalTrials.gov</a> </li></ul>
285

Broccoli Microgreens for Obese Women with Stage I-III Breast Cancer

Metabotyping of a Functional Food, Broccoli Microgreen, in Obese Breast Cancer Survivors
Icon

Nearest Location from 94107:
2452 miles
Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, MD

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07032545

Icon

Phase NA

286

Screening for Diabetes, High Cholesterol, and Heart Disease in People with Breast Cancer After Treatment

A Cardiometabolic Screening Program for Breast Cancer Survivors

Purpose: To study a screening program for prediabetes, diabetes, high cholesterol, and heart disease in breast cancer survivors, as well as a program to direct people to resources for management.

Who is this for?: People with stage I, stage II, or stage III breast cancer who completed treatment at least 3 months ago. You must be receiving care at Johns Hopkins Medical Institute; Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD; Green Spring Station in Lutherville-Timonium, MD; or Sibley Memorial Hospital in Washington, DC. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, 1-2 times in 1 year</li> <li class="seamTextUnorderedListItem">Referral to primary care, nutrition, exercise, hormone health, and/or heart health provider(s) based on risk factors</li> <li class="seamTextUnorderedListItem">Educational handouts based on risk factors</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prediabetes, diabetes, high cholesterol, and being overweight/obese are common in people with early stage breast cancer.</li> <li class="seamTextUnorderedListItem">The Healthful Eating, Activity and Weight Program (HEAWP) and Cardiovascular Disease Prevention Program are designed to help people manage these conditions.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05386719' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/gim/clinical/lifestyle-weight/' target='_blank'>Johns Hopkins: Healthful Eating, Activity and Weight Program</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/wellness-and-prevention/preventing-cardiovascular-diseases' target='_blank'>Johns Hopkins: Preventing Cardiovascular Diseases</a> </li></ul>
286

Screening for Diabetes, High Cholesterol, and Heart Disease in People with Breast Cancer After Treatment

A Cardiometabolic Screening Program for Breast Cancer Survivors
Icon

Nearest Location from 94107:
2454 miles
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05386719

Icon

Phase NA

287

Analyzing Tumor Mutations Before and After Treatment with Targeted Therapies

A Basket Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy

Purpose: To compare genetic mutations seen in a tumor sample before and after treatment with a targeted therapy. The study will investigate how tumor mutations can be used to predict a cancer's response to treatment and how they change in response to targeted therapies.

Who is this for?: People who are receiving ongoing care at Memorial Sloan Kettering Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> All participants will be asked to provide: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A tube of blood</li> <li class="seamTextUnorderedListItem">Cheek swab (also known as a buccal), or a saliva sample that contains normal genes for comparison</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Leftover tumor tissue from a previous surgery or biopsy will be used for genomic testing.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most genetic mutations found in cancer cells are not passed down from parents (inherited), but occur when the cells make mistakes when they divide.</li> <li class="seamTextUnorderedListItem">Most cancers have many mutations.</li> <li class="seamTextUnorderedListItem">Some of these mutations help drive the tumor's growth, while others are just bystanders.</li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket trials enroll people based on the kind of mutations found in their tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01775072' target='_blank'>ClinicalTrials.gov</a> </li></ul>
287

Analyzing Tumor Mutations Before and After Treatment with Targeted Therapies

A Basket Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Icon

Nearest Location from 94107:
2494 miles
Lehigh Valley Health Network
Allentown, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT01775072

Icon

Phase NA

288

Comparing 2 Combinations of Pain Medication for Mastectomy

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in an Erector Spinae Plane Block for Mastectomies in Cancer Patients: a Randomized Control Trial

Purpose: To compare 2 combinations of medications to control pain for people receiving a mastectomy.

Who is this for?: People with stage I, stage II, or stage III breast cancer or people at high risk of breast cancer who are planning to receive a mastectomy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine and dexmedetomidine, by injection guided by ultrasound</li> <li class="seamTextUnorderedListItem">Pain questionnaires after surgery, at hospital and at home</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine and liposomal bupivacaine, by injection guided by ultrasound</li> <li class="seamTextUnorderedListItem">Pain questionnaires after surgery, at hospital and at home</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine is a common method to control pain after surgery performed on the chest and chest wall.</li> <li class="seamTextUnorderedListItem">Liposomal bupivacaine is a different version of bupivacaine.</li> <li class="seamTextUnorderedListItem">Dexmedetomidine is a pain medication used for other surgeries that may be better than the standard of care for mastectomies.</li> <li class="seamTextUnorderedListItem">An ultrasound will be used to find the correct place to inject the pain medication.</li> <li class="seamTextUnorderedListItem">A mastectomy is sometimes called a partial mastectomy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06252662' target='_blank'>ClinicalTrials.gov</a> </li></ul>
288

Comparing 2 Combinations of Pain Medication for Mastectomy

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in an Erector Spinae Plane Block for Mastectomies in Cancer Patients: a Randomized Control Trial
Icon

Nearest Location from 94107:
2510 miles
Naval Medical Center Portsmouth
Portsmouth, VA

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT06252662

Icon

Phase IV

289

Digital Symptom Tracking and Health Promotion for Women on Hormone Therapy for Breast Cancer(EmSHAPE)

Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)

Purpose: This trial is studying a digital health tool that uses text messages to help women track and manage side effects from hormone therapy (also called endocrine therapy). The goal is to find out if this tool helps women manage side effects and stay on their hormone therapy as recommended, compared to usual care with a printed education handout.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III, hormone receptor positive (HR+) breast cancer, who are starting standard hormone therapy (tamoxifen, anastrozole, exemestane, or letrozole) within 16 weeks of joining the study. You must not have received hormone therapy before for your breast cancer. You must have finished breast cancer surgery, and finished chemotherapy if you had it, at least 14 days before joining. This trial is only offered at Abramson Cancer Center at the University of Pennsylvania in Philadelphia. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Digital Symptom Monitoring Program</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive text messages with links to surveys about your symptoms and educational materials about hormone therapy side effects</li> <li class="seamTextUnorderedListItem">Electronic pill bottle to track how often you take your medication</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive a printed handout describing hormone therapy and its possible side effects</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying whether a digital tool, made up of text messages, symptom surveys, and an electronic pill bottle, can help women better manage the side effects of hormone therapy and stay on treatment for the recommended amount of time, compared to a printed education handout alone. </li> <li class="seamTextUnorderedListItem">Hormone therapy (also called endocrine therapy) works by lowering the amount of estrogen in the body or blocking its effects, which helps slow or stop the growth of hormone receptor positive breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07454499' target='_blank'>ClinicalTrials.gov</a> </li></ul>
289

Digital Symptom Tracking and Health Promotion for Women on Hormone Therapy for Breast Cancer(EmSHAPE)

Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
Icon

Nearest Location from 94107:
2517 miles
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07454499

Icon

Phase NA

290

A Study of Diet and Physical Activity in Women With Stage 0-III Breast Cancer

The MILES Study: A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

Purpose: The purpose of this study is to learn how diet and physical activity change over time after a breast cancer diagnosis, through treatment, and into survivorship.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer. You must have been newly diagnosed within the past 60 days and be scheduled to have breast cancer surgery with a Penn Medicine surgeon. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys about your diet, physical activity, and other lifestyle habits </li> <li class="seamTextUnorderedListItem">Urine sample at 3 time points- at diagnosis, about 1 month after surgery, and about 6 months after surgery </li> <li class="seamTextUnorderedListItem">Some participants will also take part in one on one interviews, online or in person, about lifestyle habits after a breast cancer diagnosis</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study looks at how eating habits and physical activity change after a breast cancer diagnosis and through treatment. </li> <li class="seamTextUnorderedListItem">Participants complete surveys and give urine samples that are tested using a method called metabolomics, which measures natural chemicals in the body that can reflect diet and activity. </li> <li class="seamTextUnorderedListItem">The goal is to create simple, reliable tools that can help newly diagnosed patients build and maintain healthy habits during treatment and survivorship.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07655934' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/about-breast-cancer/breast-cancer-diet-nutrition/' target='_blank'>Breast Cancer Research Foundation: How Diet Impacts Breast Cancer Risk and Outcomes</a> </li></ul>
290

A Study of Diet and Physical Activity in Women With Stage 0-III Breast Cancer

The MILES Study: A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship
Icon

Nearest Location from 94107:
2517 miles
Abamson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT07655934

Icon

Phase NA

291

Looking for Disseminated Tumor Cells in Bone Marrow After Breast Cancer Treatment to Guide Decisions About Additional Treatment

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer (SURMOUNT)

Purpose: To look for, study, and treat disseminated tumor cells (DTCs) in the bone marrow of people with high-risk, early-stage breast cancer.

Who is this for?: People who have completed treatment for stage I, stage II, or stage III breast cancer within the last five years. Additionally, your cancer must be considered high risk for recurrence. For this trial, high risk is defined as node-positive, triple-negative, Oncotype score 25 or higher for ER+, HER2- disease, or the presence of residual disease after neoadjuvant (before surgery) chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive a bone marrow aspiration test (bone marrow biopsy), then your bone marrow sample will be tested for disseminated tumor cells.</p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Studies have found that people who have disseminated tumor cells (DTCs) in their bone marrow are at greater risk of having a breast cancer recurrence than people without DTCs. </li> <li class="seamTextUnorderedListItem">A bone marrow aspiration can be used to look for DTCs.</li> <li class="seamTextUnorderedListItem">If you are found to have DTCs in your bone marrow, you will have an opportunity to enroll in a separate clinical trial that is evaluating the effectiveness of using a therapy that targets DTCs to prevent recurrence.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02732171' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice/breast-cancer-tce/surmount-study' target='_blank'>Penn Medicine: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nlm.nih.gov/medlineplus/ency/article/003658.htm' target='_blank'>MedLinePlus: Bone Marrow Aspiration</a> </li></ul>
291

Looking for Disseminated Tumor Cells in Bone Marrow After Breast Cancer Treatment to Guide Decisions About Additional Treatment

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer (SURMOUNT)
Icon

Nearest Location from 94107:
2517 miles
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Icon

Visits:
1 visit a year, for 1 to 5 years

Icon

ClinicalTrials.gov: NCT02732171

Icon

Phase NA

292

Studying Immune Cell Response to Treatment for Women with Stage I-III ER+, HER2- Breast Cancer

Role of the Immune Environment in Response to Therapy in Breast Cancer

Purpose: To study differences in immune cells in different types of breast cancer.

Who is this for?: Women with stage I, stage II, or stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who are planning to receive surgery at the University of Pennsylvania Health System. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue samples from surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immune system cells play an important role in finding and killing cancer cells.</li> <li class="seamTextUnorderedListItem">This study will compare immune system cells and their role in outcomes after treatment in different types of breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05396612' target='_blank'>ClinicalTrials.gov</a> </li></ul>
292

Studying Immune Cell Response to Treatment for Women with Stage I-III ER+, HER2- Breast Cancer

Role of the Immune Environment in Response to Therapy in Breast Cancer
Icon

Nearest Location from 94107:
2517 miles
Abramson Cancer Center
Philadelphia, PA

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT05396612

Icon

Phase NA

293

Abemaciclib CDK4/6 Inhibitor With or Without Hydroxychloroquine for Stage I-III Breast Cancer At Risk of Recurrence

A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients ("ABBY")

Purpose: To study the safety, effects (good and bad), and ability of abemaciclib (Verzenio®) CDK4/6 inhibitor with and without hydroxychloroquine (Plaquenil®), an experimental cancer drug, to reduce or eliminate breast cancer cells in the bone marrow.

Who is this for?: People with stage I, stage II, or stage III breast cancer who completed treatment and have one of the following recurrence risk factors: 1) lymph node positive; 2) triple negative (ER-, PR-, HER2-); 3) estrogen receptor positive (ER+), HER2 negative (HER2-), lymph node negative; 4) leftover tumor found in your breast or lymph node (residual disease) after neoadjuvant (before surgery) chemotherapy. You must not have received treatment with a CDK4/6 inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily for 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Hydroxychloroquine (Plaquenil®), by mouth, daily for 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK4/6 inhibitor. CDK4/6 inhibitors block two enzymes, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Hydroxychloroquine (Plaquenil®) is an experimental cancer drug that may help cancer drugs work better.</li> <li class="seamTextUnorderedListItem">The drugs may target bone marrow disseminated tumor cells (DTCs).</li> <li class="seamTextUnorderedListItem">This trial requires bone marrow testing through another research study.</li> <li class="seamTextUnorderedListItem">Residual disease refers to cancer cells that are present after treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04523857' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://i2b.us/repurposing-drugs-as-expanding-cancer-treatment-palette-hydroxychloroquine/' target='_blank'>Institute of Integrative BioOncology: Hydroxychloroquine for Cancer</a> </li></ul>
293

Abemaciclib CDK4/6 Inhibitor With or Without Hydroxychloroquine for Stage I-III Breast Cancer At Risk of Recurrence

A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients ("ABBY")
Icon

Nearest Location from 94107:
2517 miles
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04523857

Icon

Phase II

294

An Experimental Tracer in PET/CT Scans to Find Breast Cancer Tumors

Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer

Purpose: To study the safety and effectiveness of an experimental PET/CT scan tracer (a radioactive substance that looks for and attaches to cancer cells).

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have at least one tumor 1.5 cm or larger. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following 1 to 4 times: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">(18F)F-GLN tracer, by IV, then a PET/CT scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">Cancer cells use a protein called glutamine to grow--they use more of it than healthy cells. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F) F-GLN--it shows which cells in your body are using a lot of glutamine. </li> <li class="seamTextUnorderedListItem">A (18F) F-GLN PET/CT scan may work better than standard of care PET/CT scans in finding cancer tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03863457' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/pet' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/beyond-sugar-what-cancer-cells-need-grow' target='_blank'>Memorial Sloan Kettering Cancer Center: Beyond Sugar, What Cancer Cells Need to Grow</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373500/' target='_blank'>Journal Article: Metabolic Imaging of Glutamine in Cancer</a> </li></ul>
294

An Experimental Tracer in PET/CT Scans to Find Breast Cancer Tumors

Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer
Icon

Nearest Location from 94107:
2517 miles
University of Pennsylvania
Philadelphia, PA

Icon

Visits:
1 to 4 visits

Icon

ClinicalTrials.gov: NCT03863457

Icon

Phase I

295

PET/DBT Scans with FES to Measure ER+ Disease for Women with Newly Diagnosed Stage I-III Breast Cancer

Pilot Study Evaluating the Uptake of [18F]Fluoroestradiol (FES) BPET/DBT in Primary Breast Cancer to Measure the Localized Extent of Estrogen Receptor Positive Disease

Purpose: To study the use of PET/DBT scans with FES to measure the amount of estrogen receptor positive (ER+) breast cancer cells.

Who is this for?: Women with newly diagnosed stage I, stage II, or stage III estrogen receptor positive (ER+) who have not yet started treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/DBT scan with FES, by IV, 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A digital breast tomosynthesis (DBT) is an advanced mammogram that takes multiple pictures of your breast from more angles than a standard mammogram.</li> <li class="seamTextUnorderedListItem">FES is a radioactive tracer that is given in a vein before PET scans to help identify areas of active cancer.</li> <li class="seamTextUnorderedListItem">This trial is studying ways to improve breast cancer imaging scans and will not be used to make treatment decisions.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05659797' target='_blank'>ClinicalTrials.gov</a> </li></ul>
295

PET/DBT Scans with FES to Measure ER+ Disease for Women with Newly Diagnosed Stage I-III Breast Cancer

Pilot Study Evaluating the Uptake of [18F]Fluoroestradiol (FES) BPET/DBT in Primary Breast Cancer to Measure the Localized Extent of Estrogen Receptor Positive Disease
Icon

Nearest Location from 94107:
2518 miles
University of Pennsylvania
Philadelphia, PA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT05659797

Icon

Phase I

296

Reducing Calories During Radiation Therapy for DCIS or Stage I-III Breast Cancer

SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SABR) With and Without Caloric Restriction for Early Stage Breast Cancer

Purpose: To determine if neoadjuvant (before surgery) calorie restriction during radiation therapy decreases the size of tumor tissue, compared to radiation therapy alone.

Who is this for?: People age 40 and older with DCIS, stage I, stage II, or stage III node negative breast cancer or age 50 and older if you have triple negative (ER-, PR-, HER2-) breast cancer. You must have not yet received chemotherapy, radiation, or surgery. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic ablative radiation therapy (SABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organ.</li> <li class="seamTextUnorderedListItem">Giving SABR before surgery may make the tumor smaller.</li> <li class="seamTextUnorderedListItem">Adding dietary restriction to radiation therapy may help increase the effectiveness of the radiation and decrease the spread of the cancer to other places in the body.</li> <li class="seamTextUnorderedListItem">The reduced calorie diet consists of reducing your calorie intake by 25%.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04959474' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://stanfordhealthcare.org/medical-treatments/s/stereotactic-body-radiation-therapy.html#:~:text=Stereotactic%20ablative%20radiotherapy%20(SABR)%2C,dose%20to%20the%20surrounding%20organs.' target='_blank'>Stanford: Stereotactic Ablative Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.jefferson.edu/university/jmc/departments/radiation_oncology/news/07212014.html' target='_blank'>Thomas Jefferson University: Calorie Restriction and Breast Cancer</a> </li></ul>
296

Reducing Calories During Radiation Therapy for DCIS or Stage I-III Breast Cancer

SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SABR) With and Without Caloric Restriction for Early Stage Breast Cancer
Icon

Nearest Location from 94107:
2519 miles
Thomas Jefferson University Hospital
Philadelphia, PA

Icon

Visits:
5 visits

Icon

ClinicalTrials.gov: NCT04959474

Icon

Phase NA

297

Exploring How Social Factors Affect Inflammation

EXploring Inflammation and Social deTerminants (EXIST) Study in Breast Cancer Patients

Purpose: To understand how social factors such as housing, food access, transportation, and safety, may affect inflammation in people with breast cancer.

Who is this for?: Women with newly diagnosed stage 0 (DCIS), stage I, stage II, or stage III breast cancer, who have not yet received treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample, 1 time</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Food Diary from last 24 hours</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests will measure a protein called IL-6, which helps doctors see how much inflammation is in the body.</li> <li class="seamTextUnorderedListItem">The questionnaires will identify social determinants of health (SDOH), the non-medical factors that influence your health, such as race, gender identity, education, occupation, access to health services and economic resources.</li> <li class="seamTextUnorderedListItem">Inflammation is a known contributor to cancer progression and metastases.</li> <li class="seamTextUnorderedListItem">The study will explore the relationship between social determinants of health, and levels of inflammation.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07478016' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health' target='_blank'>US Department of Health and Human Services: Social Determinants of Health</a> </li></ul>
297

Exploring How Social Factors Affect Inflammation

EXploring Inflammation and Social deTerminants (EXIST) Study in Breast Cancer Patients
Icon

Nearest Location from 94107:
2519 miles
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, PA

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07478016

Icon

Phase NA

298

Revaree Plus Vaginal Suppository for Women with Stage 0-III HR+ Breast Cancer and Vaginal Dryness

Evaluation of Revaree Plus in Women With Breast Cancer

Purpose: To study whether Revaree Plus vaginal suppository improves vaginal health for women with vaginal dryness due to breast cancer treatment.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have completed chemotherapy and radiation (if recommended) and are currently receiving an aromatase inhibitor or tamoxifen (Nolvadex®) and experiencing vaginal dryness. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Revaree Plus, by vaginal suppository</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times within 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vaginal dryness is a common side effect of hormone therapy, which includes aromatase inhibitors and tamoxifen (Nolvadex®).</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Revaree Plus is a medicine called hyaluronic acid that is delivered by insertion into the vagina with a suppository.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07042581' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://hellobonafide.com/products/revaree-plus' target='_blank'>Bonafide: Revaree Plus</a> </li></ul>
298

Revaree Plus Vaginal Suppository for Women with Stage 0-III HR+ Breast Cancer and Vaginal Dryness

Evaluation of Revaree Plus in Women With Breast Cancer
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, NJ

Icon

Visits:
2 visits within 2 months

Icon

ClinicalTrials.gov: NCT07042581

Icon

Phase IV

299

Understanding Genetic and Lifestyle Factors That Affect Breast Cancer Risk

Genomic and Non-Genomic Factors Associated With Breast Cancer Risk Factors and Outcomes

Purpose: To understand how genetic and non‑genetic factors are associated with breast cancer risk and recurrence.

Who is this for?: Women with an abnormal finding on a breast exam or imaging test; or newly diagnosed with stage 0 (DCIS), stage I, stage II, stage III breast cancer who are planning to have surgery. Must be receiving care at Memorial Sloan Kettering (MSK). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and tissue samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The goal of this study is to understand why breast cancer risk and outcomes, including recurrence, may be different for people with different backgrounds by looking at genetic information, blood and tissue samples, and survey responses.</li> <li class="seamTextUnorderedListItem">Collecting samples of blood and tissue from patients with and without breast cancer can help determine which factors may be linked to breast cancer risk and outcomes.</li> <li class="seamTextUnorderedListItem">This is a research only study and does not provide cancer treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07294703' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/genetic-testing.html' target='_blank'>American Cancer Society: Genetic Counseling and Testing for Breast Cancer Risk</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing for Breast Cancer</a> </li></ul>
299

Understanding Genetic and Lifestyle Factors That Affect Breast Cancer Risk

Genomic and Non-Genomic Factors Associated With Breast Cancer Risk Factors and Outcomes
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
4 visits over 5 years

Icon

ClinicalTrials.gov: NCT07294703

Icon

Phase NA

300

Preventing and Improving Sexual Health Concerns for People with DCIS and Stage I-III Breast Cancer

Randomized Pilot Prevention Trial to Improve Sexual and Vulvovaginal Health Concerns in Premenopausal Female Breast Cancer Patients Receiving Ovarian Suppression

Purpose: To study whether sexual health counseling and using a non-hormonal vaginal moisturizer at the start of hormone therapy may prevent or reduce sexual side effects.

Who is this for?: Premenopausal or perimenopausal women with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive recommendations for vaginal moisturizers</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sexual health counseling</li> <li class="seamTextUnorderedListItem">Receive non-hormonal moisturizers, 3-5 times per week</li> <li class="seamTextUnorderedListItem">Consultation with pelvic floor physical therapist</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">If you are in group 1, you will receive recommendations for vaginal moisturizers but will purchase the moisturizers at your local pharmacy.</li> <li class="seamTextUnorderedListItem">If you are in group 2, you will receive non-hormonal vaginal moisturizers, such as: Hyalogyn, Replens, Liquibeads, or Vitamin E capsules.</li> <li class="seamTextUnorderedListItem">Sexual side effects include vaginal dryness and sexual dysfunction.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05910294' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/sex-intimacy' target='_blank'>Breastcancer.org: Sexual Health During and After Breast Cancer</a> </li></ul>
300

Preventing and Improving Sexual Health Concerns for People with DCIS and Stage I-III Breast Cancer

Randomized Pilot Prevention Trial to Improve Sexual and Vulvovaginal Health Concerns in Premenopausal Female Breast Cancer Patients Receiving Ovarian Suppression
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05910294

Icon

Phase NA

301

Sexual and Reproductive Health of Women Treated for Breast Cancer

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Purpose: To study how to identify which women are most likely to develop early menopause or sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment.

Who is this for?: Women, 50 or younger, diagnosed with DCIS or stage I, stage II, or stage III breast cancer who are within one month of starting treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sexual and Reproductive Health survey, 9 times over 5 years</li> <li class="seamTextUnorderedListItem">If you receive chemotherapy, optional blood draw, 3 times over 2 years</li> <li class="seamTextUnorderedListItem">If you are premenopausal and only receive tamoxifen, blood draws, 12 times over 2 years and transvaginal ultrasound, 2 times, at baseline and 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer and its treatment may affect sexual and reproductive health.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling women with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01788839' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.mskcc.org/cancer-care/trial/12-249' target='_blank'>Memorial Sloan Kettering Cancer Center: Study Website</a> </li></ul>
301

Sexual and Reproductive Health of Women Treated for Breast Cancer

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ

Icon

Visits:
4 visits over 1 year, then annual visits for 5 years

Icon

ClinicalTrials.gov: NCT01788839

Icon

Phase NA

302

Three Days of Radiation Therapy in Women with DCIS or Stage I Breast Cancer

Ultra-Short External Beam-Based Accelerated Partial Breast Irradiation (APBI): A Phase II Toxicity Study Nested With a Non-inferiority Assessment of APBI in New Patient Cohorts

Purpose: To study the effects (good and bad) of three days of accelerated partial breast irradiation (APBI) after a lumpectomy.

Who is this for?: Women 45 years or older with ductal carcinoma in situ (DCIS) or stage I breast cancer who have had a lumpectomy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Accelerated Partial Breast Irradiation (APBI), daily, for 3 days</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Three days is a shorter course of radiation than patients would typically receive.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04084730' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/apbr-vs-wbr-for-lower-recurrence-risk-after-lx' target='_blank'>Breastcancer.org: Accelerated Partial-Breast Radiation Slightly Less Effective Than Whole-Breast Radiation for Preventing Breast Cancer Recurrence After Lumpectomy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2018/breast-cancer-radiation-therapy-whole-partial-recurrence' target='_blank'>Cancer.gov: Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning</a> </li></ul>
302

Three Days of Radiation Therapy in Women with DCIS or Stage I Breast Cancer

Ultra-Short External Beam-Based Accelerated Partial Breast Irradiation (APBI): A Phase II Toxicity Study Nested With a Non-inferiority Assessment of APBI in New Patient Cohorts
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ

Icon

Visits:
Daily visits for 3 days

Icon

ClinicalTrials.gov: NCT04084730

Icon

Phase II

303

Side Effects and Resource Navigation Program for People With Breast Cancer Receiving Immunotherapy

I CARE (Immunotherapy Cutaneous Adverse Events REsearch) - A Trial With Diverse Cancer Patients to Determine the Impact of SDoH and Side Effects Navigation Program on Treatment Continuation

Purpose: To find out whether a navigation program helps people better manage their immunotherapy treatment and everyday essential needs, such as food, transportation, and housing, compared with usual care.

Who is this for?: People with stage I, stage II, stage III, or stage IV breast cancer who are planning to receive or are starting immunotherapy (immune checkpoint inhibitors) as part of their treatment. You must be within a few weeks of starting immunotherapy. You must have at least one essential need, such as food, transportation, or housing. This trial is also enrolling people with other types of cancer. You must be receiving care at a Memorial Sloan Kettering Cancer Center location. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Immunotherapy CARE navigation program, monthly </li> <li class="seamTextUnorderedListItem">Staff will help you report side effects and symptoms and connect you with support for essential needs such as food, transportation, and housing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Checkups, tests, and questionnaires, monthly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">I CARE, a navigation program that is being studied to see if monthly support with reporting side effects and meeting essential needs helps people stay on their immunotherapy treatment and improves their quality of life. </li> <li class="seamTextUnorderedListItem">Immunotherapy uses the body's own immune system to help fight cancer. In this trial, the immunotherapy is part of your regular treatment, not something the trial provides.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07646847' target='_blank'>ClinicalTrials.gov</a> </li></ul>
303

Side Effects and Resource Navigation Program for People With Breast Cancer Receiving Immunotherapy

I CARE (Immunotherapy Cutaneous Adverse Events REsearch) - A Trial With Diverse Cancer Patients to Determine the Impact of SDoH and Side Effects Navigation Program on Treatment Continuation
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
About 1 visit per month, for 6 months

Icon

ClinicalTrials.gov: NCT07646847

Icon

Phase NA

304

Learning Why Some Women Develop Lymphedema After Surgery and Others Do Not

A Prospective Surveillance Program for Assessment and Treatment of Breast Cancer-Related Lymphedema After Axillary Lymph Node Dissection

Purpose: To study why some women develop lymphedema after breast cancer surgery that includes an axillary lymph node dissection (ALND).

Who is this for?: Women recently diagnosed with stage I, stage II or stage III breast cancer. You must be planning to have a breast cancer surgery at Memorial Sloan Kettering Cancer Center that includes the removal of nearby lymph nodes under the arm (ALND) View full eligibility criteria

What's involved?

<p class="seamTextPara"> Over 2 years, you will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5 arm measurements</li> <li class="seamTextUnorderedListItem">5 height and weight measurements</li> <li class="seamTextUnorderedListItem">5 quality of life questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Breast tissue taken during surgery will be studied for signs of inflammation, which may increase a woman's risk for lymphedema.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a painful swelling of the hand, wrist and/or arm that can occur after breast cancer surgery.</li> <li class="seamTextUnorderedListItem">The surgery that removes lymph nodes from your underarm area is called an axillary lymph node dissection (ALND).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02743858' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-pdq' target='_blank'>NCI: Lymphedema PDQ</a> </li></ul>
304

Learning Why Some Women Develop Lymphedema After Surgery and Others Do Not

A Prospective Surveillance Program for Assessment and Treatment of Breast Cancer-Related Lymphedema After Axillary Lymph Node Dissection
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, NJ

Icon

Visits:
5 visits, over 2 years

Icon

ClinicalTrials.gov: NCT02743858

Icon

Phase NA

305

One-Time Counseling Session to Reduce Depression, Anxiety, and Distress for Women With Stage I-III Breast Cancer

Piloting Single Session Consultation for Cancer (SSC-C) to Alleviate Distress Among Breast Cancer Patients

Purpose: To study if a single counseling session for cancer can help reduce distress and improve quality of life.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are on a waitlist of at least 2 weeks for Memorial Sloan Kettering Counseling Center intake and who live in New York, New Jersey, or Connecticut. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Booklet from the American Cancer Society called <q>After Diagnosis: A Guide for Patients and Families</q></li> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Counseling program, 1 hour, 1 time</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The counseling program in this study is designed to reduce anxiety and depression symptoms in people with cancer who are waiting to receive outpatient psychotherapy services. It is a problem-solving program that will try to strengthen a person's belief in her ability to manage the challenges of the cancer diagnosis and treatment.</li> <li class="seamTextUnorderedListItem">The Usual Care booklet includes information about cancer, living with cancer, making treatment decisions, talking to others about cancer, cancer treatment, and questions for the cancer care team.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07218250' target='_blank'>ClinicalTrials.gov</a> </li></ul>
305

One-Time Counseling Session to Reduce Depression, Anxiety, and Distress for Women With Stage I-III Breast Cancer

Piloting Single Session Consultation for Cancer (SSC-C) to Alleviate Distress Among Breast Cancer Patients
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, NJ

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT07218250

Icon

Phase NA

306

Language Translation During Appointments for People With Stage I-IV Breast Cancer

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)

Purpose: To measure 3 different ways of translating medical conversations from English to Spanish or Mandarin.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer that was diagnosed within the last 2 months and whose preferred language is Spanish or Mandarin. You must be receiving care at Memorial Sloan Kettering Cancer Center in New York City, NY. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Translation of medical conversation in real time, audio only</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Translation of medical conversation after the speaker has stopped talking, audio only</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Translation of medical conversation after the speaker has stopped talking, audio and video</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People who do not speak English well can better understand medical conversations that are conducted in or translated to their preferred language.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06721065' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.interprefy.com/resources/how-remote-simultaneous-interpretation-works#:~:text=Remote%20Simultaneous%20Interpretation%20(RSI)%20is,no%20equipment%20and%20no%20barriers.' target='_blank'>Interprefy: Remote Simultaneous Interpretation</a> </li><li class='seamTextUnorderedListItem'><a href='https://interpreter.io/Blog/understanding-consecutive-interpretation-a-simple-guide.html#:~:text=In%20consecutive%20interpretation%2C%20the%20interpreter,to%20jot%20down%20key%20points.' target='_blank'>Interpreter.io: Remote Consecutive Interpretation</a> </li></ul>
306

Language Translation During Appointments for People With Stage I-IV Breast Cancer

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, NJ

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT06721065

Icon

Phase NA

307

Antibiotic Beads During Surgery to Prevent Infection After Mastectomy for Women With Stage I-III Breast Cancer or High-Risk Women

A Randomized Controlled Trial to Determine the Efficacy of Local Antibiotic Delivery in the Prevention of Breast Tissue Expander-Associated Infections

Purpose: To study whether Stimulan Rapid Cure reduces the risk of infections and affects the risk of seroma in people receiving tissue expanders during mastectomy.

Who is this for?: Women with stage I, stage II, or stage III breast cancer, or high-risk women, who are planning to receive a mastectomy and immediate breast reconstruction that involves placement of a tissue expander at Memorial Sloan Kettering Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue expander, during surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue expander, during surgery</li> <li class="seamTextUnorderedListItem">Stimulan Rapid Cure, during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Seroma is a possible complication of surgery that involves fluid buildup under the skin.</li> <li class="seamTextUnorderedListItem">Stimulan Rapid Cure is a treatment of beads containing the antibiotics vancomycin and gentamicin.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07220967' target='_blank'>ClinicalTrials.gov</a> </li></ul>
307

Antibiotic Beads During Surgery to Prevent Infection After Mastectomy for Women With Stage I-III Breast Cancer or High-Risk Women

A Randomized Controlled Trial to Determine the Efficacy of Local Antibiotic Delivery in the Prevention of Breast Tissue Expander-Associated Infections
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT07220967

Icon

Phase IV

308

Managing Lymphedema After Lymph Node Surgery for Women with Stage I-III Breast Cancer

A Prospective Cohort Study of Patients Undergoing ALND for Treatment of Breast Cancer: The Efficacy of a Comprehensive Prevention Program in Decreasing the Incidence of Lymphedema and Improving Quality of Life

Purpose: To study the ability of a lymphedema prevention program to help lymph fluid drain out of the arm, prevent lymphedema, and improve quality of life.

Who is this for?: Women 18-75 years old with stage I, stage II, or stage III breast cancer who are planning to receive axillary lymph node dissection or sentinel lymph node biopsy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immediate lymphatic reconstruction (ILR) during lymph node surgery</li> <li class="seamTextUnorderedListItem">Lymphatic massage, at home, 3 times every week for 3 months</li> <li class="seamTextUnorderedListItem">Compression garments, daily for 3 months</li> <li class="seamTextUnorderedListItem">Arm measurements, up to 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is the build up of fluid and abnormal swelling of the arm (in the case of axillary lymph node dissection or sentinel lymph node biopsy surgery).</li> <li class="seamTextUnorderedListItem">Lymphedema is caused by damage to the lymphatic system and inability to drain excess lymph fluid.</li> <li class="seamTextUnorderedListItem">Immediate Lymphatic Reconstruction (ILR) is a procedure to rebuild damaged lymphatic system.</li> <li class="seamTextUnorderedListItem">Lymphatic massage may help reduce swelling in your body.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06144164' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/about-your-immediate-lymphatic-reconstruction-ilr-procedure#:~:text=ILR%20is%20a%20procedure%20to,your%20axillary%20lymph%20node%20dissection.' target='_blank'>Memorial Sloan Kettering Cancer Center: About Your Immediate Lymphatic Reconstruction (ILR) Procedure</a> </li></ul>
308

Managing Lymphedema After Lymph Node Surgery for Women with Stage I-III Breast Cancer

A Prospective Cohort Study of Patients Undergoing ALND for Treatment of Breast Cancer: The Efficacy of a Comprehensive Prevention Program in Decreasing the Incidence of Lymphedema and Improving Quality of Life
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06144164

Icon

Phase III

309

Surveys to Study Using Telehealth in Cancer Care for People with Stage I-IV Breast Cancer

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Purpose: To study the ability of enhanced telehealth to reduce the need to make in-person visits.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving care at Memorial Sloan Kettering Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care in-person visit(s)</li> <li class="seamTextUnorderedListItem">Surveys, 2 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enhanced telehealth visit(s)</li> <li class="seamTextUnorderedListItem">Surveys, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care.</li> <li class="seamTextUnorderedListItem">Cancer care can be easier by reducing the need to make in-person visits.</li> <li class="seamTextUnorderedListItem">This could be done using a new option called enhanced telehealth.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06954337' target='_blank'>ClinicalTrials.gov</a> </li></ul>
309

Surveys to Study Using Telehealth in Cancer Care for People with Stage I-IV Breast Cancer

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT06954337

Icon

Phase NA

310

Mastectomy With or Without Gabapentin for Stage I-III Breast Cancer

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol

Purpose: To study whether gabapentin (Neurontin®) should be a standard part of mastectomy pain control.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive a mastectomy at the Josie Robertson Surgical Center (New York or New Jersey). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gabapentin (Neurontin®) before surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No gabapentin (Neurontin®) before surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gabapentin (Neurontin®) is used to treat nerve pain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07308717' target='_blank'>ClinicalTrials.gov</a> </li></ul>
310

Mastectomy With or Without Gabapentin for Stage I-III Breast Cancer

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT07308717

Icon

Phase IV

311

Managing High Blood Pressure During Treatment for Women with Stage I-IV Breast Cancer

Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT), A Randomized Controlled Trial

Purpose: To compare the safety and effects (good and bad) of 2 methods of managing high blood pressure during breast cancer treatment.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer and high blood pressure who are planning to receive chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard doses of high blood pressure medication</li> <li class="seamTextUnorderedListItem">Dietary and lifestyle changes</li> <li class="seamTextUnorderedListItem">Echocardiograms, 3 times</li> <li class="seamTextUnorderedListItem">Exercise tests, 3 times</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Higher doses of high blood pressure medication</li> <li class="seamTextUnorderedListItem">Dietary and lifestyle changes</li> <li class="seamTextUnorderedListItem">Echocardiograms, 3 times</li> <li class="seamTextUnorderedListItem">Exercise tests, 3 times</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, such as high blood pressure, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">Dietary changes include limiting salt intake.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06023576' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/side-effects/heart-health' target='_blank'>Living Beyond Breast Cancer: Heart Health</a> </li></ul>
311

Managing High Blood Pressure During Treatment for Women with Stage I-IV Breast Cancer

Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT), A Randomized Controlled Trial
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
4 visits within 1 year

Icon

ClinicalTrials.gov: NCT06023576

Icon

Phase II

312

Exercise During Chemotherapy for People with Stage I-III Breast Cancer

Phase 2 Trial of Adaptive Versus Standard Dosing of Aerobic Training in Patients Receiving Chemotherapy for Primary Breast Cance

Purpose: To study how 2 types of walking aerobic training affect cardiorespiratory fitness.

Who is this for?: Women with newly diagnosed stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. You must not be performing more than 1.5 hours of exercise per week. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Adaptive Aerobic Training</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking aerobic training, 1.5-5 hours per week for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard (Fixed) Aerobic Training</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking aerobic training, 1.5 hours per week for 1 year</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardiorespiratory fitness (CRF) is the ability of your heart and lungs to deliver oxygen to your body’s muscles and organs during physical activity.</li> <li class="seamTextUnorderedListItem">Aerobic exercise refers to cardiovascular exercise, which includes activities such as walking, running, biking, and swimming.</li> <li class="seamTextUnorderedListItem">Adaptive aerobic training consists of changing the amount of exercise depending on your response.</li> <li class="seamTextUnorderedListItem">Standard (fixed) aerobic training consists of a fixed, constant amount of exercise.</li> <li class="seamTextUnorderedListItem">Some of your walking will be supervised remotely (online).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05716893' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/exercise-during-after-cancer-treatment-level-1' target='_blank'>Memorial Sloan Kettering Cancer Center: Exercise During and After Cancer Treatment</a> </li></ul>
312

Exercise During Chemotherapy for People with Stage I-III Breast Cancer

Phase 2 Trial of Adaptive Versus Standard Dosing of Aerobic Training in Patients Receiving Chemotherapy for Primary Breast Cance
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05716893

Icon

Phase II

313

Studying Bone Changes in Post-Menopausal Women with Stage I-IV Breast Cancer After Treatment with Aromatase Inhibitor and Denosumab

Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation

Purpose: To gather information about changes in the bones after stopping treatment with an aromatase inhibitor and denosumab (Xgeva®).

Who is this for?: Postmenopausal women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have completed treatment with an aromatase Inhibitor before or within 6 months of completing at least 2 doses of denosumab (Xgeva®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical exam, 5 visits within 2 years</li> <li class="seamTextUnorderedListItem">DEXA scan, 2 times within 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The physical exam will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work.</li> <li class="seamTextUnorderedListItem">Dual-energy X-ray absorptiometry (DEXA) scans use x-ray energy to measure bone density (thickness and strength of bones).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05590949' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/radiation-health/data-research/facts-stats/dexa-scan.html' target='_blank'>CDC: DEXA Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a610023.html' target='_blank'>MedlinePlus: Denosumab (Xgeva®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li></ul>
313

Studying Bone Changes in Post-Menopausal Women with Stage I-IV Breast Cancer After Treatment with Aromatase Inhibitor and Denosumab

Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
5 visits

Icon

ClinicalTrials.gov: NCT05590949

Icon

Phase NA

314

Changes in Thinking and Memory Over Time for Women with Stage I-III Breast Cancer After Treatment

Cognitive Aging in Older Long-term Breast Cancer Survivors (TRAC)

Purpose: To study how differences in mental function develop over time in breast cancer survivors compared to people without a history of cancer.

Who is this for?: Women 65-80 years old with stage I, stage II, or stage III breast cancer who were diagnosed between 55-60 years old (5-25 years ago) and have completed treatment, and people who do not have a history of breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online surveys</li> <li class="seamTextUnorderedListItem">Saliva (spit) sample, by mail</li> <li class="seamTextUnorderedListItem">Urine sample</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Problems with thinking such as problems with memory, attention, and information processing may occur in people who were previously treated for breast cancer compared to those without a history of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06334354' target='_blank'>ClinicalTrials.gov</a> </li></ul>
314

Changes in Thinking and Memory Over Time for Women with Stage I-III Breast Cancer After Treatment

Cognitive Aging in Older Long-term Breast Cancer Survivors (TRAC)
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06334354

Icon

Phase NA

315

Radiation Before Mastectomy with Immediate Reconstruction for Stage III Breast Cancer

Feasibility of Preoperative Radiotherapy in T4 Breast Cancer Patients Who Are Responders to Neoadjuvant Chemotherapy to Allow for Immediate Reconstruction: A Prospective Study

Purpose: To study the safety and effects (good and bad) of an alternative treatment approach: radiation followed by mastectomy with immediate reconstruction.

Who is this for?: Women with advanced (some stage III) breast cancer who have responded to neoadjuvant (before surgery) chemotherapy and are planning to undergo mastectomy with immediate reconstruction. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Biopsy</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation</li> </ul> <p class="seamTextPara"> followed 2-6 weeks later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Total mastectomy with immediate autologous reconstruction</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies. </li> <li class="seamTextUnorderedListItem">Mastectomy is a type of surgery to remove the entire breast.</li> <li class="seamTextUnorderedListItem">Immediate autologous reconstruction is breast reconstruction surgery immediately following your mastectomy. The surgeon will take tissue from another part of your body and use it to re-create your breast.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy. The MRI scan will help guide your biopsy before radiation and surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05412225' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation-therapy' target='_blank'>Breastcancer.org: Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/mastectomy' target='_blank'>Breastcancer.org: Mastectomy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/autologous-flap' target='_blank'>Breastcancer.org: Immediate Autologous Reconstruction</a> </li></ul>
315

Radiation Before Mastectomy with Immediate Reconstruction for Stage III Breast Cancer

Feasibility of Preoperative Radiotherapy in T4 Breast Cancer Patients Who Are Responders to Neoadjuvant Chemotherapy to Allow for Immediate Reconstruction: A Prospective Study
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
May require hospitalization

Icon

ClinicalTrials.gov: NCT05412225

Icon

Phase I

316

Dose Selection of Capecitabine or 5-Fluorouracil According to Genetic Testing for the DYPD Gene for Stage I-IV Breast Cancer

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Purpose: To study the safety and effects (good and bad) of 5-fluorouracil (5-FU) or capecitabine (Xeloda®) chemotherapy when the dose is selected based on testing of the DPYD gene.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive 5-fluorouracil (5-FU) or capecitabine (Xeloda®). You must have received DPYD genetic testing. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups, depending on your DPYD genetic testing results: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Normal DPYD Gene</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-fluorouracil (5-FU), by injection, standard dose OR </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by injection, standard dose</li> <li class="seamTextUnorderedListItem">Dose will be reduced if needed</li> <li class="seamTextUnorderedListItem">Dose may be increased if tolerated</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: DPYD Gene Variant</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-fluorouracil (5-FU), by injection, half the standard dose OR </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by injection, half the standard dose</li> <li class="seamTextUnorderedListItem">Dose may be increased if tolerated</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">5-Fluorouracil (5-FU) and capecitabine (Xeloda®) are chemotherapy drugs commonly used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">People can respond differently to these drugs due to genetic variations. The FDA now recommends testing for these genetic variants.</li> <li class="seamTextUnorderedListItem">This trial will test dosing of these drugs guided by genetic testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07158164' target='_blank'>ClinicalTrials.gov</a> </li></ul>
316

Dose Selection of Capecitabine or 5-Fluorouracil According to Genetic Testing for the DYPD Gene for Stage I-IV Breast Cancer

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Icon

Nearest Location from 94107:
2541 miles
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, NJ

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07158164

Icon

Phase IV

317

Imaging Scans Before and During Surgery for Women with Stage 0-III Breast Cancer

Phase I/IIa Study of Pre-operative Multiparametric MRI and pHLIP® ICG Intra-operative Fluorescence Imaging of Primary Breast Cancer

Purpose: To study whether enhanced MRI scans before surgery and near infrared fluorescent (NIRF) imaging scans during surgery are safe and improve surgery outcomes.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who are planning to receive a lumpectomy. You must not have received treatment before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 1-3 weeks before surgery</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">pHLIP ICG tracer, by IV, at least 1 time before surgery</li> <li class="seamTextUnorderedListItem">NIRF imaging scan, during surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">An enhanced MRI scan before surgery may provide better information about the tumor and improve outcomes.</li> <li class="seamTextUnorderedListItem">A near infrared fluorescent (NIRF) imaging scan is a new type of imaging scan used to produce body pictures using infrared light.</li> <li class="seamTextUnorderedListItem">pHLIP ICG is an experimental tracer for NIRF imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">Near infrared fluorescent (NIRF) imaging scans during surgery may allow the surgeon to see the cancer cells more clearly and remove them completely.</li> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05130801' target='_blank'>ClinicalTrials.gov</a> </li></ul>
317

Imaging Scans Before and During Surgery for Women with Stage 0-III Breast Cancer

Phase I/IIa Study of Pre-operative Multiparametric MRI and pHLIP® ICG Intra-operative Fluorescence Imaging of Primary Breast Cancer
Icon

Nearest Location from 94107:
2561 miles
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, NJ

Icon

Visits:
At least 4 visits within 1-2 months

Icon

ClinicalTrials.gov: NCT05130801

Icon

Phase I-II

318

Aerobic Exercise to Improve Cardiovascular Health in Post-Menopausal Women After Breast Cancer Treatment

A Randomized Trial to Minimize Non-Response to Aerobic Training in Post-Menopausal Women With Early Stage Breast Cancer

Purpose: To study how different amounts of aerobic exercise improves cardiovascular health after breast cancer treatment.

Who is this for?: Postmenopausal women with stage I, stage II, or stage III breast cancer who have completed treatment with surgery and radiation, chemotherapy, or trastuzumab (Herceptin®) within the past 1-5 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised aerobic exercise, 5 hours/week for 4 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised aerobic exercise, 2.5 hours/week for 8 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised aerobic exercise, 5 hours/week for 8 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised aerobic exercise, 2.5 hours/week for 4 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aerobic exercise is physical activity of light-to-moderate intensity that uses the large muscle groups (muscles in your legs, buttocks, back, and chest) and can be performed for at least 10 minutes.</li> <li class="seamTextUnorderedListItem">The researchers will study the effects of different exercise programs on your cardiovascular health, which is how well your body uses oxygen, how well your heart pumps blood, how well your lungs function, and how healthy your blood vessels are.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04458532' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/exercise' target='_blank'>Breastcancer.org: Exercise</a> </li></ul>
318

Aerobic Exercise to Improve Cardiovascular Health in Post-Menopausal Women After Breast Cancer Treatment

A Randomized Trial to Minimize Non-Response to Aerobic Training in Post-Menopausal Women With Early Stage Breast Cancer
Icon

Nearest Location from 94107:
2567 miles
Memorial Sloan Kettering Cancer Center
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04458532

Icon

Phase NA

319

Improving Mental Health for Older Adults with Breast Cancer

Mental Health Care Initiation Intervention for Older Adults With Cancer

Purpose: To study the ability of the Open Door for Cancer (OD-C) approach to improve mental health for older adults with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who were diagnosed at age 65 or older and are currently receiving treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Open Door for Cancer (OD-C) approach, by phone or videoconference, 3 sessions within 1.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mental health screening</li> <li class="seamTextUnorderedListItem">Referrals to support resources</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Open Door for Cancer (OD-C) approach includes the following: 1) Provide education about depression and treatment options; 2) Identify treatment preferences and a personal goal achievable with mental health care; 3) Assess barriers to starting treatment; 4) Referrals to additional support; 5) Address barriers to accessing care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06037954' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/taking-care-of-mental-health/how-breast-cancer-affects-mental-health' target='_blank'>Breastcancer.org: How Breast Cancer Can Affect Mental Health</a> </li></ul>
319

Improving Mental Health for Older Adults with Breast Cancer

Mental Health Care Initiation Intervention for Older Adults With Cancer
Icon

Nearest Location from 94107:
2567 miles
Memorial Sloan Kettering Cancer Center
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06037954

Icon

Phase NA

320

A Counseling Study (Meaning Centered Psychotherapy) for Latinos with Advanced Breast Cancer

Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer

Purpose: To study the effects (good and bad) of whether Meaning Centered Psychotherapy for Latinos (MCP-L), a structured form of counseling adapted into Spanish, helps lower anxiety and depression and improves quality of life for people living with advanced cancer, compared with cognitive behavioral therapy (CBT).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. You must be 18 or older and able to read and communicate in Spanish. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"> Meaning Centered Psychotherapy for Latinos (MCP-L), given as one on one counseling sessions, each about 60 minutes, weekly or spaced out based on your preference</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive behavioral therapy (CBT)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Living with advanced cancer can bring anxiety, depression, and questions about meaning and purpose.</li> <li class="seamTextUnorderedListItem">This study looks at Meaning Centered Psychotherapy for Latinos (MCP-L), a counseling program that has been culturally adapted into Spanish.</li> <li class="seamTextUnorderedListItem">The study compares MCP-L with cognitive behavioral therapy (CBT), a widely used talk therapy, to see which better reduces anxiety and depression and improves quality of life.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07225309' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/taking-care-of-mental-health/types-of-support/cognitive-behavioral-therapy' target='_blank'>Living Beyond Breast Cancer: Cognitive Behavioral Therapy (CBT) for Breast Cancer</a> </li></ul>
320

A Counseling Study (Meaning Centered Psychotherapy) for Latinos with Advanced Breast Cancer

Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer
Icon

Nearest Location from 94107:
2567 miles
Memorial Sloan Kettering Cancer Center
New York, NY

Icon

Visits:
About 7 sessions over up to 3 months

Icon

ClinicalTrials.gov: NCT07225309

Icon

Phase NA

321

Personalized Breast Holder to Improve Comfort during Radiation in Women With Stage 0-2 Breast Cancer

Accelerated Partial Breast Radiotherapy Study of a Personalized Holder for Prone Breast Immobilization to Enhance Local Delivery

Purpose: To find out whether a personalized, custom made breast holder called VENUS SHELL is safe and whether it helps position the breast more accurately and comfortably during radiation given while lying face down (prone).

Who is this for?: Women with stage 0 (DCIS), stage I, or stage II breast cancer who have already had breast conserving surgery (lumpectomy) and are planning to receive radiation within 3 months after surgery. You must be 40 or older and have no known BRCA1 or BRCA2 gene mutation. You must be receiving care at NYU Langone Health in New York. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized breast holder called VENUS SHELL during your radiation </li> <li class="seamTextUnorderedListItem">Attend a study visit before radiation to have a breast surface scan (no radiation), which is used to make your personalized VENUS SHELL holder</li> <li class="seamTextUnorderedListItem">Use your VENUS SHELL during radiation planning and during treatment</li> <li class="seamTextUnorderedListItem">Complete questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">During radiation, you lie on your stomach so the breast hangs down and away from the chest, heart, and lungs. </li> <li class="seamTextUnorderedListItem">The VENUS SHELL is molded to fit your own breast so it stays still and in the same position at each session. </li> <li class="seamTextUnorderedListItem">The device is being studied to see if it can make positioning more accurate, make treatment more comfortable, and help deliver partial breast radiation more quickly.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07711847' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/types/breast-cancer/treatment/radiation-for-breast-cancer.html' target='_blank'>American Cancer Society: Radiation Therapy</a> </li></ul>
321

Personalized Breast Holder to Improve Comfort during Radiation in Women With Stage 0-2 Breast Cancer

Accelerated Partial Breast Radiotherapy Study of a Personalized Holder for Prone Breast Immobilization to Enhance Local Delivery
Icon

Nearest Location from 94107:
2568 miles
NYU Grossman School of Medicine
New York, NY

Icon

Visits:
Coincides with routine radiation care. Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07711847

Icon

Phase NA

322

Partial Breast Radiation After Lumpectomy Without Lymph Node Surgery for Women with Breast Cancer

RADIation After no Axillary Nodal Sampling (RADIANS)

Purpose: To study the safety and effects (good and bad) of giving partial breast radiation to people who have breast conserving surgery (lumpectomy) but do not have their underarm lymph nodes checked or removed. Partial breast radiation targets only the part of the breast where the cancer was, rather than treating the whole breast. This study looks at whether skipping lymph node surgery in this group is safe over time.

Who is this for?: Women with stage I or stage II or some stage III with no signs that the cancer has spread to the lymph nodes based on exam and imaging. You must be planning to have breast conserving surgery (lumpectomy) without a sentinel lymph node biopsy or an axillary lymph node dissection. You must be receiving care at NYU Langone Health in New York. View full eligibility criteria

What's involved?

<p class="seamTextPara"> After your lumpectomy, you will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Partial breast radiation</li> <li class="seamTextUnorderedListItem">Underarm (axillary) ultrasound before radiation begins </li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study looks at partial breast radiation, a type of radiation therapy that treats only the part of the breast where the cancer was found instead of the whole breast. </li> <li class="seamTextUnorderedListItem">Normally, people with this type of breast cancer have their underarm lymph nodes checked or removed during surgery to see if the cancer has spread. This study is testing whether it is safe to skip that lymph node surgery in women whose cancer appears to be early and has not spread, based on exam and imaging.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07723209' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/lymph-node-removal/sentinel-node-dissection' target='_blank'>Breastcancer.org: Sentinel Lymph Node Biopsy</a> </li></ul>
322

Partial Breast Radiation After Lumpectomy Without Lymph Node Surgery for Women with Breast Cancer

RADIation After no Axillary Nodal Sampling (RADIANS)
Icon

Nearest Location from 94107:
2568 miles
NYU Langone Health
New York, NY

Icon

Visits:
Number of visits unavailable, up to 2 years

Icon

ClinicalTrials.gov: NCT07723209

Icon

Phase NA

323

Elacestrant, Trastuzumab, and Pertuzumab for Advanced Triple Positive Breast Cancer

Elacestrant in Advanced Triple Positive Breast Cancer, a Phase II Evaluation (ELATE)

Purpose: To study the safety, effects (good and bad) of elacestrant (Orserdu®) combined with trastuzumab (Herceptin®) and pertuzumab (Perjeta®)in triple-positive breast cancer.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) triple-positive breast cancer (hormone receptor-positive (ER+ and PR+) , and HER2 positive (HER2+)) whose cancer has progressed after at least one prior line of standard treatment. This trial is enrolling people both with and without an ESR1 mutation. You must not have received a SERD before, and up to two prior lines of chemotherapy for metastatic disease are allowed. You must be receiving care at NYU Langone Health in New York, NY. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be placed in 1 of 2 groups based on whether your cancer has an ESR1 mutation. Everyone receives the same three treatments: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth, once daily</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant is a selective estrogen receptor degrader (SERD), a type of hormone therapy that attaches to and breaks down the estrogen receptor to help slow or stop cancer growth. </li> <li class="seamTextUnorderedListItem">Trastuzumab and pertuzumab are HER2 targeted therapies that work together to block the HER2 protein, which helps some breast cancer cells grow and divide.</li> <li class="seamTextUnorderedListItem">This trial aims to find out whether combining these treatments helps control triple-positive breast cancer that has progressed after treatment, including in cancers with an ESR1 mutation.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07612215' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/blog/good-news-for-hormone-receptor-positive-breast-cancer/' target='_blank'>Breast Cancer Research Foundation: Good News for Hormone Receptor-Positive Breast Cancer: What to Know</a> </li></ul>
323

Elacestrant, Trastuzumab, and Pertuzumab for Advanced Triple Positive Breast Cancer

Elacestrant in Advanced Triple Positive Breast Cancer, a Phase II Evaluation (ELATE)
Icon

Nearest Location from 94107:
2568 miles
NYU Langone Health
New York, NY

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT07612215

Icon

Phase I-II

324

Radiotherapy Delivered Over 1 Week Compared to 2 Weeks for Women With Stage 0-II Breast Cancer

Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of radiation delivered over 1 week compared to 2 weeks.

Who is this for?: Women with stage 0 (DCIS), stage I, or stage II breast cancer who have received a mastectomy and are planning to receive radiation. You must not have cancer in your lymph nodes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, daily for 5 days</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation, daily for 10 days</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06960707' target='_blank'>ClinicalTrials.gov</a> </li></ul>
324

Radiotherapy Delivered Over 1 Week Compared to 2 Weeks for Women With Stage 0-II Breast Cancer

Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)
Icon

Nearest Location from 94107:
2569 miles
Brooklyn Methodist Hospital
New York, NY

Icon

Visits:
5 visits within 1 week or 10 within 2 weeks

Icon

ClinicalTrials.gov: NCT06960707

Icon

Phase III

325

Tirzepatide (GLP1 Medication) for Postmenopausal Women with a History of Hormone Receptor Positive Breast Cancer and Obesity

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Purpose: To study the safety and effects (good and bad) of tirzepatide, a medication that activates two natural hormone receptors, GLP1 and GIP, which help control appetite, blood sugar, and insulin levels.

Who is this for?: Postmenopausal women with a history of stage 0, stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer, who have completed curative treatment, such as surgery, chemotherapy, or radiation, at least 3 months ago. You must also have a body mass index (BMI) of 30 or higher, or 27.5 or higher if you are of Asian ancestry. You must not currently be taking a CDK4/6 inhibitor or anti-HER2 therapy, and you must not have taken another GLP1 medication within the last 3 months. You must be able to receive care at Weill Cornell Medicine in New York, NY. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tirzepatide by injection, once a week, for about 6 months</li> <li class="seamTextUnorderedListItem">Body composition scans, blood tests, and a stool sample </li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying tirzepatide, a medication already approved for weight management and type 2 diabetes.</li> <li class="seamTextUnorderedListItem">Tirzepatide works by activating GLP1 and GIP, two hormone receptors that help control appetite, blood sugar, and insulin. </li> <li class="seamTextUnorderedListItem">Carrying extra weight after breast cancer treatment has been linked to poorer long term health, and therefore researchers want to see if tirzepatide is a practical option for postmenopausal breast cancer survivors with obesity.</li> <li class="seamTextUnorderedListItem">Researchers want to learn whether it can help improve weight, body fat, blood sugar, insulin, and other markers of metabolic health.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07257484' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/news/GLP-1s-research-SABCS' target='_blank'>Breastcancer.org: 5 New Findings About GLP-1s and Breast Cancer</a> </li></ul>
325

Tirzepatide (GLP1 Medication) for Postmenopausal Women with a History of Hormone Receptor Positive Breast Cancer and Obesity

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Icon

Nearest Location from 94107:
2569 miles
Weill Cornell Medicine
New York, NY

Icon

Visits:
About 1 visit per month for 6 months

Icon

ClinicalTrials.gov: NCT07257484

Icon

Phase IV

326

Video or Brochure to Educate Non-English Speaking Latinx Women with Breast Cancer About Radiation Therapy and Cancer Clinical Trials

Audiovisual Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology

Purpose: To develop educational materials to prepare Latinx Spanish-speaking people for radiation therapy and to improve understanding about participating in cancer clinical trials.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are Spanish speakers of Latinx background (from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry) and who are planning to receive radiation therapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to Group 1 or 2: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a video with educational information about radiation therapy.</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a brochure with written information about radiation therapy.</li> </ul> <p class="seamTextPara"> You will also be randomly assigned to Group 3 or 4: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch a video with educational information about cancer clinical trials.</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a brochure with written information about cancer clinical trials.</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low understanding of health information and language barriers can lead to low trial enrollment in minority and/or non-English speakers and produce trial results that don't reflect this population.</li> <li class="seamTextUnorderedListItem">Culturally appropriate audiovisual materials may improve knowledge about radiotherapy and increase chances of completing treatment, as well as improve knowledge about clinical trials and increase enrollment in Latinx/Spanish-speaking people.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05351424' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astro.org/Patient-Care-and-Research/Provider-Resources/Patient-Brochures' target='_blank'>American Society for Radiation Oncology: Patient Brochures</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/patient-education/cancer-treatment-research-studies' target='_blank'>National Cancer Institute: Taking Part in Cancer Research Studies</a> </li></ul>
326

Video or Brochure to Educate Non-English Speaking Latinx Women with Breast Cancer About Radiation Therapy and Cancer Clinical Trials

Audiovisual Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology
Icon

Nearest Location from 94107:
2569 miles
Columbia University Irving Medical Center
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05351424

Icon

Phase NA

327

Thermal Treatment for Stage I Breast Cancer and Benign Breast Tumors

Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)

Purpose: To study the effects of harmonic motion imaging (HMI) and focused ultrasound (FUS) ablation before surgery (neoadjuvant).

Who is this for?: Women with a benign breast tumor or some stage I breast cancer who have not yet received surgery or radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Harmonic motion imaging (HMI) scan, 2 times</li> <li class="seamTextUnorderedListItem">Focus ultrasound (FUS) ablation of tumor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Harmonic motion imaging (HMI) is a type of scan that can look for changes in tissue before and after focused ultrasound (FUS) ablation.</li> <li class="seamTextUnorderedListItem">Focused ultrasound (FUS) ablation applies high-intensity focused ultrasound waves to a tumor, which ablates (heats) the tumor tissue to kill cancer cells.</li> <li class="seamTextUnorderedListItem">The main advantage of focused ultrasound (FUS) ablation is that it avoids surgery. Without surgery, recovery from the procedure is faster with less pain, and cosmetological results may be improved.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li> <li class="seamTextUnorderedListItem">The two most common types of benign breast lumps are cysts and fibroadenomas.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05219695' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ueil.bme.columbia.edu/research-projects/harmonic-motion-imaging' target='_blank'>Columbia University: Harmonic Motion Imaging</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/other/high-intensity-focused-ultrasound-hifu' target='_blank'>Cancer Research UK: High-Intensity Focused Ultrasound</a> </li></ul>
327

Thermal Treatment for Stage I Breast Cancer and Benign Breast Tumors

Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
Icon

Nearest Location from 94107:
2569 miles
Columbia University Irving Medical Center/NYP
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05219695

Icon

Phase I

328

Pain Medication Dispensing Device for People with Stage I-IV Breast Cancer Planning to Receive Surgery

Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills After Cancer-Related Surgery

Purpose: To study the ability of Addinex (ADX-27) pill dispensing system to safely store and dispense pain medication.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Addinex (ADX-27) pill dispensing system with mobile app, 3 months</li> <li class="seamTextUnorderedListItem">Phone interview, 1 time</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Addinex (ADX-27) is a password protected pill dispensing system. It allows for the return and disposal of unused opioids.</li> <li class="seamTextUnorderedListItem">Opioids are pain medications often given after surgery.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05585788' target='_blank'>ClinicalTrials.gov</a> </li></ul>
328

Pain Medication Dispensing Device for People with Stage I-IV Breast Cancer Planning to Receive Surgery

Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills After Cancer-Related Surgery
Icon

Nearest Location from 94107:
2569 miles
Columbia University Medical Center
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05585788

Icon

Phase NA

329

Ultrasound Scan to Predict Response to Chemotherapy Before Surgery for Women with Stage I-III Breast Cancer

Predicting Response to Neoadjuvant Chemotherapy Using Harmonic Motion Imaging in Women With Breast Cancer

Purpose: To study the use of harmonic motion imaging (HMI) ultrasound scans to predict response to chemotherapy before surgery (neoadjuvant).

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Harmonic motion imaging (HMI) ultrasound scan, 3 times within 7 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Being able to predict a lack of response to chemotherapy before surgery (neoadjuvant) could allow doctors to stop ineffective treatment and start a new treatment to achieve better tumor response and overall survival.</li> <li class="seamTextUnorderedListItem">Harmonic motion imaging (HMI) is a new non-invasive ultrasound scan.</li> <li class="seamTextUnorderedListItem">Ultrasound scans use sound waves to produce images of structures within your body.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04824027' target='_blank'>ClinicalTrials.gov</a> </li></ul>
329

Ultrasound Scan to Predict Response to Chemotherapy Before Surgery for Women with Stage I-III Breast Cancer

Predicting Response to Neoadjuvant Chemotherapy Using Harmonic Motion Imaging in Women With Breast Cancer
Icon

Nearest Location from 94107:
2569 miles
Columbia University Irving Medical Center/NYP
New York, NY

Icon

Visits:
3 visits within 7 months

Icon

ClinicalTrials.gov: NCT04824027

Icon

Phase NA

330

Leflunomide for Advanced HER2 Negative and/or PTEN Mutated Breast Cancer

A Phase IA/IB Trial of Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of leflunomide, an experimental drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) and/or PTEN mutated breast cancer who have no standard treatment options available. If you have HER2- breast cancer, you must not have received more than 3 lines of chemotherapy and 2 lines of antibody drug conjugates (ADC) for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leflunomide, by mouth, daily</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leflunomide is an drug drug that is FDA approved for some types of arthritis.</li> <li class="seamTextUnorderedListItem">Leflunomide may also work for cancer. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04997993' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/leflunomide-oral-route/description/drg-20067158' target='_blank'>Mayo Clinic: Leflunomide</a> </li></ul>
330

Leflunomide for Advanced HER2 Negative and/or PTEN Mutated Breast Cancer

A Phase IA/IB Trial of Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Icon

Nearest Location from 94107:
2569 miles
Icahn School of Medicine at Mount Sinai
New York, NY

Icon

Visits:
3 visits in 1 month, then 1 visit every month

Icon

ClinicalTrials.gov: NCT04997993

Icon

Phase I

331

Brodalumab to Manage Immunotherapy Side Effects for People with Advanced Breast Cancer

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: a Pilot Study

Purpose: To study the safety and ability of brodalumab to manage side effects from immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who are experiencing side effects from immunotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brodalumab, by injection, weekly for 3 weeks, then every 2 weeks for 5.5 months</li> <li class="seamTextUnorderedListItem">Steroids (if needed)</li> <li class="seamTextUnorderedListItem">CT scan, 3 times within 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer immunotherapy can cause side effects.</li> <li class="seamTextUnorderedListItem">Side effects from immunotherapy can be similar to symptoms of autoimmune conditions.</li> <li class="seamTextUnorderedListItem">Brodalumab is FDA approved to treat people with autoimmune diseases (diseases where the immune system is activated against normal organs), and safe doses and treatment schedules have been determined in these people.</li> <li class="seamTextUnorderedListItem">Therefore, this trial will study the use of brodalumab to manage immunotherapy side effects.</li> <li class="seamTextUnorderedListItem">In this trial, the use of brodalumab is considered experimental.</li> <li class="seamTextUnorderedListItem">In this trial, visits will be a combination of in-person and virtual.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06673329' target='_blank'>ClinicalTrials.gov</a> </li></ul>
331

Brodalumab to Manage Immunotherapy Side Effects for People with Advanced Breast Cancer

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: a Pilot Study
Icon

Nearest Location from 94107:
2569 miles
Columbia University Irving Medical Center
New York, NY

Icon

Visits:
1 visit every 1-2 weeks for 6 months

Icon

ClinicalTrials.gov: NCT06673329

Icon

Phase I

332

Developing Genetic Testing Education for Diverse Groups of People with Breast Cancer

Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients

Purpose: To develop educational materials about genetic testing for people that speak different languages and have diverse cultural backgrounds.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing is a type of test that detects changes to the genes, the DNA instructions that are passed on from the mother and father.</li> <li class="seamTextUnorderedListItem">The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder.</li> <li class="seamTextUnorderedListItem">The information gathered from your interview will be used to develop educational materials about genetic testing.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04751435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease Control and Prevention: Genetic Testing</a> </li></ul>
332

Developing Genetic Testing Education for Diverse Groups of People with Breast Cancer

Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients
Icon

Nearest Location from 94107:
2570 miles
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04751435

Icon

Phase NA

333

Desloratadine to Prevent Peripheral Neuropathy in People with Breast Cancer

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)

Purpose: This trial is looking at whether desloratadine, a common allergy medication (antihistamine), can help prevent or lessen nerve damage caused by taxane chemotherapy. This nerve damage, called peripheral neuropathy, can cause numbness, tingling, or pain in the hands and feet.

Who is this for?: People with stage I, stage II, or stage III breast cancer, who are planning to receive taxane-based chemotherapy (such as paclitaxel or docetaxel) for at least 12 weeks, either before or after surgery. You must not have already received chemotherapy for this breast cancer diagnosis, and you must not currently have peripheral neuropathy (numbness, tingling, or nerve pain). This trial is currently only open at one location, in the Bronx, NY. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Desloratadine, by mouth, every other day, for 12 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo (inactive pill), by mouth, daily, for 12 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 80% of people with cancer receive some chemotherapy drugs called taxanes experience neuropathy. Taxanes are paclitaxel (Taxol®) and docetaxel (Taxotere®).</li> <li class="seamTextUnorderedListItem">Neuropathy is pain in your hands and feet from nerve damage as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Desloratadine is an antihistamine, a type of drug normally used for allergies. It works by blocking histamine receptors, which researchers believe may help calm the inflammation that contributes to nerve damage during chemotherapy. </li> <li class="seamTextUnorderedListItem">Researchers will also look at whether desloratadine changes certain inflammation markers and gut bacteria that may be linked to nerve damage.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07109817' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/neuropathy' target='_blank'>Breastcancer.org: Peripheral Neuropathy</a> </li></ul>
333

Desloratadine to Prevent Peripheral Neuropathy in People with Breast Cancer

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)
Icon

Nearest Location from 94107:
2572 miles
Montefiore Medical Center
The Bronx, NY

Icon

Visits:
Coincides with routine chemotherapy care

Icon

ClinicalTrials.gov: NCT07109817

Icon

Phase II

334

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Global Cardio Oncology Registry

Purpose: To collect information on the diagnosis and treatment of cardiovascular health and risk factors in people with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of health information</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">This study uses clinical, laboratory, imaging, demographic, and socioeconomic information to study cardiovascular (heart and blood vessels) health and risk factors before, during, or after cancer treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05598879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.heart.org/en/news/2020/02/19/what-women-need-to-know-about-breast-cancer-and-heart-disease' target='_blank'>American Heart Association: Breast Cancer and Heart Disease</a> </li></ul>
334

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Global Cardio Oncology Registry
Icon

Nearest Location from 94107:
2573 miles
Cleveland Clinic Florida
Weston, FL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05598879

Icon

Phase NA

335

Reiki Before Surgery for Women with Stage 0-III Breast Cancer Who Live in Bronx County, NY

Pilot Study of Medical Reiki for Women Undergoing Surgery for Breast Cancer: Impact on Quality of Life, Medical Recovery Metrics, and Cortisol

Purpose: To study the impact of reiki before surgery on surgery recovery, quality of life, and stress.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who are planning to receive a mastectomy. You must live in Bronx County, New York. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Reiki, before surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for reiki, before surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Reiki is a form of energy therapy involving light touch. It is a process of targeting the energy fields around the patient's body and is believed to stimulate the patient's natural ability to heal itself.</li> <li class="seamTextUnorderedListItem">Reiki is a safe treatment that emphasizes spirituality in healing and wellness whose origins are rooted in ancient Tibetan traditions.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06524895' target='_blank'>ClinicalTrials.gov</a> </li></ul>
335

Reiki Before Surgery for Women with Stage 0-III Breast Cancer Who Live in Bronx County, NY

Pilot Study of Medical Reiki for Women Undergoing Surgery for Breast Cancer: Impact on Quality of Life, Medical Recovery Metrics, and Cortisol
Icon

Nearest Location from 94107:
2574 miles
Montefiore Medical Center
The Bronx, NY

Icon

Visits:
Coincides with surgery

Icon

ClinicalTrials.gov: NCT06524895

Icon

Phase NA

336

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer

Purpose: To study the ability of TMEM-MRI, an experimental type of MRI scan, to detect breast cancer cells.

Who is this for?: People with a breast mass that is suspected to be breast cancer, or people with stage I, stage II, or some stage III breast cancer who have not yet received treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TMEM-MRI scan, 1 time</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Biopsy (if you have not yet received one)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Tumor Microenvironment of Metastasis - Magnetic Resonance Imaging (TMEM-MRI) scans are an experimental type of MRI scan that can detect tumor areas that are more likely to travel to other sites in the body.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may be useful to identify tumors with a higher chance of coming back (recurrence) after treatment.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may also be useful for studying the response to neoadjuvant (before surgery) treatment such as chemotherapy and hormone therapy.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03694756' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>
336

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer
Icon

Nearest Location from 94107:
2574 miles
Montefiore Medical Center
The Bronx, NY

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT03694756

Icon

Phase NA

337

Improving Scalp Cooling and Reducing Hair Loss During Chemotherapy for Stage I-III Breast Cancer

Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color: A Clinical and Mechanistic Study

Purpose: To determine if hairstyles can improve the ability of a scalp cooling cap to decrease hair loss.

Who is this for?: People with stage I, stage II, or stage III breast cancer with type 3 (curly) or type 4 (kinky-curly) hair who are planning to receive paclitaxel (Taxol®) or docetaxel (Taxotere®) chemotherapy. You must not have received or be planning to receive doxorubicin (Doxil®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Scalp Cooling with Hairstyles</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear scalp cooling cap with braids, twists, or cornrows</li> <li class="seamTextUnorderedListItem">Hair samples and examinations</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Scalp Cooling with Water and Conditioner</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear scalp cooling cap with water and conditioner on the hair and scalp</li> <li class="seamTextUnorderedListItem">Hair samples and examinations</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: No Scalp Cooling</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No scalp cooling</li> <li class="seamTextUnorderedListItem">Hair samples and examinations</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Scalp cooling helps prevent hair loss due to chemotherapy.</li> <li class="seamTextUnorderedListItem">Scalp cooling may be less effective in people of color because their hair type can prevent the scalp cooling cap from making contact with the scalp.</li> <li class="seamTextUnorderedListItem">Hairstyles such as cornrows, braids, or twists or the use of water and conditioner on the hair and scalp may increase contact of the scalp cooling cap with the scalp, help the cap work better, and may therefore help prevent hair loss.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, you can choose from receiving braids, twists, or cornrows.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with lung cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05213936' target='_blank'>ClinicalTrials.gov</a> </li></ul>
337

Improving Scalp Cooling and Reducing Hair Loss During Chemotherapy for Stage I-III Breast Cancer

Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color: A Clinical and Mechanistic Study
Icon

Nearest Location from 94107:
2574 miles
Montefiore Medical Center
The Bronx, NY

Icon

Visits:
At least 2 visits

Icon

ClinicalTrials.gov: NCT05213936

Icon

Phase NA

338

Diet and Exercise Program to Improve Healthy Behavior for People with Stage 0-III Breast Cancer

Precise Oncology Interventions in Nutrition and Training (OnPoint)

Purpose: To study if breast cancer survivors who receive a personal referral to a nutrition and exercise program will eat a healthier diet and be more physically active.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer who completed treatment at least 6 months ago. You must exercise less than 2.5 hours every week and/or not eat a healthy diet. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear a Fitbit, 2 months</li> <li class="seamTextUnorderedListItem">Text or phone call, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Nutrition class, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Exercise program, in person or virtual, 2 times every week for 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear a Fitbit, 2 months</li> <li class="seamTextUnorderedListItem">Text or phone call, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Nutrition class, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Exercise program, in person or virtual, 2 times every week for 2 months</li> <li class="seamTextUnorderedListItem">Checklist to monitor diet and exercise, 1 time</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear a Fitbit, 2 months</li> <li class="seamTextUnorderedListItem">Text or phone call, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Nutrition class, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Exercise program, in person or virtual, 2 times every week for 2 months</li> <li class="seamTextUnorderedListItem">Meeting with dietician, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Meeting with exercise expert, weekly for 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personal sessions with diet and exercise experts may help people treated for breast cancer live healthier lifestyles.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06534918' target='_blank'>ClinicalTrials.gov</a> </li></ul>
338

Diet and Exercise Program to Improve Healthy Behavior for People with Stage 0-III Breast Cancer

Precise Oncology Interventions in Nutrition and Training (OnPoint)
Icon

Nearest Location from 94107:
2591 miles
University of Miami
Miami, FL

Icon

Visits:
Up to 1-2 visits every week for 2 months

Icon

ClinicalTrials.gov: NCT06534918

Icon

Phase NA

339

Improving Physical Activity and Diet for Hispanic Women After Treatment

Pilot Study of a Multigenerational Digital Lifestyle Intervention for Hispanic Female Cancer Survivors and Their Families

Purpose: To study the ability of the With Love, Grandma (Con Carino, Abuelita) digital lifestyle program to improve the physical activity and diet of Hispanic women cancer survivors and their adult daughters.

Who is this for?: Hispanic women with stage I, stage II, or stage III breast cancer who have completed treatment, are a grandmother with an adult daughter, own a smartphone, and live in South Florida. You must be overweight or engage in no more than 2.5 hours of physical activity per week. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">With Love, Grandma (Con Carino, Abuelita) digital lifestyle program, 2-3 months</li> <li class="seamTextUnorderedListItem">Video meetings with coach, weekly for 2-3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard Treatment</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care intervention</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The With Love, Grandma (Con Carino, Abuelita) digital lifestyle program includes 8 modules on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting.</li> <li class="seamTextUnorderedListItem">Your daughter will also participate in this trial.</li> <li class="seamTextUnorderedListItem">Each family will virtually meet with a coach for 15-30 minutes per week.</li> <li class="seamTextUnorderedListItem">This trial is available in English and Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05721976' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/exercise' target='_blank'>Breastcancer.org: Exercise</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/diet-nutrition' target='_blank'>Breastcancer.org: Diet and Nutrition</a> </li></ul>
339

Improving Physical Activity and Diet for Hispanic Women After Treatment

Pilot Study of a Multigenerational Digital Lifestyle Intervention for Hispanic Female Cancer Survivors and Their Families
Icon

Nearest Location from 94107:
2591 miles
University of Miami
Miami, FL

Icon

Visits:
2 visits in 2-3 months

Icon

ClinicalTrials.gov: NCT05721976

Icon

Phase NA

340

Chinese Herbal Product to Reduce Pain and Itching from Radiation for Women with Stage II-III Breast Cancer

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

Purpose: To study a Chinese herbal product for the temporary relief of pain and itching after radiation.

Who is this for?: Women with stage II or some stage III breast cancer who have received a mastectomy and are planning to receive radiation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rub product on your chest skin, daily for 4.5 months</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Chinese herbal product in this study is an over the counter (available without a prescription) product with 1% menthol.</li> <li class="seamTextUnorderedListItem">You will apply the product to your skin 2 times every day during radiation and continue for up to 3 months after radiation is complete.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04650256' target='_blank'>ClinicalTrials.gov</a> </li></ul>
340

Chinese Herbal Product to Reduce Pain and Itching from Radiation for Women with Stage II-III Breast Cancer

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
Icon

Nearest Location from 94107:
2591 miles
University of Miami
Miami, FL

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT04650256

Icon

Phase NA

341

Radiation for People who Cannot Receive Surgery for Stage I-IV Breast Cancer

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of adding radiation to routine medications for breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who cannot or do not want to receive surgery. You must not be receiving systemic therapy (except for hormone therapy, HER2-targeted therapy, or immunotherapy). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups, depending on node status: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Lymph Nodes Negative for Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-breast radiation, 5 times</li> <li class="seamTextUnorderedListItem">CT or MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Lymph Nodes Positive for Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-breast and lymph node radiation, 5 times</li> <li class="seamTextUnorderedListItem">CT or MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patients who cannot receive surgery for breast cancer have limited effective treatment options. Radiation may provide long-lasting control of the tumor in patients who cannot or do not wish to receive surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07122713' target='_blank'>ClinicalTrials.gov</a> </li></ul>
341

Radiation for People who Cannot Receive Surgery for Stage I-IV Breast Cancer

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery
Icon

Nearest Location from 94107:
2604 miles
Stony Brook University Cancer Center
Stony Brook, NY

Icon

Visits:
5 visits, then follow-up for up to 5 years

Icon

ClinicalTrials.gov: NCT07122713

Icon

Phase NA

342

Contrast Enhanced Mammography Before Surgery for People Receiving Neoadjuvant Chemotherapy for Stage I-III Breast Cancer

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy

Purpose: To study the ability of contrast enhanced mammograms to predict the anti-cancer effects of neoadjuvant (before surgery) chemotherapy

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram with Omnipaque, by IV, 1-2 times during or after chemotherapy</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammograms with Omnipaque is a type of imaging called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT).</li> <li class="seamTextUnorderedListItem">Omnipaque is a contrast agent that helps detect and visualize cancer cells.</li> <li class="seamTextUnorderedListItem">The device used to obtain images is called Siemens MAMMOMAT. This device produces 2D and 3D images that allows the radiologist to <q>see through</q> the breast tissue for better detection and localization of breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06220214' target='_blank'>ClinicalTrials.gov</a> </li></ul>
342

Contrast Enhanced Mammography Before Surgery for People Receiving Neoadjuvant Chemotherapy for Stage I-III Breast Cancer

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy
Icon

Nearest Location from 94107:
2604 miles
Stony Brook Breast Center
Stony Brook, NY

Icon

Visits:
1-2 visits within 5 months

Icon

ClinicalTrials.gov: NCT06220214

Icon

Phase I

343

Fezolinetant to Reduce Hot Flashes in Women with Stage I-III Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Purpose: To study the effects (good and bad) of fezolinetant (Veozah®) vs placebo to reduce hot flashes. You must not also be currently receiving other cancer treatments such as chemotherapy, targeted therapy, or immunotherapy.

Who is this for?: Women, age 40-65 years, with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving hormone therapy and having hot flashes. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fezolinetant (Veozah®), by mouth, for 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, for 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy in this study is one of the following: tamoxifen (Nolvadex®), letrozole (Femara®), anastrozole (Arimidex®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Fezolinetant (Veozah®) is a non-hormonal, FDA-approved drug to treat hot flashes. It works by modifying the brain's regulation of body temperature.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06917313' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.veozah.com/?utm_source=google&utm_medium=cpc&utm_campaign=Astellas_VEOZ_B_Google_Search_DTC_Brand_BrandGeneric_Conversion_6995&utm_term=fezolinetant&utm_content=Astellas_B_GenericCoreB_Exact_7173&utm_campaignid=20122710868&utm_adgroupid=149201' target='_blank'>Astellas: Fezolinetant (Veozah®)</a> </li></ul>
343

Fezolinetant to Reduce Hot Flashes in Women with Stage I-III Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Icon

Nearest Location from 94107:
2614 miles
Yale University
New Haven, CT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06917313

Icon

Phase II

344

Promoting Exercise After Treatment for People With Stage 0-III Breast Cancer

Increasing Physical Activity Among Breast Cancer Survivors: Use of the ORBIT Model to Refine and Test a Novel Approach to Exercise Promotion Based on Affect-regulation (Study 2)

Purpose: To study the ability of 2 exercise programs to increase physical activity for breast cancer survivors.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have completed treatment within the last 5 years. You must exercise less than 1 hour every week over the last 6 months. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Affect-Based Exercise</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visit to discuss exercise program, 2 times</li> <li class="seamTextUnorderedListItem">Exercise program</li> <li class="seamTextUnorderedListItem">Affect-based exercise, up to 2.5 hours every week for 3 months</li> <li class="seamTextUnorderedListItem">Wear a smart watch</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Effort-Based Exercise</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visit to discuss exercise program, 2 times</li> <li class="seamTextUnorderedListItem">Exercise program</li> <li class="seamTextUnorderedListItem">Effort-based exercise, up to 2.5 hours every week for 3 months</li> <li class="seamTextUnorderedListItem">Wear a smart watch</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise may improve fatigue, pain, quality of life, and sleep in people treated for breast cancer.</li> <li class="seamTextUnorderedListItem">The exercise program includes definitions of exercise, guidelines for safe exercise, and strategies to overcome barriers to exercise. You will also be asked to describe your previous exercise and will be given an exercise plan.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, you will be asked to <q>select a pace of exercise that makes you feel as good as possible.</q></li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will be asked to <q>select a pace that would make it challenging for you to carry on more than a short conversation.</q></li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06258993' target='_blank'>ClinicalTrials.gov</a> </li></ul>
344

Promoting Exercise After Treatment for People With Stage 0-III Breast Cancer

Increasing Physical Activity Among Breast Cancer Survivors: Use of the ORBIT Model to Refine and Test a Novel Approach to Exercise Promotion Based on Affect-regulation (Study 2)
Icon

Nearest Location from 94107:
2619 miles
Dartmouth-Hitchcock Clinic
Lebanon, NH

Icon

Visits:
At least 2 visits within 3 months

Icon

ClinicalTrials.gov: NCT06258993

Icon

Phase NA

345

MRI Scan with Wearable Device to Improve Breast Cancer Detection

Evaluation of the Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) Imaging System Platform in Breast Cancer Patients

Purpose: To study if using a wearable device during MRI scans improves the ability to take breast images and detect breast cancer.

Who is this for?: Women newly diagnosed with stage I, some stage II, or some stage III breast cancer who have not yet received surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan with wearable device</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">The wearable device is attached to the breast using an adhesive nipple cover and breast tape.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06400563' target='_blank'>ClinicalTrials.gov</a> </li></ul>
345

MRI Scan with Wearable Device to Improve Breast Cancer Detection

Evaluation of the Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) Imaging System Platform in Breast Cancer Patients
Icon

Nearest Location from 94107:
2619 miles
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT06400563

Icon

Phase NA

346

Estradiol Hormone Therapy for Postmenopausal Women with Advanced ER+ Breast Cancer

Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of estradiol (Estrace®) hormone therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer who have received at least 1 line of hormone therapy for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol (Estrace®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol (Estrace®) is type of hormone therapy for advanced ER+ breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05716516' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drugs.com/estrace.html#:~:text=Estrace%20is%20used%20to%20treat,natural%20estrogen%20in%20the%20body.' target='_blank'>Drugs.com: Estradiol (Estrace®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>
346

Estradiol Hormone Therapy for Postmenopausal Women with Advanced ER+ Breast Cancer

Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer
Icon

Nearest Location from 94107:
2619 miles
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05716516

Icon

Phase II

347

Preventing Mouth Sores Due to Dato-DXd With Dexamethasone Mouthwash for Advanced HR+, HER2- or Triple Negative Breast Cancer

Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)

Purpose: To study if a dexamethasone mouthwash can prevent mouth sores following treatment with datopotamab deruxtecan (Dato-DXd; Datroway®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer whose cancer has progressed on at least one line of therapy OR people with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed on hormone therapy and a CDK 4/6 inhibitor and 1 prior line of chemotherapy and/or antibody-drug conjugate (ADC). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd; Datroway®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Dexamethasone mouthwash, 5 days per week for 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd; Datroway®) is an antibody-drug conjugate (ADC), which is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">A common side effect of datopotamab deruxtecan (Dato-DXd; Datroway®) is mouth sores and inflammation of the inside of the mouth, called stomatitis.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors are palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06974604' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/digestive-system/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2024&utm_content=Email122024' target='_blank'>Metastatic Trial Talk: Managing Side Effects of Treatment: Digestive System Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://datroway.com/?gclsrc=aw.ds&gad_source=1&gad_campaignid=22411693368&gbraid=0AAAAA-nL_-d3XIFfFFEx4zohhCrXvhfIZ&gclid=Cj0KCQiAjJTKBhCjARIsAIMC4481LG5Jq8xB9UdmzCJ1we3heac32-SwjTGI7Na6ktS2O8VU50e0DxoaAjnfEALw_wcB' target='_blank'>Daiichi Sankyo: Datopotamab Deruxtecan (Dato-DXd; Datroway®)</a> </li></ul>
347

Preventing Mouth Sores Due to Dato-DXd With Dexamethasone Mouthwash for Advanced HR+, HER2- or Triple Negative Breast Cancer

Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)
Icon

Nearest Location from 94107:
2684 miles
Rhode Island and the Miriam Hospitals (Brown University Health)
Providence, RI

Icon

Visits:
Every 3 weeks

Icon

ClinicalTrials.gov: NCT06974604

Icon

Phase II

348

Impact of Lymphedema on Quality of Life After Breast Cancer

Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer.

Purpose: To determine how the symptoms and functional disability that accompany lymphedema can impact breast cancer survivors' quality of life.

Who is this for?: Women with breast cancer without axillary lymph node malignancy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> All participants will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires and arm measurements</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer treatments can result in long-term, painful swelling of the arm and hand, a condition called lymphedema.</li> <li class="seamTextUnorderedListItem">To be eligible, participants must be planning to have surgery and receive follow-up care for breast cancer at Massachusetts General Hospital.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01521741' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>BreastCancer.org: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-pdq#section/all' target='_blank'>National Cancer Institute: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/lymphedema.html' target='_blank'>American Cancer Society: Lymphedema</a> </li></ul>
348

Impact of Lymphedema on Quality of Life After Breast Cancer

Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer.
Icon

Nearest Location from 94107:
2691 miles
Massachusetts General Hospital
Boston, MA

Icon

Visits:
Coincides with standard follow-up care

Icon

ClinicalTrials.gov: NCT01521741

Icon

Phase NA

349

Registry to Improve Cancer Prevention, Early Detection, and Treatment

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer

Purpose: To collect information and samples to improve prevention, early detection, and treatment of cancer.

Who is this for?: People with stage 0 (DCIS or LCIS), stage I, stage II, or stage III breast cancer, or people with high risk of breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide tissue, blood, saliva, urine, and/or stool sample(s) at routine visit</li> <li class="seamTextUnorderedListItem">Complete surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">By participating in this study, your family members are also eligible to participate in this study.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05463796' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://inadvancestudy.dana-farber.org/home' target='_blank'>Dana-Farber Cancer Institute: Trial Information Page</a> </li></ul>
349

Registry to Improve Cancer Prevention, Early Detection, and Treatment

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
Icon

Nearest Location from 94107:
2693 miles
Dana Farber Cancer Institute
Boston, MA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT05463796

Icon

Phase NA

350

Mammogram Decision Support for Women Age 80 and Older with Breast Cancer Survivors

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

Purpose: This study is testing whether a shared decision-making toolkit can help older breast cancer survivors make informed choices about continuing routine mammograms.

Who is this for?: Women with DCIS (stage 0) or stage I or stage II or stage III breast cancer, aged 80 and older ,who have had breast surgery at least 12 months ago, still have at least one breast, and not have not had their cancer come back (no recurrence or metastatic disease). Must not be receiving active cancer treatment (except hormone therapy or CDK4/6 inhibitors). View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The toolkit includes educational materials, communication guidance, and information to support personalized discussions between patients and their clinicians. </li> <li class="seamTextUnorderedListItem">This trial focuses on improving how care decisions are made, rather than testing a new drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07123649' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.docwirenews.com/post/for-the-first-time-mammography-guidelines-for-older-breast-cancer-survivors-are-issued' target='_blank'>Docwirenews: For The First Time, Mammography Guidelines for Older Breast Cancer Survivors Are Issued</a> </li></ul>
350

Mammogram Decision Support for Women Age 80 and Older with Breast Cancer Survivors

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
Icon

Nearest Location from 94107:
2693 miles
Dana-Farber Cancer Institute
Boston, MA

Icon

Visits:
1-2 visits per year, up to 2 years

Icon

ClinicalTrials.gov: NCT07123649

Icon

Phase II

351

Studying the Lymphatic System to Understand Lymphedema

Variable Anatomy and Function of the Arm's Alternate Lymphatic Pathway

Purpose: To study the structures of the lymphatic system to understand why people develop lymphedema and others do not.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who have had at least 10 lymph nodes removed during axillary lymph node dissection (ALND) at least 2 years ago and did not develop lymphedema, and women without a history of breast cancer or lymphedema. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical exam</li> <li class="seamTextUnorderedListItem">Lymphatic system mapping with indocyanine green (ICG) tracer, by injection</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">Ultrasound scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The lymphatic system helps drain extra fluid and waste from your body.</li> <li class="seamTextUnorderedListItem">When the lymphatic system is damaged during lymph node removal or surgery, it can cause lymphedema.</li> <li class="seamTextUnorderedListItem">Lymphedema is swelling of the arm and may happen in people who have received certain breast cancer treatments.</li> <li class="seamTextUnorderedListItem">Other symptoms of lymphedema can include fatigue, tightness, pain, and infections.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body.</li> <li class="seamTextUnorderedListItem">Indocyanine green (ICG) is a standard of care tracer used to improve the ability to take body pictures during imaging scans.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05253352' target='_blank'>ClinicalTrials.gov</a> </li></ul>
351

Studying the Lymphatic System to Understand Lymphedema

Variable Anatomy and Function of the Arm's Alternate Lymphatic Pathway
Icon

Nearest Location from 94107:
2693 miles
Beth Israel Deaconess Medical Center
Boston, MA

Icon

Visits:
At least 2 visits

Icon

ClinicalTrials.gov: NCT05253352

Icon

Phase NA

352

Screening Women with Breast Cancer for Edema and Lymphedema During Targeted Therapy

Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer

Purpose: To study the onset of edema (swelling) and breast cancer-related lymphedema in women with breast cancer.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving targeted therapy after surgery at Massachusetts General Hospital Breast Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Informational brochure about lymphedema risk</li> <li class="seamTextUnorderedListItem">Lymphedema screening program card</li> <li class="seamTextUnorderedListItem">Measurement of arm volume with perometer and SOZO device, every 3 months up to 5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Edema is swelling of body tissues due to excess fluid.</li> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling that occurs following damage to the lymphatic system, which can happen after breast cancer surgery.</li> <li class="seamTextUnorderedListItem">The perometer uses light sensors to calculate the length and volume of your arms.</li> <li class="seamTextUnorderedListItem">The SOZO device measures the amount of fluid in your arm(s).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05142800' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>
352

Screening Women with Breast Cancer for Edema and Lymphedema During Targeted Therapy

Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer
Icon

Nearest Location from 94107:
2693 miles
Massachusetts General Hospital
Boston, MA

Icon

Visits:
1 visit every 3 months up to 5 years

Icon

ClinicalTrials.gov: NCT05142800

Icon

Phase NA

353

Blood and Tissue Sample Study to Look at Changes in Blood Cells From Chemotherapy and Radiation in People With Breast Cancer

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

Purpose: This study is collecting blood, tissue, and other samples to learn how certain changes in blood stem cells (called clonal hematopoiesis) affect people getting chemotherapy or radiation for cancer.

Who is this for?: People with stage I, stage II, stage III or stage IV breast cancer who are planning to start chemotherapy or radiation for their breast cancer. People with a prior history of blood cancer (such as leukemia, lymphoma, or myeloma) cannot join. People with certain blood cancer precursor conditions (CHIP, CCUS, MBL, or MGUS) can still join. You must be receiving care at Dana-Farber Cancer Institute in Boston, Massachusetts. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete survey </li> <li class="seamTextUnorderedListItem">Give samples such as blood, a buccal (cheek) swab or mouthwash, and possibly urine, stool, tissue from a biopsy or surgery, or other body fluids</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Clonal hematopoiesis happens when a group of blood stem cells with a genetic change grows faster than other blood cells. Over time, and especially after chemotherapy or radiation, this can raise the chance of developing a blood cancer later on. </li> <li class="seamTextUnorderedListItem">Researchers want to use the information and samples collected to find ways to predict who is most likely to develop these blood cancers after cancer treatment, and to work toward ways to catch or prevent this earlier.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07675967' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/5-things-to-know-about-clonal-hematopoiesis.h00-159780390.html' target='_blank'>MD Anderson: 5 things to know about clonal hematopoiesis</a> </li></ul>
353

Blood and Tissue Sample Study to Look at Changes in Blood Cells From Chemotherapy and Radiation in People With Breast Cancer

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Icon

Nearest Location from 94107:
2693 miles
Dana-Farber Cancer Institute
Boston, MA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT07675967

Icon

Phase NA

354

Imaging to Identify Lymph Nodes and Limit Lymph Node Removal for Women with Stage III Inflammatory Breast Cancer

Refining Local-Regional Therapy for Inflammatory Breast Cancer (IBC)

Purpose: To identify the first lymph nodes that drain the breast to limit lymph node removal and reduce the risk of lymphedema in women with inflammatory breast cancer.

Who is this for?: Women with stage III inflammatory breast cancer who have not yet received treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphoscintigraphy with radioactive dye, by injection, 2 times</li> <li class="seamTextUnorderedListItem">Lymph node surgery</li> <li class="seamTextUnorderedListItem">Questionnaires, 6 times within 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lymphoscintigraphy, also called sentinel lymph node mapping, is an imaging procedure used to identify how lymph nodes drain.</li> <li class="seamTextUnorderedListItem">It is used to evaluate if breast cancer has spread to the axillary lymph nodes (lymph nodes under the arm) in non-inflammatory breast cancer.</li> <li class="seamTextUnorderedListItem">In non-inflammatory breast cancer, these lymph nodes are tested first, and if they are free of cancer, additional lymph nodes are not removed. </li> <li class="seamTextUnorderedListItem">By safely limiting lymph node removal, the likelihood of developing lymphedema (arm swelling) has been reduced in people with non-inflammatory breast cancer.</li> <li class="seamTextUnorderedListItem">It is not known whether lymphoscintigraphy can safely reduce lymph node removal and lymphedema in people with inflammatory breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04636710' target='_blank'>ClinicalTrials.gov</a> </li></ul>
354

Imaging to Identify Lymph Nodes and Limit Lymph Node Removal for Women with Stage III Inflammatory Breast Cancer

Refining Local-Regional Therapy for Inflammatory Breast Cancer (IBC)
Icon

Nearest Location from 94107:
2693 miles
Dana Farber Cancer Institute
Boston, MA

Icon

Visits:
6 visits within 2 years

Icon

ClinicalTrials.gov: NCT04636710

Icon

Phase NA

355

Injection of Pain Medication in the Spinal Versus Chest Area Before Mastectomy and Reconstruction for Stage 0-III Breast Cancer and People at High Risk for Breast Cancer

Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction

Purpose: To compare the effectiveness of pain blocks in two different locations on pain and physical well-being.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer or people at high risk for breast cancer who are planning to receive a mastectomy followed by immediate breast reconstruction with an implant. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pain medication injected into the spinal area, before surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pain medication injected into the upper chest area, before surgery</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pain management after mastectomy may be different depending on where pain medications are injected.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07209436' target='_blank'>ClinicalTrials.gov</a> </li></ul>
355

Injection of Pain Medication in the Spinal Versus Chest Area Before Mastectomy and Reconstruction for Stage 0-III Breast Cancer and People at High Risk for Breast Cancer

Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
Icon

Nearest Location from 94107:
2694 miles
Massachusetts General Hospital
Boston, MA

Icon

Visits:
Coincides with surgery, follow-up at 1 year

Icon

ClinicalTrials.gov: NCT07209436

Icon

Phase NA

356

Virtual Mindfulness Approaches for Women With Depression Who Are Survivors of Stage 0-III Breast Cancer

Harnessing E-Mindfulness Approaches for Living After Breast Cancer-HEAL-ABC

Purpose: To study if a digital mindfulness meditation-based program can improve the mental health and well-being of younger breast cancer survivors with depression.

Who is this for?: Women who were age 18 to 50 years old when diagnosed with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, who have completed breast cancer treatment (except hormone therapy or trastuzumab if recommended) 6 months to 5 years ago, and have symptoms of depression. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mindfulness, live virtual sessions, 2-hour sessions weekly for 6 weeks</li> <li class="seamTextUnorderedListItem">Practice mindfulness techniques, 5-20 minutes daily</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mindfulness, virtual sessions by app</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guided audio mindfulness meditations, virtual sessions by app</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mindfulness meditation programs provided in person are helpful for younger breast cancer survivors. This study will compare different digital approaches for mindfulness training to see which is the most effective.</li> <li class="seamTextUnorderedListItem">Mindfulness delivered live provides structured lessons and guided exercises in mindfulness as well as opportunities for reflection and group discussion.</li> <li class="seamTextUnorderedListItem">Mindfulness delivered by app provides sequential new content and exercises that build on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06748222' target='_blank'>ClinicalTrials.gov</a> </li></ul>
356

Virtual Mindfulness Approaches for Women With Depression Who Are Survivors of Stage 0-III Breast Cancer

Harnessing E-Mindfulness Approaches for Living After Breast Cancer-HEAL-ABC
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06748222

Icon

Phase III

357

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Purpose: To study if a computer that has been taught how to match people to clinical trials (artificial intelligence) can help increase enrollment in clinical trials.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already decided to enroll in a clinical trial. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A clinical trial matching report based on your medical records that you can review with your doctor.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use artificial intelligence and virtual tumor boards to help match people to clinical trials.</li> <li class="seamTextUnorderedListItem">The researchers will also create a registry to study the medical and financial effects of this program. </li> <li class="seamTextUnorderedListItem">This is an international trial that is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03452774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://massivebio.com/' target='_blank'>Massive Bio Study Information Page</a> </li></ul>
357

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT03452774

Icon

Phase NA

358

Home Based Exercise Program to Preserve Strength and Prevent Disability During Chemotherapy for People With Breast Cancer

Distance-Based Exercise to Preserve Function and Prevent Disability

Purpose: To find out whether a guided exercise program can be successfully delivered to people from their own homes through video (telehealth) sessions while they are receiving chemotherapy.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are about to start, or have recently started, chemotherapy. You must be 18 to 64 years old and able to walk for 6 minutes, and you should not already be doing regular strength training or competitive sports. This trial is also enrolling people with other types of cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised video (telehealth) sessions 2 times a week</li> <li class="seamTextUnorderedListItem">Aerobic exercise on your own for a total of about 50 minutes each week</li> <li class="seamTextUnorderedListItem">You will receive equipment to use at home, such as a stationary bike, workbook, gloves, and resistance bands</li> <li class="seamTextUnorderedListItem">You will wear an activity tracker (accelerometer) throughout the study</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy can cause side effects like fatigue and loss of strength that make it harder to work, care for family, and do everyday activities. This study looks at whether a home based exercise program can help prevent those side effects and make it easier to stay active during treatment.</li> <li class="seamTextUnorderedListItem">Regular exercise during cancer treatment may help protect strength and physical function and reduce side effects like fatigue, but starting an exercise routine can be hard during treatment. </li> <li class="seamTextUnorderedListItem">Researchers want to learn whether delivering the program virtually is a practical way to help people stay active in their own homes while going through chemotherapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07059884' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/kimmel-cancer-center/cancers-we-treat/breast-gynecologic-malignancies-group/treatment-and-services/exercise-and-breast-cancer' target='_blank'>Johns Hopkins: Exercise and Breast Cancer</a> </li></ul>
358

Home Based Exercise Program to Preserve Strength and Prevent Disability During Chemotherapy for People With Breast Cancer

Distance-Based Exercise to Preserve Function and Prevent Disability
No Travel Required
Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07059884

Icon

Phase NA

359

Impact of DCISionRT Test on Treatment Decisions for Women with DCIS and LCIS

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy (PREDICT)

Purpose: To study the impact of the DCISionRT test on treatment decisions for people with DCIS or LCIS.

Who is this for?: Women 30-85 years old with stage 0 (DCIS or LCIS) breast cancer who were diagnosed in the last 4 months and are planning to receive or have received a lumpectomy. You must have received the DCISionRT test. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide access to the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health data</li> <li class="seamTextUnorderedListItem">Imaging data</li> <li class="seamTextUnorderedListItem">Tissue samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The DCISionRT test predicts the risk of recurrence over 10 years and the benefit from radiation therapy.</li> <li class="seamTextUnorderedListItem">Your doctor will complete surveys before and after receiving the DCISionRT test. The surveys will study how the DCISionRT test results were used to make treatment decisions.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03448926' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://preludedx.com/patients/' target='_blank'>PreludeDx: DCISionRT</a> </li></ul>
359

Impact of DCISionRT Test on Treatment Decisions for Women with DCIS and LCIS

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy (PREDICT)
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT03448926

Icon

Phase NA

360

Virtual Intervention to Improve the Well-Being of Black Women With Stage 0-IV Breast Cancer

Project SOAR Awakenings: Randomized Controlled Trial for Black American Women Diagnosed With Breast Cancer

Purpose: To promote well-being and decrease depression and fatigue.

Who is this for?: Black women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Project SOAR Gatherings, virtual, 1.5- to 2-hour discussions, weekly for 1 month</li> <li class="seamTextUnorderedListItem">Questionnaires, virtual, 3 times within 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive materials by mail for use on your own</li> <li class="seamTextUnorderedListItem">Questionnaires, virtual, 3 times within 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Project SOAR sessions are based on books and articles that participants will receive. The sessions aim to help Black women accept their emotions, care for themselves, accept help from others, and manage stress.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07208084' target='_blank'>ClinicalTrials.gov</a> </li></ul>
360

Virtual Intervention to Improve the Well-Being of Black Women With Stage 0-IV Breast Cancer

Project SOAR Awakenings: Randomized Controlled Trial for Black American Women Diagnosed With Breast Cancer
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07208084

Icon

Phase NA

361

Studying the Relationship Between Inherited KRAS Mutations and Breast Cancer Risk

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Purpose: To study the relationship between the KRAS mutation and cancer risk.

Who is this for?: People with stage I, stage II, stage III, and stage IV (metastatic) breast cancer, or people with a family history of breast cancer. You must also have endometriosis or an autoimmune condition. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Saliva sample to test for the KRAS mutation</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An inherited KRAS genetic mutation may increase a person's risk of developing breast or other types of cancer.</li> <li class="seamTextUnorderedListItem">This study will follow participants for 10 years. </li> <li class="seamTextUnorderedListItem">The researchers will also look at the effect that different lifestyle factors have on cancer risk. </li> <li class="seamTextUnorderedListItem">Participants will be able to get their KRAS mutation test results after submitting their sample at a discounted cost ($295).</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02253251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://miradx.com/test/kras-variant/' target='_blank'>MiraKind Research Company: KRAS-Variant</a> </li><li class='seamTextUnorderedListItem'><a href='http://mirakind.org/study-eligibility-questionnaire/' target='_blank'>Research Company: Eligibility Survey</a> </li></ul>
361

Studying the Relationship Between Inherited KRAS Mutations and Breast Cancer Risk

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT02253251

Icon

Phase NA

362

Group Therapy to Manage Joint Pain From Hormone Therapy for Women with Stage I-III HR+ Breast Cancer

Enhanced Pain Coping in Cancer (EPIC)

Purpose: To study if group therapy can help breast cancer survivors manage joint pain caused by aromatase inhibitors.

Who is this for?: Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who completed treatment at least 1 month ago. You must be receiving letrozole (Femara®), anastrozole (Arimidex®), or exemestane (Aromasin®) aromatase inhibitor and be planning to continue for at least 1 year. You must have joint pain. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Group therapy that includes mindfulness and other coping strategies, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Practice learned skills, at home, 15 minutes every day for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Group therapy that includes discussion on chronic pain and cancer survivorship, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Write in a journal, at home, 15 minutes every day for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Joint pain is common in people taking aromatase inhibitors. This pain can make some people decide to stop taking their medication. </li> <li class="seamTextUnorderedListItem">This study will look at the effects of 2 different types of group therapy on your cancer-related symptoms (such as pain, fatigue, and anxiety), your ability to continue taking aromatase inhibitors on a regular schedule, and your quality of life.</li> <li class="seamTextUnorderedListItem">All sessions in Group 1 and Group 2 are 2 hours each.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06728579' target='_blank'>ClinicalTrials.gov</a> </li></ul>
362

Group Therapy to Manage Joint Pain From Hormone Therapy for Women with Stage I-III HR+ Breast Cancer

Enhanced Pain Coping in Cancer (EPIC)
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06728579

Icon

Phase II

363

Mindfulness Program to Promote Sexual Health after Breast Cancer

Virtual Mindful After Cancer Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors

Purpose: To study the effects of a mindfulness-based program and how it may help improve quality of life and sexual health in women with breast cancer.

Who is this for?: Women with stage I or stage II or stage III or stage IV (metastatic) breast cancer who were diagnosed at least 6 months ago, and have at least one concern related to sexual health or body image. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is testing a virtual program called Mindful After Cancer (MAC). The program is designed to help people with breast (and gynecologic) cancer manage concerns about sexual health and body image after treatment.</li> <li class="seamTextUnorderedListItem">Researchers with test how well the program can help in areas such as: sexual well-being and satisfaction, body image, emotional health (including anxiety and mood), mindfulness, self-confidence in managing health, and overall quality of life.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07055854' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/wellness-body-image/how-breast-cancer-impacts-your-body-image' target='_blank'>Living Beyond Breast Cancer: Body Image and Breast Cancer</a> </li></ul>
363

Mindfulness Program to Promote Sexual Health after Breast Cancer

Virtual Mindful After Cancer Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07055854

Icon

Phase I

364

Support Improving Treatment Completion for People in Rural Counties with Stage I-III Breast Cancer

Improving the Timeliness and Quality of Care for Rural Patients With Solid Tumors

Purpose: To study if the CARES intervention improves the time to start and complete treatment for people living in rural counties.

Who is this for?: People with stage I, stage II, or stage III breast cancer who live in a rural county and are planning to receive treatment at University of Colorado Health System. You must have no insurance or not enough insurance. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive CARES navigation and counseling, virtually or in person, up to 20 times within 6 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive list of resources</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The CARES (Cancer Advocacy, Resources, Education and Support) intervention includes up to 10 navigation and 10 counseling sessions provided by oncology nurses and counselors. </li> <li class="seamTextUnorderedListItem">CARES sessions will be scheduled during key treatment transition points.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04916990' target='_blank'>ClinicalTrials.gov</a> </li></ul>
364

Support Improving Treatment Completion for People in Rural Counties with Stage I-III Breast Cancer

Improving the Timeliness and Quality of Care for Rural Patients With Solid Tumors
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT04916990

Icon

Phase NA

365

Fasting at Night to Improve Cognition After Chemotherapy for People with Stage I-IV Breast Cancer

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors (RESTORE)

Purpose: To study how fasting at night affects health, quality of life, and cognitive ability.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who completed chemotherapy at least 3 months ago and who are having cognitive (thinking) problems. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fast at night, 6 nights every week for 2 months</li> <li class="seamTextUnorderedListItem">Health education videos, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Cognitive tests, 2 times in 2 months</li> <li class="seamTextUnorderedListItem">Surveys, 2 times in 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health education videos, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Cognitive tests, 2 times in 2 months</li> <li class="seamTextUnorderedListItem">Surveys, 2 times in 2 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">When you are fasting, you are still allowed to drink water, coffee, and tea.</li> <li class="seamTextUnorderedListItem">Cognitive problems are problems with thinking (cognition).</li> <li class="seamTextUnorderedListItem">This trial's enrollment will be racially diverse (at least 50% of participants will be Black, Hispanic, and/or Native American).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06938555' target='_blank'>ClinicalTrials.gov</a> </li></ul>
365

Fasting at Night to Improve Cognition After Chemotherapy for People with Stage I-IV Breast Cancer

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors (RESTORE)
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06938555

Icon

Phase NA

366

Online Meditation to Reduce Anxiety and Depression After Treatment for Women with Stage I-III Breast Cancer

The SUPORT Project: Leveraging Social Connection by Including Informal Caregivers in an Internet Video Conference-based Compassion Meditation Intervention to Reduce Psychological Distress in Breast Cancer Survivors

Purpose: To study if meditation with or without caregivers will reduce depression and anxiety in breast cancer survivors.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who completed treatment between 3 months and 5 years ago. You may still be receiving hormone therapy or trastuzumab (Herceptin®). You must have a partner or caregiver who lives with you and is willing to participate. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Meditation sessions without your partner, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Meditation sessions with your partner, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Health Education</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Health education sessions with your partner, virtual, weekly for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many breast cancer survivors (around 70%) experience depression and/or anxiety after finishing cancer treatments.</li> <li class="seamTextUnorderedListItem">Meditation may reduce feelings of anxiety and depression.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05676255' target='_blank'>ClinicalTrials.gov</a> </li></ul>
366

Online Meditation to Reduce Anxiety and Depression After Treatment for Women with Stage I-III Breast Cancer

The SUPORT Project: Leveraging Social Connection by Including Informal Caregivers in an Internet Video Conference-based Compassion Meditation Intervention to Reduce Psychological Distress in Breast Cancer Survivors
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT05676255

Icon

Phase II

367

Remote Exercise Program to Reduce Fatigue for Stage 0-III Breast Cancer Survivors Living in Rural Areas

Effects of a Telehealth Exercise Program for Rural Cancer Survivors With Cancer-related Fatigue Including Integrated Longitudinal Assessments of Objective Physical Function and Fatty Acid Oxidation

Purpose: To study whether a virtual exercise program reduces cancer-related fatigue.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who completed treatment that included hormone therapy, radiation, chemotherapy, and/or immunotherapy within the last 5 years. You may currently be receiving hormone therapy. You must live in a rural area and have moderate or worse fatigue. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, virtual, for 3 months</li> <li class="seamTextUnorderedListItem">Surveys, 2 times per month</li> <li class="seamTextUnorderedListItem">Blood samples, by self collection, 2 times per month</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Waitlist Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys, 2 times per month</li> <li class="seamTextUnorderedListItem">Blood samples, by self collection, 2 times per month</li> </ul> <p class="seamTextPara"> followed by (3 months later): </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise program, virtual, for 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise may help improve cancer-related fatigue.</li> <li class="seamTextUnorderedListItem">The exercise program in this study includes virtual exercise sessions with cancer exercise specialists, additional exercise programming delivered by an app, and regular symptom monitoring by emailed surveys.</li> <li class="seamTextUnorderedListItem">The study includes 2 optional visits to the study site for laboratory-based exercise assessment before and after the program.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people with prostate cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07001241' target='_blank'>ClinicalTrials.gov</a> </li></ul>
367

Remote Exercise Program to Reduce Fatigue for Stage 0-III Breast Cancer Survivors Living in Rural Areas

Effects of a Telehealth Exercise Program for Rural Cancer Survivors With Cancer-related Fatigue Including Integrated Longitudinal Assessments of Objective Physical Function and Fatty Acid Oxidation
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07001241

Icon

Phase II

368

Online Pain and Depression Support Program for Asian Women with Stage I-IV Breast Cancer

Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors (CAI)

Purpose: To study if an online pain and depression management program can support Asian women with breast cancer.

Who is this for?: Chinese, Korean, or Japanese women who were diagnosed with breast cancer in the past and are experiencing pain and depression. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: CAI (Web App Based, Individualized Coaching and Support Program for Cancer Pain)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized information and support program, online</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: CAPA (Web App Based Information and Coaching/Support Program for Cancer Pain Management)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General information and support program, online</li> <li class="seamTextUnorderedListItem">Fitbit</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"> The pain and depression management program provides web-based information, coaching, and support that is culturally tailored to Asian American women with breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also available in Mandarin (simplified or traditional), Korean, and Japanese.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06085313' target='_blank'>ClinicalTrials.gov</a> </li></ul>
368

Online Pain and Depression Support Program for Asian Women with Stage I-IV Breast Cancer

Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors (CAI)
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06085313

Icon

Phase NA

369

Susan G. Komen ShareForCures Research Registry

ShareForCures: Susan G. Komen's People-powered, Data-driven Breast Cancer Research Registry

Purpose: To create a research registry of data from people with breast cancer, including minority and marginalized people, to ensure data is as diverse as the people touched by the disease.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue samples</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Saliva samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will have a better understanding of breast cancer and everyone can potentially benefit from scientific advances and improvements in care.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05654246' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/shareforcures/' target='_blank'>Susan G. Komen: ShareForCures</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/npcr/value/registries.htm' target='_blank'>Centers for Disease Control and Prevention: How Cancer Registries Work</a> </li></ul>
369

Susan G. Komen ShareForCures Research Registry

ShareForCures: Susan G. Komen's People-powered, Data-driven Breast Cancer Research Registry
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT05654246

Icon

Phase NA

370

Questionnaires to Understand Financial Impacts of Surgery and COVID-19 for Women Receiving a Mastectomy

Financial Toxicity in Patients Undergoing Breast Reconstruction: The Impact of Out of Pocket Costs, Lost Wages and Unemployment

Purpose: To collect information about the financial impact of breast cancer surgery and to learn if the COVID-19 pandemic affects patient costs of breast reconstruction.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer or women at high risk for breast cancer who are planning to receive a mastectomy and breast reconstruction at MD Anderson Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, virtual, 4 times within 2 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People receiving breast reconstruction after a mastectomy are at high risk for financial toxicity (harmful effects of high health care cost on well-being).</li> <li class="seamTextUnorderedListItem">The COVID-19 pandemic may affect these costs.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04169542' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/resources-support/find-financial-support-cancer/' target='_blank'>Metastatic Trial Talk: Where to Find Financial Support</a> </li></ul>
370

Questionnaires to Understand Financial Impacts of Surgery and COVID-19 for Women Receiving a Mastectomy

Financial Toxicity in Patients Undergoing Breast Reconstruction: The Impact of Out of Pocket Costs, Lost Wages and Unemployment
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT04169542

Icon

Phase NA

371

Virtual Reminders to Increase Physical Activity for People With Stage I-III Breast Cancer and Chronic Pain

An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

Purpose: To study the best time to deliver a message to increase physical activity and how often participants experience pain in the 24 hours after receiving a message to increase physical activity.

Who is this for?: People, 65 years and older, with stage I, stage II, or stage III breast cancer who have completed cancer treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Messages to report pain, virtual, 4 times a day for 1 month</li> <li class="seamTextUnorderedListItem">Messages to increase physical activity, virtual, 4 times a day for 1 month</li> <li class="seamTextUnorderedListItem">Wear activity monitor, 1 month</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying the best time to send a message to promote physical activity by cancer survivors who experience chronic pain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07227077' target='_blank'>ClinicalTrials.gov</a> </li></ul>
371

Virtual Reminders to Increase Physical Activity for People With Stage I-III Breast Cancer and Chronic Pain

An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07227077

Icon

Phase NA

372

Empowerment and Navigation Sessions for Latina Women Ages 30+ with Breast Cancer or a Family History of Breast/Ovarian Cancer

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

Purpose: To compare the impact of empowerment and navigation sessions with standard of care sessions on whether Latina women decide to receive genetic testing and/or genetic counseling.

Who is this for?: Latina women ages 30+ with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or with a family history of breast or ovarian cancer. You must have one social determinant of health risk factor, such as: perceived financial struggles, transportation difficulties, exposure to violence, housing challenges, social isolation/challenges. You must not have received genetic testing or genetic counseling. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, breast cancer screening, and diet and physical activity for breast cancer prevention.</li> <li class="seamTextUnorderedListItem">Standard of care sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, how to share breast cancer information, and testimonials and include role playing activities and group discussions.</li> <li class="seamTextUnorderedListItem">You can receive up to $100 for participation.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05483283' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/making-the-case-for-health-equity.pdf' target='_blank'>American Cancer Society: Health Equity and Social Determinants of Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health' target='_blank'>US Department of Health and Human Services: Social Determinants of Health</a> </li></ul>
372

Empowerment and Navigation Sessions for Latina Women Ages 30+ with Breast Cancer or a Family History of Breast/Ovarian Cancer

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT05483283

Icon

Phase NA

373

Resistant Potato Starch Dietary Supplement for Reducing Joint and Muscle Pain in People Taking an Aromatase Inhibitor for Breast Cancer

Phase 2 Study of Aromatase Inhibitor-Associated Musculoskeletal Symptom Prevention With Resistant Potato Starch (AIMSS-RPS)

Purpose: To study whether a dietary supplement called resistant potato starch can help reduce joint and muscle pain (such as joint stiffness and achiness) that is commonly caused by aromatase inhibitor therapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer, or people at high risk of developing breast cancer who are planning to start aromatase inhibitor therapy and expect to take it for at least 6 months, have mild to moderate joint pain (rated 0–6 on a 0–10 scale) in the week before enrolling. You must not have previously taken an aromatase inhibitor (except as part of fertility treatment), and you must be receiving care at the University of Michigan Rogel Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistant potato starch (RPS), by mouth, once daily, for 6 months</li> <li class="seamTextUnorderedListItem">Treatment diary to track your dose</li> <li class="seamTextUnorderedListItem">Questionnaires </li> <li class="seamTextUnorderedListItem">Provide stool samples, 2 times</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are hormonal therapy medicines used to treat or help prevent breast cancer.</li> <li class="seamTextUnorderedListItem">Many people who take aromatase inhibitors develop joint pain, stiffness, and discomfort, a condition known as aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Research suggests that lower levels of beneficial gut bacteria may be linked to the development of these joint and muscle symptoms. </li> <li class="seamTextUnorderedListItem">Resistant potato starch is a plant-based carbohydrate that may help promote the growth of beneficial gut bacteria, which may in turn help reduce joint pain and stiffness in people taking aromatase inhibitor therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07443943' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/pain/bone-joint' target='_blank'>Breastcancer.org: Joint and Bone Pain From Breast Cancer Treatment</a> </li></ul>
373

Resistant Potato Starch Dietary Supplement for Reducing Joint and Muscle Pain in People Taking an Aromatase Inhibitor for Breast Cancer

Phase 2 Study of Aromatase Inhibitor-Associated Musculoskeletal Symptom Prevention With Resistant Potato Starch (AIMSS-RPS)
No Travel Required
Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07443943

Icon

Phase II

374

Virtual Tool to Help Make Chemotherapy Decisions for People with Stage I-IV Breast Cancer

CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making

Purpose: To see if a virtual tool that informs people about chemotherapy-induced peripheral neuropathy (CIPN) helps people make decisions about chemotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), or docetaxel (Taxotere) chemotherapy and are experiencing peripheral neuropathy (nerve pain, discomfort, sensation changes, or weakness). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual chemotherapy decision tool</li> <li class="seamTextUnorderedListItem">Surveys</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropathy is pain, discomfort, sensation changes, and weakness from nerve damage.</li> <li class="seamTextUnorderedListItem">Chemotherapy-induced peripheral neuropathy (CIPN) is neuropathy in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Around half of people who develop CIPN still have it 3 years later.</li> <li class="seamTextUnorderedListItem">A virtual decision tool that provides information about permanent CIPN and prepares patients for a discussion with their doctor may lead to improvements in treatment decision-making.</li> <li class="seamTextUnorderedListItem">This trial is enrolling virtually and does not require any in person visits.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06915168' target='_blank'>ClinicalTrials.gov</a> </li></ul>
374

Virtual Tool to Help Make Chemotherapy Decisions for People with Stage I-IV Breast Cancer

CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06915168

Icon

Phase NA

375

Mobile App to Reduce Emotional Distress in Women Under Age 45 With Breast Cancer

Utility of a Mobile Application for Young Women With Breast Cancer

Purpose: To study the effects of using a mobile health application (the Mighty Pro app) to understand if it can help reduce cancer‑related emotional distress.

Who is this for?: Women, under age 45, with stage0 (DCIS) or stage I or stage II or stage III or stage IV breast cancer, experiencing moderate to high cancer‑related distress, and who are receiving care at Wake Forest Baptist Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Intervention</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Use of Mighty Pro mobile application, for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at whether using a mobile health application can help reduce cancer‑related distress in young women with breast cancer.</li> <li class="seamTextUnorderedListItem">The Mighty Pro app includes educational content and social connection for people with breast cancer.</li> <li class="seamTextUnorderedListItem">This trial does not require any in‑person visits and participation takes place using a mobile device over a 12‑month period.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07009093' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/emotional-health/managing-emotional-side-effects?utm_source=ppc&utm_medium=search&utm_campaign=in-treatment&utm_id=journey&gad_source=1&gad_campaignid=22665797719&gbraid=0AAAAAoX38tAgGRpQ7upZLxlLw_64Mdgcb&gclid=EAI' target='_blank'>Living Beyond Breast Cancer: Managing emotional side effects</a> </li></ul>
375

Mobile App to Reduce Emotional Distress in Women Under Age 45 With Breast Cancer

Utility of a Mobile Application for Young Women With Breast Cancer
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07009093

Icon

Phase NA

376

Online Portal to Educate and Refer Racially Diverse People to Clinical Trials

Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida

Purpose: To study the tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adults with cancer and their family members through referral to cancer clinical trials.

Who is this for?: People who are Black, African American, Hispanic, and/or Latinx. People with cancer and their family members may enroll in this trial. You must live in Florida. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ALEX (Agent Leveraging Empathy for eXams) portal</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care portal</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Racial and ethnic minorities are underrepresented in cancer clinical trials.</li> <li class="seamTextUnorderedListItem">The ALEX (Agent Leveraging Empathy for eXams) Research Portal uses culturally responsive, virtual community health educators to reach diverse populations.</li> <li class="seamTextUnorderedListItem">Clinicians can utilize the ALEX portal to refer patients to trials. Community health educators can use the portal to help provide information to patients and schedule follow-ups. Patients and family members can use the portal to access key information and make referrals.</li> <li class="seamTextUnorderedListItem">The standard of care portal provides participants with access to existing online cancer clinical trial resources in one location.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05655494' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/diversity-in-clinical-trials-2/' target='_blank'>Steps Toward Expanding Eligibility Criteria to Increase Diversity in Clinical Trials</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/diversity-in-clinical-trials/' target='_blank'>The Lack of Diversity in Clinical Trials</a> </li></ul>
376

Online Portal to Educate and Refer Racially Diverse People to Clinical Trials

Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT05655494

Icon

Phase NA

377

Virtual Program to Increase Symptom Management and Health Care Visits for Young Adults with Stage I-III Breast Cancer

Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors (AYA STEPS)

Purpose: To study a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and receive recommended follow-up care.

Who is this for?: People, age 18-39 years, with stage I, stage II, or stage III breast cancer who have completed all cancer treatments (except hormone therapy if recommended) within the last 3 months and whose diagnosis was 1-5 years ago. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AYA STEPS, virtual, 6 sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education, virtual, 6 sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AYA STEPS provides cognitive-behavioral and related skills to improve participants' ability to self-manage symptoms and increase health care visits.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06371768' target='_blank'>ClinicalTrials.gov</a> </li></ul>
377

Virtual Program to Increase Symptom Management and Health Care Visits for Young Adults with Stage I-III Breast Cancer

Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors (AYA STEPS)
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06371768

Icon

Phase NA

378

Coping Program for Women with Stage I to IV Breast Cancer with Pain

Brief Pain Coping Skills Training for Older Women With Breast Cancer and Pain: An Efficacy-Effectiveness Randomized Controlled Trial

Purpose: This trial is looking at whether a telehealth pain coping program can help lower pain and improve quality of life for women being treated for breast cancer. The program, called Pain Coping Skills Training, teaches practical skills for managing pain through one counseling session followed by short weekly support calls.

Who is this for?: Women age 55 or older with stage I, stage II, stage III, or stage IV breast cancer who have ongoing pain. You must have reported pain on at least 10 days in the past month, with a worst pain rating of 4 or higher on a scale of 0 to 10 in the past week. You must be receiving cancer care at a Duke Cancer Network clinic. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups. </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Pain Coping Skills Training</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One telehealth session with a study nurse, about 50 minutes, followed by 5 weekly 15 minute phone calls </li> <li class="seamTextUnorderedListItem">2 follow up surveys, at 10 weeks and 15 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will continue your regular care </li> <li class="seamTextUnorderedListItem">2 follow up surveys, at 10 weeks and 15 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying Pain Coping Skills Training, a behavioral program that teaches skills for managing pain, such as relaxation and ways to change thoughts and behaviors linked to pain. </li> <li class="seamTextUnorderedListItem">Researchers want to learn whether this telehealth based program can lower pain severity, reduce how much pain interferes with daily life, and improve quality of life, compared with usual care.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07300995' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/pain/managing-pain' target='_blank'>Breastcancer.org: Breast Cancer Pain Relief and Management</a> </li></ul>
378

Coping Program for Women with Stage I to IV Breast Cancer with Pain

Brief Pain Coping Skills Training for Older Women With Breast Cancer and Pain: An Efficacy-Effectiveness Randomized Controlled Trial
No Travel Required
Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07300995

Icon

Phase NA

379

CSC Online Survey: The Cancer Experience Registry

Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis (CER)

Purpose: To learn more about the emotional and social experiences and needs of people affected by cancer.

Who is this for?: People diagnosed with DCIS, stage I, stage II, stage III, or metastatic (stage IV) breast cancer and people who provide care to individuals diagnosed with cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> Participation in this study involves the completion of an online questionnaire. The questionnaire may be accessed at the following link: </p> <a href="http://www.cancersupportcommunity.org/MainMenu/ResearchTraining/Cancer-Experience-Registry.html" target="_blank">www.cancerexperienceregistry.org</a>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers hope to use this information to improve the educational materials and the overall quality of care that cancer patients receive. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people diagnosed with other types of cancer. </li> <li class="seamTextUnorderedListItem">The data collected from this study can be found <a href="https://www.cancersupportcommunity.org/RegistryIndexReport2017" target="_blank">here.</a></li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02333604' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerexperienceregistry.org/' target='_blank'>Cancer Support Community Study Website: Cancer Experience Registry</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancersupportcommunity.org/RegistryIndexReport2017' target='_blank'>Cancer Support Community: Cancer Experience Registry Index Report 2017</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youtube.com/watch?v=SyyUYqyNaCc' target='_blank'>Cancer Support Community YouTube Channel: What is the Cancer Experience Registry?</a> </li></ul>
379

CSC Online Survey: The Cancer Experience Registry

Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis (CER)
No Travel Required
Icon

Visits:
Online surveys

Icon

ClinicalTrials.gov: NCT02333604

Icon

Phase NA

380

Surveys on a Mobile Phone to Study Stress and Cognitive Abilities for Women With Stage 0-III Breast Cancer

Daily Stress Process and Daily Cognitive Performance Among Racially Diverse Breast Cancer Survivors: A Feasibility and Validation Study

Purpose: To study a mobile daily diary designed to measure daily stress and cognitive (thinking) function.

Who is this for?: Asian, Black, Latina, or white women, age 40 and older, with stage 0 (DCIS), stage I, stage II, or stage III breast cancer whose diagnosis was at least 5 years ago. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mobile phone</li> <li class="seamTextUnorderedListItem">Surveys, virtual, daily for 2 weeks</li> <li class="seamTextUnorderedListItem">Cognitive (thinking) tests, virtual, daily for 2 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The surveys ask about sleep, outlook, anticipated stress, positive experiences, and daily experiences (stressors, mood, and physical symptoms). </li> <li class="seamTextUnorderedListItem">The surveys are available in English, Spanish, or Chinese.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07054723' target='_blank'>ClinicalTrials.gov</a> </li></ul>
380

Surveys on a Mobile Phone to Study Stress and Cognitive Abilities for Women With Stage 0-III Breast Cancer

Daily Stress Process and Daily Cognitive Performance Among Racially Diverse Breast Cancer Survivors: A Feasibility and Validation Study
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT07054723

Icon

Phase NA

381

Saliva Samples and Questionnaires to Study How Genes Affect Breast Cancer Risk

The Rutgers University Genetics Coordinating Center Breast Cancer Study

Purpose: To study how genes impact breast cancer risk.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer, and people who have not been diagnosed with breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide saliva (spit) sample, by mail</li> <li class="seamTextUnorderedListItem">Questionnaires, online</li> <li class="seamTextUnorderedListItem">Access to your health records (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">By participating in this study, you will receive information about your genetic risk for free.</li> <li class="seamTextUnorderedListItem">Mutations in genes called BRCA1 and BRCA2 explain only about 25% of the genetic cause of breast cancer. </li> <li class="seamTextUnorderedListItem">Researchers are trying to learn more about the genetic cause of breast cancer, which will help researchers create new treatments and improve current treatment options.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06773897' target='_blank'>ClinicalTrials.gov</a> </li></ul>
381

Saliva Samples and Questionnaires to Study How Genes Affect Breast Cancer Risk

The Rutgers University Genetics Coordinating Center Breast Cancer Study
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06773897

Icon

Phase NA

382

Educational Program to Improve Side Effects for People With HER2+ or HER2 Low Breast Cancer Receiving Targeted Therapy

Patient-Centered Care-Improving the Patient Experience in the Management of Adverse Events (AEs) Associated With Antibody Drug Conjugates (ADCs)

Purpose: To study whether educational programs can help improve how patients and clinicians recognize, discuss, and manage side effects from HER2 targeted antibody drug conjugates (ADC) treatments.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer with HER2 positive (HER2+) or HER2 low breast cancer, who are currently receiving HER2 targeted antibody drug conjugates (ADCs), or about to start treatment with a HER2 targeted ADC. You must be receiving care at NYU Langone Health. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Recorded educational videos </li> <li class="seamTextUnorderedListItem">Online surveys</li> <li class="seamTextUnorderedListItem">3 virtual visits, within 6 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">This is an all‑virtual study focused on education and communication. There are no study drugs given.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06927895' target='_blank'>ClinicalTrials.gov</a> </li></ul>
382

Educational Program to Improve Side Effects for People With HER2+ or HER2 Low Breast Cancer Receiving Targeted Therapy

Patient-Centered Care-Improving the Patient Experience in the Management of Adverse Events (AEs) Associated With Antibody Drug Conjugates (ADCs)
No Travel Required
Icon

Visits:
3 virtual visits, within 6 months

Icon

ClinicalTrials.gov: NCT06927895

Icon

Phase NA

383

Remote Physical Activity Program for People With Stage 0-III Breast Cancer

A Pilot Sequential, Multiple Assignment, Randomized Trial (SMART) of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

Purpose: To learn whether a remotely delivered physical activity program can help breast cancer survivors safely increase how much they exercise each week.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, or stage III breast cancer who finished their main cancer treatment (surgery, chemotherapy, and radiation) within the past 5 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be asked to do the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Meet with the exercise specialist 3 times to help you get started increasing your weekly activity</li> <li class="seamTextUnorderedListItem">Wear an activity monitor (smartwatch) to help you track your activity</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is studying a home based physical activity program for people who have finished treatment for early stage breast cancer.</li> <li class="seamTextUnorderedListItem">The program uses coaching from an exercise specialist, a personalized exercise plan, and an activity tracker to help survivors build up to the recommended goal of about 150 minutes of activity per week.</li> <li class="seamTextUnorderedListItem">The trial also tests a <q>step up</q> version of the program that adds extra coaching for people who have not yet reached the recommended amount of weekly activity, to see if that added support helps them become more active.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07706556' target='_blank'>ClinicalTrials.gov</a> </li></ul>
383

Remote Physical Activity Program for People With Stage 0-III Breast Cancer

A Pilot Sequential, Multiple Assignment, Randomized Trial (SMART) of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors
No Travel Required
Icon

Visits:
No in person visits required

Icon

ClinicalTrials.gov: NCT07706556

Icon

Phase NA

384

A Supportive Care App (SHIELD Portal) for Women With Stage 0 to Stage III Hormone Receptor Positive Breast Cancer

Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention

Purpose: This trial is testing a new web and mobile app called the SHIELD portal. The portal is a supportive care tool built to help track cancer and treatment related symptoms and side effects, and to share self management information and resources during long term hormone (endocrine) therapy.

Who is this for?: Premenopausal women with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer. You must have been diagnosed between the ages of 18 and 49, and be in active treatment, including long term hormone (endocrine) therapy, at the time you join. You must be receiving care at Dana-Farber Cancer Institute in Boston, Massachusetts. Much of this trial can be done virtually. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to the SHIELD portal, which you can use on a smartphone, tablet, or computer </li> <li class="seamTextUnorderedListItem">Survey assessments on the portal at the start and again after 3 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The SHIELD portal is being studied as a way to support women during long term hormone therapy for breast cancer. </li> <li class="seamTextUnorderedListItem">The portal includes educational modules, tools to track symptoms and side effects, tailored information based on the concerns you report, and health behavior tools.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07482384' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/side-effects' target='_blank'>Breastcancer.org: Side Effects of Hormonal Therapy for Breast Cancer</a> </li></ul>
384

A Supportive Care App (SHIELD Portal) for Women With Stage 0 to Stage III Hormone Receptor Positive Breast Cancer

Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention
No Travel Required
Icon

Visits:
No in person visits required, up to 3 months

Icon

ClinicalTrials.gov: NCT07482384

Icon

Phase NA

385

Genetic Testing Educational Video for People with Stage I-IV Breast Cancer

Video Education With Result Dependent dIsclosure

Purpose: To study if an educational video improves knowledge of genetic testing for inherited cancer risk and could be used as an alternative to genetic counseling before genetic testing.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not received genetic testing. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch educational video about genetic testing for inherited cancer risk</li> <li class="seamTextUnorderedListItem">Complete interview, by video or telephone</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times in 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive genetic counseling</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times in 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The video summarizes the core educational components of a genetic counseling visit.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05225428' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease Control and Prevention: Genetic Testing</a> </li></ul>
385

Genetic Testing Educational Video for People with Stage I-IV Breast Cancer

Video Education With Result Dependent dIsclosure
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT05225428

Icon

Phase NA

386

Understanding the Experience of People with Advanced Breast Cancer Receiving Hospice Care

The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients with Metastatic Breast Cancer Receiving Hospice Care

Purpose: To better understand the in-home hospice experience for people with advanced breast cancer and their caregivers.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who live in Massachusetts and are planning to receive hospice care at home. Caregivers are also eligible to participate. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Telehealth appointments, by Zoom or phone, weekly for 1 month</li> <li class="seamTextUnorderedListItem">Survey, by email or phone</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Usual Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Survey, by email or phone</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Telehealth check-in appointments will be with your oncology care team (doctor, physician assistant, nurse practitioner, or hospice nurse) by Zoom or phone call.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06507930' target='_blank'>ClinicalTrials.gov</a> </li></ul>
386

Understanding the Experience of People with Advanced Breast Cancer Receiving Hospice Care

The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients with Metastatic Breast Cancer Receiving Hospice Care
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT06507930

Icon

Phase NA

387

Artificial Intelligence (AI) Symptom Support App for People with Breast Cancer

Pilot Randomized Controlled Trial of a Remote Monitoring and Symptom Management Intervention (ASSIST) Among Patients Receiving Systemic Therapy

Purpose: To study the ability of an artificial intelligence (AI) phone app (ASSIST) to help manage symptoms during cancer treatment.

Who is this for?: People with stage I or stage II or stage III or stage 4 (metastatic) breast cancer who are about to start, or have recently started (within 4 weeks), systemic treatment (such as chemotherapy, targeted therapy, or immunotherapy). View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at a smartphone-based AI application called ASSIST that helps monitor symptoms and provide support during cancer treatment. Researchers want to understand if patients can use the app regularly and if they find it helpful and easy to use, compared with standard care alone.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07553572' target='_blank'>ClinicalTrials.gov</a> </li></ul>
387

Artificial Intelligence (AI) Symptom Support App for People with Breast Cancer

Pilot Randomized Controlled Trial of a Remote Monitoring and Symptom Management Intervention (ASSIST) Among Patients Receiving Systemic Therapy
No Travel Required
Icon

Visits:
No Visits Required, up to 3 months

Icon

ClinicalTrials.gov: NCT07553572

Icon

Phase NA